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Proliferative glomerulonephritis (GN), seen in patients with Goodpasture’s disease or 
systemic lupus erythematosus (SLE), is characterised by glomerular infiltration of 
macrophages and T cells as well as proliferation of intrinsic renal cells. Significant insights 
into the pathogenesis of GN have been obtained through the use of experimental rodent 
models, such as nephrotoxic nephritis (NTN). In this thesis I have investigated the role of two 
important immunological molecules in NTN: Fas ligand (FasL) and Fc gamma receptor IIB 
(FcγRIIB). 
FasL is a well-known inducer of apoptosis in cells expressing its receptor Fas; 
however FasL also mediates non-apoptotic pro-inflammatory responses. FasL is widely 
expressed throughout the hematopoietic system but is also expressed within healthy and 
diseased kidney. I describe a novel role for FasL in the promotion of NTN independent from 
antibody and T cell responses. This pathological effect correlates with enhanced glomerular 
inflammation and appears to be dependent on FasL expression on both circulating leukocytes 
and intrinsic renal cells. Additionally, I have shown FasL-defective mesangial cells have 
impaired signalling through the IL-1R with a reduction in MCP-1 production. 
FcγRIIB is the sole inhibitory Fc receptor for IgG and is involved in the negative 
regulation of B cells and cellular activation. FcγRIIB is widely expressed throughout the 
hematopoietic system but is also expressed on mesangial cells within the kidney. FcγRIIB 
deficiency greatly exacerbates NTN. Here I use cell-specific deletion to demonstrate the 
critical importance of FcγRIIB expressed on myeloid cells rather than B cells in the 
protection from NTN. Further to this, I highlight a role for FcγRIIB on intrinsic renal cells, 
possibly mesangial cells, in the protection from NTN. Overall, these data widen our 
knowledge on the pathogenesis of GN and open up possibilities for finding future novel 
treatments.  
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The work described in this thesis is a study of the pathogenesis of glomerulonephritis 
using the murine model, nephrotoxic nephritis (NTN). I have focused on the role of the death 
ligand, Fas ligand (FasL) and the inhibitory Fc receptor, Fc gamma receptor IIB (FcγRIIB), 
two key molecules in the modulation of the inflammatory immune response. 
This introductory chapter begins with an overview of immune-mediated 
glomerulonephritis in humans and the description of three commonly employed animal 
models, including important pathological insights previously gained from their use. Evidence 
for the involvement of both humoral and cell-mediated mechanisms in the pathogenesis of 
glomerulonephritis, gained from studies using nephrotoxic nephritis, is then reviewed. 
Following this I go onto describe the structure, function and expression of FasL and Fc 
gamma receptors (FcγR), their roles in autoimmunity and inflammation, and observations 
from studies, in both humans and animals, supporting roles for both in glomerulonephritis. 
The chapter ends with the project hypotheses and aims. 
The second chapter describes methods, followed by four results chapters, each 
divided into introduction, aim, experimental design, results, discussion and conclusion. 
Chapter 3 describes experiments comparing NTN in FasL-deficient mice with wild-type 
(WT) controls and in vitro studies looking at the differences between cultured FasL-deficient 
and WT splenocytes following stimulation with cytokines. In Chapter 4, I discuss how bone 
marrow chimeras were created to examine the role of FasL on circulating leukocytes and 
intrinsic renal cells in vivo together with in vitro studies looking at mesangial cell expression 
of FasL and differences between cultured FasL-deficient and WT mesangial cells, following 
stimulation with cytokines. Chapter 5 includes work from a collaboration in the Netherlands, 
looking at the role of FcγRIIB expressed by different cell lineages in NTN, compared to WT 
and FcγRIIB-deficient mice. Chapter 6 carries on this work comparing results from bone 
marrow transplant experiments between WT mice and complete FcγRIIB knockouts and 
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confirming expression of FcγRIIB on mesangial cells. The final chapter, Chapter 7, is a 
discussion of the limitations and future directions of all the work described. 
 
 
1.2 Immunopathogenesis of immune glomerular disease 
Proliferative glomerulonephritis (GN) is characterised histologically by glomerular 
hypercellularity caused by infiltration of circulating leukocytes (neutrophils, monocytes and 
T cells) into the glomerulus as well as proliferation of intrinsic renal cells (epithelial and 
mesangial cells). This hypercellularity is often accompanied by glomerular thrombosis, 
necrosis and the formation of crescents that may eventually lead to destruction of the 
glomerulus and rapid loss of renal function (Figure 1.1). Clinical features of proliferative GN 
include haematuria, proteinuria, hypoalbuminuria, hypertension and renal failure. Certain 
forms of proliferative GN can resolve, either spontaneously or with treatment, but most lead 
to long term scarring and are a significant cause of morbidity and mortality.  
GN usually occurs secondary to antibody-mediated processes, cell-mediated 
processes, or both. When antibody-mediated processes predominate, and the immune 
deposits are on the outside of the basement membrane, injury is mediated by either non-
complement fixing antibodies or by the complement C5b-9 attack complex without 
significant infiltration of circulating leukocytes or proliferation of intrinsic renal cells. GN 
can be classified depending on several factors, such as the clinical presentation of disease, the 
morphological changes within the glomerulus, or the immune mechanism causing the 
damage. The immunological categorisation of GN is based on the Gell-Coombs classification 
for hypersensitivity reactions that requires a pre-sensitised (immune) state of the host. 
Immune-mediated GN falls into three categories: GN caused by antibodies to intrinsic renal 
antigens (Type II hypersensitivity reaction), GN caused by deposition of immune complexes 
(Type III hypersensitivity reaction) and pauci-immune GN (related to anti-neutrophil 
cytoplasmic antibodies (ANCA) or Type IV delayed-type hypersensitivity (DTH) reaction), 
where few or no antibodies are deposited within the kidney. The general pathogenesis of each 
major group, along with examples of specific diseases, will be discussed in the following 
sections. 




Figure 1.1 Histopathological image of human crescentic glomerulonephritis. 
Periodic acid-Schiff (PAS) stain of a renal biopsy showing crescent formation (**) (Araki 
and Ogane, 2008). This image has been reproduced with the permission of the right holder, 
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1.2.1 Antibodies to intrinsic renal antigens 
Antibodies against endogenous antigens are referred to as autoantibodies and are 
generated following a loss of tolerance to self-antigens within the host. Goodpasture’s, or 
anti-glomerular basement membrane (GBM) antibody disease, is a rare autoimmune disorder 
in which circulating autoantibodies are directed against the non-collagenous domain (NC1) of 
the α3 chain of type IV collagen found in the GBM of the kidney, lung, choroid plexus, retina 
and cochlea (Kalluri et al., 1991; Kalluri et al., 1995; Saus et al., 1988; Turner et al., 1992). 
The disease is characterised by rapidly progressive GN, with or without pulmonary 
haemorrhage. Rarely it follows a relapsing-remitting course. Immunofluorescence studies of 
diseased glomeruli reveal linear staining of immunoglobulin (Ig) G along the GBM. 
Lerner et al. proved the pathogenic properties of anti-GBM antibodies using passive 
transfer experiments. Antibodies obtained from the kidneys of patients with Goodpasture’s 
disease were infused into squirrel monkeys and found to induce GN (Lerner et al., 1967). As 
well as humoral immunity, cellular immunity has also been proven to play a role in disease 
pathogenesis. Auto-reactive T cells have been shown to contribute to anti-GBM disease with 
both CD8+ and CD4+ T cells, reactive to α3 (IV) collagen, being isolated from patients with 
the disease (Kalluri et al., 1997; Merkel et al., 1996; Salama et al., 2001). Regulatory CD25+ 
T cells have been found to play a role in inhibiting the autoimmune response and may be 
responsible for re-establishing tolerance, perhaps explaining the single-hit nature of the 
disease (Salama et al., 2003). 
 
1.2.2 Deposition of immune complexes 
Immune complexes form when there is roughly a balance of antibodies to soluble 
antigens in the circulation, allowing extensive cross-linking. These soluble antigens can be 
either exogenous or endogenous. Exogenous antigens can include bacterial products (notably 
streptococcus which is the cause of post-infectious GN), hepatitis B or C viral antigens and 
malarial antigens. In diseases such as systemic lupus erythematosus (SLE) autoantibodies are 
generated against endogenous nuclear components, such as RNA, DNA and histones.  
Cross-linking of antigens to antibodies causes the formation of large immune 
complexes. These immune complexes are difficult to clear and can deposit in vessel walls, 
such as those of the glomerulus, inducing an inflammatory response. The pattern of GN that 
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results following immune complex deposition depends upon the class of antibody involved 
and the location of the deposits. Immune complexes deposited in the mesangium, such as in 
lupus nephritis, cause mesangial proliferation, but they can also be deposited in the sub-
epithelial or sub-endothelial compartments, causing basement membrane thickening or 
crescents, respectively. Some immune complex diseases, such as post-infectious GN, may 
resolve spontaneously; however many lead to renal scarring.  
 
1.2.3 Pauci-immune glomerulonephritis 
Pauci-immune GN differs from anti-GBM disease, lupus nephritis and post-infectious 
GN in that there is little or no deposition of immunoglobulin within the kidney. It is one 
feature of a group of rare systemic vasculitides, such as Wegener’s granulomatosis, Churg-
Strauss syndrome and microscopic polyangiitis, which are characterised by inflammation and 
necrosis of small blood vessels. In the kidney the disease is characterised by segmental 
necrosis of glomerular tufts, capillary rupture and bleeding into the Bowman’s space, as well 
as accumulation and proliferation of monocytes and epithelial cells resulting in the formation 
of crescents (Harper and Savage, 2000).  
The aetiology of these vasculitides is unknown. However, ANCA have been 
implicated in the pathogenesis (Falk and Jennette, 2002; Jennette et al., 1989). These 
antibodies are directed against components of azurophilic granules in neutrophils, in 
particular proteinase 3 (PR3) and myeloperoxidase (MPO), and ANCA titres have been found 
to correlate with human disease activity (Egner and Chapel, 1990; Jennette et al., 1989). 
Immunofluorescence of PR3-ANCA on normal neutrophils produces a typical cytoplasmic 
granular stain (c-ANCA) whereas MPO-ANCA produces a perinuclear-staining pattern (p-
ANCA). The most direct in vivo evidence that ANCA are pathogenic in humans comes from 
a single case report of transplacental transfer of MPO-ANCA from a mother to a neonate, 
resulting in neonatal pulmonary haemorrhage and GN (Bansal and Tobin, 2004). 
In vitro studies have shown that ANCA can activate monocytes, but not macrophages, 
and neutrophils primed with tumour necrosis factor (TNF)-α to express azurophilic granules 
on their surface. Binding of ANCA results in a respiratory burst, the release of reactive 
oxygen species (ROS), and secretion of pro-inflammatory cytokines (Charles et al., 1992; 
Falk et al., 1990). Complement has also recently been implicated as an amplifying loop in the 
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inflammation process. ANCA can bind either the MPO/PR3 ligands or FcγR on neutrophils 
resulting in activation. These neutrophils can then stimulate the complement alternative 
pathway, which in turn amplifies the neutrophil pro-inflammatory response (Halbwachs-
Mecarelli et al., 2011). There is also a hypothesis that proposes ANCA can activate 
neutrophils by ligating FcγR. In vitro studies on human neutrophils, using specific 
monoclonal blocking antibodies, showed that blocking FcγRIIa prevented ANCA-induced 
respiratory burst, whereas blocking FcγRIIIb had no effect (Mulder et al., 1994; Porges et al., 
1994). This could be due to activation-induced receptor shedding following FcγRIIIb 
engagement, Kocher et al. have shown that ANCA preferentially bind FcγRIIIb, almost 10-
fold more than FcγRIIa (Kocher et al., 1998).  
Cell-mediated immune responses are also involved. CD4+ and CD8+ T cells have 
been found in the kidneys of patients with pauci-immune GN (Bolton et al., 1987). PR3- and 
MPO-specific T cells have been identified in the peripheral blood of patients with 
vasculitides, and ANCA-associated vasculitis (AAV) patients have been found to have 
ANCA-specific memory helper T (Th)-17 cells, suggesting T cells may mediate the effector 
stage of the immune response (Griffith et al., 1996a; Nogueira et al., 2010). 
Despite the evidence suggesting a role for ANCA in pauci-immune GN, a small 
subgroup of patients (roughly 20%) remain persistently ANCA-negative. The pathogenesis of 
ANCA-negative pauci-immune GN is unknown, however neutrophils are still thought to play 
a central role (Chen et al., 2009). There is also some evidence to suggest that anti-endothelial 
cell antibodies (AECA) may be involved, although they are not always present in the sera of 
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1.3 Experimental animal models of immune glomerular disease 
Through clinical studies it has been possible to determine disease patterns in GN, as 
well as identify biomarkers of disease activity and injury; however it has been difficult to 
separate out disease effector mechanisms. In order to study the pathogenic mechanisms 
involved in GN, the development of animal models has been necessary. The development of 
gene targeting and transgenic technology in rodents in the past 20 years has facilitated 
investigation of the roles of individual molecules in disease, allowing a greater understanding 
of the cellular processes involved and the identification of possible therapeutic targets.  
In the following sections, there are descriptions of three commonly used rodent 
models: nephrotoxic nephritis, experimental autoimmune glomerulonephritis and 
experimental autoimmune vasculitis. Their strengths, weaknesses and important pathological 
insights from their use are highlighted. 
 
1.3.1 Nephrotoxic nephritis 
Nephrotoxic nephritis (NTN) was one of the first experimental models used to look at 
immune-mediated glomerular injury and has been studied in a variety of species including 
rabbits, rats and mice, and in its most severe form is similar to human crescentic GN. The 
accelerated murine variant of this model has been used extensively in this thesis. NTN has 
two distinct phases, the heterologous phase and the autologous phase. 
The heterologous phase refers to the glomerular injury and inflammation that results 
from the binding of the foreign antibody onto the GBM of the animal prior to the host 
adaptive immune response (Hammer and Dixon, 1963). The antibody is usually raised in 
rabbits or sheep immunised with GBM antigens and is called nephrotoxic serum (NTS). NTS 
is injected into the susceptible animal and binds to the GBM producing immediate 
inflammation with structural and functional damage. The model is characterised by a peak in 
neutrophil influx a few hours after injection and a peak in proteinuria within the first 24 
hours. The model is dependent on the concentration of NTS injected. Following low doses of 
NTS the disease can resolve quickly, otherwise the autologous phase of the injury develops. 
 The autologous phase follows 5-7 days after the induction of the heterologous phase. 
It is characterised by the development of an immune response against the sheep or rabbit 
P.E.H.Sharp  2013 
 
 34 
antibodies that are deposited on the GBM with the development of autologous antibodies that 
become deposited in the glomerulus, and also a T cell response, leading to mixed 
proliferative and thrombotic injury. As the disease progresses further, it becomes difficult to 
differentiate between the effects of the heterologous antibody and the host immune response, 
but the two are considered separately as a theoretical concept. 
These circulating host antibodies were thought either to represent an immune 
response to the heterologous antibody, deposited in the glomerular capillaries, or alternatively 
an immune response against glomerular antigens released following injury in the 
heterologous phase. Hammer and Dixon conducted a series of experiments looking at the 
development of the autologous phase. Firstly, they found rats tolerised at birth with the 
heterologous antibody did not develop the autologous phase and secondly, the autologous 
phase could be transferred to tolerised rats by passive transfer of rat anti-NTS antibodies. 
This suggests that the autologous phase is largely or entirely dependent on responses to the 
heterologous antibody (Hammer and Dixon, 1963). 
In the accelerated model of NTN, the animals are pre-immunised against the 
heterologous immunoglobulin, which results in the autologous phase being initiated with the 
injection of NTS. This accelerated model is more reproducible and results in rapid injury. 
Studies using NTN have shed light on the involvement of many immune effectors in 
glomerulonephritis, including macrophages, T cells, complement, FcγR and intrinsic renal 
cells, as well as the release of pro- and anti-inflammatory cytokines. The factors effecting the 
development of NTN are described in detail in Section 1.4. 
 
1.3.2 Experimental autoimmune glomerulonephritis 
Experimental autoimmune glomerulonephritis (EAG) is a model in which GN is 
induced by immunisation with heterologous or homologous antigenic material from the 
GBM. Following immunisation, an autoimmune kidney disease develops with linear 
deposition of anti-GBM antibodies, similar to human anti-GBM disease. EAG was first 
described in the 1960’s by Steblay, who immunised sheep with human collagenase-
solubilised GBM in complete Freund’s adjuvant (CFA) and observed a uniformly fatal 
crescentic GN (Steblay, 1962). This model has since been reproduced in susceptible strains of 
rats and mice by immunisation with preparations of bovine or rat GBM or, more recently, a 
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recombinant version of the rat α3 chain of type IV collagen (α3(IV)NC1) (Abbate et al., 
1998). 
Studies in susceptible strains of rat, such as Wistar Kyoto (WKY) and Brown Norway 
(BN), have provided good models of human disease and confirmed a role for both humoral 
and cell-mediated responses in the pathogenesis of disease. Reynolds et al. showed that 
passive transfer of eluted anti-GBM antibodies from the kidneys of WKY rats with EAG 
resulted in linear deposition of IgG on the GBM of both WKY and Lewis (LEW) rats. 
However, only the susceptible WKY strain developed crescentic GN, showing the 
importance of the inflammatory response to antibody deposition (Reynolds et al., 2006). A 
role for T cells in disease initiation has also been highlighted. Transfer of splenic CD4+ T 
cells from EAG rats primed naïve recipients for disease (Reynolds et al., 1993) and transfer 
of in vitro activated CD4+ T cells, from immunised rats, resulted in crescentic GN in the 
absence of IgG binding to the GBM, suggesting a direct role for T cells in glomerular injury 
(Wu et al., 2002). 
Several mouse strains, such as SJL, DBA/1 and CD1, are susceptible to EAG but in 
mice the disease is less reproducible and takes longer to develop, which limits the possibility 
of functional susceptibility studies (Hopfer et al., 2003). However, studies of EAG in mice 
have confirmed a role for T cells in disease. T cell receptor-deficient mice (TcR-/-), that do 
not express α/β or γ/δ TcR, do not develop disease following either immunisation with 
α3(IV)NC1 collagen or passive transfer of anti-α3(IV)NC1 antibodies generated in disease-
susceptible mice (Kalluri et al., 1997). Dean et al. also demonstrated, using B cell-deficient 
mice (µ chain-deficient), that cell-mediated immunity is sufficient for the induction of EAG, 
but then went on to prove that humoral immunity alone is sufficient, as transfer of sera from 
EAG C57BL/6 mice to RAG-1-/- mice (lacking mature B and T cells) induced disease (Dean 
et al., 2005). Mice deficient in the inhibitory FcγRIIB are also susceptible to EAG. This 
supports the suggestion of a role for this receptor in maintaining immunological tolerance. 
FcγRIIB-deficient animals have generalised enhanced antibody responses and heightened 
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1.3.3 Experimental autoimmune vasculitis 
To study directly the role of ANCA in the pathogenesis of AAV, different mouse and 
rat models have been developed. Xiao et al. described one such mouse model in 2002 (Xiao 
et al., 2002a). Immunisation of MPO-deficient mice with mouse MPO in CFA produced an 
immune response against MPO. When splenocytes from these mice were transferred to RAG-
2-/- mice, which lack mature B and T cells, or purified anti-MPO IgG was injected into RAG-
2-/- or WT mice, the recipient mice developed severe necrotising and crescentic GN and 
pulmonary haemorrhage, remarkably similar to human AAV (Xiao et al., 2002a). The use of 
this model has highlighted a role for complement in pauci-immune GN. The development of 
crescentic GN, following anti-MPO antibodies, could be blocked by complement (C3) 
depletion (Xiao et al., 2007). Then, using the model in knockout mice lacking either C5, 
involved in both the classical pathway and alternative pathway, the classical pathway 
component C4, or the alternative pathway component factor B, it was found that C5-/- and 
factor B-/- mice were protected, suggesting a role for the alternative complement pathway in 
disease pathogenesis (Xiao et al., 2007). However, this model is not strictly autoimmune as it 
does not involve breaking tolerance and nor is the transfer of splenocytes a good example of 
pauci-immune GN because there is a moderate amount of glomerular IgG deposition.  
In an alternative mouse model, MPO-/- mice were immunised with MPO before being 
irradiated and transplanted with MPO-positive bone marrow, resulting in the development of 
pauci-immune necrotising GN and pulmonary capillaritis, and indicating that bone marrow-
derived cells are sufficient and necessary for induction of disease (Schreiber et al., 2006). 
Other studies using these models have also highlighted roles for TNF-α (Huugen et al., 
2005), interleukin (IL)-17A (Gan et al., 2010), and primed neutrophils in pauci-immune GN 
(Schreiber et al., 2006; Xiao et al., 2005). 
In the rat model of experimental autoimmune vasculitis (EAV), disease is induced in 
WKY rats by immunisation with purified human MPO in CFA. After 6 to 7 weeks, the rats 
developed high titres of ANCA, as well as a pauci-immune GN and lung haemorrhage (Little 
et al., 2005). This model has since been optimised, by using higher doses of human MPO and 
altering the adjuvant by addition of pertussis toxin and killed Mycobacterium tuberculosis, to 
produce a reliable, reproducible system (Little et al., 2009). Studies in this model have 
suggested TNF-α as a potential therapeutic target of AAV (Little et al., 2006). 
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As with MPO-ANCA, there are many in vitro observations to suggest a role for PR3-
ANCA in the pathogenesis of AAV, but until recently a reliable animal model was not 
available. Immunisation of mice with human PR3 did not trigger an immune response and 
passive transfer of mouse PR3-specific polyclonal antibodies into WT mice did not induce 
renal or pulmonary disease (Pfister et al., 2004). However, Little et al. have found that by 
generating chimeric mice with a human immune system, human anti-PR3 autoantibodies 
were pathogenic and induced acute vasculitis (Little et al., 2011).  
 
 
1.4 Pathogenesis of glomerulonephritis 
1.4.1 Fc gamma receptors 
For FcγR in GN please see Section 1.10. 
  
1.4.2 Complement 
The complement system comprises a number of small proteins circulating in the 
blood that ‘complement’ the ability of antibodies and phagocytic cells in clearing external 
pathogens. Complement components are generally synthesised by the liver as inactive pre-
cursors that, following certain triggers, are cleaved by proteases to produce active proteins 
and start a sequential amplification cascade. Inappropriate complement activation is 
prevented in normal tissue by different soluble and membrane-bound inhibitors. However, 
unregulated activation has been implicated in various immune-mediated diseases, such as 
rheumatoid arthritis (RA) and multiple sclerosis (MS), and deposition of complement 
proteins in glomeruli is a common finding in human GN. Activation of complement mediates 
tissue damage via a number of mechanisms, including the generation of chemotactic 
anaphylatoxins, C3a and C5a, and by insertion of the membrane attack complex (MAC/C5b-
9) into cells, which disrupts intracellular homeostasis leading to cell lysis and death.  
Several studies have been performed to identify the importance of complement, and 
its different components, in the development of GN. Two initial studies looked at the roles of 
C3, a central component of the complement system, and C4, a member of the classical 
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pathway, using knockout mice. Deficiency in both C3 and C4 was found to protect mice from 
proteinuria and histological lesions; however Sheerin et al. found the degree of protection 
was greater in the C3-deficient animals. This suggests a pathogenic role for both the 
alternative and classical complement pathways in NTN (Hebert et al., 1998; Sheerin et al., 
1997). Other studies have looked at proteins involved in controlling complement activation, 
showing how unregulated activation of complement also results in the initiation of renal 
damage. Decay-accelerating factor (DAF, CD55), CD59 and Factor H are inhibitory 
complement regulatory proteins. DAF is involved in inhibiting the activation of C3; CD59 
prevents the formation of the terminal part of the complement system, C5-9b; Factor H 
regulates complement activation by possessing cofactor activity for the Factor I-mediated 
C3b cleavage, iC3b. Deficiency of DAF, CD59 or Factor H in mice exacerbated accelerated 
NTN with increased proteinuria and histological lesions (Pickering et al., 2002; Sogabe et al., 
2001; Turnberg et al., 2003). 
In contrast, complement may also play a protective role in GN. Humans and mice 
deficient in complement component C1q are both predisposed to developing SLE. The 
glomeruli of C1q-deficient mice induced with accelerated NTN developed severe thrombosis 
and had increased IgG deposits, infiltrating neutrophils and apoptotic cells when compared to 
age- and sex-matched WT control mice (Robson et al., 2001). These findings suggest a 
protective role for C1q in the clearance of immune complexes and apoptotic cells within the 
kidney.  
 
1.4.3 Circulating leukocytes 
1.4.3.1 Neutrophils 
Neutrophils are one of the first inflammatory cells to migrate to sites of inflammation 
where they play a critical role in driving acute inflammation by expressing and secreting 
cytokines, recruiting and activating other cells of the immune system, and by releasing 
proteolytic enzymes. During NTN, neutrophils have been shown to accumulate within the 
glomeruli immediately following the dose of NTS, with their influx peaking within the first 
few hours (Cochrane et al., 1965).  
The role of neutrophils in NTN has been studied in mice using varying approaches. 
Schrijver et al. depleted mice of neutrophils by using total body irradiation and found that 
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after a low dose of NTS the mice were completely protected from albuminuria but when the 
dose was increased the albuminuria returned, although it was markedly reduced (Schrijver et 
al., 1990). This indicates that neutrophils play a key role in mediating albuminuria, but at 
higher doses of NTS other factors, such as complement, can induce disease directly. Kitching 
et al. used a different approach by inducing non-accelerated NTN in granulocyte colony-
stimulating factor (G-CSF) deficient mice, which have low levels of circulating neutrophils. 
Following NTS injection these mice were protected from neutrophil infiltration and 
proteinuria (Kitching et al., 2002).  
NTN has also been studied in Beige mice, deficient in neutrophil neutral proteinases. 
Compared to WT C57BL/6 mice, Beige mice had remarkably reduced levels of albuminuria 
despite a comparable influx of neutrophils following the injection of NTS (Feith et al., 1993; 
Schrijver et al., 1989). This led to the conclusion that neutrophil proteinases are important in 
mediating the glomerular damage that leads to proteinuria.  
 
1.4.3.2 T cells 
The presence of T lymphocytes in human renal biopsies and their role in experimental 
animal models of GN has been well documented. T cells play a role in adaptive immunity by 
enhancing antibody production by B cells, by recruitment and activation of macrophages, and 
by mediating cellular cytotoxicity. Several experimental studies in animal models have 
demonstrated a role for T cells in GN. These have focused on the role of CD4+ T cells, 
including their subsets Th1, Th2 and Th17, and to a lesser extent the role of CD8+ T cells. 
More recently, a role for regulatory T cells (Treg) has also been explored. 
 
1.4.3.2.1 CD4+ T cells 
CD4+ T cells are also known as helper T cells (Th cells) as they have no cytotoxic or 
phagocytic activity but instead activate or direct other immune cells. They are essential in 
determining B cell antibody class switching, activating CD8+ cytotoxic T cells and 
maximising the activity of phagocytes such as macrophages. The prominent accumulation of 
CD4+ T cells in crescentic GN provides evidence for a role for ‘helper’ T cells in driving 
crescentic injury. 
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The role of CD4+ T cells in NTN was first explored using CD4-deficient mice. 
Compared to WT mice, CD4-/- mice showed only mild proliferative changes whilst crescents 
and proteinuria were absent (Tipping et al., 1998). To follow this up, NTN was then induced 
in knockout mice lacking major histocompatibility complex (MHC) Class II, which is 
required for antigen presentation to CD4+ T cells. MHC Class II-/- mice were protected from 
developing glomerular crescents, CD4+ T cell infiltration and renal injury, supporting the role 
of CD4+ T cells in crescentic GN (Li et al., 1998). 
CD4+ T cells may be contributing to crescentic GN via two possible mechanisms. 
They may provide help to B cells to produce an autologous antibody response, or they may 
be causing direct damage by activating macrophages locally in the kidney – a DTH reaction. 
To assess whether DTH mechanisms play a role in glomerular crescent formation, T cell 
depletion was induced using CD4 or CD5 monoclonal antibodies, during the effector phase 
of NTN in rats. The humoral response was unaffected; however, there was a significant 
reduction in crescents, macrophage accumulation and proteinuria in the rats treated with anti-
CD4 and anti-CD5 monoclonal antibodies compared to the rats treated with an isotype 
control (Huang et al., 1994). 
The phenotype of CD4+ T cells also plays an important factor in the development of 
NTN. There are three distinct subsets of Th cell, Th1, Th2 and Th17, which mature from naïve 
T helper cells (Th0) following activation by lineage-specific cytokines (Figure 1.2). As Th17 
cells were not identified until 2005, initial experiments only looked at the role of Th1 and Th2 
cells. C57BL/6 mice demonstrate a predominant Th1 immune response, driven by interferon 
(IFN)-γ and IL-12, which are important in directing a DTH response, activating macrophages 
and cytotoxic T cells and inducing IgG subclass switching. When induced with NTN, 
C57BL/6 mice develop a pronounced DTH response to the sheep IgG and severe crescentic 
GN with prominent T cell and macrophage infiltration (Huang et al., 1997c). In contrast, 
BALB/c mice are prone to a Th2 response, which develops under the influence of IL-4 and 
IL-13 and is important in allergy, mast cell/IgE-mediated type hypersensitivity responses, and 
production of IgE and IgG with lower complement fixing capacity. When BALB/c mice were 
induced with NTN they did not develop a DTH response and had significantly less crescent 
formation and lymphocyte infiltration (Huang et al., 1997a). Further support that NTN is 
directed by a Th1 response came from studies in mice deficient in the co-stimulatory 
molecules CD28, CD80 and CD86. Stimulation of CD80 or CD86 on antigen-presenting cells 
(APC) by CD28 on T cells can affect the polarisation of CD4+ T cells towards a Th1 or Th2 
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profile, respectively. Mice deficient in CD28 and CD80 were completely protected from 
accelerated NTN, in contrast to mice deficient in CD86 that showed exacerbated glomerular 
injury and crescent formation (Nitta et al., 2003; Odobasic et al., 2005b). 
The role of specific Th1/Th2 cytokines in the development of GN has also been 
explored. Mice deficient in IFN-γ, the IFN-γ receptor or IL-12 all show attenuation of renal 
injury compared to WT mice (Haas et al., 1995; Kitching et al., 1999a; Kitching et al., 2005), 
and neutralisation of IL-12 in C57BL/6 mice also attenuated crescent formation and cell-
mediated injury (Kitching et al., 1999b). Conversely, mice deficient in IL-4 or IL-10 have an 
enhanced Th1 response and develop severe crescentic GN with increased renal impairment, 
crescent formation and T cell and macrophage recruitment (Kitching et al., 1998; Kitching et 
al., 2000). By changing the balance of cytokines it is possible to alter the Th1/Th2 immune 
response and therefore influence the disease state. C57BL/6 mice treated with exogenous IL-
4, IL-10 or a combination of both, either before or after injury was established, were 
protected from crescentic GN, with reduced crescent formation, proteinuria and renal 
impairment compared to untreated mice (Kitching et al., 1997; Tipping et al., 1997). 
Conversely, administration of IL-12 to BALB/c mice with GN induced a Th1 response and 
crescent formation (Kitching et al., 1999b). 
Since the identification of Th17 cells in 2005 their role in NTN has been explored. 
Th17 cells polarise in the presence of IL-6 and transforming growth factor (TGF)-β and play 
an important role in autoimmunity and the recruitment, activation and migration of 
neutrophils. Initial experiments looked at IL-23, involved in Th17 cell expansion and 
survival, and IL-17, the main effector cytokine produced by Th17 cells. One group found that 
both IL-23p19-/- and IL-17-/- mice were protected from nephritis compared to WT mice at day 
10 (Paust et al., 2009). However, another group found that although IL-17-/- mice were 
protected from disease early on at day 6, by day 21 IL-17-/- and IL-23p19-/- mice had more 
severe disease than WT mice (Odobasic et al., 2011). Other experiments have looked at 
receptors important in the differentiation of CD4+ T cells into Th17 cells, such as the 
dopamine type 1-like receptor (D1-like-R) that is expressed on dendritic cells. Blocking this 
receptor with an antagonist inhibited IL-17 production and attenuated crescentic GN in mice 
with NTN (Okada et al., 2009). Another important receptor is retinoid orphan receptor 
(ROR)-γt, which is crucial for Th17 effector cytokine secretion. RORγt-/- mice were protected 
from histological and functional renal injury with fewer glomerular crescents and lower 
albuminuria and serum urea compared to WT mice (Steinmetz et al., 2011). The discovery of 
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Th17 cells has confounded our original understanding of the role of Th1 cells in GN. In a 
mouse model of antigen-specific GN, Th1 and Th17 cells were both found to induce 
proliferative GN (Summers et al., 2009). Also, IL-12p35-/- mice developed less severe 
crescentic GN than WT mice and had a decreased Th1 response but an increased Th17 
response (Odobasic et al., 2011). 
Together these studies highlight roles for both Th1 and Th17 cells in crescentic GN. 
IFN-γ and IL-17A both contribute to early glomerular injury; however later on during the 
course of disease IL-17A attenuates crescentic GN by suppressing the Th1 response, 














Figure 1.2 The T helper cell subsets, Th1, Th2, Th17 and Treg. 
Following activation by antigen presenting cells, naïve CD4+ T cells differentiate into Th1, 
Th2, Th17 or Treg cells depending on the cytokine milieu. In the presence of IL-12 and IFN-γ 
Th cells differentiate into Th1 cells, in the presence of IL-4 they differentiate into Th2 cells, in 
the presence of IL-23 (following stimulation with IL-6 and TGF-β) they differentiate into 
Th17 cells, and in the presence of TGF-β they differentiate into Treg cells. The phenotypes of 
Th1 and Th2 cells are stable; however there is considerable plasticity within Th17 cells, which 
can convert to dual cytokine producing phenotypes under the right conditions (not shown in 
diagram). Each Th cell subset secrets a unique milieu of cytokines that work to regulate other 
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1.4.3.2.2 CD8+ T cells 
The presence of CD8+ T cells in glomeruli during GN has been demonstrated in both 
human biopsies and experimental animal models. CD8+ T cells are also known as cytotoxic T 
cells (Tc) due to their ability to induce the death of infected, damaged or dysfunctional cells. 
Tc express TcR that recognise specific antigenic peptides presented by Class I MHC 
molecules, present on the surface of all nucleated cells, as well as the CD8 glycoprotein. 
CD8+ T cells are recognised as being cytotoxic once they become activated following antigen 
presentation.  
The role of CD8+ T cells in GN has been explored in both rats and mice with 
contrasting results being seen. Administration of an anti-CD8 antibody in the WKY rat 
models of EAG and NTN prevented the development of proteinuria and influx of 
macrophages (Huang et al., 1997b; Reynolds et al., 2002). However, CD8-deficient mice 
with NTN developed an accelerated, severe crescentic GN (Tipping et al., 1998), and TAP-1 
knockout mice (TAP delivers peptides for presentation by Class I MHC molecules) with 
NTN developed similar GN to normal littermate controls (Li et al., 2000). 
 
1.4.3.2.3 Regulatory T cells 
Regulatory T cells (Treg) are a specialised subset of T cell that suppress the immune 
response of other cells, maintaining immune system homeostasis and tolerance to self-
antigens. Naturally occurring Treg are made in the thymus and constitutively express CD4, 
CD25 and FoxP3. CD4+CD25+ T cells comprise around 5-10% of the peripheral CD4+ T cell 
subpopulation in humans and mice. They exert their function by inhibiting the overactivation 
of dendritic cells and Th cells through the production of cytokines, such as IL-10 and TGF-β, 
and via MHC-class-II-mediated suppression of dendritic cell maturation. They can also 
stimulate macrophages and dendritic cells to produce indoleamine 2,3-dioxygenase, an 
enzyme that breaks down tryptophan through kynurenine pathway, which has an anti-
proliferative effect on T cells.  
Impairment of Treg function has been found to contribute to several autoimmune 
diseases, including GN, and the role of Treg in the mouse model of NTN has been explored. 
Transfer of 1x106 CD4+CD25+ Treg, purified from naïve mice, one day before administration 
of NTS, was found to dramatically decrease proteinuria, cell infiltration and glomerular 
damage compared to the transfer of CD4+CD25- T cells, providing evidence for therapeutic 
P.E.H.Sharp  2013 
 
 45 
potential to control the onset and course of NTN. Tracking green fluorescent protein-
transgenic Treg revealed a predominant migration towards secondary lymphoid organs, with 
an increase of Treg in the lymph nodes, which was regulated by the chemokine receptor CCR7 
(Eller et al., 2010; Wolf et al., 2005). Paust et al. used DEREG mice, which express the 
diphtheria toxin (DTx) receptor under the control of the FoxP3 promoter, to selectively and 
efficiently deplete Treg by injection of DTx prior to induction of NTN. Treg depletion 
aggravated the course of NTN, increased systemic and renal IFN-γ, and increased recruitment 
of Th1 cells into the kidney, without an effect on Th17 cells, suggesting that Treg are important 
in controlling the Th1 immune response during NTN (Paust et al., 2011). 
 
1.4.3.3 B cells 
B lymphocytes are an essential component of the adaptive immune system where they 
play a central role in the humoral immune response. The principal functions of B cells are to 
produce antibodies against antigens, to act as APC, and to eventually develop into memory B 
cells. The development of the autologous phase of NTN is characterised by the presence of 
circulating host antibodies against the rabbit or sheep antigen deposited on the GBM, 
indicating a clear role for B cells in disease.  
Li et al. investigated the role of B cells in NTN using mice with deletion of the µ 
immunoglobulin heavy chain (µ-chain deficient mice). Homozygous µ-chain deficient mice 
fail to develop mature B cells or produce immunoglobulin; however they have intact cell-
mediated immunity. Following induction of NTN, both homozygous and heterozygous mice 
developed proliferative GN, with homozygous mice developing essentially the same degree 
of injury as heterozygous mice, despite the absence of circulating and deposited mouse 
antibody. The immunopathological features seen in the homozygous mice are similar to those 
seen in pauci-immune crescentic human GN. This study demonstrates that GN can develop 
independently of an antibody response as a result of DTH (Li et al., 1997).  
 
1.4.3.4 Macrophages 
Accumulation of macrophages within the glomerulus and interstitium is a prominent 
feature of experimental models of GN, including autologous NTN (Nikolic-Paterson and 
Atkins, 2001). Macrophages are a heterogeneous population of cells predominantly 
P.E.H.Sharp  2013 
 
 46 
associated with phagocytosis. However, they exhibit a wide array of responses depending on 
their activation state. In vitro studies have identified four activation states of macrophages: 
the classical pathway, the alternative pathway, the type II pathway, and activation by 
apoptotic cells. Classically-activated macrophages are activated by two stimuli; IFN-γ and a 
microbial trigger e.g. lipopolysaccharide (LPS), and are involved in microbial killing and 
adaptive immunity. Classically-activated macrophages are found at sites of immune-mediated 
GN, especially during the initiation of immune responses (Erwig et al., 2000). Alternatively-
activated macrophages are less well defined and develop after exposure to IL-4 and IL-13, 
produced by Th2 cells. They are associated with resolution of inflammation by restricting 
self-damage and promoting repair. More recently the type II pathway has been proposed 
(Anderson and Mosser, 2002). Ligation of FcγR on activated macrophages in conjunction 
with an inflammatory stimulus, e.g. LPS, results in a macrophage with similar activity to the 
alternatively-activated macrophage; however they do not induce arginase production and 
preserve their ability to produce pro-inflammatory cytokines, e.g. TNF-α and IL-1 (Gerber 
and Mosser, 2001). Macrophages are also activated by apoptotic cells. Apoptotic cells 
express cell surface markers that allow recognition and phagocytosis by macrophages, to 
prevent the release of potentially toxic contents into the surrounding tissue. Phagocytosis of 
apoptotic cells has been well documented in vivo in experimental as well as clinical disease 
states. Macrophages involved in the removal of apoptotic cells develop an anti-inflammatory 
phenotype involved in controlling immunological responses (Wilson et al., 2004). However, 
it must be noted that these activation pathways have been defined through in vitro studies and 
are therefore unlikely to be as clear-cut in vivo. 
A number of different strategies have been employed to address the role of 
macrophages in contributing to renal injury in animal models of GN. A few studies have 
looked at depleting circulating macrophages. One approach was the use of microencapsulated 
clodronate, which is taken up preferentially by macrophages, and is an effective method to 
deplete their numbers. Used in rats with accelerated NTN, it was found that it reduced 
glomerular macrophage influx and proteinuria, whilst there was no effect on glomerular T 
cell infiltration (Huang et al., 1997b). Another approach was the administration of anti-
macrophage serum. Rabbits treated with anti-rabbit macrophage serum had reduced 
circulating monocytes and were protected from macrophage accumulation within the 
glomeruli and proteinuria (Holdsworth et al., 1981). Duffield et al. used transgenic mice 
modified to express the human diphtheria toxin receptor (DTR) under the control of the 
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CD11b promoter, CD11b-DTR. Injection of DTx through day 15 to 20 of crescentic GN 
allowed selective, specific ablation of renal inflammatory macrophages and reduced the 
number of glomerular crescents, improved renal function and reduced proteinuria (Duffield et 
al., 2005). 
Adoptive transfer studies have further demonstrated that macrophages can induce 
proteinuria and mesangial cell proliferation. Rats were treated with cyclophosphamide two 
days before the injection of NTS to deplete leukocytes and then reconstituted with either 
bone marrow derived macrophages or a macrophage cell line, NR8383, 24 hours following 
the injection. Pre-treatment with cyclophosphamide prevented glomerular leukocyte 
accumulation, proteinuria, mesangial cell proliferation and hypercellularity in accelerated 
NTN, whilst adoptive transfer of macrophages into cyclophosphamide-treated rats reversed 
the protective role. The degree of renal injury correlated with the number of transferred 
glomerular macrophages (Ikezumi et al., 2003). 
Other studies have focussed on targeting the cytokines involved in monocyte 
recruitment and macrophage activation. Blocking pro-inflammatory cytokines, such as IL-1, 
TNF-α and MIF (macrophage migration inhibition factor) was found to inhibit the 
accumulation and activation of both interstitial and glomerular macrophages and suppress 
renal injury in rats, due to their role in the upregulation of chemokines and leukocyte 
adhesion molecules within the kidney (Hruby et al., 1991; Lan et al., 1997a; Lan et al., 1993; 
Lan et al., 1997b; Tang et al., 1994). Direct blockade of chemokines, e.g. monocyte 
chemoattractant protein (MCP)-1 and RANTES, in mice with NTN was found to prevent 
proteinuria, crescent formation and leukocyte infiltration (Lloyd et al., 1997). Also, blocking 
leukocyte adhesion molecules, e.g. intercellular adhesion molecule (ICAM)-1 and 
osteopontin, in rats has proven effective in inhibiting renal macrophage infiltration and injury 
(Nishikawa et al., 1993; Yu et al., 1998). However, when NTN was induced in MCP-1 
deficient mice, they were protected from tubular injury but not glomerular injury (Tesch et 
al., 1999).  
Distinct macrophage phenotypes have been shown to contribute to kidney injury and 
repair in ischemia reperfusion. Classically-activated, pro-inflammatory macrophages are 
recruited into the kidney within the first 48 hours following injury. At the onset of repair 
these can then switch to an alternatively activated phenotype, promoting the resolution of 
inflammation (Lee et al., 2011). With regards to NTN, rats treated with IL-4 were found to 
have significantly reduced proteinuria and glomerular injury compared to untreated rats. 
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Treatment from the start of induction of NTN was associated with markedly decreased 
infiltration of macrophages, whereas delaying treatment until inflammation was established 
did not alter macrophage numbers, suggesting that the IL-4 may be acting to reduce 
macrophage activation (Cook et al., 1999). 
Although these studies strongly support a role for macrophages in the pathogenesis of 
GN, it must be remembered that blockade of cytokines and chemokines not only alters the 
infiltration and activation of macrophages, but also other leukocytes that are involved in the 
progression of renal injury. 
 
1.4.3.5 Dendritic cells 
The primary role of dendritic cells is antigen presentation. Dendritic cells exist in 
virtually all tissues, both lymphatic and non-lymphatic, where they perform sentinel functions 
and gather antigens for transport to the draining lymph nodes for T cell activation. An 
extensive network of dendritic cells has been identified in the tubulointerstitium of both 
healthy and inflamed murine kidneys, with dendritic cells accumulating around, but not 
within, the glomeruli during NTN (Kruger et al., 2004; Soos et al., 2006). Kidney dendritic 
cells have been shown to attenuate the early phase of NTN, by stimulating the production of 
IL-10 by CD4+ T cells, and their depletion aggravates disease (Scholz et al., 2008). However, 
the phenotype and activation state of kidney dendritic cells changes during the course of non-
accelerated NTN. Surface expression of CD40 and CD80, which have been shown to be 
involved in leukocyte recruitment and accumulation (Odobasic et al., 2005a; Odobasic et al., 
2005b; Ruth et al., 2004), increased with progression of disease, whereas expression of 
inducible co-stimulatory molecule ligand (ICOS-L), that can induce IL-10 and is protective in 
NTN (Odobasic et al., 2006), decreased significantly (Hochheiser et al., 2011). Depletion of 
kidney dendritic cells during this later stage of disease was found to be protective rather than 
harmful (Hochheiser et al., 2011). 
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1.4.3.6 Mast cells 
Mast cells are classically considered innate immune cells with a role in first-line 
defence against infection and also in allergic reactions. However, recent advances in 
autoimmunity research have suggested a role for mast cells in the pathogenic responses that 
exacerbate disease. Mast cells develop from CD34+ bone marrow cells and circulate in the 
blood in an immature form until they set up residency in a particular tissue and mature. They 
are mainly found in tissues that form barriers between self and the environment, such as the 
skin, respiratory tract and gut, as well as being associated with blood vessels, lymphatic 
vessels and nerves. Activation of mast cells, via receptor binding, cell-cell contact or physical 
activators, causes them to release an array of preformed molecules that are stored in granules, 
such as ligands for T cells and B cells. Mast cells have been implicated in RA and MS, and 
more recently their role in GN has been explored, although the results are conflicting.  
Initial experiments into the role of mast cells in GN made use of mast cell-deficient 
mice, KitW/Wv. Timoshanko et al. found that mast cell-deficient mice were protected from 
crescentic GN and had reduced DTH response following induction of non-accelerated NTN, 
and that adoptive transfer of mast cells to these mice restored susceptibility to similar levels 
as seen in WT mice (Timoshanko et al., 2006). However, independently of each other, 
Hochegger et al. and Kanamaru et al. found the contrary, as they observed that KitW/Wv mice 
developed more severe proteinuria, glomerular damage and an increase in macrophage 
accumulation, following induction of accelerated NTN, when compared to WT (Kit+/+) mice. 
In addition, reconstitution of mast cells in KitW/Wv mice protected them from NTN (Hochegger 
et al., 2005; Kanamaru et al., 2006). Kanamaru et al. also went on to show that the protective 
role of mast cells was independent of the activating FcγR, as reconstitution of KitW/Wv mice 
with FcRγ-/- mast cells still conferred protection (Kanamaru et al., 2006). Deterioration of 
renal function correlated with thick layers of subendothelial glomerular deposits, which were 
found to be rich in fibrin and type I collagen, in the KitW/Wv mice, suggesting a deficiency in 
repair mechanisms. This was supported by a decrease in the activity of two crucial enzymes 
in the plasminogen/plasmin system. These results indicated that mast cells exert a protective 
role in accelerated NTN by mediating remodelling and repair (Kanamaru et al., 2006).  
Interestingly, no mast cells were detected in the kidneys of WT mice or mast cell-
reconstituted KitW/Wv mice following induction of accelerated NTN, whereas they were 
following the induction of the non-accelerated disease model (Hochegger et al., 2005; 
Kanamaru et al., 2006; Timoshanko et al., 2006). Further investigation revealed an increase 
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in mast cells in the renal draining lymph nodes of the mice with accelerated NTN (Hochegger 
et al., 2005). These results suggest that during acute, accelerated disease mast cells act in the 
draining lymph nodes as immunoregulatory cells that can counteract injury and control 
repair; however, during chronic, non-accelerated disease, mast cells are contributory in 
mounting a Th1-directed DTH immune response that promotes injury.  
Recently, two groups have further explored the relationship between mast cells and 
Treg, supporting the evidence that mast cells play a protective, immunoregulatory role during 
murine GN. Eller et al. found that transfer of Treg into WT animals almost completely 
prevented the development of glomerular damage and produced an increase of mast cells in 
the renal draining lymph nodes following induction of accelerated NTN, whereas transfer of 
Treg into mast cell-deficient mice resulted in no protective effects (Eller et al., 2011). Further 
to this they found that blocking the cytokine IL-9, known to be involved in mast cell 
recruitment and proliferation, or transferring Treg from IL-9-deficient mice, abrogated 
protection from NTN (Eller et al., 2011). Gan et al. found, following the induction of AAV as 
a result of autoimmunity to MPO, mast cell-deficient mice exhibited more severe focal 
necrotising GN, as well as increased anti-MPO CD4+ T cells and enhanced DTH responses. 
Furthermore, the draining lymph nodes around the sites of immunisation had fewer Treg and 
reduced production of IL-10 in mice lacking mast cells (Gan et al., 2012). Ex vivo, mast cells 
were found to enhance Treg suppression through IL-10. Reconstitution of mast cell-deficient 
mice with IL-10-/- mast cells led to enhanced autoimmunity to MPO and greater disease 
severity when compared to reconstitution with IL-10-producing mast cells (Gan et al., 2012). 
Taken together, these results suggest that, in acute disease settings, there is a close interaction 
between mast cells and Treg in controlling CD4+ T cell responses within the draining lymph 
nodes.  
As well as using mast cell-deficient mice, GN has also been induced in mice deficient 
in mouse mast cell protease (mMCP)-4, the murine counterpart of human mast cell chymase. 
mMCP-4 is a mast cell-specific protease that is released from secretory granules and involved 
in tissue homeostasis. mMCP-4-/- mice were protected from accelerated NTN. During the 
heterologous stage of disease there was no difference between WT and mMCP-4-deficient 
mice, indicating that mast cells may exert protective functions in the initial stages but 
prolonged activation can result in damage further down the line (Scandiuzzi et al., 2010).  
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1.4.3 Intrinsic renal cells 
As well as infiltrating leukocytes, intrinsic renal cells, within the glomerulus, also 
play a major role in the development of GN. The glomerulus is a capillary tuft surrounded by 
Bowman’s capsule. The glomerular capillary wall consists of three main layers: a thin layer 
of fenestrated endothelial cells, the GBM, and podocytes. Located centrally within the 
glomerulus, between the capillary loops and the glomerular basement membrane, is the 
mesangium, which is made up of mesangial cells and their surrounding extracellular matrix. 
Lining the inside of the Bowman’s capsule are parietal epithelial cells (Figure 1.3). Most of 
our knowledge on the role of intrinsic renal cells during GN comes from in vitro experiments; 
however, the generation of bone marrow chimeric mice has proved a useful tool to address 
this question using in vivo models of GN. Evidence for the role of mesangial cells, 











Figure 1.3 Schematic representation of the glomerulus.   
Blood enters the glomerulus by the afferent arteriole and leaves by the efferent arteriole. 
Within the glomerulus, blood is filtered through the capillary wall, which consists of 
endothelial cells, the GBM, and podocytes, and urine collects in the urinary space 
(Bowman’s space) where it is passed to the proximal tubule. Centrally within the glomerulus, 
among the glomerular capillaries, is the mesangium. Lining the inside of the Bowman’s 
capsule are parietal epithelial cells (Leeuwis et al., 2010). This image has been reproduced 
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1.4.3.1 Mesangial cells 
Mesangial cells are specialised pericytes, of mesenchymal origin, that have the 
characteristics of modified smooth muscle cells. The primary roles of mesangial cells are 
maintaining the structure of the glomerulus and controlling the glomerular filtration rate. 
They also modulate glomerular injury by generating mediators of inflammation and by 
phagocytosis of macromolecules and immune complexes (Schlondorff, 1987). Proliferation 
of mesangial cells and deposition of extracellular mesangial matrix are commonly observed 
in many forms of GN, such as IgA nephropathy and SLE. The precise role of mesangial cells 
in the pathogenesis of GN is still not fully understood.  
Mesangial cells are thought to be involved in antigen presentation and co-stimulation. 
Resting mesangial cells do not express MHC Class II; however following stimulation with 
IFN-γ they start to express MHC Class II in a dose- and time-dependent manner. 
Furthermore, a combination of IFN-γ and TNF-α or IL-1β resulted in an enhanced induction 
of MHC Class II compared to IFN-γ alone. TNF-α and IL-1β, either alone or together, had no 
effect in enhancing MHC Class II (Martin et al., 1989). As mentioned in Section 1.4.3.2.1, 
MHC Class II-deficient mice are protected from crescentic GN, CD4+ T cell infiltration and 
glomerular injury (Li et al., 1998). The role of intrinsic renal cell MHC Class II was further 
explored in accelerated NTN using MHC Class II chimeric mice. MHC Class II-deficient 
mice were transplanted with the bone marrow and thymus of WT animals. Despite having 
normal T and B cell populations and MHC Class II expression in secondary lymphoid organs 
they were protected from crescentic GN, CD4+ T cell infiltration and glomerular injury. 
These data suggest a pivotal role for intrinsic renal cell MHC Class II interaction with CD4+ 
T cells in the development of cell-mediated renal injury (Li et al., 1998).  
Mesangial cells also express the co-stimulatory molecule CD40 that binds to CD154 
on T cells and enhances their activation. CD40-/- mice do not develop immunity in response 
to sheep globulin and thus fail to develop effector responses in NTN. Transplantation of WT 
bone marrow into CD40-/- mice restored their ability to develop antigen-specific immune 
responses; however they had minimal T cell and macrophage influx and were protected from 
renal injury, suggesting a role for mesangial cell CD40 expression in the development of 
NTN (Ruth et al., 2003). 
Mesangial cells can produce an array of cytokines and inflammatory mediators that 
are involved in glomerular injury. TNF-α, IFN-γ, IL-6 and IL-12 are pro-inflammatory 
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cytokines produced by mesangial cells and are important mediators in the development of 
GN (Bussolati et al., 1999; Gomez-Guerrero et al., 1994; Zoja et al., 1991). Bone marrow 
transplantation experiments have shown that intrinsic renal cell production of TNF-α, IFN-γ 
and IL-12 are required for full expression of murine crescentic GN (Timoshanko et al., 2002; 
Timoshanko et al., 2001; Timoshanko et al., 2003). TNF-α, IFN-γ and IgG aggregates have 
also been shown to induce mesangial cell expression of chemokines with specificity for 
monocyte/macrophage recruitment, such as M-CSF (macrophage colony-stimulating factor) 
and MCP-1 (Satriano et al., 1993; Zoja et al., 1991). 
Mesangial cells also produce cytokines that can have anti-inflammatory effects within 
the kidney, such as IL-4 and IL-10. These cytokines act to alter the activation state of 
leukocytes, such as macrophages, to protect against glomerular damage. IL-4 and IL-10 are 
both potent inhibitors of the Th1 response and inactivate the pro-inflammatory macrophage 
phenotype. In vivo, IL-10-deficient mice and IL-4-deficient mice were found to develop more 
severe NTN compared to WT mice (Kitching et al., 1998; Kitching et al., 2000), and 
administration of either IL-4, IL-10 or both to WT mice with NTN was found to attenuate 
disease (Kitching et al., 1997; Tipping et al., 1997).  
 
1.4.3.2 Endothelial cells 
The glomerular endothelium is a highly fenestrated barrier and, unlike most 
fenestrated capillaries, its pores are not spanned by diaphragms. The fenestrations are 70-100 
nm in diameter, constituting around 20-50% of the entire endothelial surface (Bulger et al., 
1983), which allows for the free filtration of fluid, plasma solutes and proteins, but not red 
blood cells. Until recently, it was believed the endothelium did not contribute to the 
permselectivity of the glomerular barrier, due to the large size of the pores, so it has long 
been neglected as playing a role in proteinuria. However, lately, research has paid more 
attention to the endothelial surface layer (ESL), which is produced by, and surrounds, the 
endothelial cells. The ESL is of similar thickness to the GBM and has two elements, the 
glycocalyx, which refers to the covalently bonded plasma-membrane-bound part of the layer, 
and the cell coat, a larger, more loosely associated part of the layer. The ESL is composed of 
negatively charged glycoproteins, glycosaminoglycans and membrane-associated and 
secreted proteoglycans (Haraldsson et al., 2008).  
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Glomerular endothelial cells are difficult to culture, with the cellular phenotype being 
lost after a few passages. As well as this, the cell coat is easily disturbed, and therefore rather 
elusive. However, various studies have overcome these complications and more is being 
understood about the roles of these cells in GN. In vivo, disruption of the ESL with 
chondroitinase or hyaluronidase was found to increase the permeability of the glomerular 
capillary wall to albumin, but not neutral Ficoll, indicating a defect in charge selectivity 
(Dane et al., 2013; Jeansson and Haraldsson, 2006). Also, displacement of the cell coat in 
rats, using an injection of hypertonic sodium chloride in the left renal artery, increased 
fractional clearance of albumin 12-fold without morphological changes, compared to rats 
treated with isotonic sodium saline (Friden et al., 2011). These results are supported in vitro, 
in both primary and immortalised human glomerular endothelial cells, where treatment with 
puromycin aminonucleoside, neuraminidase or human heparanase reduced the thickness of 
the glycocalyx and caused an increase in albumin passage across the cell monolayers 
(Bjornson et al., 2005; Singh et al., 2007). 
As well as contributing to the permselectivity of the glomerular filtration barrier, the 
ESL is also involved in the regulation of coagulation pathways and preventing leukocyte 
adhesion to the underlying endothelial cells. Disruption of the glycocalyx and subsequent 
exposure of the endothelial cells to pro-inflammatory molecules, such as TNF-α, IL-1 and 
MCP-1, leads to the expression of tissue factor, which is necessary for thrombosis formation 
(Dosquet et al., 1995; Grabowski and Lam, 1995; Kirchhofer et al., 1994). The glycocalyx 
houses endothelial cell adhesion molecules, such as P-selectin, ICAM-1, and VCAM-1. 
However, the thickness of the glycocalyx ranges from 0.2-0.5µm in capillaries and 2-3µm in 
small arteries, whereas P-selectin, the molecule that initiates leukocyte rolling, only extends 
38nm from the cell surface (Reitsma et al., 2007).  
Apoptotic endothelial cells have also been shown to contribute to thrombotic events 
due to increased adherence of platelets to the endothelium and their subsequent activation 
(Bombeli et al., 1999). 
 
  




Podocytes, or visceral epithelial cells, are pericyte-like cells found within the 
Bowman’s capsule where they wrap around the glomerular capillaries and play a major role 
in establishing the selective permeability of the glomerular filtration barrier. Podocytes are 
highly differentiated, polarised cells with limited capability to undergo cell division. Mature 
podocytes consist of a cell body with major processes that branch into foot processes. Foot 
processes on adjacent podocytes form an interdigitating network, separated by a slit 
diaphragm, which can modulate the permeability of the filtration barrier through changes in 
morphology (Greka and Mundel, 2012).  
Proteinuria is a hallmark of glomerular injury, with its severity acting to predict the 
progression of renal disease. Podocyte injury, due to damage of the actin cytoskeleton leading 
to a shortening of the foot processes and disruption of the slit diaphragm, is major cause of 
proteinuria in both human and experimental models of glomerular diseases. A number of 
inflammatory mediators, including cytokines, chemokines and growth factors, have been 
implicated in this process.  
TNF-α and IL-1 have both been found to play an important role in proteinuria. 
Stimulation of podocytes with TNF-α and IL-1 activates NF-κB, resulting in the upregulation 
of pro-inflammatory cytokines (Brahler et al., 2012; Bruggeman et al., 2011). In vitro, 
podocytes with abrogated activation of NF-κB, via inhibition of NF-κB essential modulator 
(NEMO) or neutralisation of TNFR2, had a marked reduction in pro-inflammatory cytokine 
secretion following stimulation with TNF-α and IL-1, compared to WT podocytes (Brahler et 
al., 2012; Bruggeman et al., 2011). In vivo, mice with a podocyte-specific deletion of NEMO 
recovered much faster from GN, showing rapid remission of proteinuria and restoration of 
podocyte morphology compared to WT mice (Brahler et al., 2012).  
Treatment with IFN-β has been found to reduce proteinuria in rats with NTN, Thy-1 
nephritis and puromycin aminonucleoside nephrosis, without an effect on glomerular 
inflammation, suggesting IFN-β may have a direct effect on the glomerular filtration barrier 
(Satchell et al., 2007). In vitro studies, using human glomerular endothelial cell monolayers 
or podocyte monolayers, showed that treatment with IFN-β reduced permeability of the cell 
layer, thought to be due to increased integrity of intracellular junctions by upregulation of 
junctional adhesion molecules or resistance to their downregulation (Satchell et al., 2007).  
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Similar to mesangial cells, podocytes are thought to be involved in antigen 
presentation. Podocytes have been shown to express MHC Class I, MHC Class II and ICAM-
1 in a model of necrotising crescentic GN in vivo, as well as following stimulation with IFN-γ 
in vitro (Coers et al., 1994). More recently, it has been shown that deletion of MHC Class II 
on podocytes only can protect from the induction of anti-GBM disease (Goldwich et al., 
2013). 
Podocytes are known to both secrete and respond to certain chemokines and 
cytokines. Podocytes have been found to release MCP-1 and IL-8 (CXCR1), suggesting they 
may actively participate in cell recruitment during GN (Huber et al., 2002; Natori et al., 
1997), as well as IL-6 (Hughes et al., 2001). Podocytes are also a prominent source of TNF-α 
in human membranous nephritis (Neale et al., 1995) and are known to express the receptors 
for IL-4 and IL-13, the presence of which can disrupt cell function (Lai et al., 2007; Van Den 
Berg et al., 2000). 
Podocytes have also been found to contribute to glomerular crescents, both in animal 
models of GN as well as human disease (Bariety et al., 2005; Le Hir et al., 2001; Moeller et 
al., 2004; Thorner et al., 2008). Originally, it was thought crescents were composed of 
parietal epithelial cells, monocytes/macrophages and myofibroblasts, with podocytes being 
excluded as participants due to the absence of podocyte markers. However, in a study to 
investigate the formation of crescents in mice, 6-10 days following induction of NTN 
podocytes were seen to bridge the gap between the glomerular tuft and Bowman’s capsule, as 
well as detach from the GBM and infiltrate the parietal epithelial cells. During this process 
these podocytes appeared to lose their phenotypic markers (Le Hir et al., 2001). This 
observation was later confirmed in a NTN study in which podocytes were genetically tagged 
with β-galactosidase. Six days after induction of disease, kidney sections were enzymatically 
stained with X-gal and crescents were found to comprise 25-50% podocytes, despite the cells 
being negative for podocyte-specific antigens. Suggesting, that during NTN, podocytes 
undergo profound phenotypic changes (Moeller et al., 2004). Studies in human GN have also 
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1.5 Fas ligand 
1.5.1 Introduction 
The TNF superfamily is a growing family of cytokines that have varied and 
pleiotropic actions but share a common structural motif, the TNF homology domain (THD), 
which allows self-trimerisation and receptor binding. TNF-α was the first family member to 
be identified over 25 years ago and was named due to its ability to cause necrosis of tumours 
(Aggarwal et al., 1985). Since then 18 other members have been isolated and cloned. Fas 
ligand (FasL, CD95L) is the sixth member of the TNF superfamily and is best characterised 
for binding its receptor, Fas (APO-1, CD95), and causing apoptosis of the Fas-bearing cell.  
FasL was first detected as the natural ligand for Fas in 1993 (Suda et al., 1993). 
Molecular cloning, purification and characterisation revealed FasL to be a heavily 
glycosylated, 40kDa, type-II transmembrane protein, with an intracellular N-terminus, an 
extracellular C-terminus and a single transmembrane domain, belonging to the TNF 
superfamily (Suda and Nagata, 1994; Suda et al., 1993). The N-terminal region of FasL has 
no signal sequence but the C-terminus contains the THD, a stretch of 150 amino acids with 
significant homology (20-25%) to the corresponding region in other TNF family members, 
such as TNF-α and TNF-β (lymphotoxin) (Nagata and Golstein, 1995; Suda et al., 1993). 
Biologically active FasL exists as a homotrimer (Suda and Nagata, 1994). 
Fas was first identified by two independent groups in 1989 (Trauth et al., 1989; 
Yonehara et al., 1989). Purification and molecular cloning of Fas in the early 1990’s 
highlighted its significant sequence homology to the members of the TNF receptor (TNFR) 
superfamily (Itoh et al., 1991; Oehm et al., 1992; Watanabe-Fukunaga et al., 1992b). Fas is a 
45kDa, type-I membrane protein, with an intracellular C-terminus, extracellular N-terminus 
and a single transmembrane domain, belonging to the TNFR superfamily (Itoh et al., 1991; 
Oehm et al., 1992). All members of the TNFR superfamily have a well conserved (17-30%) 
N-terminal region that contains 2-6 tandem repeats of a cysteine-rich domain, of which Fas 
contains three (Itoh et al., 1991). The cytoplasmic domain of Fas is relatively abundant in 
charged amino acids but shows little homology to other members of the TNFR superfamily, 
except for a stretch of 80 amino acids, which are conserved in TNF-R1, known as the death 
domain (DD) due to its importance in cytotoxicity (Itoh and Nagata, 1993; Itoh et al., 1991; 
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Tartaglia et al., 1993). Similarly to FasL, Fas exists as a preassembled homotrimer (Chan et 
al., 2000; Papoff et al., 1999; Siegel et al., 2000). 
In 1998 a second receptor for FasL was identified. Decoy receptor 3 (DcR3) contains 
four tandem cysteine-rich domains; however it lacks a transmembrane domain and is instead 
synthesised as a secreted, soluble protein. Fas and DcR3 both bind FasL with comparable 
affinities of 1.1nM and 0.8nM, respectively. DcR3 is thought to act as an immunomodulatory 
protein (Pitti et al., 1998). 
Similarly to TNF-α, and other members of the TNF superfamily, FasL can be cleaved 
by a matrix metalloproteinase (MMP) to a soluble form (Kayagaki et al., 1995; Tanaka et al., 
1995). Matrilysin (MMP7) cleaves FasL at the leucine residues in the site ‘ELAELR’, found 
between the transmembrane and trimerisation domains, to form a 26kDa protein (Powell et 
al., 1999; Vargo-Gogola et al., 2002). Soluble FasL (sFasL) retains its ability to form a 
trimeric structure and bind to the Fas receptor (Tanaka et al., 1995). 
 
1.5.2 Fas-Fas ligand induced apoptosis 
FasL, acting through Fas, is best characterised for inducing apoptosis in the Fas-
bearing cell. How the binding of FasL to Fas initiates Fas activation is not completely known; 
however, the intracellular sequence of events following ligation are well documented. 
Initially, through homologous DD interactions, Fas recruits FADD, Fas-associated protein 
with death domain (MORT1) (Boldin et al., 1995; Chinnaiyan et al., 1995). The DD of 
FADD is located at the C-terminus, whilst the N-terminal region contains another protein-
protein interaction domain, the death effector domain (DED). It is the DED that is 
responsible for downstream signal transduction, as it is required for the recruitment of 
procaspase-8 (MACH, FLICE), an aspartate–specific cysteine protease present in the 
cytoplasm as an inactive zymogen, which contains two DED at its N-terminus (Boldin et al., 
1996; Muzio et al., 1996). This assembly of proteins has been named the death inducing 
signalling complex (DISC) and assembles within seconds after FasL engagement to Fas 
(Kischkel et al., 1995).  
Following dimerisation at the DISC, procaspase-8 undergoes a conformational change 
that allows it to gain full enzymatic activity and leads to its autoproteolytic processing, 
releasing active caspase-8 into the cytoplasm (Medema et al., 1997). From here active 
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caspase-8 can now go on to cleave other caspases, leading to a ‘caspase cascade’ (Figure 
1.4). Due to its position at the start of the cascade, caspase-8 is known as an initiator caspase. 
One of the lead effector caspases cleaved by caspase-8 is caspase-3. Caspase-3 is responsible 
for the cleavage of most of the proteins characteristic of apoptosis and the proteins involved 
in inducing the morphological changes observed during programmed cell death (Earnshaw et 
al., 1999). 
Despite retaining its ability to trimerise and bind the Fas receptor, sFasL is a weak 
inducer of apoptosis. Naturally processed sFasL was 1000-fold less active at inducing 
apoptosis compared to membrane-bound FasL (Schneider et al., 1998) and comparisons of 
mice deficient in either membrane-bound FasL or sFasL showed that the membrane-bound 
form only is essential for Fas-induced apoptosis (O' Reilly et al., 2009). However, cross-
linking of sFasL was found to restore its cytotoxic activity both in vitro and in vivo (Dupont 
and Warrens, 2007; Schneider et al., 1998). The precise functions of sFasL are still not fully 
understood, however it appears that cleavage of FasL into the soluble form may serve to 
downregulate FasL activity. 
  




Figure 1.4 Intracellular signalling events following ligation of Fas ligand to Fas. 
Fas ligand binds to Fas as a homotrimer and Fas recruits FADD, which in turn recruits 
procaspase-8 forming the DISC. Procaspase-8 is cleaved to its active form and activates the 
caspase cascade, resulting in death of the Fas-bearing cell (Green and Ferguson, 2001). This 
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1.5.3 Fas ligand expression 
Fas expression is ubiquitous, so for this reason expression of FasL needs to be tightly 
controlled to regulate FasL-induced apoptosis. It was initially thought that FasL was 
predominantly expressed by lymphatic cells as FasL expression is inducible in T cells 
(Kasibhatla et al., 1998; Oshimi et al., 1996; Suda et al., 1995), natural killer (NK) cells 
(Montel et al., 1995), and B cells (Hahne et al., 1996; Tanner and Alfieri, 1999). However it 
has now become recognised that it is also expressed by myeloid cells, such as CD8+ dendritic 
cells (Suss and Shortman, 1996) and mature, activated macrophages (Badley et al., 1996; 
Boyle et al., 2001; Dockrell et al., 1998; Kiener et al., 1997) and non-lymphoid tissues, such 
as the lung (Gochuico et al., 1998; Suda et al., 1995), small intestine (Bonfoco et al., 1998; 
Suda et al., 1995), and kidney in both humans (Tsukinoki et al., 2004) and mice (Lorz et al., 
2000).  
 
1.5.4 Fas ligand and immune privilege 
Immunologically-privileged sites are defined as sites where an immune response is 
not initiated when antigen is introduced, thought to be because the sites concerned cannot 
tolerate the non-specific damage that may occur during an inflammatory response. These 
areas include the brain, testis, ovary, pregnant uterus and the anterior chamber of the eye. 
Although these sites have long been recognised as being immune privileged it was not until 
1995 that this was associated with FasL.  
In 1995, two independent groups identified expression of FasL in the eye and testis. 
Bellgrau et al. derived testis grafts from mice expressing functional FasL and those 
expressing defective FasL and transplanted them under the kidney capsule of allogenic 
animals. The grafts from mice with functional FasL survived indefinitely whereas the grafts 
expressing non-functional FasL were rejected. Polymerase chain reaction (PCR) analysis of 
isolated RNA showed FasL expression by testicular Sertoli cells (Bellgrau et al., 1995). 
Griffith et al. injected herpes simplex virus-type 1 (HSV-1 (KOS)) into the anterior chamber 
of the eye of WT mice and mice with non-functioning Fas or FasL. They observed extensive 
apoptosis of infiltrating neutrophils and lymphocytes in the eyes of WT mice but not in the 
mice with defective Fas-FasL signalling. To test whether this was due to defective FasL in 
the eye or because of a toxic effect from the inflammatory cells they created bone marrow 
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chimeras where mice with defective FasL were irradiated and reconstituted with bone 
marrow from WT mice. Following infection the mice still had an intense inflammatory 
response, proving that FasL is expressed in the eye during infection (Griffith et al., 1995). 
Following this they also analysed RNA isolated from the eye and other organs and showed 
that FasL is expressed by the eye, testis and spleen but not the heart or skin (Griffith et al., 
1995; Griffith et al., 1996b). Both groups went on to conclude that non-hematopoietic cells at 
sites of immune privilege express FasL and are able to kill infiltrating leukocytes.  
However, in 1997 Allison et al. created transgenic mice expressing FasL on islet β-
cells and transplanted foetal pancreata under the kidney capsules of allogenic animals. This 
failed to protect the grafts from rejection and resulted in granulocytic infiltration into the 
pancreata, indicating that FasL expression alone may not be sufficient to establish immune 
privilege and demonstrating a pro-inflammatory function of FasL (Allison et al., 1997). 
Features of immune privilege are also found within cancers, where it is known as 
‘tumour evasion’ or ‘tumour counterattack’. Tumour cells express FasL to kill infiltrating 
leukocytes and are also resistant to Fas-mediated apoptosis which allows them to evade death 
(O'Connell et al., 1999a). FasL expression has been identified on many different cancers, 
including esophageal cancer, human breast cancer, and colon adenocarcinomas (O'Connell et 
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1.6 Fas ligand and autoimmunity 
Our understanding of the roles of Fas and FasL come from studying mice with 
defective Fas-FasL signalling. Autoimmunity is seen both in animal models of Fas/FasL 
deficiency and in humans with autoimmune lymphoproliferative syndrome (ALPS), who 
carry mutations on the proteins involved in Fas-FasL signalling. Mouse models of FasL 
deficiency and ALPS are described in the following sections.  
 
1.6.1 Mouse models of Fas ligand deficiency 
1.6.1.1 Lpr, gld and lprcg mice 
Lymphoproliferative (lpr) and generalised lymphoproliferative disease (gld) are 
autosomal recessive, single gene mutations that both arose spontaneously and were first 
identified by the Jackson Laboratories. The lpr mutation first arose in the MRL mouse strain 
in 1977 and in 1984 the gld mutation was identified in the inbred mouse strain C3H/HeJ 
(Murphy and Roths, 1977; Roths et al., 1984). Genetic linkage studies pinpointed the lpr and 
gld mutations to chromosomes 19 and 1, respectively (Roths et al., 1984; Watanabe et al., 
1991), and in the early 1990’s Fas and FasL were mapped to the sites of the mutations 
(Takahashi et al., 1994; Watanabe-Fukunaga et al., 1992a). In lpr mice the mutated Fas gene 
contains an early transposable element that results in impaired transcription. However, 
expression of Fas is not completely inhibited, and full length Fas mRNA has been detected at 
very low levels in the liver and thymus of lpr mice (Adachi et al., 1993; Kobayashi et al., 
1993). The gld mutation is caused by a point mutation in the C-terminus of the coding region 
for FasL. Expression of FasL is not inhibited and the full-length protein is synthesised and 
sent to the cell membrane; however the mutation changes a phenylalanine to a leucine that 
affects the ability of FasL to bind to Fas (Takahashi et al., 1994). A third mutation also exists, 
lprcg (lpr complementing gld), which was identified in 1990 in the CBA/KlJms (CBA) strain 
of mouse. Lprcg mice carry a point mutation in the cytoplasmic region of Fas that leads to the 
replacement of an isoleucine with an asparagine. This results in a conformational change in 
the fold of the DD and upsets the ability of Fas to bind its downstream adaptor protein, 
FADD, altering signalling through the receptor (Matsuzawa et al., 1990). 
Homozygosity at any of the loci results in massive non-malignant 
lymphoproliferation, lymphadenopathy, splenomegaly, autoantibody production, including 
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anti-DNA antibodies, and the presence of mature peripheral double negative (DN) T cells, 
that express the TcR, CD3, and the B cell marker, B220, but are negative for CD4 and CD8. 
Genetic background plays a large role in the severity of autoimmunity seen in both lpr and 
gld mice. MRL mice are predisposed to autoimmune disease and develop late onset GN, 
dying within the second year of life. When combined with the lpr gene, this predisposition is 
accelerated, with 50% mortality at 5-6 months due to early onset, aggressive, and fatal renal 
disease. Intercrossing the lpr gene onto strains of mice with no predisposition to 
autoimmunity, such as C3H/HeJ, C57BL/6, and AKR/J, was found to shorten survival of the 
mice and induce autoantibodies; however GN was not seen until 13-16 months of age and 
was minimal (Kelley and Roths, 1985). The same phenomenon is also seen with the lprcg and 
gld genes. Both were originally identified on strains of mice not predisposed to 
autoimmunity, CBA and C3H/HeJ, respectively. However, intercrossing these genetic 
mutations onto an MRL background accelerated the onset of GN in these mice (Kimura et al., 
1992). 
 
1.6.1.2 Fas and Fas ligand knockout mice 
FasL expression is not abolished in gld mice and there are reports that some residual 
activity may remain. Karray et al. created a FasL knockout mouse on a C57BL/6 background, 
using the Cre-loxP-based strategy, to investigate the in vivo functions of FasL. Germline 
deletion of FasL resulted in a severe phenotype with FasL-/- mice exhibiting extreme 
splenomegaly and lymphadenopathy associated with lymphocytic infiltration into multiple 
organs, and autoimmune disease with histological signs of GN. This accelerated phenotype 
led to premature death at 4 months of more than 50% of the homozygous mice. This is in 
stark contrast to the mild disease usually seen in gld mice on the same genetic background 
and shows that the expressed FasL in gld mice has a residual function (Karray et al., 2004). 
To determine the cellular subset responsible for the prevention of autoimmunity in 
FasL-deficient mice, Mabrouk et al. created conditional knockouts lacking FasL on B cells, T 
cells and myeloid cells. Deletion of FasL on T cells or B cells resulted in a mild autoimmune 
syndrome, suggesting that FasL deficiencies in different cell types are likely to be additive, 
but FasL deficiency in myeloid cells did not result in an autoimmune phenotype. Loss of 
FasL on T cells also led to the accumulation of T cells, B cells and dendritic cells in the 
lymph nodes (Mabrouk et al., 2008). Similar results were seen when Fas was deleted from 
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specific cellular subsets. Deletion of Fas on T cells, B cells or T cells and B cells was 
insufficient for the pathogenesis of lymphoproliferative disease (Hao et al., 2004; Stranges et 
al., 2007). 
 
1.6.1.3 Membrane-bound versus soluble Fas ligand 
Recently, O’Reilly et al. used gene targeting to create mice that selectively express 
either the membrane-bound form of FasL or sFasL, on a C57BL/6 background. Mice 
expressing the membrane-bound form of FasL appeared normal and their T cells readily 
killed target cells, whereas mice expressing sFasL only developed lymphadenopathy and 
hypergammaglobulinemia similar to gld mice. Interestingly, these mice also developed a 
severe SLE-like autoimmune kidney disease, which only rarely occurs in gld mice on the 
C57BL/6 background and tends to develop much later. It was hypothesised that this was 
because these mice produced excess sFasL that could bind to its receptor Fas and activate 
NF-κB (nuclear factor kappa-B), driving production of pro-inflammatory cytokines (O' Reilly 
et al., 2009). 
 
1.6.2 Autoimmune lymphoproliferative syndrome 
Autoimmune lymphoproliferative syndrome (ALPS) is a human disorder of 
lymphocyte homeostasis and immunological tolerance first described in 1967 by Canale and 
Smith (Canale and Smith, 1967). It is characterised by accumulation of benign lymphocytes, 
accompanied by splenomegaly and lymphadenopathy, hypergammaglobulinemia, 
autoimmunity, and the presence of mature peripheral DN T cells. In 1992, Sneller et al. 
investigated two similar patients with progressive lymphoproliferative disease and 
autoimmunity and found they had a high population of the usually rare peripheral DN T cells. 
Drawing comparisons between the phenotypes seen in the patients and the phenotypes seen in 
lpr and gld mice it was suggested that these patients had a human equivalent of the murine 
disease (Sneller et al., 1992). In the same year, mutations in Fas and FasL were identified as 
being the cause of the phenotypes seen in the lpr and gld mice, respectively (Takahashi et al., 
1994; Watanabe-Fukunaga et al., 1992a), and shortly thereafter it was documented by two 
groups that mutations in Fas were responsible for the human disease (Fisher et al., 1995; 
Rieux-Laucat et al., 1995).  
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Subsequent studies of mutations in ALPS patients have shown that ALPS can result 
from mutations not only in the Fas gene but also in other molecules involved in apoptotic 
pathways, which are not limited to the Fas-FasL signalling pathway. To date there are five 
classifications of ALPS and four classifications of ALPS-related disorders, which incorporate 
mutations in caspase-8 or proteins involved in the mitochondrial apoptotic pathway (Oliveira 
et al., 2010).  
Autoimmune phenomena are also frequent in ALPS patients, with circulating 
autoantibodies seen in around 90% of cases (Straus et al., 1999). However, the autoimmune 
aggression is largely directed at blood cells, with little report of other autoimmune disease 
such as GN, hepatitis, arthritis or colitis (Deutsch et al., 2004). ALPS patients have also been 
reported to have elevated levels of circulating IL-10 (Fuss et al., 1997; Lopatin et al., 2001; 
Magerus-Chatinet et al., 2009). 
In vitro studies with T cells have shown that ALPS patients’ CD4+DR+ T cells were 
shifted to a Th2 phenotype with increased production of IL-4 and IL-5 but decreased levels of 
IFN-γ and IL-2 when compared to control cells. DN T cells were found to produce very low 
levels of cytokines. ALPS patients’ monocytes/macrophages were also found to produce 30-
fold less IL-12 than control individuals (Fuss et al., 1997). Th1 cells and Th17 cells are more 
sensitive to Fas-mediated apoptosis compared to Th2 cells (Fang et al., 2010). In an 
environment where Fas-FasL signalling is defective, but not completely deleted, Th1 cells are 
placed more at risk, allowing Th2 cells to accumulate. This, along with decreased production 
of IL-12 by monocytes/macrophages, could play a part in ALPS patients having a skewed 
Th2 response (Fuss et al., 1997).  
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1.6.3 Lymphocyte homeostasis 
Homeostasis of a cell population is dependent on the rate of cell proliferation, cell 
differentiation and also cell death, occurring through apoptosis. Tight maintenance of 
immune system homeostasis is vital for controlling an immune response. Lpr, gld and lprcg 
mice, as well as ALPS patients, all develop progressive lymphadenopathy, which 
predominantly involves the accumulation of DN T cells but also the accumulation of regular 
CD4+ and CD8+ T cells and B cells. This led to the conclusion that Fas-FasL signalling plays 
a critical role in lymphocyte homeostasis.  
Fas-FasL signalling has been shown to be involved in both the activation and deletion 
of T cells. In vitro, anti-Fas antibodies were found to co-stimulate freshly isolated human T 
lymphocytes, along with anti-CD3 antibodies, causing T cell proliferation and secretion of 
cytokines (Alderson et al., 1993). This is supported in vivo; T cell activation was defective in 
mice carrying a mutation in the downstream signalling molecule FADD (Kennedy et al., 
1999; Newton et al., 1998; Walsh et al., 1998; Zhang et al., 1998). Following an immune 
response, activated T cells need to be removed to downregulate the inflammatory reaction 
and prevent irreversible damage from occurring. This is done by a process called activation-
induced cell death (AICD). Chronic restimulation of the TcR sensitises T cells to FasL-
induced apoptosis (Kabelitz et al., 1993). In vitro, ligation of Fas on activated human T cells, 
by either a monoclonal anti-Fas antibody or recombinant human FasL, resulted in apoptosis 
of the cells (Alderson et al., 1995), whilst in vivo, lpr, gld, and lprcg  mice show reduced, but 
not completely absent, deletion of peripheral T cells (Bossu et al., 1993; Russell et al., 1993; 
Russell and Wang, 1993). Activated CD8+ T cells can also undergo Fas-induced AICD 
(Miyawaki et al., 1992), although a Fas-independent mechanism also contributes to the 
deletion of these cells (Ramaswamy et al., 2009). However, the Fas-FasL pathway plays no 
part in thymic negative selection as self-reactive T cells are effectively deleted in the thymus 
of lpr, gld, and lprcg mice (Singer and Abbas, 1994; Zhang et al., 2005). 
Fas signalling also regulates B cell and dendritic cell homeostasis. Fas-FasL 
signalling is dispensable for B cell development but important in mediating peripheral B cell 
tolerance because lpr, gld, and lprcg mice accumulate B cells and have elevated levels of 
autoantibodies (Cohen and Eisenberg, 1991; Fields et al., 2001; Fukuyama et al., 1998). Mice 
lacking Fas on their B cells only, develop characteristic lymphadenopathy, splenomegaly, 
high autoantibody titres and accumulate T cells in a similar manner to lpr, gld, and lprcg mice, 
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emphasising the role of Fas in maintaining peripheral B cell tolerance (Stranges et al., 2007). 
Dendritic cells are also eliminated through Fas-FasL apoptosis, and this may serve to down 
modulate antigen presentation. Accumulation of dendritic cells is seen in lpr mice and also 
human patients harboring caspase 10 mutations (Fields et al., 2001; Wang et al., 1999).  
 
 
1.7 Fas ligand and inflammation 
1.7.1 Evidence for a pro-inflammatory role of Fas ligand 
As well as an immune regulatory role, ligation of Fas has also been shown to cause a 
pro-inflammatory response by activating transcription factors, which in turn leads to the 
production of cytokines and the recruitment and activation of immune cells. The pro-
inflammatory effect of FasL on monocytes and macrophages has been researched 
extensively, but is still not fully understood. In vivo, injection of a membrane-bound cell-free 
form of FasL into the peritoneum of mice led to the rapid activation and subsequent demise 
of Mac1high resident peritoneal macrophages, as measured by an increase in gene expression 
of neutrophil chemotactic factors, IL-1β, macrophage inflammatory protein (MIP)-2, MIP-
1α, and MIP-1β (Hohlbaum et al., 2001), whilst in vitro, Fas ligation on human monocytes 
and monocyte-derived macrophages resulted in the release of TNF-α and IL-8. Also, 
conditioned medium from Fas-activated monocytes and macrophages induced the directed 
migration of neutrophils in a chemotaxis assay (Park et al., 2003).  
The induction of chemokine and cytokine synthesis by macrophages is due to the 
activation and nuclear translocation of the transcription factor NF-κB. Fas ligation on 
macrophages enhances NF-κB signalling through the IL-1 receptor (IL-1R) and toll-like 
receptor 4 (TLR4). IL-1R and TLR4 share a common adaptor protein, MyD88, which carries 
a DD sequence. Through homologous DD interactions, FADD associates with MyD88, 
sequestering it from IL-1R and TLR4 signalling. However, when FasL signals through Fas 
and FADD is required for DISC assembly, MyD88 is released for IL-1R and TLR4 signalling 
allowing activation of NF-κB (Altemeier et al., 2007; Bannerman et al., 2002; Ma et al., 
2004).  
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More recently, FasL has been implicated in the activation of macrophages. Chakour et 
al. found that FasL and IFN-γ acted synergistically to activate bone marrow-derived 
macrophages (BMDM), as reflected by enhanced secretion of TNF-α, IL-6 and nitric oxide 
(NO) and the induction of their microbicidal activity. The presence of IL-4 decreased this 
synergy (Chakour et al., 2009). Fas signalling has also been shown to recruit and activate Syk 
kinase, leading to the activation of phosphoinositide 3-kinase (PI3K) and MMP-9 and 
ultimately the migration of peripheral blood myeloid cells (Letellier et al., 2010). In cultured 
dermal fibroblasts, signalling through Fas upregulated vascular endothelial growth factor 
(VEGF) and MCP-1 expression (Fujiwara et al., 2007). 
As already mentioned, sFasL is a weak inducer of apoptosis, suggesting that cleavage 
of FasL from the membrane may serve to downregulate its apoptotic activity. However, this 
does not mean sFasL does not play an important role in the immune system as it has been 
shown to act as a potent chemoattractant for polymorphonuclear neutrophils (PMN). Using a 
recombinant soluble form of human FasL and a Boyden Chamber, Seino et al. found sFasL 
acted as a chemoattractant for both human and mouse PMN, and also HL-60 cells when 
differentiated into neutrophils or monocytes. This activity could be abolished using a 
neutralising anti-FasL monoclonal antibody. PMN derived from lpr mice, that express very 
few Fas molecules, did not respond to sFasL, whereas PMN derived from lprcg mice 
responded normally (Seino et al., 1998). Two groups went on to conclude that FasL exerts its 
pro-inflammatory effects via neutrophil recruitment but not activation. Neutrophils exposed 
to sFasL did not display detectable changes in Ca2+ and did not undergo superoxide 
production or exocytosis of primary or secondary granules (Dupont and Warrens, 2007; 
Ottonello et al., 1999). As well as having chemotactic activity, sFasL was also found to 
induce IL-6 and IL-8 gene expression in serum-starved human fibroblasts. Sensitisation of 
the gene-inducing activity by serum starvation correlated with NF-κB activation by sFasL 
(Ahn et al., 2001). 
 
  
P.E.H.Sharp  2013 
 
 71 
1.7.2 Evidence for a role of Fas ligand in inflammatory diseases 
A few groups have concentrated on looking at the role of the Fas-FasL system in 
inflammatory diseases using well established animal models and either lpr or gld mice. In 
1997, two groups simultaneously published results in the same journal that lpr and gld mice 
were resistant to the induction of experimental autoimmune encephalomyelitis (EAE), the T 
cell-dependent animal model of the autoimmune demyelinating disease MS. Despite EAE 
being a T cell-dependent model, the T cell responses of both lpr and gld mice were found to 
be unaffected when compared to WT mice, suggesting that the Fas-FasL system plays a 
critical role in disease development by mediating apoptosis within the target tissue (Sabelko 
et al., 1997; Waldner et al., 1997). One of the groups then went on to show, using adoptive 
transfer, that FasL was playing a dual role in the initiation and the recovery of EAE. Transfer 
of gld lymphocytes into WT mice was found to attenuate disease, suggesting a role for T cell 
FasL in disease initiation, however gld mice receiving WT lymphocytes developed prolonged 
clinical signs of disease, suggesting FasL expressed by cells of the central nervous system 
plays a role in disease recovery (Sabelko-Downes et al., 1999). 
Research has also been conducted looking at the role of Fas/FasL in autoimmune 
diabetes using non-obese diabetic (NOD) mice. NOD-lpr mice are protected from developing 
autoimmune diabetes and adoptive transfer of lymphocytes from diabetic NOD mice into 
NOD-lpr mice failed to induce disease, suggesting that the Fas-FasL system might be critical 
for autoimmune β cell destruction in the pancreas (Chervonsky et al., 1997; Itoh et al., 1997). 
However, this was later disproved by two groups who found the Fas-FasL system played 
little role in β cell apoptosis (Allison and Strasser, 1998; Kim et al., 1999). In 2000, Kim et 
al. set about to solve the paradox and found that lymphocytes from NOD-lpr mice were 
constitutively expressing FasL and having a cytotoxic effect on the lymphocytes from the 
NOD mice. Blocking FasL with an anti-FasL antibody reversed the inhibition of disease 
following lymphocyte transfer, supporting the previous reports that FasL is not an effector 
molecule in autoimmune β cell destruction (Kim et al., 2000). This result has not stopped 
other groups looking at the role of FasL in autoimmune diabetes. Mohamood et al. found that 
NOD-gld mice were protected from developing disease and, by creating bone marrow 
chimeras with NOD-WT mice, that partial disruption of FasL protects from disease because 
inactivation of FasL in either the hematopoietic or non-hematopoietic compartment was 
sufficient for protection (Mohamood et al., 2007). Similar results were then demonstrated 
genetically in NOD-gld/+ mice, heterozygous for the FasL mutation. These mice were 
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protected from both autoimmune diabetes and T cell lymphoproliferation (Mohamood et al., 
2007).  
Other inflammatory diseases examined include experimental autoimmune uveitis 
(EAU), collagen-induced arthritis (CIA), inflammatory lung disease, experimental stroke, and 
spinal cord injury. Gld mice are protected from EAU; a T cell-mediated autoimmune disease, 
with FasL expression on cells of the immune system important for induction of disease. It 
was also noted that lpr and gld T cells, in vitro¸ responded less to antigen compared to WT T 
cells and produced less of a Th1 response, as measured by IFN-γ production (Wahlsten et al., 
2000). 
CIA is a T cell-mediated, chronic inflammatory disease, bearing the hallmarks of RA. 
One feature of the disease that contributes to joint damage is synovial hyperplasia, which is 
thought to be due to an imbalance between the rates of cell proliferation and apoptosis. Lpr 
mice on a DBA/1 background are protected from CIA (Ma et al., 2004; Tu-Rapp et al., 2004). 
Interestingly, the mice still had elevated levels of the critical pro-inflammatory cytokine IL-
1β in their joints; however there was inefficient activation of the IL-1R signalling pathway 
due to disruption of Fas signalling (Ma et al., 2004).  
Both lpr and gld mice were protected from developing acute pulmonary damage in 
the animal model of IgG immune complex-induced lung injury. In WT lungs, there was a 
marked increase in Fas expression associated with the lung injury and striking evidence of 
activated caspase-3, which was diminished in inflamed lungs from lpr mice. Also, intra-
tracheal administration of a monoclonal Fas-activating antibody in WT mice was found to 
induce production of MIP-2 and keratinocyte chemoattractant (KC) in bronchoalveolar 
lavage fluids. Levels of these chemokines in bronchoalveolar lavage fluids from lpr mice, 
following lung injury, were significantly lower compared to WT mice. These data together 
suggest that the Fas/FasL system regulates acute lung inflammation by positively affecting 
CXC-chemokine production and enhancing neutrophil influx and tissue damage (Neff et al., 
2005).  
Recently, the role of FasL in experimental stroke has been explored. Focal cerebral 
ischemia was induced for 2 hours by right middle cerebral artery occlusion in WT and gld 
mice. Gld mice showed profoundly reduced brain damage and improved neurological 
performance from 6 to 72 hours after ischemic stroke. The production of inflammatory 
cytokines was attenuated in the gld mice, as was the recruitment of neutrophils. In addition, 
P.E.H.Sharp  2013 
 
 73 
CD8+ T cell numbers were also reduced and the Th1/Th2 balance was skewed towards a Th2 
response in both the brain and peripheral blood, offering further support that gld mice are 
predisposed towards a Th2 response (Niu et al., 2011).  
Expression of FasL can also be induced on myeloid cells in spinal cord injury, where 
it binds and stimulates Fas to activate PI3K and MMP-9 via recruitment and activation of Syk 
kinase. This leads to increased migration of inflammatory cells to the site of injury. Deletion 
of FasL on myeloid cells only greatly reduced the numbers of infiltrating neutrophils and 
macrophages in the injured spinal cord and led to functional recovery. However, deletion of 
Fas on neural cells did not lead to functional recovery, indicating that FasL on myeloid cells 
is important for cell migration and injury (Letellier et al., 2010).   
 
1.7.3 Evidence for a role of Fas ligand in renal injury 
Fas and FasL are both widely expressed throughout the kidney. Fas is constitutively 
expressed on mesangial and tubular cells, podocytes and fibroblasts, with upregulation 
occurring during inflammation (Sanchez-Nino et al., 2010), as well as on glomerular 
endothelial cells, with upregulation occurring following exposure to pro-inflammatory 
cytokines (Sata et al., 2000). FasL expression has been shown in both normal and injured 
kidneys in humans and mice. Normal expression of FasL in the kidney is by tubular epithelial 
cells; however during injury expression is upregulated within the glomerulus, with mesangial 
cells being a potential source (Lorz et al., 2000; Tsukinoki et al., 2004). Other possible 
sources of renal FasL are thought to be podocytes, endothelial cells and fibroblasts (Ortiz et 
al., 1999; Ross et al., 2005). Dual expression of both Fas and FasL could result in 
paracrine/autocrine cell death. However, on tubular cells for example, Fas and FasL are 
segregated from each other: Fas is restricted to the basolateral surface whilst FasL is 
sequestered to an intracellular compartment and the apical surface (Tan and Hunziker, 2003). 
This segregation is lost upon disruption of tight junctions by physical injury, ischemia or pro-
inflammatory cytokines.  
In vivo, FasL has been implicated as playing a pathogenic role in kidney injury. 
Following induction of ischemia-reperfusion injury (IRI), gld mice had significantly lower 
serum creatinine and fewer TNF-α-producing T lymphocytes in the kidneys and lymph 
nodes, compared to WT mice. Blockade of FasL in WT mice with a monoclonal antibody 
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protected them from IRI (Ko et al., 2011). Furthermore, transfer of gld splenocytes to WT 
mice attenuated IRI whereas transfer of WT splenocytes to gld mice enhanced injury, 
demonstrating that FasL expression on leukocytes mediates acute kidney injury (Ko et al., 
2011). When studying obstruction-induced renal tubular cell apoptosis in a model of 
unilateral ureteral obstruction (UUO), it was found that IL-18 significantly increased the 
expression of FasL. Similarly, small interfering RNA (siRNA) knockdown of FasL 
significantly reduced IL-18-induced apoptosis (Zhang et al., 2011). In a model of cisplatin-
induced nephropathy it was found blockade of FasL, with a monoclonal anti-FasL antibody, 
protected SCID-beige mice (lacking B cells, T cells and NK cells) from disease, suggesting 
expression of FasL by tubular epithelial cells is capable of causing apoptosis of neighbouring 
tubular cells (Linkermann et al., 2011). This was then supported in vitro by co-incubation of 
primary tubular cells with segments of thick ascending limb (Linkermann et al., 2011). 
There is mounting evidence that FasL plays a role in GN, although the results are 
conflicting as to whether its role is pro-inflammatory or anti-inflammatory. Lpr and gld mice, 
when bred on permissive backgrounds, such as MRL, develop spontaneous autoimmunity 
and a lupus-like GN, suggesting a protective role for FasL (Izui et al., 1984). This has 
recently been attributed to the membrane-bound form of FasL. Mice bred to express sFasL 
only, on a C57BL/6 background, developed a lupus-like GN more severe than gld mice on 
the same background, whereas mice expressing membrane-bound FasL only appeared 
normal. The authors hypothesised that this result was seen due to a combination of the 
autoimmune phenomena, resulting from the deletion of membrane-bound FasL, and an 
increase in pro-inflammatory activity, caused by an increase in sFasL. However, it is not 
possible to compare directly these mice, as FasL activity is not completely abrogated in gld 
mice (O' Reilly et al., 2009). However, FasL also appears to play a damaging role in GN. 
Agonistic anti-Fas antibodies were found to induce glomerular cell apoptosis and injury in 
mice in vivo and treatment of lupus prone mice, NZB/W F1, with an anti-FasL monoclonal 
blocking antibody twice a week for 15 weeks, was found to prevent the development of lupus 
nephritis, although the mice had higher autoantibody titres (Gonzalez-Cuadrado et al., 1997; 
Nakajima et al., 2000). 
Although conflicting, it must be noted that results from experiments using antibody 
blockade are not directly comparable to loss-of-function gene mutations present from birth. 
This is especially true with the Fas-FasL system, which plays a complicated dual-role in the 
regulation of autoimmunity and inflammation. The defect in apoptosis in the gld mice means 
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they are prone to developing spontaneous autoimmunity, due to the role of FasL in mediating 
lymphocyte homeostasis. The lack of functional FasL in these mice leads to an accumulation 
of B cells and T cells and an inability to maintain peripheral B cell tolerance (Stranges et al., 
2007). It should be noted though, that this is strain dependent. In some strains, such as 
C57BL/6, compensatory systems are in place that can slow the onset or severity of 
autoimmunity; TNF-TNF receptor-mediated apoptosis has been shown to partially 
compensate for the Fas deletion in lpr mice on a C57BL/6 background (Zhou et al., 1996). In 
the lupus prone mice however, where FasL-dependent apoptosis of lymphocytes is intact, it 
appears FasL may be playing a pro-inflammatory role, either via its role in neutrophil 
recruitment or its role in IL-1 signalling (Nakajima et al., 2000).  
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1.8 Fc gamma receptors 
1.8.1 Introduction 
Fc receptors (FcR) are a family of cell surface molecules that bind the Fc part of the 
constant region of immunoglobulins and contribute to the protective functions of the immune 
system. They are mainly expressed on cells of haematopoietic lineage such as NK cells, 
macrophages, neutrophils, mast cells, dendritic cells, and B cells. Their cross-linking with 
immunoglobulins can initiate an array of cellular responses; phagocytosis, endocytosis, 
antibody-dependent cell-mediated cytotoxicity (ADCC), mast cell degranulation, 
immunomodulation of antibody responses, and lymphocyte proliferation.  
 Fc gamma receptors (FcγR) specifically bind the Fc portion of IgG. Based on genetic 
and structural analysis there are three classes of FcγR in humans and four classes in mice 
(Figure 1.5). The high affinity receptor, FcγRI (CD64), is capable of binding monomeric IgG 
(especially IgG2a) and the low affinity receptors, FcγRII (CD32) and FcγRIII (CD16), 
preferentially bind complexed IgG (Dijstelbloem et al., 2001). FcγRIV (CD16-2), which is 
only found in mice, is also a low affinity receptor that binds IgG2a and IgG2b with no 
affinity for IgG1 or IgG3 (Nimmerjahn et al., 2005).  
The human FcγR system is more complex than the murine system. Mice express four 
different FcγRs: FcγRI, FcγRIIB, FcγRIII and FcγRIV; whereas humans express six: FcγRI, 
FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA and FcγRIIIB (Radaev and Sun, 2002). In addition 
there are also several allelic variants for most of the human FcγR genes, with the exception of 
FcγRI and FcγRIIC (Nimmerjahn and Ravetch, 2008). Based on the sequence similarity in 
the extracellular portion of the FcγR, as well as the genomic localisation, FcγRI and FcγRIIB 
are homologous between mice and humans, whereas it appears mouse FcγRIV is most 
closely related to human FcγRIIIA and mouse FcγRIII is most closely related to human 
FcγRIIA. There are no murine equivalents to human FcγRIIC and FcγRIIIB (Nimmerjahn 
and Ravetch, 2006) (Figure 1.5). 
Human and murine FcγR are structurally related. They are type I membrane proteins 
(although soluble molecules can occur through alternative splicing of FcγR transcripts or 
proteolysis), except for FcγRIIIB that is glycosylphosphatidylinositol (GPI)-anchored, and 
contain either two (FcγRII, FcγRIII and FcγRIV) or three (FcγRI) Ig-like domains in their 
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extracellular region. The third Ig-like domain of FcγRI is thought to be responsible for its 
increased affinity to bind monomeric IgG (Radaev and Sun, 2002).  




Figure 1.5 Mouse and human Fc gamma receptors. 
Human and murine activating and inhibitory FcγR (Nimmerjahn and Ravetch, 2008). This 




P.E.H.Sharp  2013 
 
 79 
1.8.2 Fc gamma receptor signalling 
FcγR can be functionally divided into activating receptors and inhibiting receptors. In 
humans the activating receptors are FcγRI, FcγRIIA, FcγRIIC, FcγRIIIA and FcγRIIIB, and 
in mice they are FcγRI, FcγRIII and FcγRIV. FcγRIIB is the sole inhibitory FcγR in both 
humans and mice. With the exception of FcγRIIIB, functional activating FcγR either contain 
an immunoreceptor tyrosine-based activation motif (ITAM), responsible for cell signalling, 
in their cytoplasmic tail (in humans FcγRIIA and FcγRIIC), or are associated with an ITAM 
containing non-covalently attached intracellular signal-transducing adaptor molecule, a FcR γ 
(FcRγ) chain (in humans FcγRI and FcγRIIIA and in mice FcγRI, FcγRIII and FcγRIV) 
(Cambier, 1995; Reth, 1989). FcγRIIIB is not associated with a FcRγ chain and does not 
contain an ITAM within its cytoplasmic tail, instead it is thought to act synergistically with 
other receptors, such as FcγRIIA, and use their signalling apparatus for signal transduction 
and cell activation (Unkeless et al., 1995; Wirthmueller et al., 1992). The inhibitory receptor, 
FcγRIIB, carries an immunoreceptor tyrosine-based inhibition motif (ITIM) within its 
cytoplasmic tail (Daeron et al., 1995). Activating and inhibitory FcγR are often co-expressed 
on cells and, when co-aggregated at the cell surface, the net signal to the cell depends upon 
the sum total of the activator and inhibitor signals. Expression of activating and inhibiting 
receptors is tightly controlled by the cytokine milieu surrounding the cell (Pricop et al., 2001; 
Radeke et al., 2002) 
The ITAM is composed of a twice-repeated YxxL/I amino acid sequence flanking 7 
variable residues (x represents any amino acid) (Reth, 1989). The ITAM has no intrinsic 
enzymatic activity; however, following receptor cross-linking by immune complexes, 
tyrosine phosphorylation of the ITAM is induced by SRC kinase family members. 
Phosphorylation of the ITAM generates SRC homology 2 (SH2) docking sites that recruit 
and activate members of the Syk-family of kinases. Syk can then activate various 
downstream targets, such as PI3K, which leads to the production of phosphatidylinositol 
(3,4,5)-triphosphate (PIP3), a key product in the recruitment of further downstream 
molecules. The responses that result from FcγR signalling largely depends on the cell type 
involved, but they mainly fall into two main categories of activation or internalisation 
(Nimmerjahn and Ravetch, 2008; Ravetch and Bolland, 2001). 
The ITIM is composed of a six amino acid sequence, S/I/V/LxYxxI/V/L, where x 
denotes any amino acid (Daeron et al., 1995; Muta et al., 1994). Following receptor cross-
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linking to ITAM-bearing receptors by immune complexes, tyrosine phosphorylation of the 
ITIM is induced by SRC kinase family members. This phosphorylation results in the 
recruitment of phosphatases, such as SHIP (SH2-domain-contraining inositol polyphosphate 
5’ phosphatase), that interfere with the signalling pathways being stimulated by the 
phosphorylated ITAM, namely by hydrolysing PIP3 (Nimmerjahn and Ravetch, 2006, 2008; 
Ravetch and Bolland, 2001). 
 
1.8.3 Fc gamma receptor expression 
The activating FcγR are widely expressed throughout the haematopoietic system. 
However not all cells express all activating FcγR. In humans, FcγRI is constitutively 
expressed by monocytes and macrophages and can be induced in neutrophils and eosinophils 
following stimulation with IFN-γ (Goulding et al., 1992; Valerius et al., 1990). FcγRIIA and 
FcγRIIC are expressed by myeloid cells. FcγRIIIA is found on NK cells, a subset of 
macrophages (Edwards et al., 1997), but is not present on the majority of circulating 
monocytes, however stimulation with TGF-β can induce expression during activation and 
maturation to macrophages in vitro (Wong et al., 1991). FcγRIIIB is expressed solely on 
neutrophils (Edwards et al., 1997). A similar picture is seen in mice. Monocytes and 
macrophages express FcγRI, FcγRIII and FcγRIV; dendritic cells express FcγRI and FcγRIII; 
neutrophils express FcγRIII and FcγRIV; and NK cells express FcγRIII (Nimmerjahn and 
Ravetch, 2008). 
The inhibitory FcγR, FcγRIIB, is the most widely expressed, being found on most 
cells of myeloid and lymphoid lineage (with the exception of NK cells and T cells) where it is 
responsible for the negative regulation of activating FcγR. FcγRIIB is the only antibody-
binding Fc receptor expressed on B cells where it plays a role in downregulating B cell 
activation, proliferation, and antibody secretion, as well as maintaining peripheral tolerance 
(Boross et al., 2011; Takai et al., 1996). 
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1.9 Functions of Fc gamma receptors 
Binding of IgG to FcγR can initiate various functions, depending on the cell type and 
the balance of activating and inhibitory receptors being ligated. The overall organisation of 
human and murine FcγR is similar. The cellular distribution and signalling capacities of FcγR 
overlap between the two species, so by studying the murine receptors we can gain insight into 
the functions of their human counterparts. The generation of FcγR-deficient mice has made it 
possible to dissect the functions of FcγR in vivo and study the roles of these receptors in 
inflammation and autoimmunity. These functions can be classified into two major categories: 
regulation of cellular responses and uptake of immune complexes (Figure 1.6). The 
involvement of FcγR in each of these roles will be discussed in the following sections.  




Figure 1.6 Major functions of Fc gamma receptors. 
(A) Positive and negative regulation of cellular signalling. (B) Immune complex uptake for 
antigen presentation of clearance. Adapted from (Takai, 2005). This image has been 
reproduced with the permission of the rights holder, Springer Science + Business Media. 
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1.9.1 Regulation of cellular responses 
Clustering of activating and inhibitory FcγR on the cell surface allows for the tight 
regulation of cell activation or suppression, which is critical for defence against IgG-
complexed antigens. FcγR are expressed on most leukocytes, with the exception of T cells, 
allowing positive and negative regulation of both the adaptive and innate immune response. 
Co-aggregation of activating FcγR can lead to various cellular responses such as oxidative 
burst, cytokine release, and phagocytosis by macrophages, ADCC by NK cells, and 
degranulation of mast cells. FcγRIIB physiologically acts as a negative regulator. With the 
exception of NK cells, that only express activating FcγR, FcγRIIB acts to dampen the effects 
of immune complex-triggered activation. 
 The generation of single and multiple FcγR knockout mice has provided the 
opportunity to study the roles of FcγR in vivo and in vitro and dissect their specific functions 
in different cellular subsets. Initial studies into the functions of FcγR were done using FcRγ 
chain-deficient mice (FcRγ-/-). These mice lack the γ chain necessary for signalling through 
activating FcγR and show an absence of surface expression of FcγRI, FcγRIII, FcγRIV and 
also the high-affinity IgE receptor, Fc epsilon receptor (FcεRI). Mast cell degranulation, seen 
in immediate hypersensitivity responses such as allergy, is initiated by IgE binding to FcεRI. 
In keeping with this, both cutaneous and systemic IgE-mediated anaphylaxis was found to be 
absent in FcRγ-/- mice (Takai et al., 1994). However, passive systemic anaphylaxis, following 
IgG stimulation was also attenuated, suggesting a role for FcγR in mast cell degranulation 
(Miyajima et al., 1997). Further studies, using single FcγR knockout mice, went on to show 
enhanced mast cell degranulation in FcγRIIB-/- mice and that FcγRIII, in particular, was 
responsible for IgG-mediated anaphylaxis rather than FcγRI (Hazenbos et al., 1996; Ioan-
Facsinay et al., 2002; Ujike et al., 1999). Mast cells do not express FcγRIV. 
Macrophages and monocytes from mice express all four classes of FcγR. 
Phagocytosis of antibody-coated particles was found to be inhibited in FcRγ-/- macrophages 
compared to WT macrophages, despite normal binding (Takai et al., 1994). However, 
macrophages from FcγRI-/- mice were found to have impaired binding of IgG2a-opsonised 
particles (Ioan-Facsinay et al., 2002) and macrophages from FcγRIII-/- mice were found to 
have impaired binding and phagocytosis of IgG1-opsonised particles (Hazenbos et al., 1996). 
As well as impaired binding of IgG2a-opsonised particles, ADCC was also decreased in 
FcγRI-/- macrophages (Ioan-Facsinay et al., 2002). In contrast, FcγRIIB-/- macrophages were 
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shown to have enhanced phagocytic activity of IgG2b-opsonised particles and, following 
FcγRIII cross-linking with a FcγRII/III specific antibody, calcium influx was also greatly 
increased compared to WT macrophages (Clynes et al., 1999). To date little work has been 
done on the role of FcγRIV on macrophages and monocytes in mice. FcγRIV binds IgG2a 
and IgG2b but not IgG1 or IgG3. This could explain in part why, in the absence of FcγRI, 
macrophages still have the capability to phagocytose IgG2a-opsonised particles. 
NK cells have the capability to kill IgG-coated target cells by ADCC. FcγRIII is the 
sole FcR expressed by NK cells and therefore mediates all antibody dependent responses on 
these cells. As expected, ADCC was abolished in both FcRγ-/- mice (Takai et al., 1994) and 
FcγRIII-/- mice (Hazenbos et al., 1996). 
As mentioned in Section 1.8.3, FcγRIIB is the only FcR expressed on B cells and its 
inhibitory function has best been demonstrated on these cells. FcγRIIB plays an important 
role in B cell regulation and survival. Cross-linking of the B cell receptor (BcR) with 
FcγRIIB by immune complexes activates a distinct ITIM-dependent pathway that inhibits B 
cell proliferation, maturation and the production of cytokines (Phillips and Parker, 1984). 
However, cross-linking of FcγRIIB in the absence of the BcR initiates a bim-dependent 
apoptosis pathway (Ashman et al., 1996; Pearse et al., 1999; Tzeng et al., 2005; Xiang et al., 
2007). This mechanism allows FcγRIIB to maintain peripheral tolerance and delete self-
reactive B cells. Immune complexes will preferentially aggregate FcγRIIB if the BcR has a 
low affinity for the antigen. In contrast, the BcR will preferentially bind immune complexes 
with high affinity cognate antigen, thus providing a survival signal (Pearse et al., 1999). 
Reduced expression of FcγRIIB can therefore promote B cell survival as well as lower their 
activation threshold. Studies using FcγRIIB-deficient mice have highlighted the importance 
of the receptor in B cell regulation. FcγRIIB-/- mice have hyper-reactive B cells that produce 
increased antibody titres in response to both thymus-dependent and thymus-independent 
antigens (Takai et al., 1996).  
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1.9.2 Uptake of immune complexes 
Uptake of immune complexes by dendritic cells and macrophages is important for 
antigen presentation and immune complex clearance. Dendritic cells are the only APC 
capable of initiating adaptive immune responses. To do this they must first go through a 
differentiation process called ‘maturation’. FcγR have been found to play a central role in 
dendritic cell maturation. Cross-linking of FcγR by immune complexes induced maturation 
of human dendritic cells in vitro (Banki et al., 2003; Boruchov et al., 2005). This affect was 
abolished in murine FcRγ-/- dendritic cells (Sedlik et al., 2003) but not in FcγRI-/- or FcγRIII-/- 
dendritic cells, suggesting both receptors are capable of inducing maturation (Sedlik et al., 
2003). FcγRIV is also highly expressed in dendritic cells and likely to be involved in 
initiating their maturation (Nimmerjahn et al., 2005; Nimmerjahn and Ravetch, 2006). 
FcγRIIB expression on dendritic cells appears to be important in preventing inappropriate 
activation and controlling the degree of activation. Selective blockade of FcγRIIB resulted in 
spontaneous maturation of dendritic cells (Boruchov et al., 2005; Dhodapkar et al., 2005). 
As well as maturation, FcγR are also involved in immune complex uptake and antigen 
presentation by dendritic cells. FcγR-mediated antigen uptake was found to enhance the 
antigen presentation of the dendritic cells, resulting in the activation of both CD4+ and CD8+ 
T cells (Amigorena and Bonnerot, 1999; Regnault et al., 1999). FcγRIIB controls the 
magnitude of this response. Dendritic cells from FcγRIIB-/- mice generate a stronger and 
longer-lasting immune response both in vitro and in vivo (Kalergis and Ravetch, 2002). 
Following an antigen-antibody reaction, immune complexes need to be efficiently 
removed from circulation because their deposition in tissues and organs can set off reactions 
resulting in inflammation and tissue damage (Jancar and Sanchez Crespo, 2005; Mayadas et 
al., 2009). Deposition of immune complexes is a prominent feature of several autoimmune 
diseases, for example, SLE (Bagavant and Fu, 2009; Niederer et al., 2010). 
Immune complex clearance is regulated by the mononuclear phagocyte system. 
Erythrocytes, in primates, or platelets, in non-primates, bind to immune complexes through 
their complement receptor 1 (CR1) and transport them to the liver or spleen. Once there, the 
immune complexes are removed from the erythrocytes by proteolytic cleavage of CR1 and 
internalised by tissue-resident phagocytes, with the erythrocytes returning to circulation 
(Cornacoff et al., 1983; Nardin et al., 1999). 
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The role of FcγR in this process has been highlighted both in vivo and in vitro. In 
vivo, blockade of murine FcγR with a monoclonal antibody inhibited the binding and 
internalisation of CR1-bound immune complexes (Kurlander et al., 1984) and in vitro, the 
application of anti-FcγRI antibody on U937 cells prevented recognition and transfer of 
erythrocyte CR1-bound immune complexes (Craig et al., 2000). 
 
 
1.10 Fc gamma receptors in glomerulonephritis 
Many forms of human GN, such as lupus nephritis and Goodpasture’s disease, are 
characterised by deposition of immune complexes within the kidney, suggesting the 
involvement of FcγR. Further evidence for the involvement of FcγR in autoimmune diseases, 
and subsequently GN, comes from genetic studies of humans, rats, and autoimmune prone 
strains of mice, as well as the generation of different FcγR-deficient mice. The roles of 
activating and inhibiting FcγR in autoimmunity and GN are discussed in the following two 
sections.   
 
1.10.1 Activating Fc gamma receptors 
Initial studies to look at the roles of activating FcγR in GN were carried out in FcRγ-/-
mice. FcRγ-/- mice were found to be protected from accelerated NTN with no glomerular 
crescents, thrombosis, proteinuria or renal failure and reduced leukocyte influx, despite 
producing a similar immune response to WT mice (Park et al., 1998; Suzuki et al., 1998). In 
vitro data from Radeke et al. showed that expression of FcγR was upregulated on mesangial 
cells following stimulation with IFN-γ and LPS (Radeke et al., 2002). However, results from 
bone marrow transplantation experiments performed between WT and FcRγ-/- mice showed 
that susceptibility to disease was entirely dependent on FcγR expression on circulating 
leukocytes (Tarzi et al., 2002).  
However, using FcRγ-/- mice is not conclusive proof that activating FcγR are involved 
in immune-mediated nephritis because the FcRγ chain is the intracellular signalling subunit 
for more than just the FcγR, such as the collagen receptor glycoprotein VI (GPVI) (Berlanga 
et al., 2002). Development of mice lacking the α chains of specific FcγR has helped with 
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discovering which of the activating receptors are important. Deletion of FcγRIII was found to 
protect mice from the heterologous model of NTN (Coxon et al., 2001). This was initially 
explained by the heterologous phase of NTN being neutrophil-dependent since FcγRI is not 
expressed on neutrophils; however, this theory does not account for FcγRIV. To date, little 
research has been carried out on the role of FcγRIV in GN, although there are some 
suggestions that it works alongside FcγRIII in the manifestations of disease due to its 
selective affinity for IgG2a and IgG2b (Giorgini et al., 2008). In accelerated NTN, deletion of 
FcγRIII alone was not sufficient to protect from disease, suggesting roles for FcγRI and 
FcγRIV (Tarzi et al., 2003).  
A link between FcγRIII and GN has also been found in rats and humans. WKY rats 
are highly susceptible to NTN and EAG when compared to other rat strains, such as LEW or 
BN. Injury and crescent formation in NTN are macrophage driven. Ten days following a 
single injection of NTS, WKY rats consistently develop NTN, whereas LEW, BN and Wistar 
show no crescent formation, no proteinuria and minimal glomerular macrophage infiltration. 
F1 rats (WKY and LEW) show an intermediate phenotype and F2 rats span the range of the 
parental strains (Aitman et al., 2006).  
Aitman et al. carried out a genome wide screen for NTN susceptibility loci in the F2 
strain and found two major quantitative trait loci (QTL) on chromosomes 13 and 16, 
designated Crgn1 and Crgn2 respectively. Both loci were strongly linked to crescent 
formation and proteinuria, and Crgn1 was also found to be linked to macrophage infiltration. 
Crgn1 was found to contain several candidate genes, including the genes for FcγRII (Fcgr2) 
and FcγRIII (Fcgr3). Sequencing of Fcgr2 revealed a point mutation, G388T, which changes 
codon 103 from arginine in LEW rats to leucine in WKY rats. Sequencing of Fcgr3 revealed 
genomic rearrangement involving the Fcgr3 locus. Further investigation showed that WKY 
rats had lost a rat-specific Fcgr3 paralogue, Fcgr3-related sequence (Fcgr3-rs), which results 
in macrophage overactivity, inhibition of FcγRIII mediated phagocytosis, and susceptibility 
to GN. Studies in humans revealed that low copy number of FCGR3B, an orthologue of rat 
Fcgr3, was associated with GN in patients with SLE (Aitman et al., 2006). An explanation 
for the relationship between copy number variation of FcγRIIIB and SLE susceptibility is the 
reduced expression of FcγRIIIB on neutrophils and consequently the reduced clearance of 
immune complexes (Willcocks et al., 2008). 
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1.10.2 Inhibitory Fc gamma receptor 
Several autoimmune disease-prone strains of mice, such as NZB, BXSB, MRL, and 
NOD, contain a polymorphism in the promoter region of the FcγRIIB gene that is absent in 
control mouse strains, for example BALB/c and C57BL/6. The autoimmune haplotype is 
associated with reduced cell surface expression of FcγRIIB on macrophages and activated B 
cells, and with hyperactive macrophages resembling those in FcγRIIB-/- mice (Pritchard et al., 
2000). Over-expression of FcγRIIB on B cells, but not macrophages, was found to inhibit the 
development of spontaneous SLE (Brownlie et al., 2008). FcγRIIB deficiency in Mrl-MpJ 
mice was found to lead to autoimmunity with chronic B cell activation, serum reactivity to 
several autoantigens, and kidney pathology by 8 months of age (McGaha et al., 2008).  
The outcome of FcγRIIB deficiency in control mice is strain-dependent. The 
129/B6/FcγRIIB-/- strain was backcrossed for 12 generations onto both BALB/c and C57BL/6 
strains. C57BL/6 FcγRIIB-/- mice were susceptible to spontaneous SLE with anti-DNA and 
anti-chromatin antibodies, and fatal autoimmune GN with a mean survival of 9 months, 
whereas BALB/c FcγRIIB-/- mice maintained tolerance and were resistant to autoimmunity. 
Autoimmunity was shown to be dependent on the loss of peripheral tolerance by FcγRIIB-/- B 
cells in the B6 background (Bolland and Ravetch, 2000). However, loss of FcγRIIB alone is 
not sufficient to induce autoimmunity. Boross et al. generated an FcγRIIB knockout strain, 
by gene targeting in B6-derived embryonic stem (ES) cells, and found that the mice did not 
develop spontaneous disease, but when the B6 FcγRIIB-/- mice were crossed with the 
autoimmune-prone Yaa B6 strain, the Yaa offspring did develop fatal lupus. These results 
indicate that FcγRIIB deficiency amplifies spontaneous autoimmunity determined by 
underlying autoimmune susceptibility loci (Boross et al., 2011). FcγRIIB-/- mice show 
enhanced antibody responses and are susceptible to EAG as well as accelerated NTN 
(Nakamura et al., 2000; Sharp et al., 2012; Suzuki et al., 1998). However, the conditional 
deletion of FcγRIIB on either B cells or myeloid cells did not increase incidence of EAG 
compared to FcγRIIB-/- mice (Sharp et al., 2012), although, it must be noted, deletion of 
FcγRIIB was insufficient on myeloid cells in this model. 
To date, little work has been done on the role of FcγRIIB expressed by mesangial 
cells in GN. Two reports, one in vivo and one in vitro, have confirmed mesangial cell 
FcγRIIB expression and shown downregulation of the receptor during disease or following 
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IFN-γ and LPS stimulation (Ichii et al., 2008; Radeke et al., 2002). However, whether it plays 
a role in protection from injury has not been investigated.   
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1.11 Project hypothesis and aims 
Due to the key roles of FasL and FcγRIIB in modulating the inflammatory immune 
response, loss of function of either, on certain genetic backgrounds, results in the 
development of severe autoimmune phenotypes. FasL and FcγRIIB are expressed on 
circulating leukocytes and intrinsic renal cells, such as mesangial cells, both of which are 
important in the development of GN. Therefore, I have investigated their role in accelerated 
NTN. My original hypothesis was that FasL plays a pro-inflammatory role in the induction of 
autoimmune GN and its absence would attenuate disease, whereas FcγRIIB plays an anti-
inflammatory role and its absence would exacerbate disease. To test these hypotheses I tried 
to answer the following questions:  
 
1.11.1 What is the role of Fas ligand in glomerulonephritis? Is there a difference 
between the immune responses of WT and gld mice? 
Due to the conflicting arguments for the role of FasL in GN, due to its roles in the 
immune response, inflammation and apoptosis, I decided to start by investigating whether 
defective FasL, on a non-permissive background, was protective in accelerated NTN, a model 
similar to immune complex GN. To address this the disease model was induced in WT and 
gld mice on a C57BL/6 background and renal injury was assessed. The role of FasL in 
lymphocyte homeostasis is well documented, with gld and lpr mice, as well as ALPS 
patients, having overactive immune responses and a predisposition to autoimmunity. In light 
of this, I then investigated the immune response of gld mice compared to WT mice. To do 
this, I re-challenged pre-immunised WT and gld splenocytes with sheep IgG, CD3/CD28 
beads or PMA & ionomycin and measured proliferation and cytokine production. The results 
are analysed and discussed in Chapter 3. 
 
1.11.2 Is Fas ligand expression on infiltrating leukocytes or intrinsic renal cells more 
critical for disease development? 
FasL is known to be expressed on circulating leukocytes and has been shown to be 
upregulated during renal injury, with mesangial cells being identified as a source within the 
glomerulus. Both infiltrating leukocytes and intrinsic renal cells have been shown to play key 
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roles in the development of GN. FasL expression on circulating leukocytes has been found to 
be the main driving force for disease in EAU and kidney IRI. However, in EAE, FasL was 
found to play a dual role in inflammation and recovery, with expression on both circulating 
leukocytes and cells of the central nervous system contributing to disease. Therefore I wanted 
to know whether FasL on intrinsic renal cells or infiltrating leukocytes plays a role in GN. 
This question is addressed in Chapter 4 by the creation of bone marrow chimeras expressing 
functional FasL on their circulating cells but not intrinsic renal cells, and vice versa, and then 
inducing accelerated NTN. These mice were compared to WT mice transplanted with WT 
bone marrow and gld mice transplanted with gld bone marrow. Defective FasL has also been 
shown to interrupt IL-1R signalling in macrophages, resulting in reduced production of MCP-
1. As mesangial cells express FasL and also produce MCP-1, I decided to culture mesangial 
cells from WT and gld mice, stimulate them with IL-1β, and assess the differences in 
cytokine production. 
 
1.11.3 What is the role of FcγRIIB in glomerulonephritis? 
FcγRIIB-deficiency (FcγRIIB-/-) has already been shown to aggravate accelerated 
NTN in mice, due to its role in negatively regulating the immune response. FcγRIIB is widely 
expressed on cells of both myeloid and lymphoid origin; however, its precise role on specific 
cell types in GN has not been determined. Therefore, to ascertain the role of FcγRIIB in 
accelerated NTN, my collaborators created floxed FcγRIIB mice on a C57BL/6 background 
and, using Cre recombinase under cell specific promoters, successfully deleted the expression 
of FcγRIIB on B cells, dendritic cells, mast cells, and myeloid cells. Accelerated NTN was 
induced and the mice compared to WT and FcγRIIB-/- mice. 
 
1.11.4 Is FcγRIIB expressed by mesangial cells? Does mesangial cell FcγRIIB 
contribute to protection from accelerated NTN. 
Intrinsic renal cells are known to express FcγRI and FcγRIII; however, neither were 
found to play a role in the development of GN in accelerated NTN. Data suggest that intrinsic 
renal cells, possibly mesangial cells, express FcγRIIB. To confirm this I cultured mesangial 
cells and measured expression using quantitative real-time PCR (qRT-PCR), following 
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stimulation with LPS, as well as direct immunofluorescence. To determine whether 
mesangial cell FcγRIIB plays a role in protecting mice from disease I generated bone marrow 
chimeras, expressing FcγRIIB on their circulating leukocytes but not on their intrinsic renal 
cells, and vice versa, and induced accelerated NTN. These mice were compared to WT mice 













2.1.1.1 Fas ligand experiments 
Gld mice, backcrossed to a C57BL/6 background for 10 generations, were kindly 
provided by Professor David Gray, University of Edinburgh, UK, or purchased from the 
Jackson Laboratory. Homozygous gld mice were then bred to provide experimental mice at 
Central Biomedical Services (CBS), Hammersmith Hospital. Mice used in this study were 
between 6-15 weeks of age. Control age- and sex-matched C57BL/6 WT mice were 
purchased from Charles River. All mice were housed with free access to food and water and 
were kept in a specific pathogen-free environment, according to institutional guidelines. 
Experiments were performed under the terms of a licence issued by the UK Home Office. 
 
2.1.1.2 FcγRIIB experiments 
The FcγRIIB-/- mice, on a pure C57BL/6 background, were generated in Leiden 
University Medical Centre (LUMC) as previously described (Boross et al., 2011). The 
CD19Cre mice were kindly provided by Dr. Ari Waisman (Cologne) (Rickert et al., 1997). 
The Lysozyme MCre (LysMCre) mice were kindly provided by Dr. Bjorn Clausen 
(Amsterdam) (Clausen et al., 1999). The CD11cCre mice were kindly provided by Dr. Boris 
Reizis (New York) (Caton et al., 2007). The Mcpt5Cre mice were kindly provided by Dr. 
Axel Roers (Dresden) (Scholten et al., 2008). The cEBPαCre mice were kindly provided by 
Dr. Ivo Touw (Rotterdam) (Wolfler et al., 2010). All Cre mice were backcrossed to a 
C57BL/6 background for more than six generations prior to crossing onto the floxed 
background (pure C57BL/6).  During the breeding heterozygous Cre mice, carrying the 
homozygous floxed FcγRIIB gene, were continuously intercrossed with homozygous floxed 
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FcγRIIB mice on a pure C57BL/6 background, to generate floxed/floxed x Cre heterozygote 
experimental animals.  Age- and sex-matched floxed/floxed littermate controls were used as 
WT animals for the experiments. Mice were bred and housed in the animal facility, LUMC, 
Leiden, The Netherlands, and used between 6-15 weeks of age. Experiments involving mice 
with a cell-specific deletion of FcγRIIB were performed at LUMC in part by myself and by 
technicians in Leiden. Experiments were performed in accordance with the regulations of the 
ethics committee at LUMC. Analysis of serology and histology was performed at Imperial 
College London, UK.  
FcγRIIB-/- mice, on a pure C57BL/6 background, for bone marrow transplant 
experiments were kindly provided by Professor Sjef Verbeek (Leiden) (Boross et al., 2011). 
Homozygous mice were bred to provide experimental mice at CBS, Hammersmith Hospital. 
Mice used in this study were between 6-15 weeks of age. Control age- and sex-matched 
C57BL/6 WT mice were purchased from Charles River. All mice were housed with free 
access to food and water and were kept in a specific pathogen free environment, according to 
institutional guidelines. Experiments were performed under the terms of a licence issued by 















2.2.1 In vivo experiments 
2.2.1.1 Genotyping of gld mice by polymerase chain reaction 
Genomic DNA was isolated from mouse tissue (usually an ear punch). Tissue samples 
were lysed overnight at 56°C in 100µl of cell lysis buffer containing 100µg/ml proteinase K 
(Sigma-Aldrich) (added immediately before use), with agitation. For PCR analysis, the DNA 
was diluted in three volumes of distilled H2O (dH2O) and heat-inactivated at 75°C for 15 
minutes. A 12µl PCR was carried out using a PTC-200 thermal cycler (MJ Research) and a 
single pair of FasL primers (Sigma-Aldrich). Primer sequences were provided by the Jackson 
Laboratory: 
 
FasL forward: 5’CAAGACAATATTCCTGGTGCC-3’ 
FasL reverse: 5’CAATTTTGAGGAATCTAAGGCC-3’ 
 
Reagents, excluding the DNA template, were made up as a master mix sufficient for 
all samples and then aliquoted before adding the appropriate DNA template to each reaction 
tube. The reagents in each reaction tube are summarised in Table 2.1. Thermal cycling 
conditions involved initial denaturation at 94°C for 3 minutes, followed by 35 cycles of 94°C 
for 1 minute (denaturation), 55°C for 1 minute (primer annealing temperature) and 72°C for 1 
minute (extension). A final extension step at 72°C for 2 minutes was incorporated to ensure 
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PCR Reagents Volume (µl) 
MilliQ water 6.58 
10x PCR buffer (Qiagen) 1.20 
dNTP’s (2.5mM) (Promega) 0.96 
FasL forward primer (20µM) 0.60 
FasL reverse primer (20µM) 0.60 
Taq polymerase (5U/µl) (Qiagen) 0.06 
DNA (5-20ng) 2.00 
Final volume 12.0 
Table 2.1 Chemical reagents for gld PCR. 
 
The PCR products were then digested using Stu I restriction endonuclease (New 
England BioLabs). The WT product contains a restriction digestion site that cleaves the DNA 
into an 88bp and 20bp product. The mutant product contains no cleavage site. A master mix 
sufficient for all samples was made and 6µl added to each PCR reaction tube and run on a 
thermal cycler for a minimum of 4 hours at 37°C. The reagents for the restriction digestion 
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Restriction Digestion Reagents Volume (µl) 
10x buffer (New England Biolabs) 1.50 
MilliQ water 3.75 
Stu I (10U/µl) (New England Biolabs) 0.75 
Table 2.2 Chemical reagents for restriction digestion. 
 
The restriction digestion products were analysed by gel electrophoresis. 3g of agarose 
(Sigma-Aldrich) was dissolved in 100ml 1xTris Acetate EDTA (TAE), micro-waved for 3 
minutes and 10µl of Sybr green nucleic acid gel stain (Sigma-Aldrich) added to stain the 
DNA. The gel was left at room temperature for 30 minutes to set. 15µl of each sample 
(diluted 1:6 in loading dye (Bioline)) was loaded. Hyperladder V (Bioline) was used to size 
PCR products. Samples were electrophoresed in 1x TAE at 150V for 2 hours. The DNA was 
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2.2.1.2 Genotyping of FcγRIIB-/- mice by polymerase chain reaction 
Genomic DNA was isolated from mouse tissue as previously described (Section 
2.2.1.1). For PCR analysis, the DNA was diluted in three volumes of dH2O and heat 
inactivated at 75°C for 15 minutes. A 25µl PCR was carried out using a thermal cycler and 
the following FcγRIIB primers (Sigma-Aldrich). Primer sequences were taken from Boross et 
al. (Boross et al., 2011). 
 
CreRecPr1:  5’CCTTCATCTTTCCTGCCAAG-3’ 
CreRecPr6v2: 5’TCACACCAGCAACACCTCTC-3’ 
CreRecPr2:  5’AACACCAGCTGAGGGGTCT-3’ 
 
Reagents, excluding the DNA template, were made up as a master mix sufficient for 
all samples and then aliquoted before adding the appropriate DNA template to each reaction 
tube. The reagents in each reaction tube are summarised in Table 2.3. Thermal cycling 
conditions involved initial denaturation at 94°C for 2 minutes, followed by 20 cycles of a 
stepwise PCR at 94°C for 30 seconds (denaturation), a required annealing temperature at 
65°C for 1 minute 30 seconds which decreased by 0.5°C with each cycle (ending at 55°C) 
and an extension temperature at 72°C for 1 minute 30 seconds. This was followed by 20 
cycles at 94°C for 30 seconds (denaturation), an annealing temperature at 55°C for 1 minute 
30 seconds and an extension temperature at 72°C for 1 minute 30 seconds. The final 
extension at 72°C for 5 minutes was incorporated to ensure the extension of all amplification 
products. The WT band was 359bp and the recombinant band 600bp. The PCR products were 
analysed by gel electrophoresis. 2g of agarose was dissolved in 100ml 1x TAE, micro-waved 
for 3 minutes and 10µl of Sybr green nucleic acid gel stain (Sigma-Aldrich) added to stain the 
DNA. The gel was left at room temperature to set. 15µl of each sample (diluted 1:6 in loading 
dye (Bioline)) was loaded. Hyperladder IV (Bioline) was used to size PCR products. Samples 
were electrophoresed in 1x TAE at 150V for 1 hour. The DNA was visualised using a Gel 
Doc 1000 transilluminator (Bio-Rad) and photographed.  
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PCR reagents Volume (µl) 
MilliQ water 14.65 
10x PCR buffer (Qiagen) 2.50 
dNTP’s (2mM) (Promega) 2.50 
MgCl2 (50mM) (Qiagen) 1.25 
CreRecPr1 (100ng/µl) 1.00 
CreRecPr6v2 (100ng/µl) 0.50 
CreRecPr2 (100ng/µl) 0.50 
Taq polymerase (5U/µl) (Qiagen) 0.10 
DNA (5-20ng) 2.00 
Final volume 25.00 
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2.2.13 Preparation of nephrotoxic serum 
NTS was kindly prepared and characterised by Dr Ruth Tarzi. Briefly, lyophilised 
mouse GBM was made at 4°C.  Mouse kidneys were blended through a series of sieves: 
150µm, 106µm and 45µm, respectively, and washed through with cold phosphate buffered 
saline (PBS). Glomeruli were retained on the 45µm sieve. The recovered glomeruli were 
spun down at 700 x g for 5 minutes, washed twice and resuspended in cold PBS.  The 
resuspended material was then sonicated at 8µm amplitude for 30-second bursts on ice, spun 
down at 200 x g for 15 minutes and washed twice with cold PBS. The sonicated glomeruli 
were then washed twice with cold, distilled water, spun down at 700 x g for 5 minutes and 
frozen in liquid nitrogen. The GBM was lyophilised overnight and the final product stored at 
-20°C. 
Regal Group generated the sheep serum containing nephrotoxic antibody. Sheep were 
immunised with 5mg of mouse GBM subcutaneously at four sites in a 50:50 mix of saline 
and CFA (Sigma-Aldrich). This mixture was prepared by repeatedly mixing the solution 
between two glass syringes joined by a double-luer lock (Sigma-Aldrich). When fully 
homogenised, a droplet placed on water retained its form. Boost immunisations of 1mg of 
mouse GBM in a 50:50 mix of saline and incomplete Freund’s adjuvant (IFA) (Sigma-
Aldrich) were then given four times, at monthly intervals, in two subcutaneous and two 
intramuscular sites. The sheep was bled at monthly intervals, as well as terminally, and the 
serum pooled in order to enrich the antibody content. 
To purify the nephrotoxic antibody, firstly the complement in the serum was 
inactivated at 56°C for 30 minutes. A 50% saturated ammonium sulphate solution was 
obtained by adding 315g/l of ammonium sulphate slowly to the serum with constant stirring. 
The globulins were left to precipitate for 5 hours at room temperature. Following 
precipitation, serum was spun twice at 12000 x g for 10 minutes. The supernatant was 
removed and the precipitate resuspended in a minimal volume of PBS, transferred to dialysis 
tubing and dialysed against a large volume (5 litres) of PBS at 4°C. The dialysis fluid was 
changed four times over 24 hours and the content of the dialysis tubing collected and 
centrifuged at 1000 x g for 10 minutes. The supernatant was retained and sterilised using a 
0.2µm filter. Aliquots were stored at -80°C.  
The concentration of sheep IgG was determined by radial immunodiffusion. 150µl of 
rabbit anti-sheep IgG (Sigma-Aldrich) was added to 10ml 1.2% agarose gel in PBS and a gel 
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was prepared on a 3-inch glass square. 5µl of nephrotoxic globulin (neat and dilutions) or 
serial dilutions of reagent grade sheep IgG (Sigma-Aldrich) were added to wells punched into 
the gel. The gel was incubated at 4°C overnight in a humidified chamber. The following day 
the gel was washed, fixed onto GelBond film (Cambrex), dried and stained with Coomassie 
brilliant blue (Sigma-Aldrich). The diameter of the rings was measured using a micrometer 
eyepiece and the concentration of IgG in the samples was then calculated by linear regression 
with reference to the standard curve. The concentration of sheep IgG was found to be 
50mg/ml. 
 
2.2.1.4 Induction of accelerated nephrotoxic nephritis 
Mice were immunised subcutaneously with 0.2mg of sheep IgG (Sigma-Aldrich) in a 
50:50 mix of saline and CFA (Sigma-Aldrich). This mixture was prepared by repeatedly 
mixing the solution between two glass syringes joined by a double-luer lock (Sigma-Aldrich). 
When fully homogenised, a droplet placed on water retained its form. Five days after 
immunisation, the animals were injected with 200µl (diluted in 0.9% NaCl) sheep NTS via 
the tail vein. 1-15 days after NTS injection mice were humanely killed. Kidneys, spleen and 
blood, for serum, were harvested. 
 
2.2.1.5 Bone marrow transplantation 
Same sex transplants were carried out. Donor bone marrow was harvested from the 
femur, tibia and humerus by cleaning off the muscle and hair and flushing out the marrow 
into RPMI 1640 medium (Gibco) containing 100U/ml penicillin, 100µg/ml streptomycin 
(Gibco), 10% fetal calf serum (FCS) (Biosera) and 1% L-glutamine (Gibco). Cells were spun 
down at 352 x g for 5 minutes and then resuspended and counted using a haemocytometer. 
The cells were centrifuged again and resuspended in media at a final concentration of 5x107 
cells/ml.  
Recipient mice were irradiated in an IBL 637 irradiator at CBS, Hammersmith 
Hospital. The optimal irradiation dose used was 8 Gray (Gy) (Tarzi et al., 2002). Following 
irradiation, mice were injected with 200µl (10 million) bone marrow cells via the tail vein. 
During the following eight weeks the mice were housed in individually-ventilated cages with 
free access to acidified water and an autoclaved diet, according to institutional guidelines. 
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2.2.1.6 Quantification of bone marrow reconstitution in blood by flow cytometry 
Peripheral blood was taken via the tail vein into 5% EDTA from mice transplanted 
with the CD45.1 bone marrow allotype marker at 10 weeks post bone marrow 
transplantation. Red cells were lysed for 10 minutes at room temperature using 2ml of 1X 
FACS®lysing solution (BD Biosciences). Cells were spun down at 500 x g, 4°C for 5 minutes 
and the supernatant discarded. Cells were washed twice and resuspended in PBS-1% FCS. 
First cells were incubated with anti-mouse CD16/32 (eBioscience) in order to block FcγRII 
and FcγRIII (Table 2.4). Cells were then stained with FITC-labelled CD45.1 and APC-
labelled CD45.2 (both BD Biosciences) (Table 2.4). Suitable isotype controls were used. 
Flow cytometry was performed using a FACScalibur flow cytometer (BD Bioscience) and 



























eBioscience Rat/93 IgG2a, λ 0.5 
CD45.1-APC BD Bioscience A20 IgG2a, κ 1.0 
CD45.2-PE BD Bioscience 104 IgG2a, κ 1.0 
Table 2.4 Antibodies used for quantification of bone marrow reconstitution in the 
blood by flow cytometry. 
 
2.2.1.7 Quantification of bone marrow reconstitution in blood by polymerase chain 
reaction 
DNA was isolated from 100µl of blood obtained from a terminal bleed. The blood 
was lysed overnight at 56°C in 500µl of blood lysis buffer containing 100µg/ml proteinase K 
(Sigma-Aldrich) (added immediately before use). To extract the DNA, 300µl of saturated 
NaCl and 200µl of chloroform was added to each sample and vortexed. Samples were 
centrifuged at high speed for 10 minutes and the supernatant (500µl) collected. 50µl 3M 
sodium acetate and 550µl of isopropanol were added to the supernatant and mixed gently 
before centrifuging at high speed for 10 minutes. A white pellet of DNA formed at the 
bottom of the tube. The supernatant was discarded and the pellet washed twice in 70% 
ethanol before resuspending in 20µl of double distilled (dd) H2O.  
For bone marrow transplants involving gld mice, a PCR was run as before (Section 
2.2.1.1) but replacing the reverse FasL primer for an identical primer modified at the 5’ end 
with a FAM label. All samples were run in duplicate. Following the PCR one of the 
duplicates was digested as before (Section 2.2.1.1). The samples were then run on a 
Genescan (Applied Biosystems). 15µl of ROX 400 marker (Applied Biosystems) was mixed 
with 1ml of formamide (Sigma-Aldrich) and 11µl was placed in every well of a 96-well plate. 
DNA was diluted 1:4 with ddH2O and 1µl was added to the ROX mixture. The plate was run 
on an ABI 3100 Automated Sequencer (Applied Biosystems) and results were exported to 
Genemapper software (Applied Biosystems) for analysis. 
P.E.H.Sharp  2013 
 
 104 
For bone marrow transplants involving FcγRIIB-/- mice, a PCR was run as before 
(Section 2.2.1.2).  
 
2.2.1.8 Isolation of resident renal leukocytes for flow cytometric analysis 
Eight weeks following bone marrow transplantation, mice were sacrificed and the 
kidneys were collected and sliced into six cubes using a scalpel. The kidneys were not 
perfused prior to harvesting.  The kidneys were digested in RPMI 1640 medium (Gibco) 
containing 0.1% FCS (Biosera), 20mM HEPES (Gibco), 0.1% β-mercaptoethanol (Sigma-
Aldrich), 1mM L-glutamine (Gibco), 100U/ml penicillin, 100µg/ml streptomycin (Gibco), 
0.5mg/ml collagenase (Roche) and 100µg/ml DNAse I (Roche) for 25 minutes at 37°C in a 
shaking water bath. The kidneys were then blended using a syringe plunger and incubated for 
a further 15 minutes at 37°C in a shaking water bath. Following digestion the kidneys were 
filtered through a 100µm nylon mesh and washed in PBS containing 0.1% FCS.  
 
2.2.1.9 Flow cytometry of resident renal leukocytes 
Isolated kidney cell digests were counted and 3 million cells/well plated out in a V-
bottom welled plate. First, cells were blocked with anti-mouse CD16/32 (eBioscience) to 
block Fc receptors. Cells were washed with PBS and stained with the following antibodies 
obtained from eBioscience: APC-labelled CD45.1, PE-labelled CD45.2, FITC-labelled F4/80 
and PerCP Cy5.5-labelled CD11c (Table 2.5). Flow cytometry was performed using a 



















eBioscience Rat/93 IgG2a, λ 0.5 
CD45.1-APC eBioscience A20 IgG2a, κ 1.0 
CD45.2-PE eBioscience 104 IgG2a, κ 1.0 






Table 2.5 Antibodies used for flow cytometry of isolated resident renal leukocytes.  
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2.2.1.10 Assessment of the systemic immune response to sheep IgG by enzyme-linked 
immunosorbent assay 
Mouse anti-sheep IgG levels were measured in mouse serum collected at the end of 
the experiment by an enzyme-linked immunosorbent assay (ELISA). Nuncmaxisorp ELISA 
plates (Fisher Scientific) were coated overnight at 4°C with 100µg/ml sheep IgG (Sigma-
Aldrich) diluted in PBS (Table 2.6). Plates were blocked with 3% bovine serum albumin 
(BSA) (Sigma-Aldrich) for 1 hour at 37°C. The plates were then washed three times with 
PBS/0.1% Tween 20 (Sigma-Aldrich) and 100µl of serum, diluted 1:500 and 1:1000 in 1% 
BSA/PBS, incubated for 1 hour at 37°C. Following washing, 100µl of alkaline phosphatase 
conjugated goat anti-mouse IgG (Fc specific) (Sigma-Aldrich) was incubated for 1 hour at 
37°C (Table 2.6). Optical density (OD) at 405nm was measured on a EL800 ELISA plate 
reader (BioTek) using p-nitrophenyl phosphate as a substrate (Sigma-Aldrich). 
 For IgG subclass analysis, goat anti-mouse IgG1, 2b, 2c and 3 alkaline phosphatase 
conjugated antibodies (SouthernBiotech) were used for detection (Table 2.6). The OD at 

























Sigma-Aldrich Sheep polyclonal 100 1:100 




















SouthernBiotech Mouse IgG3 - 1:500 
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2.2.1.11 Measurement of serum creatinine and serum urea 
Serum creatinine and serum urea were kindly measured in the Department of Clinical 
Chemistry, Hammersmith Hospital by Mr John Meek. Serum urea was also measured using 
Urea/Ammonia kit (R-Biopharm) according to the manufacturer’s protocol. Briefly, all 
samples were diluted 1:10 in PBS. One tablet of nicotinamide adenine dinucleotide (NADH) 
was dissolved in 1ml of oxoglutarate to make reaction mixture 2 (RM2). Into a 96-well 
Nuncmaxisorp ELISA plate (Fisher Scientific) 100µl of RM2, 2µl of urease, 200µl of ddH2O 
and 10µl of diluted sample were added per well to measure urea and ammonia. This was 
repeated in a second well but without the urease to measure ammonia only. After 5 minutes 
the plate was read at 340nm and 2µl of glutamate dehydrogenase (GLDH) was added to all 
wells. After 20 minutes the plate was read at 340nm using an EL800 ELISA plate reader 
(BioTek). Concentration of urea in the sample was calculated by comparison to a positive 
control of known concentration.  
 
2.2.1.12 Measurement of urine creatinine and urinary albumin/creatinine ratio 
Individual 24-hour urine collections were performed using metabolic cages, in which 
the mice had free access to food and water. Urinary albumin concentration was measured by 
radial immunodiffusion. 150µl of rabbit anti-mouse albumin (Serotec) was added to 10ml 
1.2% agarose gel in PBS and a gel was prepared on a 3-inch glass square. 5µl of sample or 
serial dilutions of a mouse albumin standard (Sigma-Aldrich) were added to wells punched 
into the gel. The gel was incubated at 4°C overnight in a humidified chamber. The following 
day the gel was washed, fixed onto GelBond film (Cambrex), dried and stained with 
Coomassie brilliant blue (Sigma-Aldrich). The diameters of the rings were measured using a 
micrometer eyepiece and the concentration of albumin in the samples then calculated by 
linear regression with reference to the standard curve.  
Urine creatinine was kindly measured in the Department of Clinical Chemistry, 
Hammersmith Hospital by Mr John Meek. This was then used to calculate the urinary 
albumin/creatinine ratio.  
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2.2.1.13 Processing of histological specimens 
For light microscopy, half kidneys were fixed in neutral buffered formalin overnight 
or Bouin’s solution (Sigma-Aldrich) for 2 hours, transferred to 70% ethanol and processed to 
paraffin blocks. 4µm sections were stained with periodic acid-Schiff (PAS) and hematoxylin-
eosin (H&E) reagents (Leukocyte Biology, Biological Sciences, South Kensington). 
For immunofluorescence, half kidneys were placed on corkboards and snap-frozen 
embedded in Cryomatrix (Thermo Fisher Scientific) using isopentane cooled with liquid 
nitrogen. The samples were stored at -80°C until use. For staining cell surface markers, half 
kidneys were first fixed with paraformaldehyde lysine periodate (PLP) at 4°C for 4 hours, 
washed overnight in 13% (w/v) sucrose in PBS and snap frozen as above in isopentane 
cooled in liquid nitrogen. 5µm kidney sections were cut using a cryostat (Bright) onto slides 
coated with Poly-L-lysine (Surgipath). After air-drying, slides were either stained or stored at 
-80°C.  
 
2.2.1.14 Immunofluorescence staining of frozen sections 
Direct immunofluorescence was used to detect sheep and mouse IgG on sections of 
mouse kidney. Antibodies used for immunofluorescence staining are listed in Table 2.7. 
Sections were blocked with 20% serum from the species of the FITC-conjugated antibody for 
30 minutes in order to block non-specific cross-reactivity. The primary antibodies were 
diluted in PBS, incubated on the sections for one hour at room temperature in a humidified 
chamber covered with aluminium foil. The sections were washed three times in PBS and 













Source Host/Clone Concentration 
(mg/ml) 
Dilution Used 
Sheep IgG FITC 
(Fc specific) 
Sigma-Aldrich Mouse IgG1/ 
Clone GT34 
1.7 1:200 





Table 2.7 Antibodies for direct immunofluorescence (all FITC-conjugated).  
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2.2.1.15 CD45.1 and CD45.2 tissue staining 
CD45.1 and CD45.2 were stained using the avidin-biotin complex (ABC) method. 
The antibodies used are listed in Table 2.8. 5µm sections of frozen kidney fixed in PLP were 
used. Mouse spleen was used as a positive control. Endogenous peroxidase was first blocked 
by submerging the slides in 0.3% hydrogen peroxide (VWR International Ltd.) for 10 
minutes. The sections were rinsed in ddH2O and endogenous avidin and biotin were blocked. 
Avidin block (Vector Laboratories) was applied to the sections for 15 minutes, rinsed off in 
PBS then biotin block (Vector Laboratories) was applied to the sections for 15 minutes and 
rinsed off in PBS. The primary biotinylated antibody was then applied for two hours at room 
temperature in a humidified chamber. As a negative control, sections were stained with the 
primary antibody omitted and PBS used in its place. After 3 washes in PBS (5 minutes each) 
ExtrAvidin-Peroxidase (Sigma-Aldrich) was applied for 30 minutes at room temperature in a 
humidified chamber. After three washes in PBS, slides were submerged in 3,3’-
diaminobenzidine (DAB) solution for two minutes then rinsed in ddH2O. Slides were 
counterstained by immersion in filtered Harris’ haematoxylin (CellPath Ltd) for 40 seconds 
and then rinsed in a sink water bath. Slides were dipped in 1% acid alcohol and rinsed in a 
sink water bath until the sections turned blue. Sections were dehydrated by serial immersion 
for 5 minutes each in 100% ethanol (x2) and xylene (x2). Finally, slides were wiped dry and 
















Source Host/Clone Concentration 
(mg/ml) 
Dilution 
Primary Antibodies    
CD45.1-biotin eBioscience Mouse/A20 0.5 1:200 
CD45.2-biotin eBioscience Mouse/104 0.5 1:200 
Secondary Antibody    
ExtrAvidin-
Peroxidase 
Sigma-Aldrich - 2.0-2.5 1:50 
Table 2.8 Antibodies used for CD45.1 and CD45.2 staining. 
 
2.2.1.16 Immunoperoxidase staining for cell surface markers 
Immunoperoxidase staining was used to detect macrophages (CD68), neutrophils (Gr-
1) and CD4+ T cells using the Polink-2 Plus HRP (horseradish peroxidase) Rat with DAB kit 
(New Market Scientific). The antibodies used are listed in Table 2.9. 5µm sections of frozen 
kidney fixed in PLP were used. Mouse spleen was used as a positive control. First, 
endogenous peroxidase was blocked by submerging the slides in 0.3% hydrogen peroxide 
(VWR International Ltd.) for 10 minutes. The sections were then rinsed in ddH2O and the 
primary antibody, diluted in PBS, applied for one hour at room temperature in a humidified 
chamber. As a negative control, sections were stained with the primary antibody omitted and 
PBS used in its place. After three washes in PBS (2 minutes each) two drops of Rat Antibody 
Enhancer (supplied in the Polink-2 kit) were applied to each section and incubated for 10 
minutes at room temperature in a humidified chamber. After three washes in PBS (2 minutes 
each) 50µl of Polymer-HRP for Rat Antibody (supplied in the Polink-2 kit), made up an hour 
in advance containing 20% goat serum to adsorb out any cross-reactivity with goat 
immunoglobulin in the sections, was applied to each section and incubated for 10 minutes at 
room temperature in a humidified chamber. The slides were washed three times and the 
bound antibody detected with DAB. 1 drop of DAB chromagen was added per ml of DAB 
substrate (both supplied in the Polink-2 kit) and 50µl applied to the sections for two minutes. 
Sections were rinsed in a sink water bath. Slides were counterstained by immersion in filtered 
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Harris’ haematoxylin (CellPath Ltd) for 40 seconds and then rinsed in a sink water bath. 
Slides were dipped in 1% acid alcohol and rinsed in a sink water bath until the sections 
turned blue. Sections were dehydrated by serial immersion for 5 minutes each in 100% 
ethanol (x2) and xylene (x2). Finally, slides were wiped dry and mounted with DePex (BDH) 




Source Host/Clone Concentration 
(mg/ml) 
Dilution 
Primary Antibodies    
CD68 Serotec Rat FA11 1.0 1:200 
CD4 BD Biosciences Rat Monoclonal 
GK1.5 (L3T4) 
0.5 1:200 
Gr-1 Serotec Rat Monoclonal 
RB6-8C5 
1.0 1:50 





Rat Kit Kit 
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2.2.1.17 Terminal deoxynucleotidyl transferase (TdT) dUTP nick end labelling 
(TUNEL) 
Apoptotic cells were stained for on paraffin-embedded sections using the ApopTag 
Fluorescein Kit (Roche). Sections were de-paraffinised by serial immersions in xylene (x2) 
and 100% ethanol (x2) for 5 minutes each, then 95% ethanol and 70% ethanol for 3 minutes 
and finally PBS for 5 minutes. Antigen retrieval was performed to facilitate the reaction in 
fixed tissue, maximising the availability of the antigen, using 20µg/ml proteinase K (Sigma-
Aldrich) diluted in PBS for 15 minutes at room temperature. The slides were then washed in 
PBS and equilibration buffer was applied to the specimens and incubated for at least 10 
seconds at room temperature. Excess liquid was tapped off before applying working strength 
TdT enzyme, prepared by mixing 77µl of reaction buffer with 33µl of TdT enzyme, to each 
sample and incubated for 1 hour at 37°C in a humidified chamber. The specimens were 
covered with a piece of parafilm cut slightly larger than the specimen to assure even 
distribution of the reaction mixture and prevent loss due to evaporation during incubation. 
The labelling reaction was stopped by immersing the slides in stop/wash buffer for 10 
minutes at room temperature, with gentle agitation for the first 15 seconds. The slides were 
rinsed in PBS, anti-digoxigenin conjugate applied and incubated for 30 minutes at room 
temperature in a humidified chamber in the dark. The slides were washed for a final time and 
mounted with Vectashield with DAPI (Vector Laboratories).  
 
2.2.1.18 Histological analyses 
All microscope analysis and quantitative immunofluorescence was performed using 
an Olympus BX4 Microscope (Olympus Optical) at x250 magnification without knowledge 
of the samples identity. 
 
2.2.1.19 Quantitative immunofluorescence 
Immunofluorescent sections were scored either using a quantitative visual 
fluorescence scale or Image Pro Plus software (Media Cybernetics). The fluorescence scale 
used is as follows: 0: no increase in fluorescence compared to the background; 1: minimal 
increase; 2: moderate fluorescence, 3: strong fluorescence and 4: very strong fluorescence. 
To quantitate using Image Pro Plus images of glomeruli were captured using a QImaging 
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Retiga 2000R Fast 1396 camera (QImaging). Glomeruli were outlined manually on the 
computer screen and the mean fluorescence intensity over each glomerulus was measured 
electronically. For each section 20 glomeruli were examined and the mean fluorescence 
intensity recorded. Where Image Pro Plus software was used results are expressed in arbitrary 
fluorescence units (AFU). Where the quantitative visual fluorescence scale was used results 
are expressed as visual fluorescence units (VFU). 
 
2.2.1.20 Glomerular and interstitial immunoperoxidase scoring 
Glomerular macrophages (CD68+), neutrophils (Gr-1+) and CD4+ T cells were 
counted on immunoperoxidase stained sections. Only cells inside glomeruli, defined by the 
Bowman’s capsule were counted and 50 glomerular cross sections (gcs) were scored per 
kidney. 
Interstitial macrophage and CD4+ T cell staining were quantified using Image Pro 
Plus software (Media Cybernetics). A field of view of interstitium, free from glomeruli, was 
captured using a QImaging Retiga 2000R Fast 1396 camera (QImaging). The areas of 
positive staining were selected manually and measured electronically. For each section, five 
fields of view were selected, the mean area of positive staining calculated and multiplied by 
100 to produce an arbitrary unit (AU). 
 
2.2.1.21 Glomerular damage  
Glomerular thrombosis was assessed by scoring individual glomeruli on PAS-stained 
kidney sections for PAS positive material as follows: grade 0: no PAS positive material; 
grade 1: 0-25%; grade 2: 25-50%; grade 3: 50-75% and grade 4: 75-100%. 50 glomeruli were 
assessed per section and the mean glomeruli thrombosis score was calculated for each mouse. 
Glomerular crescents were defined as glomeruli containing two or more layers of cells in the 
Bowman’s space. 50 glomeruli were counted per sample and the results converted to 
percentage crescents. 
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2.2.1.22 Quantification of apoptotic cells 
Apoptotic cells were counted on TUNEL stained sections. Only apoptotic cells inside 
glomeruli, defined by Bowman’s capsule, were counted and thirty glomerular cross sections 
were scored per kidney. 
 
2.2.1.23 RNA extraction from whole kidney 
Total RNA was extracted from snap frozen kidney. 1ml of TRIzol (Invitrogen) was 
added for every 25mg of tissue and the tissue was homogenised. Samples were transferred to 
a clean eppendorf tube and 200µl of chloroform added. The samples were shaken by hand 
and left at room temperature for 5 minutes. Samples were spun down in a microcentrifuge at 
12000 x g for 15 minutes at 4°C. The clear aqueous phase was transferred to a clean 
eppendorf tube and 500µl of isopropanol added. Samples were stored at -20°C overnight. 
RNA was spun down at 12000 x g for 10 minutes at 4°C and the supernatant discarded. The 
RNA pellet was washed with 75% ethanol, spun down at 8000 x g for 8 minutes at 4°C and 
the ethanol removed. The RNA was air dried for 10 minutes, resuspended in 40µl RNase free 
water (Gibco) and heated at 55°C for 5 minutes. Total RNA concentration was determined 
using Nanodrop spectrophotometer (Labtech Int.) before being stored at -80°C. 
 
2.2.1.24 Quantitative real-time polymerase chain reaction 
 qRT-PCR was used to measure mRNA expression levels. The Brilliant II Sybr Green 
QRT-PCR Master Mix Kit, 1 Step (Agilent Technologies) was used following 
manufacturer’s instructions. RNA was used at a final concentration of 5-10ng/µl and primers 
at 200nm. A 25µl reaction was carried out in a 96-well plate (Applied Biosystems). Reagents, 
excluding the RNA template, were made up as a master mix sufficient for all samples and 
then aliquoted before adding the appropriate RNA to each reaction well. The reagents in each 
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qRT-PCR Reagents Volume (µl) 
2x SYBR Green qRT-PCR master mix (Agilent Technologies) 12.5 
Forward primer (200nM) 0.5 
Reverse primer (200nM) 0.5 
RT/RNase block enzyme mixture (Agilent Technologies) 1.0 
RNA (125-250ng) 1.00 
Final volume 25.0 
Table 2.10 Chemical reagents for qRT-PCR. 
 
Plates were run on a Mastercycler ep Realplex2 (Eppendorf). Cycling conditions 
involved a reverse transcription step at 50°C for 30 minutes, a 10 minute incubation at 95°C 
to fully activate the DNA polymerase, followed by 40 cycles of 95°C for 30 seconds 
(denaturation) and 60°C for 1 minute (primer annealing and extension). Cycle threshold (Ct) 
values, the number of cycles required for the fluorescent signal to cross to a set threshold, 
were determined for all genes analysed. Relative change in gene expression, normalised to 
GAPDH and compared to a control, was quantified using the comparative Ct method using 
the following equations.  
Normalisation to GAPDH: ΔCt = CtGENE - CtGAPDH 
Change in gene expression: ΔΔCt = ΔCtSAMPLE - ΔCtCONTROL 
Relative change in gene expression (assuming 100% efficiency of both gene 
of interest and GAPDH): 2-ΔΔCt 
Primers were designed in house and synthesised by Sigma-Aldrich. Tables 2.11 and 
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Primers  Sequences 
GAPDH Forward 5’GGGTGTGAACCACGAGAAAT-3’ 
Reverse 5’GTCTTCTGGGTGGCAGTGAT-3’ 
MCP-1 Forward 5’ATGCAGTTAATGCCCCACTC-3’ 
Reverse 5’TTCCTTATTGGGGTCAGCAC-3 
iNOS Forward 5’AAGCCCCGCTACTACTCCAT-3' 
Reverse 5’AGCTGGAAGCCACTGACACT-3' 
TNF-α Forward 5’AGCCCACGTCGTAGCAAACCACCAA-3’ 
Reverse 5’ACACCCATTCCCTTCACAGAGCAAT-3’ 
IL-6 Forward 5’ATGAACTCCTTCTCCACAAGCGC-3’  
Reverse 5’GAAGAGCCCTCAGGCTGGACTG-3’ 
Arginase Forward 5’CGCCTTTCTCAAAAGGACAG-3’ 
Reverse 5’ACAGACCGTGGGTTCTTCAC-3’ 
Mannose Receptor Forward 5’GACCTTGGACTGAGCAAAGGGG-3’ 
Reverse 5’GACATGATGTCCTCAGGAGGACG-3’ 
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Primers  Sequences 
IFN-γ Forward 5’ATCTGGAGGAACTGGCAAAA-3’ 
Reverse 5’TTCAAGACTTCAAAGAGTCTGAGG-3’ 
IL-12p40 Forward 5’GGAAGCACGGCAGCAGAATA-3' 
Reverse 5’AACTTGAGGGAGAAGTAGGAAT-3' 
IL-4 Forward 5’ACAGGAGAAGGGACGCCAT-3' 
Reverse 5’GAAGCCCTACAGACGAGCTCA-3’ 
IL-10 Forward 5’GGTTGCCAAGCCTTATCGGA-3’ 
Reverse 5’ACCTGCTCCACTGCCTTGCT-3’ 
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2.2.2 In vitro experiments 
2.2.2.1 Mesangial cell purification and culture 
For mesangial cell purification, kidneys were removed from WT, gld and FcγRIIB-/- 
mice and kept on ice in PBS supplemented with 100U/ml penicillin, 100µg/ml streptomycin 
(Gibco). The kidneys were blended using a syringe plunger and forced through a series of 
sterile sieves with successively smaller pore sizes of 150µm, 106µm and 45µm, respectively. 
Glomeruli were retained on the 45µm sieve. The recovered glomeruli were collected in a 
15ml falcon tube, resuspended in cold PBS and spun down at 157 x g for 5 minutes at 4°C to 
remove any tubules. Glomeruli were digested with 380U/ml collagenase (Sigma-Aldrich) in 
PBS for 30 minutes at 37°C with gentle agitation. Following digestion, glomeruli were spun 
down at 225 x g for 5 minutes at 4°C, washed once with cold PBS and resuspended in RPMI 
1640 medium (Gibco) supplemented with 20% fetal calf serum (FCS) (Biosera), 100U/ml 
penicillin, 100µg/ml streptomycin (Gibco), 2% L-glutamine and 1% ITS (insulin-transferrin-
selenium) liquid (Sigma-Aldrich). Finally, glomeruli were plated in 25cm2 culture flasks and 
cultured in humidified air at 37°C with 5% CO2. Medium was changed every 2 to 3 days 
thereafter.  
 
2.2.2.2 Mesangial cell characterisation 
Mesangial cells were characterised by their typical stellate morphology when 
subconfluent, while on becoming confluent they adopted the well-recognised elongated 
conformation. To exclude contamination with other cell types, immunofluorescence studies 
were carried out. 1x105 mesangial cells were added to an 8-welled chamber slide and 
incubated overnight at 37°C with 5% CO2. The following day cells were washed in PBS and 
fixed in acetone for 10 minutes. Antibodies used for immunofluorescence staining are listed 
in Table 2.13. Cells were blocked for 30 minutes with 20% serum from the species of the 
antibodies used for 30 minutes in order to block non-specific cross-reactivity. The antibodies 
were diluted in PBS, placed on the cells and incubated for 1 hour at room temperature in a 
humidified chamber covered with aluminium foil. The cells were washed 3 times in PBS. 
Secondary antibodies were diluted in PBS, placed on the cells and incubated as above. The 
cells were washed 3 times in PBS and mounted in AF1 solution (Citiflur). Cells were 
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visualised using an Olympus BX4 microscope (Olympus Optical) at x250 magnification and 
images captured using a QImaging Retiga 2000R Fast 1396 camera (QImaging). 
 
Antibody Specificity Source Host/Clone Dilution Used 
Rabbit anti-myosin Sigma-Aldrich Rabbit polyclonal 1:10 
Goat anti-rabbit IgG 
FITC 
Sigma-Aldrich Goat polyclonal 1:50 
Mouse anti-
pancytokeratin FITC 
Sigma-Aldrich Mouse monoclonal 1:50 
Table 2.13 Antibodies used for mesangial cell characterisation. 
 
2.2.2.3 Mesangial cell passage 
When the cultured mesangial cells reached 90-95% confluency, mesangial cell culture 
medium (Section 2.2.2.1) was aspirated with a sterile glass pipette. Cells were washed twice 
with 5ml (25cm2 flask) or 10ml (75cm2) of sterile PBS. 1ml (25cm2 flask) or 3ml (75cm2) of 
non-enzymatic cell dissociation buffer (Sigma-Aldrich) was added to each flask and 
incubated at 37°C for 30 minutes. The tissue flask was shaken briefly to enhance cell 
separation from the flask. The cell dissociation solution effect was quenched by adding 5 
volumes of 20% FCS culture medium. Cells were then pelleted by centrifugation at 352 x g 
for 5 minutes at 4°C. Supernatant was aspirated with a sterile glass pipette. The cell pellet 
was resuspended in an adequate volume of mesangial cell culture medium and placed in a 
fresh culture flask. Mesangial cells were used between passages 8-12 for all experiments. 
 
2.2.2.4 Mesangial cell freezing  
Mesangial cells were dissociated from the flask when confluent (see Section 2.2.2.3). 
The cell pellet from a 75cm2 flask was resuspended in 1ml of recovery cell culture freezing 
medium (Invitrogen) and transferred to a cryogenic vial (Corning). To slowly freeze the cells 
the cryogenic vial was wrapped in tissue and placed at -80°C. After 24 hours the cells were 
transferred to liquid nitrogen. 
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2.2.2.5 Mesangial cell thawing 
 A vial was taken from the liquid nitrogen and quickly thawed at 37°C in an incubator 
for 2 minutes. The cell suspension was transferred to a sterile 15ml falcon tube. 15ml of 
mesangial cell culture medium (Section 2.2.2.1) was added to the falcon tube and the cells 
were pelleted down by centrifugation at 352 x g for 5 minutes at 4°C. These cells were then 
resuspended in 15ml of mesangial cell culture medium, placed in a fresh 75cm2 culture flask 
and incubated at 37°C with 5% CO2. 
 
2.2.2.6 Preparation of heat aggregated IgG 
 Sheep and mouse IgG (reagent grade, Sigma-Aldrich) were dissolved in sterile saline 
to a stock concentration of 10mg/ml. The dissolved solution was aliquoted into autoclaved 
sterile eppendorf tubes (500µl each) and then stored at -20°C. To prepare heat-aggregated 
IgG, defrosted aliquots of filtered IgG were heat-aggregated at 63°C for 20 minutes on a heat 
block followed by microcentrifugation at high speed for 5 minutes at 4°C to remove the 
insoluble aggregates. The soluble aggregated IgG was diluted to a final concentration of 
100µg/ml with the appropriate culture medium. All the heat-aggregated IgG was prepared 
and used the same day. 
 
2.2.2.7 Stimulation of mesangial cells  
Mesangial cells from WT or gld mice were stimulated with LPS, cytokines or heat-
aggregated mouse IgG. Briefly, 1x106 mesangial cells/well were cultured in complete RPMI 
1640 mesangial cell culture medium for 24 hours in a flat-bottomed 6-well plate. Following 
this period, the medium was replaced with serum-free RPMI 1640 mesangial cell culture 
medium and incubated overnight to put the mesangial cells into quiescence. The next day, 
mesangial cells were stimulated with either 100µg/ml heat-aggregated mouse IgG, 10ng/ml 
recombinant IL-1β or TNF-α (R&D Systems), 10ng/ml LPS (Sigma-Aldrich) or left 
unstimulated in serum-free RPMI 1640 meangial cell culture medium. After 24 hours 
stimulation, supernatants were harvested and centrifuged at 10,600 x g for 5 minutes at 4°C 
to remove cellular contaminants. These supernatants were transferred to new tubes and either 
examined immediately or stored at -20°C. 
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2.2.2.8 RNA extraction from mesangial cells 
500µl of TRIzol (Invitrogen) was added to 1x106 mesangial cells, following 
stimulation, and left for 5 minutes at room temperature and then placed in an eppendorf. 
100µl of chloroform was added and the samples shaken by hand and left at room temperature 
for 5 minutes. Samples were spun down in a microcentrifuge at 12000 x g for 15 minutes at 
4°C. The clear aqueous phase was transferred to a clean eppendorf and 250µl of isopropanol 
was added. Samples were stored at -20°C overnight. RNA were spun down at 12000 x g for 
10 minutes at 4°C and the supernatant discarded. The RNA pellet was washed with 75% 
ethanol, spun down at 8000 x g for 8 minutes at 4°C and the supernatant removed. The RNA 
was air-dried for 10 minutes, resuspended in 40µl RNase free water (Gibco) and heated at 
55°C for 5 minutes before being stored at -80°C. 
 
2.2.2.9 Mesangial cell expression of Fas ligand and FcγRIIB 
Expression of FasL and FcγRIIB on mesangial cells was determined by qRT-PCR. 
Mesangial cells were stimulated as Section 2.2.2.7 and RNA extracted as Section 2.2.2.8. 
qRT-PCR was repeated as in Section 2.2.1.23. FasL and FcγRIIB primers were synthesised 
by Sigma-Aldrich and taken from Ho et al. and Ichii et al., respectively (Ho et al., 2011; Ichii 
et al., 2008): 
 
 FasL forward 5’ACCCCCACTCAAGGTCCAT-3’ 
FasL reverse 5’CGAAGTACAACCCAGTTTCGT-3’ 
 
FcγRIIB forward 5’CTGAGGCTGAGAATACGATC-3’ 
FcγRIIB reverse 5’GTGGATCGATAGCAGAGAG-3’ 
 
Expression of FcγRIIB on mesangial cells was also determined by direct 
immunofluorescence. Briefly, WT and FcγRIIB-/- mesangial cells were washed in ice-cold 
PBS and cytospins were prepared. After allowing the slides to air dry, the cells were fixed in 
acetone for 10 minutes. FITC-labelled anti-FcγRIIB (clone 17.2) antibody was diluted in PBS 
P.E.H.Sharp  2013 
 
 124 
(1:50), applied to the sections and incubated for one hour at room temperature in a 
humidified chamber covered with aluminium foil. The sections were washed three times in 
PBS and mounted in AF1 solution (Citiflur). Cells were visualised using an Olympus BX4 
microscope (Olympus Optical) at x250 magnification and images captured using a QImaging 
Retiga 2000R Fast 1396 camera (QImaging). 
 
2.2.2.10 Splenocyte culture 
For splenocyte isolation, the spleen was removed and a single cell suspension created. 
The spleen was passed through a 100µm cell strainer and splenocytes resuspended in HL-1 
serum-free splenocyte medium (Lonza Group Ltd.) containing 100U/ml penicillin, 100µg/ml 
streptomycin and L-glutamine (Gibco). Splenocytes were spun down at 626 x g for 10 
minutes and resuspended in 1ml RBC lysis buffer. Red blood cells were lysed on ice for 5 
minutes before making up the volume to 14mls with medium. Splenocytes were spun down at 
157 x g for 10 minutes and resuspended in HL-1 serum-free splenocyte medium at a final 
concentration of 8x106 splenocytes/ml.  
 
2.2.2.11 Stimulation of splenocytes 
Splenocytes from WT and gld mice were stimulated with heat-aggregated sheep IgG. 
For proliferation assays, 2x105 splenocytes/well were cultured in a round-bottomed 96-well 
plate in HL-1 serum-free splenocyte medium (Lonza Group Ltd.) (Section 2.2.2.10) in the 
presence of 100µg/ml heat-aggregated sheep IgG or CD3/CD28 beads (Invitrogen) at 37°C, 
5% CO2 for 72 hours. For cytokine assays, 4x106 splenocytes/well were cultured in a flat-
bottomed 24-well plate in HL-1 serum-free splenocyte medium (Lonza Group Ltd.) (Section 
2.2.2.10) in the presence of 100µg/ml heat-aggregated sheep IgG or 100ng/ml 
phorbolmyristate acetate (PMA) (Sigma-Aldrich) and 500ng/ml ionomycin (Sigma-Aldrich) 
at 37°C, 5% CO2. After stimulation for 72 hours, supernatants were harvested and 
centrifuged at 10,600 x g for 5 minutes at 4°C to remove cellular contaminant. Supernatants 
were transferred to fresh eppendorfs and either examined immediately or stored at -20°C. 
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2.2.2.12 Proliferation of splenocytes 
Following stimulation for 72 hours, 0.037MBq of tritiated (3H) thymidine 
(PerkinElmer) was added to each well of splenocytes and incubated for a further 24 hours at 
37°C, 5% CO2. The radioactivity uptake was counted the following day using a 1450 
MicroBetaTriLux liquid scintillation and luminescence counter (PerkinElmer). 
 
2.2.2.13 Cytokine assessment 
Supernatants collected following stimulation of mesangial cells or splenocytes were 
analysed for cytokine production by ELISA. All kits, antibodies, standards and 
concentrations used are summarised in Table 2.14. IL-10 and IL-17 were both measured 
using R&D DuoSet ELISA Development kits (R&D Systems). Briefly, Nuncmaxisorp 
ELISA plates (Fisher Scientific) were coated with capture antibody overnight at room 
temperature. Plates were washed three times with PBS/0.1% Tween 20 (Sigma Aldrich) 
between each step. Plates were blocked with 1% BSA (Sigma-Aldrich) for 1 hour before 
adding 100µl of supernatant, diluted in 1% BSA/PBS, along with a standard curve of known 
concentration of cytokine and incubated for two hours at room temperature. Following this, 
the detection antibody was applied for two hours and then streptavidin-HRP, diluted 1:200, 
for 20 minutes, both at room temperature. Tetramethylbenzidine (TMB) substrate solutions A 
and B (Cambridge Bioscience) were mixed in equal volumes, incubated for 20 minutes 
before adding 1M H2SO4. Optical density was read at 450nm on a EL800 ELISA plate reader 
(BioTek). 
  IFN-γ, IL-4 and MCP-1 were measured using Ready-SET-Go ELISA kits 
(eBioscience). Briefly, Nuncmaxisorp ELISA plates (Fisher Scientific) were coated with 
capture antibody overnight at 4°C. Plates were washed five times with PBS/0.1% Tween 20 
(Sigma-Aldrich) between each step. Plates were blocked with 1x assay diluent for 1 hour 
before adding 100µl of supernatant, diluted in 1x assay diluent, along with a standard curve 
of known concentrations of cytokine and incubated for two hours at room temperature. 
Following this the detection antibody was applied for one hour and then avidin-HRP, diluted 
1:250, for 30 minutes, both at room temperature. 1x TMB substrate solution was incubated 
for 15 minutes before adding 1M H2SO4. Optical density was read at 450nm on an EL800 
ELISA plate reader (BioTek). 
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Antibody specificity Source Host Working Concentration/ 

















































































Table 2.14 Antibodies used for detecting cytokines in supernatants by ELISA. 
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2.3 Statistical analysis 
 All results reported in this document are expressed as median (range). Non-parametric 
tests of significance were applied throughout as it could not be assumed that the distribution 
of the data was Gaussian. For comparing two unpaired groups, the Mann-Whitney U-test was 
used, and for comparing three or more groups, the Kruskal-Wallis test was used, with Dunn’s 
Multiple Comparisons test (p values given are from Dunn’s test). A probability of less than 
0.05 was considered significant. Statistical analysis was carried out using GraphPad Prism 
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2.4 Buffers and solutions 
2.4.1 Polymerase chain reaction (PCR) 
Lysis buffer for tail/toe/ear 
100mM Tris-HCl (pH 8.5), 5mM EDTA, 0.2% SDS, 200mM NaCl and 100µg/ml proteinase 
K (added immediately before use). 
 
Lysis buffer for blood 
25mM TRIS (pH 8.0), 100mM NaCl, 1% SDS and 100µg/ml of proteinase K (added 
immediately before use). 
 
TAE buffer (50x) 
40mM Tris-acetate, 1mM EDTA (pH 8.0). For use in DNA electrophoresis, TAE buffer was 
diluted down to 1x with dH2O. 
 
2.4.2 Tissue fixation 
Neutral buffered formalin (pH 7.0) 
100ml formalin, full strength (37-40% formaldehyde), 6.5g Na2HPO4, 4g NaH2PO4 and 
900ml dH2O. 
 
Paraformaldehyde lysine periodate (PLP) fixative 
Lysine stock solution: 0.2M lysine monohydrochloride (3.65g/100ml) added to an equal 
volume of 0.1M disodium hydrogen orthophosphate (1.41g/100ml for anhydrous). The 
solution was adjusted to pH 7.4 and stored at 4°C.  
4% Paraformaldehyde: paraformaldehyde was dissolved in dH2O (4g/100ml) with stirring at 
60°C in a fume hood. The solution was cleared by adding a few drops of 1M NaOH and then 
stored at 4°C. 




Immediately prior to use: 1 volume of 4% paraformaldehyde was added to 3 volumes of 
lysine stock solution and 10mM sodium metaperiodate (0.214g/100ml) was added. 
 
2.4.3 Immunohistochemistry 
Phosphate buffered saline (PBS) 
137mM NaCl, 0.27mM KCl, 8.1mM Na2PO4, 1.5mM KH2PO4, adjusted to pH 7.2. 
 
3,3’-Diaminobenzidine (DAB) solution 
0.05% (w/v) DAB, 0.003 H2O2 in PBS (pH 7.5). Stored at -20°C. 
 
Acid Alcohol 
1% HCl mixed with 70% ethanol. 
 
2.4.4 Tissue culture 
Red blood cell (RBC) lysis buffer 
4.17g NH4Cl, 0.00185g EDTA, 0.5g NaHCO3, 500ml sterile ddH2O. 
 
Splenocyte medium 
HL-1 serum-free medium containing 100U/ml penicillin, 100µg/ml streptomycin and L-
glutamine. 
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Mesangial cell medium 
RPMI-1640 medium supplemented with 20% fetal calf serum, 100U/ml penicillin, 100U/ml 
streptomycin, 2% L-glutamine and 1% insulin-transferrin-selenium growth supplement (ITS 
liquid). 
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2.5 Suppliers and distributors 
Agilent Technologies UK Ltd.   Edinburgh, UK 
Applied Biosystems/Life Technologies Corp. Carlsbad, CA, USA 
BD Biosciences     San Jose, CA, USA 
BDH       Poole, UK 
Bio-Rad Laboratories Ltd.    Hemel Hempstead, UK 
Bioline Reagents Ltd.     London, UK 
Biosera      Ringmer, UK 
BioTek      Winooski, VT, USA 
Bright Instrument Company Ltd.   Huntingdon, UK 
Cambrex      East Rutherford, NJ, USA 
Cambridge Bioscience Ltd.    Cambridge, UK 
CellPath Ltd.      Powys, UK 
Citiflur Ltd.      London, UK 
Corning Incorporated     Corning, NY, USA 
eBioscience      San Diego, CA, USA 
Eppendorf      Hamburg, Germany 
Fisher Scientific     Loughborough, UK 
Gibco/Life Technologies Ltd.    Paisley, UK 
GraphPad Software     San Diego, CA, USA 
Invitrogen/Life Technologies Ltd.   Paisley, UK 
Labtech International Ltd.    Ringmer, UK 
Lonza Group Ltd.     Basle, Switzerland 
Media Cybernetics, Inc.    Bethesda, MD, USA 
MJ Research      Waltham, MA, USA 
New England BioLabs, Inc.    Hitchin, UK  
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Newmarket Scientific Ltd.    Newmarket, UK 
Olympus Optical     London, UK 
Perkin Elmer, Inc.     Waltham, MA, USA 
Promega      Southampton, UK  
Qiagen Ltd.      Crawley, UK 
QImaging      Surrey, BC, Canada 
R&D Systems      Abingdon, UK 
R-Biopharm Rhone Ltd.    Glasgow, UK  
Regal Group      Surrey, UK 
Roche       Basle, Switzerland 
Serotec      Oxford, UK 
Sigma-Aldrich Company Ltd.   Dorset, England 
SouthernBiotech     Birmingham, AL, USA 
Surgipath Europe Ltd.     Peterborough, UK 
The Jackson Laboratory    Bar Harbor, ME, USA 
Thermo Fisher Scientific    Waltham, MA, USA 
TreeStar      Ashland, OR, USA 
Vector Laboratories     Burlingame, CA, USA 













The Role of Fas Ligand in Accelerated Nephrotoxic Nephritis 
 
3.1 Introduction 
The identification of the FasL mutation in gld mice has facilitated the study of the role 
of FasL in different diseases. FasL has been found to play a detrimental role in EAE (Sabelko 
et al., 1997; Waldner et al., 1997), autoimmune diabetes (Chervonsky et al., 1997; Itoh et al., 
1997; Mohamood et al., 2007), EAU (Wahlsten et al., 2000), acute lung injury (Neff et al., 
2005), and experimental stroke (Niu et al., 2011). In addition to its role in inducing apoptosis, 
defects in FasL have been reported to cause a reduction in signalling through the IL-1R, 
TLR4 and NF-κB (Ahn et al., 2001; Altemeier et al., 2007; Bannerman et al., 2002; Ma et al., 
2004) as well as affecting the chemoattractant properties of sFasL towards neutrophils 
(Dupont and Warrens, 2007; Ottonello et al., 1999; Seino et al., 1998). 
The role of FasL in glomerulonephritis, however, is undefined. FasL has been shown 
to be expressed in both healthy and diseased kidneys in humans and mice, with expression 
being upregulated in the glomerulus during injury (Lorz et al., 2000; Tsukinoki et al., 2004). 
Treatment of lupus-prone mice with an anti-FasL monoclonal blocking antibody prevented 
the development of nephritis, compared to untreated mice despite the presence of 
autoantibodies (Nakajima et al., 2000). However, both lpr and gld mice bred on permissive 
backgrounds develop spontaneous autoimmunity and severe nephritis (Izui et al., 1984). This 
is the first study to address the role of FasL in experimental GN. Since both circulating 
leukocytes and intrinsic renal cells express FasL, it is well placed to modulate renal disease 
either by inducing apoptosis of infiltrating cells or initiating an inflammatory response.  
The model I have used to investigate the role of FasL in GN is accelerated NTN. This 
is a model in which disease is induced following an immune response to an antibody (raised 
in sheep against GBM antigens) planted on the GBM. NTN depends on a Th1/Th17 
predominant immune response and is widely used in C57BL/6 mice. Preliminary work by my 
supervisor demonstrated protection of gld mice from NTN. The aim of the work presented in 
this chapter is to confirm this protection and establish possible mechanisms. 
P.E.H.Sharp  2013 
 
 134 
My hypothesis was that FasL is required to initiate an inflammatory response and its 
absence will protect the mice from developing GN, either due to defects in the immune 




This first chapter of the thesis was an investigation of the role of FasL in the well-
characterised model of NTN. The results were based on the assessment of disease in WT and 
gld mice. I also studied the differences in intra-renal cytokine production during NTN, as 
well as the differences in splenocyte proliferation and cytokine production, following 
stimulation with sheep IgG, CD3/CD28 beads, or PMA and ionomycin, to ask if defective 
FasL affects the immune response in gld mice.  
 
 
3.3 Experimental design 
The role of FasL in accelerated NTN was studied to elucidate its role in a model of 
immune-mediated GN and to obtain further insights into pathogenesis of the disease. 
Nephritis was induced in gld mice on a C57BL/6 background and age- and sex-matched WT 
C57BL/6 control mice. Assessment of disease was done by the following methods: (1) renal 
function was assessed by measuring albuminuria and serum urea; (2) renal morphology 
(severity of glomerular injury) was analysed in PAS-stained sections under light microscopy; 
(3) quantitation of kidney sections for infiltrating leukocytes was done by immunoperoxidase 
staining; and (4) immune responses were analysed by quantitation of sheep and mouse IgG 
deposition in the kidney and circulating levels of mouse anti-sheep IgG. Apoptotic cells and 
whole kidney mRNA cytokine and chemokine expression levels were also assessed. Since 
gld mice on a C57BL/6 background are susceptible to developing late onset autoimmunity 
with GN, baseline parameters were taken of unmanipulated gld and WT mice at 2 and 4 
months.  
To study the immune response, spleens were collected from mice either 7 days after 
immunisation with the antigen (sheep IgG) or at the termination of a day 10 NTN experiment 
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and splenocytes were isolated and stimulated with sheep IgG, CD3/CD28 beads, or PMA and 
ionomycin. Proliferation was assessed by 3H thymidine uptake and cytokine production was 
measured in the supernatant by ELISA. 
  




3.4.1 Genotyping of gld mice using polymerase chain reaction 
The genotype of gld mice was confirmed by PCR analysis and restriction digest. 
DNA was extracted from tail snips and amplified by PCR using FasL specific primers. 
Amplified DNA was digested using the restriction endonuclease StuI, resulting in bands of 
88bp and 20bp for the WT product, although the 20bp band was too small to detect, and a 
single band of 108bp for the mutated allele. The presence of the 108bp and 88bp bands 
represented a heterozygote. A negative control without DNA was used to demonstrate the 





Figure 3.1 PCR reactions of genomic DNA from WT and gld animals. 
Representative examples of WT (+/+), gld (-/-) and heterozygote (+/-) mice are shown here. 
The WT (+/+) mice show a band at 88bp, the gld (-/-) mice show a band at 108bp and the 
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3.4.2 Ageing gld mice on a C57BL/6 background developed glomerular immune 
complex deposition and mild renal dysfunction 
Mice used in the NTN experiments were between 2-4 months of age. At 2 months, the 
gld mice showed no evidence of spontaneous renal disease, as assessed by the presence of 
glomerular crescents, thrombosis, IgG immune deposits and serum urea and creatinine, 
compared to WT C57BL/6 mice of the same age.  At 4 months there was some granular IgG 
deposited in the glomeruli of the gld mice and elevated serum urea (p=0.0037). There was no 
significant difference in glomerular macrophage or CD4+ T cell numbers between WT and 
gld mice at 2 and 4 months (Table 3.1). In view of these results, young mice, aged 6-8 weeks, 











































































































Table 3.1 Baseline renal parameters of WT and gld mice at 2 and 4 months of age. 
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3.4.3 Preliminary data 
Prior to the start of my PhD project, my supervisor performed some preliminary 
experiments inducing NTN in WT and gld mice, which are outlined in Table 3.2 and Table 
3.3. In all experiments mice were pre-immunised with 0.2mg of sheep IgG in CFA and after 
five days 200µl (1:4 dilution) of NTS was administered via the tail vein. Three experiments 
were terminated on day 7 after the induction of NTN and demonstrated protection of gld mice 
from GN, with gld mice having significantly reduced glomerular thrombosis, crescents and 
serum creatinine compared to WT mice (Table 3.2 and Figure 3.2). Two further experiments 
were terminated 24 hours after the injection of NTS to measure neutrophil influx, with 
conflicting results. One experiment showed a reduction in neutrophil infiltration and reduced 
IgG deposition in the gld mice, whilst the other experiment showed no difference between the 
two groups (Table 3.3).  
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 Experiment 1 Experiment 2 Experiment 3 
Genotype WT Gld WT Gld WT Gld 
Mice 12 9 11 10 12 11 
Sex M M M M M M 
End Point (day) 7 7 7 7 7 7 
Serum Anti-Sheep 
IgG 














































































Table 3.2 Preliminary data looking at NTN in WT and gld mice at day 7. 
M = male. All data represent the median (range). The data were analysed using the Mann-
Whitney U-test (p*<0.05, p**<0.01, p***<0.001).  
 






Figure 3.2 Preliminary data looking at NTN in WT and gld mice at day 7. 
Crescents, thrombosis, urinary albumin/creatinine ratio and macrophages were compared in 
WT and gld mice 7 days after administration of NTS. WT mice had significantly more (A) 
thrombosis and (B) crescents, however there was no difference in (C) the urinary 
albumin/creatinine ratio and (D) glomerular macrophage infiltration in gld mice. All data 
represent individual values with the median. The data were analysed using the Mann-






















































































  Experiment 4 Experiment 5 
Genotype WT Gld WT Gld 
Mice 10 9 14 7 
Sex M M M M 
End Point 24 hours 24 hours 24 hours 24 hours 




Not done Not done 
Deposited Glomerular 



























Table 3.3 Preliminary data looking at NTN in WT and gld mice 24 hours after 
induction of NTN.  
M = male. All data represent the median (range). The data were analysed using the Mann-
Whitney U-test (p*<0.05, p**<0.01). 
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3.4.4 Gld mice are protected from developing glomerular crescents, thrombosis and 
renal failure 
The results from the preliminary experiments raise questions about the mechanisms of 
protection of the gld mice from NTN. FasL is involved in the deletion of T cells at the end of 
the immune response (Kabelitz et al., 1993). In this context, although gld mice were 
protected from EAE initially (Sabelko et al., 1997; Waldner et al., 1997), one report showed 
worsening of EAE at later time points (Sabelko-Downes et al., 1999). Whilst EAE is a 
different model from NTN, we wanted to look at a later time point in the disease process to 
determine whether gld mice would develop worsening disease at a later stage. It is not 
possible to maintain mice for prolonged periods after the induction of NTN, as it can lead to 
severe renal failure. We therefore chose to investigate disease up to day 15. We also 
investigated mechanisms in more detail by assessing the immune response, cell infiltration, 
levels of apoptosis and intra-renal cytokines. The first part of this chapter details the results 
obtained at day 15 after the induction of NTN. 
NTN was induced in WT and gld mice. Mice were pre-immunised with 0.2mg of 
sheep IgG in CFA and after five days 200µl (1:4 dilution) of NTS was administered via the 
tail vein. Twenty-two male animals were used (n=11 WT and n=11 gld mice) and mice were 
sacrificed on day 15. 
To assess renal function, serum urea and albuminuria, expressed as a ratio of urinary 
albumin and creatinine, were measured in all mice. WT mice had reduced renal function as 
shown by significantly higher serum urea (29 (12-47) mmol/L) and albuminuria (5.3 (0.050-
11) mg/mmol) compared to gld mice  (serum urea: 16 (10-35) mmol/L, p=0.022; 
albuminuria: 0.025 (0.010-2.2) mg/mmol, p=0.0004) (Figure 3.3). Histological damage, in 
the form of glomerular crescents and thrombosis, was assessed in all mice on PAS-stained 
sections. WT mice had significantly more glomerular damage, shown by an increase in 
thrombosis (0.3 (0.00-1.6)) and glomerular crescents (16 (0.00-40) %) compared to gld mice 
(thrombosis: 0.020 (0.00-0.14), p=0.0023; crescents: 0.00 (0.00-2.0) %, p=0.0001) (Figure 
3.4 and Figure 3.5). 




Figure 3.3 Measurement of serum urea and urinary/albumin creatinine ratio in WT 
and gld mice with NTN at day 15. 
The level of serum urea and the urinary albumin/creatinine ratio was measured in WT and gld 
mice 15 days after administration of NTS. (A) WT mice had significantly higher levels of 
serum urea and (B) albuminuria compared to gld mice. All data represent individual values 
with the median. The data were analysed using the Mann-Whitney U-test (p*<0.05, 













































Figure 3.4 Quantification of histologically abnormal glomeruli from WT and gld 
mice with NTN at day 15. 
(A) Thrombosis and (B) crescents scored on PAS-stained kidney sections from WT and gld 
mice day 15 post NTS injection. WT mice had significantly more damaged glomeruli than 
gld mice. All data represent individual values with the median. The data were analysed using 
Mann-Whitney U-test (p**<0.01 and p***<0.001). Dashed lines represent values for a group 




































Figure 3.5 PAS staining of kidneys from WT and gld mice. 
Representative PAS staining from (A) a WT mouse with a crescentic glomerulus, (B) a WT 
mouse with a thrombotic glomerulus and (C) a gld mouse with a healthy glomerulus, 15 days 
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3.4.5 There was no reduction in glomerular macrophage infiltration, but gld mice had 
fewer interstitial macrophages and glomerular and interstitial CD4+ T cells 
Kidney sections collected 15 days after administration of NTS from WT and gld mice 
were stained for macrophages (CD68) and CD4+ T cells as a measure of inflammation 
(Figure 3.6 and Figure 3.8, respectively). There was no significant difference between 
glomerular macrophage infiltration between WT and gld mice (macrophages/gcs: WT 1.8 
(0.24-4.7), gld 1.2 (0.36-4.1), p=0.43) (Figure 3.7 A); however, there were significantly 
fewer interstitial macrophages in gld mice (1.2 (0.56-3.3) arbitrary units (AU)) compared to 
WT mice (4.3 (0.29-12) AU, p=0.026) (Figure 3.7 B). Gld mice had significantly fewer 
glomerular T cells (0.19 (0.040-0.49) T cells/gcs) and interstitial T cells (0.10 (0.063-1.2) 
AU) than WT mice (T cells: 0.38 (0.12-1.1)/gcs, p=0.031; interstitial T cells: 0.57 (0.074-2.0) 






















Figure 3.6 Glomerular and interstitial macrophage infiltration in WT and gld mice 
with NTN at day 15. 
Immunohistochemistry for macrophages (CD68) on WT and gld mouse kidney sections at 














































Figure 3.7 Glomerular and interstitial macrophage infiltration in WT and gld mice 
with NTN at day 15. 
(A) Infiltration of macrophages/gcs (50 glomeruli scored per section) was measured. There 
was no significant difference in glomerular macrophage infiltration between WT and gld 
mice. (B) Interstitial macrophage infiltration (5 fields of view per section) was measured. 
There were significantly fewer interstitial macrophages in gld mice compared to WT mice. 
All data represent individual values with the median. The data were analysed using the 
Mann-Whitney U-test (ns= non-significant, p*<0.05). Dashed lines represent values for a 









Figure 3.8 Glomerular and interstitial CD4+ T cell infiltration in WT and gld mice 
with NTN at day 15. 
Immunohistochemistry for T cells (CD4) on WT and gld mouse kidney sections at day 15. 















































Figure 3.9 Glomerular and interstitial CD4+ T cell infiltration in WT and gld mice 
with NTN at day 15. 
(A) Infiltration of CD4+ T cells/gcs (50 glomeruli scored per section) was measured. WT 
mice had significantly more glomerular CD4+ T cells than gld mice. (B) Interstitial CD4+ T 
cell infiltration (5 fields of view per section) was measured. WT mice had significantly more 
interstitial CD4+ T cells than gld mice. All data represent individual values with the median. 
The data were analysed using the Mann-Whitney U-test (p*<0.05). Dashed lines represent 
values for a group of normal WT mice.   
A) 
B) 
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3.4.6 There was no reduction in glomerular neutrophil infiltration in gld mice 24 
hours after induction of NTN 
NTN is characterised by an infiltration of glomerular neutrophils, within the first two 
hours, and sFasL has been shown to act as a potent chemoattractant for the migration of 
neutrophils to sites of inflammation (Dupont and Warrens, 2007; Letellier et al., 2010; Seino 
et al., 1998). To investigate whether FasL plays a role in neutrophil recruitment in NTN we 
induced disease in WT and gld mice and sacrificed them after 24 hours. 
As the initial experiments performed to 24 hours had yielded conflicting results in 
terms of whether neutrophil infiltrate was reduced in gld mice, a third experiment was 
performed. NTN was induced, by pre-immunising with 0.2mg of sheep IgG in CFA and after 
five days administering 200µl (1:4 dilution) of NTS via the tail vein, in seventeen female 
mice (n=7 WT mice and n=10 gld mice). Female mice were used on this occasion due to 
availability of mice. 
After 24 hours, there was no significant difference in the serum urea levels of WT and 
gld mice (WT 7.2 (6.4-9.4) mmol/L, gld 6.6 (5.5-8.9) mmol/L, p=0.31) (Figure 3.10). Kidney 
sections collected at the end of the experiment were PAS-stained and neutrophils counted by 
their distinctive morphology. There was no significant difference in glomerular neutrophil 
infiltrate between the two groups (neutrophils/gcs: WT 0.6 (0.08-2.4), gld 0.59 (0.04-3.0), 








Figure 3.10 Measurement of serum urea in WT and gld mice with NTN at 24 hours. 
Serum urea levels in WT and gld mice with NTN. There was no significant difference in 
levels of serum urea between WT and gld mice at 24 hours. All data represent individual 
values with the median. The data were analysed using the Mann-Whitney U-test (ns= non-































Figure 3.11 Glomerular neutrophil infiltration in WT and gld mice with NTN at 24 
hours. 
Infiltration of neutrophils/gcs (50 glomeruli scored per section) was measured. There was no 
significant difference in neutrophil infiltration between WT and gld mice. All data represent 
individual values with the median. The data were analysed using the Mann-Whitney U-test 
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3.4.7 Systemic immune responses 
3.4.7.1 Circulating mouse antibodies against sheep IgG 
Although the IgG immune response appeared to be intact in the gld mice at the 
termination of the day 7 experiments, we confirmed this again at 24 hours and day 15, and 
also looked at the subclass responses. Certain subclasses of IgG, such as IgG2, have been 
reported to be more pathogenic than others in NTN (Robson et al., 2001).  
Mouse serum, collected at the end of the experiments, was tested for the antigen-
specific immune response against sheep IgG. At 24 hours (data shown from 24 hour 
experiment in Section 3.4.6), there was no significant difference in total circulating anti-
sheep IgG, as measured by ELISA, between WT and gld mice (median optical density at 
405nm (OD at 405nm): WT 1.3 (0.030-1.6), gld 1.2 (0.78-1.8), p=0.67) (Figure 3.12 A). 
However, at day 7 (see Table 3.2) and day 15, levels were significantly higher in the gld mice 
(results shown from day 15) (median OD at 405nm 1.8 (0.00-2.8)) compared to the WT mice 
(median OD at 405nm 0.33 (0.046-1.3), p=0.0039) (Figure 3.12 B). Levels of circulating 
anti-sheep IgG subclasses, IgG1, IgG2b, IgG2c, and IgG3, were measured at day 15. Gld 
mice had significantly higher titres of all subclasses (median OD at 405nm: IgG1 0.43 
(0.011-0.60), IgG2b 0.20 (0.0060-0.66), IgG2c 0.50 (0.021-1.4), and IgG3 0.24 (0.00-3.0)) 
compared to WT mice (median OD at 405nm: IgG1 0.19 (0.060-0.49), p=0.0071; IgG2b 
0.015 (0.0040-0.13), p=0.0022; IgG2c 0.028 (0.014-0.17), p=0.0006; IgG3 0.020 (0.0070-
1.3), p=0.015) (Figure 3.13).  
  
 




Figure 3.12 Total circulating mouse anti-sheep IgG levels in WT and gld mice with 
NTN at 24 hours and day 15. 
The total circulating levels of mouse anti-sheep IgG were measured by ELISA. (A) The total 
circulating anti-sheep IgG levels were assessed in WT and gld mice at 24 hours and showed 
no difference. However, (B) gld mice had significantly higher titres at day 15 compared to 
WT mice. All data represent individual values with the median. The data were analysed using 














































Figure 3.13 Circulating mouse anti-sheep IgG1, IgG2b, IgG2c and IgG3 levels in WT 
and gld mice with NTN at day 15. 
The circulating levels of mouse anti-sheep IgG1, IgG2b, IgG2c and IgG3 were measured by 
ELISA. At day 15, gld mice had significantly higher titres of circulating (A) IgG1, (B) 
IgG2b, (C) IgG2c, and (D) IgG3 compared to WT mice. All data represent individual values 
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3.4.7.2 Deposited glomerular IgG  
Frozen kidney sections from experiments were stained for deposited sheep IgG and 
mouse IgG by direct immunofluorescence on tissue taken at the end of the experiment. Total 
glomerular mouse IgG and sheep IgG were measured by quantitative immunofluorescence 
with the results expressed as arbitrary fluorescence units (AFU). Glomerular sheep IgG 
deposition was equivalent between WT and gld mice after 24 hours (data shown from 
experiment in Section 3.4.6) (WT 139 (98-153) AFU, gld 124 (31-147) AFU, p=0.67), 7 days 
(Table 3.2), and 15 days (WT 20 (14-32) AFU, gld 16 (10-32) AFU, p=0.13) (Figure 3.14 
and Figure 3.15). There was no significant difference in glomerular mouse IgG deposition 
between WT and gld mice at 24 hours (data shown from experiment in Section 3.4.6) (WT 95 
(0.00-135) AFU, gld 95 (0.00-170) AFU, p=0.96). However, at day 7 (Table 3.2) and day 15 
there was significantly more mouse IgG deposited in the glomeruli of gld mice (results from 
day 15) (60 (53-79) AFU) compared to the WT mice (46 (32-58) AFU, p=0.0005) (Figure 




















Figure 3.14 Immunofluorescence for glomerular sheep IgG deposition in WT and gld 
mice with NTN at 24 hours and day 15. 
The relative median glomerular immunofluorescence was measured and expressed as 
arbitrary fluorescence units (AFU). There was no significant difference in deposited sheep 
IgG between WT and gld mice at (A) 24 hours and (B) day 15. All data represent individual 


























































Figure 3.15 Immunofluorescence for glomerular sheep IgG deposition in WT and gld 
mice with NTN, at 24 hours and day 15. 
Representative glomeruli from WT and gld mice showing sheep IgG deposition at 24 hours 














Figure 3.16 Immunofluorescence for glomerular mouse IgG deposition in WT and gld 
mice with NTN, at 24 hours and day 15. 
The relative median glomerular immunofluorescence was measured and expressed as 
arbitrary fluorescence units (AFU). There was no significant difference in deposited mouse 
IgG between WT and gld mice at (A) 24 hours. At (B) day 15, gld mice had significantly 
more deposited glomerular mouse IgG than WT mice. All data represent individual values 

























































Figure 3.17 Immunofluorescence for glomerular mouse IgG deposition in WT and gld 
mice with NTN, at 24 hours and day 15. 
Representative glomeruli from WT and gld mice showing mouse IgG deposition at 24 hours 
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3.4.8 Gld mice have fewer glomerular apoptotic cells than WT mice 
FasL is best characterised for inducing apoptosis through its receptor, Fas. However, 
as discussed in the introduction (Section 1.7), non-apoptotic functions are also postulated. In 
view of the involvement of FasL in apoptosis, it was important to quantitate the presence of 
apoptosis in the kidney in our model. Paraffin-fixed kidney sections from WT and gld mice 
(day 15) were stained for apoptosis by TUNEL (Figure 3.18 A). Apoptotic cells were counted 
in 30 glomeruli per cross section. Gld mice had significantly fewer apoptotic cells than WT 
mice per glomerular cross section (WT 0.2 (0.00-0.85)/gcs, gld 0.00 (0.00-0.00)/gcs, 



























Figure 3.18 Glomerular apoptotic cells in WT and gld mice with NTN were identified 
by TUNEL staining. 
(A) Representative TUNEL staining from WT and gld mice with NTN. Arrow highlighting 
an apoptotic cell. (B) The number of apoptotic cells per glomerular cross section (gcs) in WT 
and gld mice at day 15 post NTN induction. All data represent individual values with the 
median. The data were analysed using Mann-Whitney U-test (p***<0.001). Dashed line 
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3.4.9 mRNA expression of cytokines and other mediators 
Previous data have shown that FasL is involved in the generation of pro-inflammatory 
cytokines (see Section 1.7.1) and can influence T cell phenotypes, and therefore the cytokine 
milieu (Section 1.6.2). To look at any possible differences between WT and gld mice, mRNA 
expression of cytokines, and other mediators, were measured by qRT-PCR. Whole kidney 
mRNA was extracted from frozen WT and gld kidneys from day 15 post NTS administration, 
as well as unmanipulated control mice. Mediators measured were: MCP-1, involved in the 
recruitment of macrophages; TNF-α and IL-6, pro-inflammatory cytokines secreted by 
macrophages; inducible nitrous oxide synthase (iNOS), arginase and mannose receptor (MR), 
markers of macrophage phenotype; IFN-γ and IL-12p40, Th1 cytokines; and IL-4 and IL-10, 
Th2 cytokines. Data represent relative expression, calculated using GAPDH as the 
housekeeping gene and an untreated WT mouse as the reference. 
Post NTN, MCP-1 mRNA expression in whole kidney from WT mice was 
significantly greater compared to gld mice (MCP-1: WT 16 (0.45-111), gld 2.0 (0.50-5.1), 
p=0.0013), which is consistent with the overall increase in macrophages seen in the kidneys 
of WT mice. There was also a significant difference in iNOS expression, secreted by 
classically activated pro-inflammatory macrophages, with iNOS expression being higher in 
the WT mice than in the gld mice during disease (WT 1.2 (0.70-3.3), gld 0.56 (0.26-1.3), 
p=0.0031). Surprisingly, there was also a greater increase in MR expression in WT mice with 
NTN compared to gld mice with NTN (WT 9.9 (1.2-18), gld 2.0 (1.1-5.6), p=0.0043). MR is 
expressed by alternatively activated repair macrophages; the greater number of macrophages 
in the kidneys of the WT mice can account for this difference. There was no significant 
difference in TNF-α, IL-6 or arginase mRNA expression between WT and gld mice (TNF-α: 
WT 2.2 (0.11-20), gld 1.2 (0.41-5.1), p=0.32; IL-6: WT 2.4 (1.1-5.8), gld 1.1 (0.55-6.7), 
p=0.094; arginase: WT 43 (0.47-105), gld 16 (0.78-36), p=0.10) (Figure 3.19).  
When measuring cytokines modulating T cell phenotypes, WT mice had greater 
expression of IFN-γ and IL-12p40 mRNA (IFN-γ 4.7 (0.56-14), IL-12p40 1.5 (0.41-3.6)) 
compared to gld mice (IFN-γ 1.7 (0.72-9.1), p=0.039; IL-12p40 0.40 (0.22-0.86) p=0.0005). 
IFN-γ and IL-12p40 are both Th1 cytokines, associated with a pro-inflammatory response in 
NTN. However, there was no significant difference in expression of IL-4 and IL-10, Th2 
cytokines, between WT and gld mice (IL-4: WT 0.38 (0.10-0.60), gld 0.43 (0.15-1.1), 
p=0.22; IL-10: WT 0.72 (0.21-1.4), gld 0.57 (0.32-1.2), p=0.90) (Figure 3.20).  




Figure 3.19 Whole kidney mRNA expression of MCP-1, iNOS, TNF-α, IL-6, arginase 
and MR in WT and gld mice with NTN, at day 15. 
Relative expression of (A) MCP-1, (B) iNOS, (C) TNF-α, (D) IL-6, (E) arginase and (F) MR 
were measured in whole kidney mRNA extracts. WT mice had significantly greater mRNA 
expression of MCP-1 and MR, whilst gld mice had reduced expression of iNOS. There was 
no significant difference in mRNA expression of TNF-α, IL-6 and arginase. All data 
represent individual values with the median. The data were analysed using Mann-Whitney U-















































































































































Figure 3.20 Whole kidney mRNA expression of IFN-γ, IL-12p40, IL-4 and IL-10 in 
WT and gld mice with NTN, at day 15. 
Relative expression of (A) IFN-γ, (B) IL-12p40, (C) IL-4, and (D) IL-10 were measured in 
whole kidney mRNA extracts. WT mice had significantly greater mRNA expression of IFN-γ 
and IL-12p40 compared to gld mice. There was no significant difference in mRNA 
expression of IL-4 and IL-10. All data represent individual values with the median. The data 
were analysed using Mann-Whitney U-test (ns= non-significant, p*<0.05, p***<0.001). 
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3.4.10 Renal expression of Fas ligand during NTN 
To see if FasL was upregulated in the kidney during NTN, WT whole kidney mRNA 
was also assessed for expression of FasL, at day 15 post NTS administration, by qRT-PCR. 
FasL was detected in both healthy and diseased whole kidney, with an increase of expression 

























Figure 3.21 Expression of Fas ligand in WT control and NTN whole kidney. 
Relative expression of FasL mRNA in whole kidney from unmanipulated WT mice (Control) 
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3.4.11 Splenocyte proliferation 
FasL is expressed on T cells and is involved in regulating the immune response by 
playing a role in T cell activation and proliferation (Alderson et al., 1993) as well as inducing 
apoptosis to terminate the response (Kabelitz et al., 1993). To investigate this further, in our 
model of NTN, splenocyte proliferation assays were carried out on splenocytes collected 
from WT and gld mice following pre-immunisation only (primary immune response) and at 
the termination (day 10) of a NTN experiment.  
Initially, splenocytes were stimulated with CD3/CD28 beads, to compare maximal 
stimulation of the entire splenocyte population, at day 7 following pre-immunisation with 
sheep IgG. Gld splenocytes proliferated less in response to CD3/CD28 beads compared to 
WT splenocytes (counts per minute (c.p.m): WT 340200 (220300-402500), gld 212800 
(68460-363500), p=0.023) (Figure 3.22).  
To investigate antigen specific proliferation, following both pre-immunisation and at 
the termination (day 10) of a NTN experiment (histology data not shown but consistent with 
data from other experiments presented), WT and gld splenocytes were stimulated with 
100µg/ml of sheep IgG. This was to gain better understanding of any differences there may 
be in the immune response both early on in the experiment, at the time the NTS is injected, 
and at the end of the NTN experiment. Following pre-immunisation only, gld splenocytes 
proliferated less in response to sheep IgG compared to WT splenocytes (c.p.m: WT 13000 
(7791-21360), gld  8397 (1365-9589), p=0.0033) (Figure 3.23 A). However, following 
termination of the NTN experiment, there was no significant difference in splenocyte 
proliferation in response to sheep IgG between WT and gld mice (representative results of 
one of two experiments) (c.p.m: WT 8712 (1834-12670), gld 6222 (4613-12520), p=0.71) 
(Figure 3.23 B). These results suggest that a reduction in T cell-mediated immunity in the 
early phase of disease could be contributing to the protection of gld mice from developing 
NTN, although that result is only preliminary as it was only performed once at that time 
point.  




Figure 3.22 Splenocyte proliferation following stimulation with CD3/CD28 beads. 
Splenocyte proliferation was assessed by measuring 3H thymidine incorporation at 72 hours 
following stimulation with CD3/CD28 beads, after pre-immunisation only. WT splenocytes 
proliferated significantly more than gld splenocytes. All data represent individual values with 

















Figure 3.23 Splenocyte proliferation following stimulation with 100µg/ml of sheep 
IgG. 
Splenocyte proliferation was assessed by measuring 3H thymidine incorporation at 72 hours 
following stimulation with 100µg/ml of aggregated sheep IgG. After (A) pre-immunisation 
only, WT splenocytes proliferated significantly more in response to sheep IgG than gld 
splenocytes, however (B) at the termination of the experiment, there was no significant 
difference in splenocyte proliferation in response to sheep IgG. All data represent individual 
values with the median. The data were analysed using Mann-Whitney U-test (ns= non-
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3.4.12 Splenocyte cytokine production 
NTN is thought to be driven by a Th1/Th17-deviated immune response; mice 
predisposed to a Th2 immune response, such as BALB/c mice, are protected from disease 
(Holdsworth et al., 1999; Huang et al., 1997a; Summers et al., 2009). Gld mice and humans 
carrying mutations in Fas or FasL have been found to have a Th2-deviated immune response 
(Fuss et al., 1997). To investigate whether the T cell responses of gld mice are deviated 
towards a Th2 response in NTN we looked at cytokine production, following splenocyte 
stimulation, after pre-immunisation only.  
Initially, splenocytes were stimulated with PMA and ionomycin to compare cytokine 
production of the entire splenocyte population. PMA and ionomycin were used as they are 
cheaper than CD3/CD28 beads and more splenocytes needed to be stimulated to produce 
enough cytokine for measuring by ELISA. There was a significant increase in IL-4 and IL-10 
production by gld splenocytes (IL-4 46 (28-76) pg/ml; IL-10 446 (309-554) pg/ml) compared 
to WT splenocytes (IL-4 33 (27-42) pg/ml, p=0.042; IL-10 359 (303-440) pg/ml, p=0.042). 
There was no significant difference in IFN-γ production (WT 1609 (1040-2450) pg/ml, gld 
1079 (886-2046) pg/ml, p=0.055) or IL-17 (WT 941 (626-1348) pg/ml, gld 648 (415-1101) 
pg/ml, p=0.11) although WT splenocytes trended towards producing more of a Th1/Th17 
response compared to gld splenocytes (Figure 3.24).  
To investigate antigen-specific proliferation, splenocytes from pre-immunised mice 
were stimulated with sheep IgG. There was no significant difference in IFN-γ production 
between WT and gld splenocytes (IFN-γ: WT 57 (38-1393) pg/ml, gld 75 (30-181) pg/ml, 
p=0.92) although there was a trend towards gld splenocytes producing less IL-17 (IL-17: WT 
120 (41-246) pg/ml, gld 55 (27-194) pg/ml, p=0.071) (Figure 3.25). IL-4 and IL-10 were 
measured; however, levels were below the lower detection limit of the kit.  
The greater production of IL-4 and IL-10 by the gld splenocytes after stimulation with 
PMA and ionomycin supports the reports from the literature that the overall T cell immune 
response in gld mice is predisposed to being Th2. However, following antigen-specific 
stimulation, the pattern of cytokine production from the antigen-specific T cells does not 
support this hypothesis with regard to the immune response to sheep IgG as the IL-4 
production was not increased in the gld splenocytes.  
 






Figure 3.24 Splenocyte cytokine release following stimulation with PMA and 
ionomycin.  
Splenocyte cytokine release into the supernatant was measured by ELISA at 72 hours 
following stimulation with PMA and ionomycin, after pre-immunisation only. (A) IFN-γ, (B) 
IL-4, (C) IL-10, and (D) IL-17. Gld splenocytes produced significantly more IL-4 compared 
to WT splenocytes. There was no significant difference with the other cytokines measured. 
All data represent individual values with the median. The data were analysed using Mann-































































Figure 3.25 Splenocyte cytokine release following stimulation with 100µg/ml of sheep 
IgG. 
Splenocyte cytokine release into the supernatant was measured by ELISA at 72 hours 
following stimulation with 100µg/ml of aggregated sheep IgG, after pre-immunisation only. 
(A) WT splenocytes produced significantly more IFN- γ than gld splenocytes and (B) trended 
towards producing more IL-17. All data represent individual values with the median. The 

































The results in this chapter demonstrate that gld mice were strongly protected from 
renal injury and histological damage in accelerated NTN compared to WT counterparts, 
despite no reduction in systemic antibody response or deposited antibodies in the gld mice 
and similar levels of glomerular neutrophil and macrophage infiltration. Possible reasons for 
this protection are: (1) the reduction in immune response; gld mice showed a reduction in T 
cell-mediated systemic immunity in the early phase of disease, but not at the end of the 
experiment. (2) The reduction in apoptosis; gld mice had no glomerular apoptotic cells. 
Finally, (3) the reduction in cytokine production; gld mice had fewer glomerular and 
interstitial T cells and interstitial macrophages and reduced expression of pro-inflammatory 
cytokines, MCP-1 and iNOS, and Th1 cytokines, IFN-γ and IL-12p40 in whole kidney 
compared to WT mice. 
 
 
NTN is an animal model of crescentic GN that presents with histological damage 
similar to human crescentic nephritis. It is induced by targeting an immune response to the 
glomerulus by planting foreign antigen on the GBM. In accelerated NTN, pre-immunisation 
with sheep IgG primes the immune response for the injection of heterologous anti-GBM 
antibodies. The heterologous and host antibodies localise in the glomerulus where they 
induce glomerular damage via the activation of FcγR, an important link between the innate 
and adaptive immune response, which leads to the secretion of cytokines and the recruitment 
of leukocytes. In order to exclude an effect of FasL on priming of the immune response, the 
serum levels of antibodies to sheep IgG and deposition of immunoglobulins within the 
glomerulus were measured. There was no difference in the deposition of heterologous 
antibody (sheep anti-mouse GBM antibody) on the GBM between the two groups. However, 
at day 15, gld mice had increased deposition of autologous antibody (mouse anti-sheep IgG 
antibody) and higher circulating levels of total mouse anti-sheep IgG and the different IgG 
subclasses (IgG1, IgG2b, IgG2c and IgG3). This could be explained in part by the presence 
of proteinuria in the WT mice; however, defects in lymphocyte homeostasis in gld mice 
result in an accumulation of B cells which could also account for the increased immune 
response (Fukuyama et al., 1998). The fact that there was an increase in the immune response 
of gld mice, yet they showed fewer histological manifestations of injury, as highlighted by 
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reduced glomerular crescents and thrombosis, implies that it is possible to uncouple 
glomerular immunoglobulin deposition from glomerular damage. Other members of our 
laboratory have produced similar findings. MR-, FcRγ-, and FcγRIII-deficient mice were 
protected from developing renal disease yet mounted similar systemic immune responses to 
WT mice (Chavele et al., 2010; Tarzi et al., 2003). Whilst we consistently saw higher 
deposited and circulating antibody titres in the gld mice at the end of the experiment, there 
was some heterogeneity in antibody titres at 24 hours after injection of NTS. Two of the three 
experiments showed equivalent antibody titres between WT and gld mice, whilst the third 
experiment showed a reduction in the gld mice. There can be some variability in the immune 
response from one experiment to the next, but it is also possible that the effects of the gld 
mutation vary throughout the course of the experiment, with accumulation of more antigen-
specific cells in the gld mice at later time points.  
FasL is expressed on T cells, as well as myeloid cells, and is involved in regulating 
the immune response by playing a role in T cell activation (Alderson et al., 1993) and 
inducing apoptosis at the end of the immune response (Kabelitz et al., 1993). T cell-mediated 
systemic immunity was shown to be reduced in gld mice in the early phase of the disease and 
following non-specific stimulation with CD3/CD28 beads, supporting the hypothesis that 
FasL can function as an activator of T cells (Alderson et al., 1993). Coupled with the reduced 
numbers of CD4+ T cells in the kidney, this could contribute to the protection of gld mice in 
the early phase of the experiment. However, similar to other groups’ findings, we did not find 
a difference in T cell proliferation to antigen or antibody responses at the end of the 
experiment (Ma et al., 2004; Waldner et al., 1997) and this appeared to be a consistent 
finding. Despite this, the gld mice were protected both at day 7 and at later time points.  
NTN is considered to be driven by a Th1/Th17-deviated immune response 
(Holdsworth et al., 1999; Summers et al., 2009). Gld mice, as well as patients with ALPS, 
have been shown to be skewed towards a Th2 immune response (Fuss et al., 1997; Wahlsten 
et al., 2000). In keeping with this, cultured gld splenocytes produced significantly less IFN-γ  
(as well as slightly less IL-17) following stimulation with antigen, but this does not take into 
account the presence of DN T cells which do not produce cytokines. However, following 
non-specific stimulation with PMA and ionomycin, gld splenocytes were found to produce 
significantly more IL-4 as well as slightly increased levels of IL-10. Whole kidney mRNA 
expression of IFN-γ and IL-12p40 were also found to be reduced in gld mice, although there 
was no difference in expression of the Th2 associated cytokines, IL-4 and IL-10. These 
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results cannot readily be directly related to a Th1 immune response, as they do not take into 
account the greater number of CD4+ T cells in WT mice or that IFN-γ and IL-12 are also 
produced by intrinsic renal cells (Timoshanko et al., 2002; Timoshanko et al., 2001). It is 
possible that a combination of the reduced overall T cell response and the predisposition to 
producing a Th2 immune response contributes to protection from disease in the gld mice. 
Aside from a small influx of neutrophils, there was no sign of renal dysfunction 
(increased serum urea) or inflammation (thrombosis, crescents) 24 hours after injection of 
NTS. This correlates with a time course study carried out previously by another member of 
the laboratory who showed that tubular and glomerular inflammation manifested around 48 
hours following NTS injection (Chavele et al., 2010). In accelerated NTN, proteinuria starts 
to develop from day 1, getting progressively worse as the disease manifests, however urine 
collections were not carried out for the 24 hour experiment. NTN is characterised by an 
infiltration of glomerular neutrophils, within the first two hours, followed by macrophages. 
There was no reduction in glomerular neutrophil infiltration in gld mice at 24 hours in 2/3 of 
the experiments, where the immune response was equivalent between the groups, or in 
macrophage infiltration at day 7 and day 15. Soluble FasL has been shown to act as a potent 
chemoattractant for the migration of neutrophils and macrophages to sites of inflammation 
(Dupont and Warrens, 2007; Letellier et al., 2010; Seino et al., 1998), but my results indicate 
that in accelerated NTN sFasL does not play a major role in the recruitment of inflammatory 
cells to the glomerulus. Instead it is likely that other mechanisms, such as Fc receptors or 
complement-mediated events, are involved when immune complexes are deposited, as 
similar results were reported in both acute lung inflammation (Neff et al., 2005) and CIA (Ma 
et al., 2004). 
Glomerular accumulation of macrophages is closely related to renal injury as the 
number of macrophages generally correlates with the severity of disease (Nikolic-Paterson 
and Atkins, 2001). However, other investigators in our laboratory have reported similar 
findings regarding the uncoupling of macrophage infiltration from injury. In the same model 
of NTN, FcRγ-/- and FcγRI/III-double deficient mice were protected from developing renal 
injury yet had similar numbers of glomerular macrophages, compared to WT mice (Tarzi et 
al., 2003). This suggests that the mechanisms of macrophage accumulation in immune-
mediated GN may be different from the mechanisms of activation. Evidence supporting this 
idea comes from studies in rat models of crescentic GN. Treatment of rats with the cytokines 
IL-4 and IL-11 reduced glomerular crescent formation and proteinuria, by altering 
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macrophage activation, without reducing the glomerular accumulation of macrophages (Cook 
et al., 1999; Lai et al., 2001). It has been reported that FasL is involved in macrophage 
activation, acting synergistically with IFN-γ, to increase production of IL-6, NO and TNF-α. 
The presence of IL-4 was shown to decrease this synergy (Chakour et al., 2009). Interestingly 
I saw a significant reduction in IFN-γ expression in the whole kidney of gld mice, which 
combined with the lack of active FasL, suggests there could be a reduction in macrophage 
activation in the gld mice. 
Interstitial macrophage infiltration is often thought to be a better marker of disease 
severity than glomerular infiltration in human GN (Nikolic-Paterson and Atkins, 2001). 
Although the initial insult in NTN is glomerular, damage to the integrity of the endothelium 
leads to proteinuria. Cytokines and chemokines can pass with the urine and across the tubular 
walls, causing local recruitment of macrophages to the interstitium. This can result in tubular 
injury and localised secretion of pro-inflammatory cytokines by the tubules. Gld mice were 
found to have very little glomerular damage, offering an explanation for the fact there were 
significantly fewer interstitial macrophages and dramatically reduced expression of MCP-1, a 
key chemokine in macrophage recruitment, compared to WT mice. MCP-1 expression occurs 
downstream of the IL-1R signalling pathway, of which there are multiple points of feedback 
and interaction with the Fas-FasL signalling pathway. Binding of FasL to Fas activates 
caspases, which process IL-1β for secretion, and frees the adaptor protein, MyD88, from 
FADD for signalling through the IL-1R (Ma et al., 2004). FasL signalling can also activate 
NF-κB for translocation into the nucleus (Xiao et al., 2002b). Both of these feedback points 
suggest defective FasL signalling can result in reduced MCP-1 expression. It would be 
interesting to stain for activated NF-κB in kidney sections and directly compare WT with gld 
mice following administration of NTN, to see if the lack of FasL has an effect on NF-κB 
activation in this model. 
Macrophage phenotype has been shown to be important in kidney injury and repair 
(Lee et al., 2011). Surprisingly MR, a marker for the alternatively activated, repair 
macrophage, was upregulated in WT mice. Arginase expression, also a marker for 
alternatively activated macrophages, was upregulated slightly more in WT mice, although not 
significantly. However, it must be taken into account that WT mice had significantly more 
macrophages in the whole kidney than gld mice. iNOS expression in gld mice was 
downregulated compared to unmanipulated WT and gld mice, suggesting that the majority of 
macrophages in the gld mice are programmed to repair, whereas the macrophages in the WT 
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mice are both pro- and anti-inflammatory. There are a few possible explanations for the 
differences seen in macrophage phenotype between WT and gld mice. As already mentioned, 
FasL has been shown to act synergistically with IFN-γ in the activation of macrophages 
(Chakour et al., 2009). IFN-γ is involved in the classical pathway of macrophage activation, 
which results in a macrophage with a pro-inflammatory phenotype. The lack of functional 
FasL in the gld mice, along with the reduction in IFN-γ expression, could therefore result in 
fewer pro-inflammatory macrophages. As well as this, splenocytes from gld mice were found 
to produce greater amounts of IL-4 compared to WT splenocytes (following stimulation with 
CD3/CD28 beads) and there was an increase in IL-4 expression in the whole kidney of the 
gld mice (although not significant). IL-4, along with IL-13 (which was not measured), is 
involved in the alternative pathway of macrophage activation, resulting in an anti-
inflammatory phenotype. 
The use of whole kidney mRNA is not ideal when studying cytokine expression 
because it is not possible to identify which cells are expressing which cytokines. Indeed, as 
already mentioned, expression of IFN-γ and IL-12 are not limited to T cells, and iNOS and 
MR are not limited to macrophages. Mesangial cells have been shown to express iNOS and 
MR in vitro, following stimulation with immune complexes, and in vivo, during experimental 
GN (Chavele et al., 2010; Gomez-Guerrero et al., 2002). In an ideal situation, mRNA for 
analysis would be extracted from the cells of interest only, following cell isolation and 
purification.  
Gld mice were dramatically protected from glomerular thrombosis compared to WT 
mice. Exposure of endothelial cells to pro-inflammatory molecules, such as TNF-α, IL-1 and 
MCP-1, leads to the expression of tissue factor, which is necessary for thrombosis formation 
(Dosquet et al., 1995; Grabowski and Lam, 1995; Kirchhofer et al., 1994). There was 
significant increase in expression of MCP-1 in the whole kidney of WT mice with NTN 
compared to gld mice and, although not significantly different, WT mice also expressed 
slightly more TNF-α. Both of these cytokines could possibly contribute to the greater 
incidence of thrombosis in these mice.  
As well as initiation of tissue factor expression, TNF-α, along with IFN-γ, has been 
shown to upregulate expression of Fas on endothelial cells (Sata et al., 2000), leading to 
increased sensitivity to FasL induced apoptosis (Janin et al., 2002). Apoptotic endothelial 
cells have been shown to contribute to thrombotic events due to increased adherence of 
platelets to the endothelium and their subsequent activation (Bombeli et al., 1999). WT mice 
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were found to have significantly increased expression of IFN-γ following induction of NTN, 
which along with the presence of functional FasL, places them at greater risk of thrombosis 
compared to the gld mice.  
One of the key roles of FasL is in inducing apoptosis. Apoptosis is a distinct 
mechanism of programmed cell death necessary for maintaining cellular homeostasis. 
Apoptosis can serve a dual role within inflammation. Deletion of cells can aid in the 
resolution of inflammation but inappropriate activation can cause cell damage that affects 
tissue function and remodelling (Baker et al., 1994; Savill, 1999; Sugiyama et al., 1996; Yang 
et al., 2001). It is not clear from our TUNEL staining which cells are undergoing apoptosis. It 
is likely both intrinsic renal cells and infiltrating leukocytes, although to fully determine this 
cells would need to be double-stained for fragmented DNA and cell specific markers, such as 
CD68, for macrophages, or CD4, for T cells. 
In kidney IRI, apoptosis was suggested to be pro-inflammatory as blockade of FasL 
resulted in a reduction of apoptosis, inflammatory cytokine production and injury (Ko et al., 
2011). In our model, there were no detectable glomerular apoptotic cells in gld mice. This 
could be due to the reduction in inflammation; however, another group in our laboratory 
found that MR-deficient mice have significantly more glomerular apoptotic cells than WT 
mice in the absence of inflammation, suggesting an anti-inflammatory role for apoptosis in 
NTN (Chavele et al., 2010). Due to the effects of the gld mutation on FasL function, a 
reduction in apoptotic cells would be expected; however a complete absence suggests that 
apoptosis is contributing to injury, similar to the effects seen in the IRI model, rather than 
repair, as none of the other pathways of apoptosis have been activated. Work looking at the 
effect of blocking caspase-3 in the rat in NTN solves the paradox. Caspase-3 is a central 
player in cellular apoptosis for both the extrinsic (death receptor-ligand) and intrinsic 
(mitochondrial) pathways. Inhibition of caspase-3 was found to reduce renal apoptosis, 
ameliorate inflammation and improve proteinuria (Yang et al., 2003). The dual roles of FasL 
in inducing apoptosis and inflammation make it difficult to dissect which is the cause and 
which is the effect. It would be interesting to study the role of FasL in a model of 
glomerulonephritis that requires apoptosis for repair, such as anti-Thy-1 nephritis in rats. 
The presence of FasL was also studied in WT mice. FasL can be found in two forms, 
a membrane-bound form or a soluble form (sFasL). There was an upregulation of FasL 
mRNA expression in WT whole kidneys with NTN. Due to the nature of the mutation in gld 
mice, FasL is still expressed in full and does have some residual activity (Karray et al., 2004). 
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We did not look at expression of FasL in gld mice. It would be interesting to see if expression 
increases during NTN despite the ligand being mostly inactive. Due to the reduction in 
damage in gld mice it could be postulated that expression would stay the same. As mentioned 
before, the use of whole kidney does not allow us to determine which cells are expressing 
FasL. Possible sites of expression are infiltrating leukocytes, such as macrophages and T 
cells, or intrinsic renal cells, such as tubular epithelial cells and mesangial cells. Despite other 
groups publishing work showing the detection of FasL via immunoperoxidase staining (Lorz 
et al., 2000; Tsukinoki et al., 2004), our attempts to stain for FasL in WT kidney sections 
were unsuccessful. I also attempted to detect circulating sFasL in the serum of WT mice 
without success. It is likely the methods used were not sensitive enough and the levels of 
FasL present were below the levels of detection. As few as six molecules of FasL are 
sufficient to induce FasL-dependent cell death, which is well below protein detection level by 
methods such as ELISA, immunoperoxidase staining or Western blot (Holler et al., 2003). 
Our results are in keeping with previous studies investigating the role of FasL in 
inflammatory diseases. Gld mice have been found to be protected from acute lung 
inflammation (Neff et al., 2005), EAE (Sabelko et al., 1997; Waldner et al., 1997), EAU 
(Wahlsten et al., 2000) and experimental stroke (Niu et al., 2011). A possible mechanism for 
protection in experimental stroke was proposed. Following injury the brains of WT mice 
showed high levels of sFasL and the gld mice had significantly decreased levels of 
infiltrating inflammatory cells suggesting that the chemotactic actions of FasL, rather than the 
apoptotic actions, and defects in the activation of transcription factors, are involved in the 
inflammation seen in this model (Niu et al., 2011). 
Due to availability of mice and the regulations of the UK Home Office, both male and 
female mice were used in these experiments. Female mice are much more susceptible to NTN 
than male mice, however we did not find that differences in sex affected the outcome of the 
experiments. Most of these experiments were performed on male mice. However, one of the 
three 24 hours experiments (Section 3.4.6) and one experiment to day 10 (Section 3.4.11) 
were performed on female mice, with female gld mice still being protected from disease. In 
humans, there is a higher incidence of autoimmune disease in females compared to males 
(roughly 3:1). As well as genetic polymorphisms and environmental factors being involved, 
sex hormones also play a role in susceptibility. Castration of autoimmune prone NZB/NZW 
male mice was found to accelerate the onset of lupus-like disease, whereas ovariectomised 
female NZB/NZW mice given androgens had reduced lupus-like disease (Roubinian et al., 
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1977). Although using different sexes in the experiments makes it difficult to compare 
directly the results seen, the results follow the same trend.  
Our results showed a reduction in injury despite no reduction in the antibody 
responses and only a mild reduction in the T cell-mediated immune response of gld mice. 
There was reduced apoptosis in the gld kidney, but no reduction in glomerular macrophage or 
neutrophil infiltration. We saw a strong reduction in MCP-1 mRNA in the gld kidneys, 
suggesting that cytokine production may indeed be defective in these mice. To further 
investigate the role of FasL in GN I went on to perform bone marrow transplants to find out 
whether FasL expression on circulating leukocytes, or intrinsic renal cells, is involved in the 
development of disease. I also cultured mesangial cells for in vitro studies, to determine the 
mechanism by which defective FasL can protect from inflammation.  
 
3.6 Conclusion 
Since FasL has been implicated as an initiator of inflammation, I hypothesised that 
abnormalities in FasL signalling may play a critical role in the initiation of injury in 
accelerated NTN. At this point it can be concluded that the presence of FasL in the kidney 
does contribute to the development of disease. The mechanism through which FasL promotes 
disease may relate to T cell-mediated systemic immunity, but the defects seen in the gld T 
cell responses were transient. Cell activation or apoptosis, facilitated by FasL, may also 
contribute to disease. Unfortunately, the autoimmunity enhancing effects of FasL deficiency 
may prevent its use as a therapeutic treatment; however, this study has highlighted an 
important role of FasL in initiating inflammation. The next step was to investigate whether 
FasL expression on infiltrating leukocytes or resident renal cells is more critical for the 
development of disease.   





The Role of Fas Ligand on Circulating Leukocytes and Intrinsic Renal 
Cells in Accelerated Nephrotoxic Nephritis 
 
4.1 Introduction 
Infiltrating macrophages and T cells, as well as proliferating mesangial cells, play a 
central role in the development of GN in humans and mice. FasL has been shown to be 
expressed on activated macrophages and T cells (Dockrell et al., 1998; Suda et al., 1995), the 
tubular epithelium in healthy kidney (Lorz et al., 2000) and mesangial cells during renal 
injury (Tsukinoki et al., 2004). Since gld mice were protected from NTN, it was essential to 
investigate the importance of FasL in different subsets of cells that play a role in the 
development of GN. To do this, bone marrow chimeric mice were created with the gld gene 
in their bone marrow-derived cells but not their tissue cells, and vice versa. The susceptibility 
of these mice to accelerated NTN was compared to control WT mice transplanted with WT 
bone marrow and gld mice transplanted with gld bone marrow, respectively.  
As well as causing defects in apoptosis, defective Fas-FasL signalling has also been 
shown to interfere with signalling through pathways that require the adapter protein MyD88, 
such as the IL-1R pathway and the TLR4 pathway (Altemeier et al., 2007; Bannerman et al., 
2002; Ma et al., 2004). There was a significant reduction in MCP-1 expression in whole 
kidney from gld mice with NTN compared to WT mice. This can in part be explained by the 
reduction in interstitial macrophages in the gld mice; however, mesangial cells have also 
been shown to be a source of renal MCP-1 following stimulation with IL-1β and TNF-α 
(Zoja et al., 1991). Therefore it was of interest to culture mesangial cells from WT and gld 
mice and confirm FasL expression as well as compare cytokine expression following 
stimulation with IL-1β and TNF-α. 
 




This part of the project was focused on answering whether FasL expression on 
resident renal cells or infiltrating cells (macrophages, T cells, NK cells) was more critical for 
the development of accelerated NTN. Mesangial cell expression of FasL was also assessed, 
as well as the differences in response to IL-1β and TNF-α stimulation between WT and gld 
mesangial cells in vitro. 
 
 
4.3 Experimental design 
In order to investigate if FasL expression on radioresistant renal cells or infiltrating 
leukocytes is more critical for the development of GN, bone marrow transplantation 
experiments were performed. A single dose of whole body gamma irradiation was used to 
ablate the bone marrow of both WT and gld mice. Immediately following irradiation, the 
mice received an intravenous injection of whole bone marrow. WT mice received bone 
marrow cells from gld mice (gld→WT) and vice versa (WT→gld). This resulted in WT mice 
with FasL-defective leukocytes and FasL expressing renal cells and gld mice with FasL 
expressing leukocytes and FasL-defective renal cells. As controls, WT mice were 
transplanted with WT bone marrow (WT→WT) and gld mice were transplanted with gld 
bone marrow (gld→gld). NTN was induced and disease was assessed in WT and gld 
chimeric mice as previously described (see Section 3.3).  
To investigate directly FasL on mesangial cells, mesangial cells were isolated from 
WT and gld mice and cultured in vitro. WT mesangial cells were stimulated with LPS and 
assessed by qRT-PCR for FasL. Then WT and gld mesangial cells were assessed for 
differences in response to stimulation with pro-inflammatory cytokines (IL-1β and TNF-α) 
by measuring the MCP-1 levels released into the supernatant by ELISA. 
 
 




4.4.1 Bone marrow reconstitution 
8Gy of irradiation was used, as previously optimised by Dr. Ruth Tarzi. The 
irradiated mice were intravenously injected with 1x107 bone marrow cells harvested from the 
femur, tibia and humerus of donor sex-matched mice.  
Bone marrow reconstitution was assessed by two methods. Firstly, WT mice (n=4) 
were transplanted with bone marrow marked with the allotype marker CD45.1 rather than 
CD45.2, the C57BL/6 allotype. Eight weeks post transplant blood was collected from these 
mice and stained for CD45.1 and CD45.2 for analysis by flow cytometry (mean % of CD45.1 
positive cells of total cells: 92±0.083%) (Table 4.1 & Figure 4.1). Secondly, semi-
quantitative PCR of DNA purified from mouse blood collected at the end of the experiment 
was performed as before (Section 3.4.1); however, the reverse primer was labelled with a 
fluorescent FAM marker. Following restriction digestion the products were run on a 
Genescan and the ratio of WT (88bp) versus mutant (108bp) product was calculated and 
compared to known mixtures of WT and gld DNA (0%, 5%, 10%, 25%, 50%, 75%, 90%, 
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 CD45.1 CD45.2 BMT 1 BMT 2 BMT 3 BMT 4 
CD45.1+ cells 85 0.24 84 88 65 66 
CD45.2+ cells 0 62 7.8 6.0 3.6 5.5 
CD45.1+CD45.2+ cells 0 1.45 0.37 0.22 1.2 1.2 
% CD45.1+ cells 100 0.38 91 93 93 91 
Table 4.1 Flow cytometry data to assess reconstitution of donor bone marrow in 
chimeric mice. 
CD45.1+ and CD45.2+ cells in individual CD45.1, CD45.2 and chimeric mice (BMT (bone 











Figure 4.1  Assessment of donor bone marrow reconstitution in chimeric mice by 
flow cytometry. 
Eight weeks post bone marrow transplant WT C57BL/6 mice transplanted with CD45.1 bone 
marrow were bled and the blood stained for CD45.1 and CD45.2 allotype markers. Upper left 
quadrant CD45.2+ cells, lower right quadrant CD45.1+ cells. (A) Unstained control, (B) 
CD45.1+ mouse stained for CD45.1+ cells and (C) WT CD45.2+ mouse transplanted with 
















Figure 4.2 Assessment of donor bone marrow reconstitution in chimeric mice by 
PCR. 
Different proportions of WT and gld DNA were mixed and subjected to PCR. Following 
restriction digestion the products were run on a Genescan and a standard curve of the 
percentage WT DNA compared to gld DNA plotted against the known calculated ratios of 
WT:gld DNA. In the same PCR reaction DNA from the two chimeric groups of mice were 
also run to examine the relative percentage of bone marrow reconstitution. In both groups 
(gld to WT transplanted mice represented by the blue downward triangles and WT to gld 
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4.4.2 Fas ligand from either bone marrow-derived or radioresistant intrinsic renal 
cells is sufficient to restore susceptibility to accelerated nephrotoxic nephritis 
4.4.2.1 Assessment of renal function in bone marrow transplanted mice with accelerated 
nephrotoxic nephritis 
A cohort of gld mice (n=8) were transplanted with WT bone marrow and a cohort of 
WT mice (n=9) were transplanted with gld bone marrow. As controls, WT mice (n=8) were 
transplanted with WT bone marrow and gld mice (n=7) were transplanted with gld bone 
marrow. All mice used were males. The animals were left for nine weeks for bone marrow 
reconstitution to occur and then NTN was induced by pre-immunising the mice with 0.2mg 
of sheep IgG in CFA and after five days administering 200µl (1:4 dilution) of NTS via the 
tail vein. Mice were sacrificed at day 8 to allow significant differences in disease to develop 
without excessive suffering to the animals.  
To assess kidney function serum urea and albuminuria, expressed as a ratio of urinary 
albumin/creatinine, were measured in all mice. The levels of serum urea were significantly 
lower in the gld mice transplanted with gld bone marrow compared to the gld mice 
transplanted with WT bone marrow (gld→gld 14 (10-20) mmol/L, WT→gld 37 (13-40) 
mmol/L, p=0.014), whereas there was no significant difference between the other groups 
(gld→WT 30 (11-41) mmol/L, WT→WT 34 (11-42) mmol/L) (Figure 4.3 A). Gld mice 
transplanted with gld bone marrow had a significantly lower urinary albumin/creatinine ratio 
(1.1 (0.00-6.9) mg/mmol) than gld mice transplanted with WT bone marrow (6.2 (3.3-9.1) 
mg/mmol, p=0.007) and WT mice transplanted with gld bone marrow (5.5 (0.020-7.7) 
mg/mmol, p=0.023). There was no significant difference in the urinary albumin/creatinine 
ratio between any of the groups with the WT mice transplanted with WT bone marrow (7.0 
(0.020-12) mg/mmol) (Figure 4.3 B).  




Figure 4.3 Measurement of serum urea and urinary albumin/creatinine ratio in bone 
marrow transplanted mice with NTN. 
(A) Serum urea and (B) urinary albumin/creatinine ratio post NTS administration in bone 
marrow transplanted mice. Gld mice transplanted with gld bone marrow had significantly 
lower serum urea than gld mice transplanted with WT bone marrow. Gld mice transplanted 
with gld bone marrow had a significantly lower urinary albumin/creatinine ratio than WT 
mice transplanted with gld bone marrow and WT mice transplanted with gld bone marrow. 
There was no significant difference in urinary albumin/creatinine ratio between any of the 
other groups of mice.  All data represent individual values with the median. The data were 
analysed using Mann-Whitney U-test (p*<0.05, p**<0.01). Dashed lines represent values for 
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4.4.2.2 Renal histology of bone marrow transplanted mice with accelerated nephrotoxic 
nephritis 
At day 8 after disease induction PAS-stained kidney sections were assessed for 
histological damage measured by glomerular thrombosis and crescents. Gld mice 
transplanted with gld bone marrow had significantly reduced susceptibility to glomerular 
thrombosis (0.00 (0.00-0.58)) and crescents (0.00 (0.00-0.00) %) compared to the other 
groups of mice (thrombosis: WT→gld 1.3 (0.060-3.3), p=0.0072; gld→WT 0.92 (0.004-2.1), 
p=0.0077; WT→WT 0.70 (0.00-1.6), p=0.029; crescents: WT→gld 5.0 (0.00-10) %, 
p=0.0074; WT→WT 2.0 (0.00-6.0) %, p=0.0071). There was no significant difference in 
crescents between the gld mice transplanted with gld bone marrow and the WT mice 




















Figure 4.4 Quantification of histologically abnormal glomeruli in bone marrow 
transplanted mice with NTN. 
(A) Thrombosis and (B) crescents in bone marrow transplanted mice on day 8, after NTN 
induction, scored on PAS-stained kidney sections. Gld mice that received gld bone marrow 
had less severely damaged glomeruli than the other groups of mice. All data represent 
individual values with the median. The data were analysed using Mann-Whitney U-test 



























































Figure 4.5 PAS staining of kidneys from bone marrow transplanted mice with NTN. 
Representative PAS staining from a (A) gld→gld mouse showing a healthy glomerulus, (B) 
WT→gld mouse, showing a thrombotic glomerulus, (C) gld→WT mouse, showing a 
thrombotic glomerulus, and a (D) WT→WT mouse, showing a crescentic glomerulus, 8 days 
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4.4.3 Infiltrating macrophages and T cells in bone marrow transplanted mice with 
accelerated nephrotoxic nephritis 
 As a measure of inflammation, frozen kidney sections were stained for macrophage 
and T cell infiltration at day 8 post NTS administration with anti-CD68 macrophage antibody 
(Figure 4.7) and anti-CD4 T cell antibody (Figure 4.8 A). Gld mice transplanted with gld 
bone marrow had fewer glomerular macrophages compared to WT mice transplanted with 
gld bone marrow (macrophages/gcs: gld→gld 0.74 (0.00-2.8), gld→WT 2.5 (1.1-4.6), 
p=0.023) but there was no significant difference between the other groups (macrophages/gcs: 
WT→gld 1.4 (0.52-2.6), WT→WT 1.8 (0.64-2.3)). There was no significant difference in 
glomerular T cell numbers between the four groups of mice (T cells/gcs: gld→gld 0.24 (0.12-
0.62), WT→gld 0.22 (0.06-0.32), gld→WT 0.34 (0.16-0.54), WT→WT 0.23 (0.12-0.52). 
(Macrophages: Figure 4.6 A; T cells: Figure 4.8 B).  
 Interstitial macrophage numbers were measured quantitatively with the results being 
expressed in arbitrary units (AU). Gld mice transplanted with gld bone marrow had 
significantly fewer interstitial macrophages (0.49 (0.17-3.3) AU) compared to all other 
groups of mice (interstitial macrophages: WT→gld 3.4 (2.1-9.0) AU, p=0.0037; gld→WT 
3.7 (0.83-9.9) AU, p=0.0052; WT→WT 7.1 (0.45-16.22) AU, p=0.0093). There was no 
significant difference between the other groups of transplanted mice (Figure 4.6 B). 
These results, along with the reduced kidney function (Section 4.4.1) and increased 
glomerular damage (Section 4.4.2), suggest that the presence of active FasL on either 
infiltrating leukocytes or radioresistant intrinsic renal cells is enough to convey disease in this 
model of NTN. It was hypothesised that FasL on infiltrating leukocytes would play a role in 
the development of NTN; however, the active role of FasL on radioresistant intrinsic renal 
cells in NTN was unexpected. A second bone marrow transplant experiment was undertaken 
to confirm the result. A cohort of WT mice were transplanted with gld bone marrow and as 
controls WT mice were transplanted with WT bone marrow and gld mice were transplanted 
with gld bone marrow. Again, the presence of active FasL on radioresistant intrinsic renal 
cells was found to confer susceptibility to disease, with WT mice transplanted with gld bone 
marrow having reduced kidney function. 




Figure 4.6 Macrophage infiltration in bone marrow transplanted mice with NTN. 
Macrophage infiltration (A) per glomerular cross section (gcs) (50 glomeruli scored per cross 
section) and (B) in the interstitium (expressed as arbitrary units (AU) scored using 5 separate 
fields of view). Gld mice transplanted with gld bone marrow had significantly fewer 
glomerular macrophages than WT mice transplanted with gld bone marrow and interstitial 
macrophages compared to all other groups of mice. All data represent individual values with 
the median. The data were analysed using Mann-Whitney U-test (p*<0.05, p**<0.01). 
































































Figure 4.7 Immunohistochemistry of glomerular and interstitial macrophage 
infiltration in bone marrow transplanted mice with NTN. 
Representative immunohistochemistry for macrophages (CD68) on (A) gld→gld, (B) 

















Figure 4.8 Glomerular T cell infiltration in bone marrow transplanted mice with 
NTN. 
(A) Immunohistochemistry for T cells (CD4) on gld→gld, WT→gld, gld→WT and 
WT→WT kidney sections. Arrows highlight T cells. (B) T cell infiltration per glomerular 
cross section (gcs) (50 glomeruli scored per cross section). There was no statistical difference 
in glomerular T cell numbers between the different groups of mice. All data represent 
individual values with the median. The data were analysed using Mann-Whitney U-test. 
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4.4.4  Systemic immune responses 
Mouse sera, collected at the end of the experiment, were tested for the antigen-
specific immune response against sheep IgG. The circulating anti-sheep IgG levels were 
measured by ELISA (results expressed as median optical density at 405nm (OD 405nm)). 
WT and gld mice receiving gld bone marrow had slightly higher levels of circulating sheep 
IgG than mice receiving WT bone marrow (gld→gld vs. WT →gld p=0.040, gld→gld vs. 
WT→WT p=0.040, gld→WT vs. WT→WT p=0.051) (Table 4.2 and Figure 4.9). FasL is 
known to be involved in the deletion of B cells, which can result in elevated levels of 
autoantibodies. However, despite an increased immune response, gld mice transplanted with 
gld bone marrow had less disease, showing that antibody production is not the determining 
factor for heightened susceptibility to NTN. 
Frozen kidney sections were stained for deposited sheep and mouse IgG by direct 
immunofluorescence on tissue taken at the end of the experiment (Figure 4.10 A and Figure 
4.11 A, respectively). Glomerular total sheep IgG and mouse IgG were measured by semi-
quantitative immunofluorescence, with results expressed as visual fluorescence units (VFU), 
and were equivalent between the different bone marrow transplanted groups. (Table 4.2, 
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Donor Recipient Serum anti-sheep 









Gld Gld 0.54 (0.27-0.70) 3.0 (2.0-4.0) 3.0 (2.0-3.0) 
WT Gld 0.37 (0.077-0.50) 3.0 (2.0-3.0) 3.0 (1.0-4.0) 
Gld WT 0.63 (0.25-1.0) 3.0 (2.0-4.0) 3.0 (2.0-3.0) 
WT WT 0.40 (0.25-0.60) 3.0 (2.0-4.0) 3.0 (2.0-3.0) 
Table 4.2 Circulating anti-sheep IgG levels and deposited glomerular sheep and 
mouse IgG in bone marrow transplanted mice with NTN. 

















Figure 4.9 Circulating mouse anti-sheep IgG levels in bone marrow transplanted 
mice with NTN. 
The circulating levels of mouse anti-sheep IgG were measured by ELISA. Mice transplanted 
with gld bone marrow had slightly elevated levels compared to mice transplanted with WT 
bone marrow. All data represent individual values with the median. The data were analysed 

















































Figure 4.10 Immunofluorescence of glomerular sheep IgG deposition in bone marrow 
transplanted mice with NTN. 
(A) Representative glomeruli from gld→gld, WT→gld, gld→WT and WT→WT mice 
showing sheep IgG deposition 8 days after NTS injection. All images were taken using the 
same settings. (B) Semi-quantitative analysis of glomerular immunofluorescence. There was 
no significant difference between the groups of mice. All data represent the individual values 
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Figure 4.11 Immunofluorescence of glomerular mouse IgG deposition in bone 
marrow transplanted mice with NTN. 
(A) Representative glomeruli from gld→gld, WT→gld, gld→WT and WT→WT mice 
showing mouse IgG deposition 8 days after NTS injection. All images were taken using the 
same settings. (B) Semi-quantitative analysis of glomerular immunofluorescence. There was 
no significant difference between the groups of mice. All data represent the individual values 
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4.4.5 Apoptotic cells in bone marrow transplanted mice with accelerated nephrotoxic 
nephritis 
Due to the proposed dual role of FasL in apoptosis and inflammation and the stark 
differences seen between the numbers of apoptotic cells in WT and gld mice with NTN 
(Section 3.4.8), it was important to quantitate the presence of apoptosis in the kidney in our 
model following bone marrow transplant. Paraffin-fixed kidney sections were stained for 
apoptosis by TUNEL. Apoptotic cells were counted in 30 glomeruli per cross section. Gld 
mice transplanted with gld bone marrow had significantly fewer apoptotic cells per 
glomerular cross section than gld mice transplanted with WT bone marrow and WT mice 
transplanted with WT bone marrow (apoptotic cells/gcs: gld→gld 0.067 (0.00-0.17); 
gld→WT 0.53 (0.00-0.93), p=0.0079; WT→WT 0.37 (0.00-1.0), p=0.027). There was no 
significant difference between the other groups of mice (apoptotic cells/gcs: WT→gld 0.23 



















Figure 4.12 Apoptotic cells in bone marrow transplanted kidneys with accelerated 
NTN were identified by TUNEL staining. 
Apoptotic cells per glomerular cross section (gcs) in WT and gld mice at day 8 post NTN 
induction. All data represent individual values with the median. The data were analysed using 
Mann-Whitney U-test (p*<0.05, p**<0.01). Dashed line represents values for a group of 
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4.4.6 Renal expression of MCP-1 in bone marrow transplanted mice 
MCP-1 is a key chemokine in glomerulonephritis, playing a role in macrophage 
recruitment. Expression of MCP-1 was found to be dramatically increased in WT mice 
compared to gld mice, following the induction of NTN (Section 3.4.9). To look at any 
possible differences in expression of MCP-1 between the bone marrow transplanted mice, 
whole kidney mRNA was extracted from frozen kidney of the four groups of mice and 
measured by qRT-PCR. Data represent relative expression, calculated using GAPDH as the 
housekeeping gene and a gld mouse transplanted with gld bone marrow with NTN as the 
reference. 
Gld mice transplanted with gld bone marrow expressed significantly less renal MCP-1 
(0.97 (0.64-3.6)) compared to gld mice transplanted with WT bone marrow (WT→gld 3.2 
(1.1-13), p=0.021), WT mice transplanted with gld bone marrow (2.2 (0.52-11), p=0.044), 
and WT mice transplanted with WT bone marrow (7.7 (0.69-13), p=0.032). There was no 
















Figure 4.13 Whole kidney mRNA expression of MCP-1 in bone marrow transplanted 
mice with NTN, at day 8. 
Expression of MCP-1 was measured in whole kidney mRNA extracts. Gld mice transplanted 
with gld bone marrow had significantly less MCP-1 expression than all other groups of mice. 
All data represent individual values with the median. The data were analysed using Mann-
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4.4.7 Fate of resident kidney leukocytes 
To confirm that FasL expressed by intrinsic renal cells, in the gld mice transplanted 
with WT bone marrow, was the cause of disease susceptibility, and not due to a population of 
radioresistant leukocytes, we performed further bone marrow transplant experiments using 
CD45.1+ and CD45.2+ mice to assess chimerism of kidney leukocytes. C57BL/6 (CD45.2+) 
mice (n=7) were transplanted with CD45.1+ bone marrow. Ten weeks after transplant, blood 
was collected and kidney cells were dissociated and stained for CD45.1+ and CD45.2+ cells. 
In addition, kidney cells were stained for F4/80 and CD11c to assess tissue resident 
macrophages and dendritic cells. Staining was analysed by flow cytometry. The chimerism of 
resident kidney cells (total leukocytes: 88.9±0.61% CD45.1+; macrophages (CD11c+F4/80+): 
94.6±0.47% CD45.1+ cells; dendritic cells (CD11c+F4/80-): 93.7±0.74% CD45.1+ cells) was 
broadly similar to blood (total leukocytes: 93.2±0.70% CD45.1+ cells) (Figure 4.14). 
 Frozen kidney sections were also collected and stained for CD45.1 and CD45.2. 
Sections from C57BL/6 (CD45.2) and CD45.1 mice were stained with both antibodies to 
demonstrate there was no cross reactivity between the antibodies (Figure 4.15). Sections were 
also collected from bone marrow transplanted mice without NTN and 8 days after the 
administration of NTS. The differences in CD45.1+ and CD45.2+ cell infiltrate were not 
formally quantified but, as can be seen in Figure 4.16, there are considerably more CD45.1+ 
cells than CD45.2+ cells in the bone marrow transplanted mice, both with and without NTN 
(Figure 4.16).  




Figure 4.14 Flow cytometry data to assess chimerism of resident kidney leukocytes 
following bone marrow transplantation. 
(A-B) Flow cytometry of blood taken at sacrifice; (A) whole blood and (B) CD45+ 
leukocytes. The majority of circulating leukocytes are of donor (CD45.1) origin. (C-H) Flow 
cytometry of kidney lysates. (C) Whole kidney and (D) CD45.1+ and CD45.2+ kidney 
leukocytes (selected in C). (E) CD45+ leukocytes were selected and plotted for (F) F4/80 and 















Figure 4.15 CD45.1 and CD45.2 staining of frozen kidney sections from individual 
CD45.1+ and CD45.2+ mice. 
Frozen kidney sections from CD45.1+ and CD45.2+ mice were stained for CD45.1+ and 
CD45.2+ cells (brown staining). These images highlight that there is no cross-reactivity with 
the antibodies for the alternative allotype. Arrows highlight CD45+ cells. 











Figure 4.16 CD45.1 and CD45.2 staining of frozen kidney sections from bone marrow 
transplanted (BMT) mice with and without NTN. 
Frozen kidney sections from bone marrow transplanted (BMT) mice, before and after the 
induction of NTN, were stained for CD45.1+ and CD45.2+ cells. The images highlight that 
the majority of CD45+ cells (brown staining) following the bone marrow transplant are of 
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4.4.8 The role of Fas ligand on mesangial cells 
Expression of FasL on intrinsic renal cells, specifically mesangial cells, has been 
previously reported (Lorz et al., 2000; Tsukinoki et al., 2004). Next we set out to confirm this 
by culturing both WT and gld mesangial cells and we investigated whether FasL deficiency 
has an effect on the IL-1R signalling pathway. 
 
4.4.8.1 Characterisation of mesangial cells and expression of Fas ligand 
Mesangial cells were characterised by immunofluorescence studies and their 
characteristic stellate morphology. Mesangial cells were stained for myosin and 
pancytokeratin. As expected both WT and gld mesangial cells were positive for myosin and 
negative for pancytokeratin (Figure 4.17). 
To confirm that cultured mesangial cells express FasL we used qRT-PCR. mRNA 
was extracted from unstimulated and LPS stimulated WT mesangial cells (LPS has been 
shown to upregulate FasL on mesangial cells (Tsukinoki et al., 2004)), using the TRIzol 
method, and amplified with FasL specific primers. FasL was detected from both the 
unstimulated and stimulated cells, with no difference in expression between both conditions 

















Figure 4.17 Characterisation of WT and gld mesangial cells. 
WT and gld mesangial cells were stained for myosin and pancytokeratin, both were positive 













Figure 4.18 Mesangial cell mRNA expression of Fas ligand following stimulation with 
LPS. 
Levels of mRNA expression of FasL were measured in mesangial cell mRNA extracts. There 
was no significant difference in FasL mRNA expression between unstimulated and LPS-
stimulated WT mesangial cells. All data represent individual values with the median. The 
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4.4.8.2 Fas ligand deficiency alters mesangial cell IL-1β dependent MCP-1 production, 
but not TNF-α dependent MCP-1 production 
 Defective FasL signalling has been previously reported to interrupt signalling through 
the IL-1R on macrophages, resulting in reduced expression of key cytokines and chemokines, 
such as MCP-1 (Altemeier et al., 2007; Bannerman et al., 2002; Ma et al., 2004). Gld mice 
transplanted with gld bone marrow were found to have reduced expression of MCP-1 
compared to WT mice transplanted with gld bone marrow (Section 4.4.6), suggesting MCP-1 
production by intrinsic renal cells could be affected by the defective FasL signalling.  
To investigate a possible role for FasL on mesangial cells and provide further answers 
to the reduced expression of MCP-1 in the gld mice transplanted with gld bone marrow, WT 
and gld mesangial cells were stimulated with IL-1β and MCP-1 present in the supernatant 
measured by ELISA. The mesangial cells were also stimulated with TNF-α as a control, to 
rule out a generalised defect in cytokine signalling. 
Under basal conditions, there was no significant difference in MCP-1 production 
between WT and gld mesangial cells (A: WT 103712 (89463-125951) pg/ml, gld 92467 
(68109-104305) pg/ml; B: WT 26428 (22434-34073) pg/ml, gld 26266 (24258-32320) 
pg/ml) (Figure 4.19). Gld mesangial cells produced significantly less MCP-1 than WT 
mesangial cells when stimulated with IL-1β (representative results from one of five 
experiments: WT 235986 (177817-373759) pg/ml, gld 119380 (104418-150759) pg/ml, 
p=0.0022) (Figure 4.19 A), however there was no significant difference in MCP-1 production 
following stimulation with TNF-α (representative results from one of three experiments: WT 
487867 (392922-565759) pg/ml, gld 460235 (431141-536649) pg/ml, p=0.48) (Figure 4.19 
B). 




Figure 4.19 MCP-1 production by mesangial cells following stimulation with IL-1β 
and TNF-α. 
MCP-1 measured in the supernatants of serum-starved WT and gld mesangial cells 
unstimulated or stimulated with (A) 10ng/ml of IL-1β (representative of five separate 
experiments) and (B) 10ng/ml of TNF-α (representative of three separate experiments). All 
data represent individual values with the median. The data were analysed using Mann-

















































The results shown in this chapter demonstrate that, in accelerated NTN, disease is 
dependent on FasL expression on either circulating leukocytes or resident radioresistant renal 
cells. The renal cells responsible for disease development could be mesangial cells since 
mesangial cell FasL expression has been shown to be upregulated during disease (Tsukinoki 
et al., 2004). However, we have not investigated the role of FasL on other cells in the kidney, 
such as tubular epithelial cells. There was no difference in deposited mouse IgG between the 
groups, but mice with a gld immune system had increased levels of total circulating mouse 
anti-sheep IgG compared to mice with a WT immune system. Glomerular macrophage and T 
cell infiltration was similar between the four groups. There was no significant difference in 
the number of apoptotic cells, although gld mice transplanted with gld bone marrow showed 
a trend towards having fewer apoptotic bodies than the other three groups. Finally, FasL 
expression was confirmed on WT mesangial cells and FasL-deficiency was shown to affect 
MCP-1 production via IL-1R signalling.  
 
 
The generation of knockout animals has facilitated the study of deciphering the roles 
of diverse molecules in disease development. Mice deficient in several different cytokines, 
chemokines and receptors have been used to further our understanding of the pathogenesis of 
NTN; however, many of these molecules can be expressed by both circulating leukocytes and 
intrinsic renal cells, therefore the production of bone marrow chimeras has been utilised. 
Following lethal irradiation, the recipient’s bone marrow is ablated allowing donor bone 
marrow, with a specific genetic alteration, to reconstitute in its place. This creates chimeras 
expressing different molecules, either normal or mutated, on their circulating leukocytes 
compared to tissue cells. Timoshanko et al. found that 8 weeks following bone marrow 
transplantation recipient circulating leukocytes were restored to baseline level with 
approximately 95% of cells being of donor origin, similar to our own findings (Timoshanko 
et al., 2002).  
The failure of gld bone marrow to protect WT mice from disease suggests a role for 
FasL expressed by radioresistant renal cells in the development of NTN. Expression could 
either be by intrinsic renal cells, such as mesangial cells, or a population of radioresistant 
tissue resident leukocytes. However, following bone marrow transplantation, I found the 
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population of donor resident tissue leukocytes in the kidney to be similar to that seen in the 
circulation (~90% donor cells, 10% recipient cells). It should be noted that the kidneys were 
not perfused prior to cell isolation; this means some of the 10% of recipient cells found 
within the kidney could be cells from the circulation rather than resident tissue leukocytes. 
The lifespan of resident tissue leukocytes can range from days to weeks and at the end of 
their lifetime they are replenished by circulating cells. Therefore, it is highly likely that the 
population of resident tissue leukocytes would be of similar composition to the circulating 
leukocytes; this is supported by the immunostaining of CD45.1+ and CD45.2+ cells in the 
bone marrow transplanted mice. It is possible that FasL expressed by these remaining 
recipient circulating and resident tissue leukocytes is sufficient to induce NTN, but the lack 
of reduction of disease suggests that FasL expressed by intrinsic renal cells is the cause. This 
is in contrast to the results seen in previous experiments looking at FasL in kidney IRI and 
EAU; in both cases FasL expression by circulating cells was found to be responsible for 
susceptibility to disease (Ko et al., 2011; Wahlsten et al., 2000). Although, it should be noted 
that kidney IRI does not directly involve mesangial cells, but instead tubular cells. Therefore, 
it may be that FasL on mesangial cells plays more of a prominent role in NTN, accounting 
for the discrepancies between these two disease models. In addition, in the T cell dependent 
model of EAE, transfer of gld lymphocytes into WT mice attenuated disease, whereas 
transfer of WT lymphocytes into gld mice prolonged clinical signs of disease, suggesting 
FasL on hematopoietic cells is involved in initiating the inflammatory response and FasL on 
non-hematopoietic cells is necessary for disease recovery (Sabelko-Downes et al., 1999). 
However, this model cannot be directly compared to NTN as NTN cannot be passed on by T 
cell transfer. 
At the end of the experiment we saw higher circulating antibody titres in the mice 
transplanted with gld bone marrow compared to the mice transplanted with WT bone 
marrow. As already mentioned, the defects in lymphocyte homeostasis in gld mice can result 
in an accumulation of B cells and autoantibodies. As there were increased antibody titres in 
the WT mice transplanted with gld bone marrow, this further supports the role for the 
expression of FasL on activated T cells in maintaining peripheral B cell numbers and, 
therefore, antibody titres (Stranges et al., 2007). 
Mesangial cells are specialised pericytes located among the glomerular capillaries 
within the renal corpuscle. Mesangial cells have three primary functions: filtration, structural 
support and modulation of glomerular injury. The importance of mesangial cells in the 
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development of immune-mediated glomerular diseases has been extensively studied. Through 
previous studies using bone marrow chimeras it has been found that mesangial cell 
expression of CD40 is required for the development of NTN (Ruth et al., 2003), and the 
production of pro-inflammatory cytokines, such as TNF-α, IFN-γ and IL-12, by intrinsic 
renal cells is required for full expression of crescentic GN (Timoshanko et al., 2002; 
Timoshanko et al., 2001; Timoshanko et al., 2003). 
There are a number of lines of evidence suggesting that mesangial cells express FasL. 
Upregulation of FasL mRNA and protein has been shown in whole kidney from mice with 
lupus nephritis and rats with immune complex proliferative GN (Lorz et al., 2000). 
Immunohistochemistry comparing normal and diseased kidneys from these examples 
highlighted de novo expression of FasL in the glomeruli during inflammation, which can be 
from either infiltrating leukocytes or mesangial cells (Lorz et al., 2000). In humans, FasL was 
shown to be upregulated in the glomerulus in lupus nephritis in vivo by 
immunohistochemistry, and FasL expression by mesangial cells was demonstrated in vitro 
following stimulation with IL-1β, LPS or IFN-γ (Tsukinoki et al., 2004). I have confirmed by 
qRT-PCR that mesangial cells in vitro express FasL. There was no significant difference in 
mesangial cell expression of FasL following stimulation with LPS. This could be because the 
cells were not stimulated with enough LPS or were not stimulated long enough for FasL 
expression to be upregulated.  
Gld mesangial cells in culture had an attenuated response to IL-1β compared to WT 
mesangial cells, producing significantly less MCP-1. This is in keeping with results seen by 
other groups. Two groups reported a reduction in the production of NF-κB-dependent 
cytokines by macrophages with defective FasL signalling (Altemeier et al., 2007; Ma et al., 
2004). Also, Bannerman et al. found that overexpression of FADD in human dermal 
microvascular endothelial cells (HMEC-1) blocked LPS and IL-1β NF-κB activation, 
whereas the absence of FADD in mouse embryo fibroblasts (MEF) enhanced NF-κB activity 
and the production of NF-κB-dependent cytokines (Bannerman et al., 2002). It is reasonable 
to assume that part of the effect seen in mesangial cells is due to the same interruption in the 
signalling pathway seen in the macrophages. That is, the defect in FasL signalling renders 
FADD free to sequester MyD88 away from the IL-1R signalling pathway. FasL signalling 
has also been shown to activate directly NF-κB (Ahn et al., 2001; Imamura et al., 2004). This 
too could account for the difference seen in MCP-1 production. My attempts to culture gld 
and WT BMDM and confirm the same result were unsuccessful due to the method of 
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culturing not being reproducible. These observations offer an explanation for the differences 
seen in levels of MCP-1 mRNA expression in the bone marrow transplanted mice. Relative 
expression of MCP-1 was determined using one of the gld mice transplanted with gld bone 
marrow as the reference. Ideally relative expression should have been determined using an 
untreated WT mouse as the reference, to compare accurately whether expression was 
increased in all groups of mice. However, the results show that MCP-1 production is 
significantly increased in all mice expressing functional FasL compared to the mice only 
expressing the mutated version. It would also be interesting to look at relative expression of 
other important modulators of inflammation, such as IL-1β, INF-γ and TNF-α. 
Despite concentrating on the effects of the gld mutation on mesangial cells they are 
not the only intrinsic renal cells that express FasL. Glomerular endothelial cells, podocytes 
and tubular epithelial cells have been shown to be a source of FasL within the kidney, and 
therefore may contribute to susceptibility to NTN (Lorz et al., 2000; Ortiz et al., 1999; Ross 
et al., 2005). As previously mentioned (Section 1.4.3.2 and Section 3.5), endothelial cells 
have been found to contribute to thrombosis. Disruption of the glycocalyx exposes the 
endothelial cells to pro-inflammatory molecules, such as TNF-α, IL-1 and MCP-1, and leads 
to the formation of tissue factor (Dosquet et al., 1995; Grabowski and Lam, 1995; Kirchhofer 
et al., 1994). Also, podocyte injury is a major cause of proteinuria in both humans and mice. 
Stimulation of podocytes with TNF-α and IL-1 activates NF-κB, resulting in the upregulation 
of pro-inflammatory cytokines such as MCP-1 (Brahler et al., 2012; Bruggeman et al., 2011; 
Natori et al., 1997) and tubular epithelial cells have been shown to be the main source of 
renal MCP-1 during NTN, due to cytokines and chemokines exiting the glomerulus in the 
urine, following the initial glomerular injury, and causing localised injury and inflammation 
in the interstitium (Tesch et al., 1999). These data are in keeping with my results as I saw a 
reduction in thrombosis, proteinuria and interstitial macrophage infiltration in the gld mice 
transplanted with gld bone marrow compared to the WT mice transplanted with gld bone 
marrow. Taking into account the effect of the gld mutation on the IL-1R signalling pathway 
and MCP-1 production, it would be interesting to culture WT and gld glomerular endothelial 
cells, podocytes and tubular epithelial cells and compare differences in MCP-1 production as 
I have done with the mesangial cells. It would also be of interest to look at the production of 
other cytokines that are downstream of NF-κB. Direct activation of NF-κB via FasL 
signalling has been shown to induce the expression of the pro-inflammatory cytokines IL-6 
and IL-8 (Ahn et al., 2001; Imamura et al., 2004), both of which have been shown to be 
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involved in kidney injury (Nechemia-Arbely et al., 2008; Niemir et al., 2004). Other 
important cytokines downstream of NF-κB include TNF-α and IL-12. These too are produced 
by intrinsic renal cells and are important in the development of GN (Timoshanko et al., 2001; 
Timoshanko et al., 2003). 
As mentioned in Section 3.5, one of the key roles of FasL is in inducing apoptosis. 
Again it is unclear which cells are undergoing apoptosis. However, there were more apoptotic 
cells (although not always significantly different) in all groups of mice expressing functional 
FasL on either one or both cellular compartments compared to the gld mice transplanted with 
gld bone marrow, suggesting both circulating leukocytes and intrinsic renal cells are capable 
of inducing apoptosis. Apoptotic endothelial cells have been shown to contribute to 
thrombotic events due to increased adherence of platelets to the endothelium and their 
subsequent activation (Bombeli et al., 1999), which can lead us to assume that the apoptotic 
cells represent both infiltrating leukocytes and intrinsic renal cells. Within the interstitium, 
FasL on tubular epithelial cells has been shown to induce tubular epithelial cell ‘fratricide’ 
following cisplatin-induced kidney injury (Linkermann et al., 2011). This suggests that in the 
WT mice transplanted with gld bone marrow there is a possibility that neighbouring 
glomerular cells may be responsible for inducing apoptosis of each other.  
Cleavage of FasL to its soluble form is thought to act to downregulate its apoptotic 
activity (Dupont and Warrens, 2007; O' Reilly et al., 2009; Schneider et al., 1998) and sFasL 
has been shown to play an important role in the activation of NF-κB and the production of 
pro-inflammatory cytokines (Ahn et al., 2001; O' Reilly et al., 2009). There are few studies 
looking at the role of sFasL in GN or kidney disease. One study by Perianayagam et al., 
measured both sFasL and soluble Fas (sFas) in the serum of patients with chronic kidney 
failure and found serum sFas to be significantly higher in patients and those undergoing 
dialysis compared to healthy controls, whereas there was no difference in the levels of sFasL 
(Perianayagam et al., 2000). However, immunoblot analysis revealed large ~60kDa 
aggregates in the sera that could represent sFasL-sFas complexes, suggesting the method of 
detection of sFasL could not recognise sFasL bound to sFas (Perianayagam et al., 2000). 
Attempts to detect sFasL by ELISA in the serum of WT mice with NTN were unsuccessful 
due to the lower detection limits of the kit; however, it would be of interest to see if there is a 
correlation between levels of sFasL and severity of disease.  




Based on these data, I can conclude that expression of FasL on circulating leukocytes 
or intrinsic renal cells can facilitate injury in accelerated NTN. My in vitro results looking at 
mesangial cells, as well as previous evidence present in the literature, suggest this is likely to 
be due to disrupted signalling through the IL-1R pathway as well as reduced direct activation 
of NF-κB by FasL. The result of this disrupted signalling affects the expression of pro-
inflammatory cytokines, highlighted by the reduced levels of MCP-1 in the supernatant of gld 
mesangial cells, and therefore possibly the recruitment and activation of macrophages to the 
kidney during disease. This is the first study to show a role for intrinsic renal cell FasL in 
GN. 
  





The Role of Fc Gamma Receptor IIB in Accelerated Nephrotoxic Nephritis 
 
5.1 Introduction 
FcγRIIB is the only inhibitory FcγR in both humans and mice and is the most widely 
expressed, being found on cells of both myeloid and lymphoid origin, with the exception of T 
cells and NK cells. FcγRIIB plays an important role in the negative regulation of the 
activating FcγR and the BcR, controlling both the effector responses of myeloid cells as well 
as antibody production by B cells (Takai et al., 1996).  
FcγRIIB-/- mice are more susceptible to the induction of CIA (Yuasa et al., 1999), 
inducible alveolitis (Clynes et al., 1999), EAG and NTN (Boross et al., 2011; Nakamura et 
al., 2000; Sharp et al., 2012; Suzuki et al., 1998). However, the cell types responsible for this 
are not known.  
Autoimmune-prone mice show a reduced expression of FcγRIIB on both B cells and 
myeloid cells, with increased circulating autoantibody titres and hyperactive macrophages 
(Pritchard et al., 2000). In mice, overexpression of FcγRIIB on B cells resulted in a reduced 
immune response, earlier resolution of CIA, and reduced spontaneous SLE, whereas 
overexpression on macrophages had no effect on CIA except increased mortality after 
Streptococcus pneumonia infection (Brownlie et al., 2008). However, deletion of FcγRIIB 
from B cells alone did not increase susceptibility to EAG when compared to WT control 
mice, whereas FcγRIIB-/- mice were more susceptible, indicating that defects in FcγRIIB 
expression on both the B cell and myeloid compartment are required for full expression of 
disease (Sharp et al., 2012).  
FcγRIIB-/- B cells have been shown to produce increased titres of antibody to T cell 
dependent antigens (Boross et al., 2011), but it is not known if this is sufficient in NTN to 
account for the increased disease in the FcγRIIB-/- mice. Macrophages deficient in FcγRIIB 
show enhanced phagocytic and calcium flux responses following FcγRIII crosslinking 
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(Clynes et al., 1999), suggesting NTN could be exacerbated in mice carrying a deletion of 
FcγRIIB in these cells.  
Dendritic cells are involved in the immune response and their altered function is 
known to play a major role in autoimmunity. Selective blockade of FcγRIIB results in 
spontaneous maturation of dendritic cells (Boruchov et al., 2005; Dhodapkar et al., 2005) and 
dendritic cells from FcγRIIB-/- mice generate stronger and longer-lasting immune responses 
both in vitro and in vivo (Kalergis and Ravetch, 2002).  
The presence of mast cells in the kidney tubulointerstitium has been associated with 
kidney fibrosis in human GN (Ehara and Shigematsu, 1998). However, in NTN, there are 
conflicting reports of the roles of mast cells. Timoshanko et al. found that mast cell-deficient 
KitW/W-v mice were protected from non-accelerated NTN, with reduced glomerular crescent 
formation and reduced T cell and macrophage infiltration, but a similar immune response, 
compared to WT mice (Timoshanko et al., 2006). In contrast, Hochegger et al., using the 
same strain of mice, found accelerated NTN was exacerbated (Hochegger et al., 2005). In a 
subsequent report, Eller et al. determined that, during accelerated NTN, mast cells were 
recruited to the renal draining lymph nodes by IL-9, produced by Treg, where they enhanced 
the immunosuppressive properties of the Treg (Eller et al., 2011). FcγRIIB-/- mice show 
enhanced mast cell degranulation (Ujike et al., 1999), therefore suggesting that the presence 
of FcγRIIB-/- mast cells in the kidney could exacerbate NTN. It is not know whether deletion 
of FcγRIIB on mast cells could modulate an effect on the immune response. 
Cre-loxP recombination is a site-specific recombinase technology widely used to 
carry out deletions, insertions, translocations and inversions in the DNA of cells. Cre is a 38 
kDa recombinase protein from bacteriophage P1 which recognises a loxP site, a 34bp 
sequence consisting of two 13bp inverted repeats separated by an 8bp asymmetric spacer 
region (Sauer, 1998). Two mouse lines are required for a conditional gene deletion. Firstly, a 
conventional transgenic mouse in which Cre is targeted to a tissue- or cell-specific promoter, 
and secondly, a mouse strain in which the target gene is flanked by two loxP sites in a direct 
orientation (“floxed” gene). Depending on the orientation of the loxP sites, crossing the mice 
can result in excision of the gene of interest, but only in the cells expressing Cre 
recombinase, therefore only inactivating the gene in the target tissue (Orban et al., 1992). 
To further dissect the role of FcγRIIB on specific cell types in GN, mice with a cell-
specific deletion of FcγRIIB in B cells, myeloid cells, dendritic cells, or mast cells were 
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created using the Cre-loxP system. This is the first study to look at the role of FcγRIIB in 




This part of the thesis was an investigation of the role of the inhibitory FcγR, 
FcγRIIB, on specific cell lineages in accelerated NTN. The results were based on the 
assessment of disease in mice where FcγRIIB had been deleted in B cells, myeloid cells, 




5.3 Experimental design 
To gain further insight into the role of FcγRIIB in immune-mediated GN, floxed 
FcγRIIB mice on a C57BL/6 background were generated by Professor Sjef Verbeek, LUMC, 
Leiden, The Netherlands, and crossed with mice expressing Cre recombinase under cell-
specific promoters to delete FcγRIIB from specific cell lineages. Cre recombinase expression 
was driven by the CD19 promoter to delete FcγRIIB from B cells (FcγRIIBCD19Cre mice), the 
Lysozyme M promoter to delete FcγRIIB from macrophages and neutrophils (FcγRIIBLysMCre 
mice), the cEBPα promoter to delete FcγRIIB from myeloid cells (including macrophages, 
neutrophils, and dendritic cells) (FcγRIIBcEBPαCre mice), the CD11c promoter to delete 
FcγRIIB from dendritic cells (FcγRIIBCD11cCre mice) and the Mcpt5 promoter to delete 
FcγRIIB from mast cells (FcγRIIBMcpt5Cre mice). Nephritis was induced in mice with the cell-
specific deletion of FcγRIIB, and age- and sex-matched littermate WT and full knockout 
controls, at LUMC by Professor Sjef Verbeek using our NTS. Mice were monitored clinically 
and I travelled to LUMC to sacrifice the mice at the end of the experiments. Assessment of 
disease was carried out as previously described by myself at Imperial College London, UK 
(see Section 3.3). 
  




5.4.1 Genotyping of FcγRIIB-/- mice using polymerase chain reaction 
The genotype of FcγRIIB-/- mice was confirmed by PCR analysis. DNA was extracted 
from tail snips and amplified by PCR using FcγRIIB specific primers. A band of 359bp was 
seen for the WT allele and 600bp for the targeted allele. The presence of both bands 
represented a heterozygote. A negative control, without DNA, was used to demonstrate the 
specificity of the assay (Figure 5.1). 
Genotyping of mice carrying the cell-specific deletion of FcγRIIB was carried out in 





Figure 5.1 PCR reactions of genomic DNA from WT and FcγRIIB-/- animals. 
Representative examples of WT (+/+), FcγRIIB-/- (-/-) and heterozygote (+/-) mice are shown 
here. The WT (+/+) mice show a band at 359bp, the FcγRIIB-/- (-/-) mice show a band at 
600bp and the heterozygote (+/-) mice show bands at 359bp and 600bp. The negative control 
(-VE) has no bands. 
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5.4.2 Phenotyping of FcγRIIB cell-specific knockout mice using flow cytometry 
The phenotype of FcγRIIB cell-specific knockout mice was confirmed by flow 
cytometric analysis of circulating leukocytes, resident splenic macrophages and dendritic 
cells, and peritoneal lavage sample mast cells from FcγRIIB-/- mice, FcγRIIBCD19Cre mice, 
FcγRIIBCD11cCre mice, FcγRIIBMcpt5Cre mice, FcγRIIBcEBPαCre mice, FcγRIIBLysMCre mice, and 
WT C57BL/6 controls by Sara Mangsbo, LUMC.  
To assess FcγRIIB expression on B cells, dendritic cells, macrophages, and 
neutrophils, heparinised whole blood or single cell suspensions obtained from the spleen 
were stained for CD19, B220 (both B cell markers), CD11c (dendritic cell marker), CD11b 
(macrophage marker when CD11c negative), Gr-1 (neutrophil marker), and FcγRIIB (clone 
Ly17.2) (Figure 5.2 A-C). To assess FcγRIIB expression on mast cells, peritoneal lavage 
samples were collected and stained for CD117, FcεR (both mast cell markers), and FcγRIIB 
(Figure 5.2 D). 
FcγRIIBCD19Cre mice showed deletion of FcγRIIB from both circulating and splenic B 
cells comparable with FcγRIIB-/- mice, with no deletion from circulating neutrophils and 
monocytes or splenic macrophages (Figure 5.2 A). Deletion of FcγRIIB on circulating 
monocytes and neutrophils from FcγRIIBcEBPαCre mice was comparable with FcγRIIB-/- mice 
but, in the spleen, there was only, approximately, 50% deletion of FcγRIIB from 
macrophages and dendritic cells (Figure 5.2 B). Splenic dendritic cells from FcγRIIBCD11cCre 
mice had comparable deletion of FcγRIIB as dendritic cells from FcγRIIB-/- mice, with no 
deletion on splenic macrophages or B cells (Figure 5.2 C). FcγRIIB deletion in the 
FcγRIIBMcpt5Cre mice was confined to mast cells, with no deletion from macrophages or 
dendritic cells (Figure 5.2 D). 
Deletion of FcγRIIB on macrophages and neutrophils in FcγRIIBLysMCre mice was not 
fully effective. There was a 50% reduction in expression of FcγRIIB on circulating 
monocytes and an even smaller reduction on splenic macrophages. Expression of FcγRIIB on 
WT neutrophils was very low and was comparable with FcγRIIBLysMCre mice (data not shown, 
please see (Natori et al., 1997)). Therefore, to assess the role of FcγRIIB on macrophages and 
neutrophils, we decided to switch to using the FcγRIIBcEBPαCre mice, despite the deletion 
being less specific. 




Figure 5.2 Flow cytometry of blood, spleen and lavage cells for FcγRIIB expression 
in the cell-specific knockout mice. 
Deletion of FcγRIIB from (A) FcγRIIBCD19Cre mice, (B) FcγRIIBcEBPαCre mice, (C) 
FcγRIIBCD11cCre mice, and (D) FcγRIIBMcpt5Cre mice compared to WT and FcγRIIB-/- mice 
showing cell specific deletion. Solid black line: WT mice. Dotted black line: cell-specific 
knockout mice. Solid grey line: FcγRIIB-/- mice. 
B) FcγRIIBcEBPαCre mice (FcγRIIB expression →) 
C) FcγRIIBCD11cCre mice (FcγRIIB expression →) 
D) FcγRIIBMcpt5Cre mice (FcγRIIB expression →) 
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5.4.3 Nephrotoxic nephritis in WT and FcγRIIB knockout mice 
NTN was induced in three different experiments. In Experiment 1 NTN was induced 
in WT, FcγRIIB-/- and FcγRIIBCD19Cre mice, in Experiment 2 NTN was induced in WT, 
FcγRIIB-/-, FcγRIIBCD11cCre, FcγRIIBMcpt5Cre and FcγRIIBcEBPαCre mice and in Experiment 3 
NTN was induced in WT, FcγRIIBCD19Cre and FcγRIIBcEBPαCre mice. In addition, two other 
experiments were performed, one comparing FcγRIIBCD19Cre to WT and FcγRIIB-/- mice, with 
the same results to those shown, and another comparing WT and FcγRIIB-/- mice to 
FcγRIIBLysMCre. This latter experiment was flawed, due to the poor deletion of FcγRIIB on the 
myeloid cell compartment, but showed no increase in disease in FcγRIIBLysMCre mice 
compared to WT (data not shown). In all experiments, mice were pre-immunised with 0.2mg 
of sheep IgG in CFA and after five days 200µl of NTS was administered via the tail vein. In 
Experiment 1 and 2 a 1:20 dilution of NTS was used, in Experiment 3 a 1:10 dilution was 
used. In Experiment 1, 29 female animals were used (n=10 WT, n=10 FcγRIIB-/-, and n=9 
FcγRIIBCD19Cremice). In Experiment 2, 56 female animals were used (n=12 WT, n=11 
FcγRIIB-/-, n=10 FcγRIIBCD11cCre, n=12 FcγRIIBMcpt5Cre, and n=11 FcγRIIBcEBPαCre mice). In 
Experiment 3, 23 female animals were used (n=7 WT, n=8 FcγRIIBCD19Cre and n=7 
FcγRIIBcEBPαCre mice). Mice were monitored clinically and sacrificed when disease became 
too severe. Mice from Experiment 1 were sacrificed at day 5. In Experiment 2, FcγRIIB-/- 
mice were sacrificed at day 6 and the rest at day 8. Mice from Experiment 3 were sacrificed 
at day 7. 
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5.4.3.1 FcγRIIB-/- mice are susceptible to renal failure, histological damage and 
increased glomerular macrophage infiltration, however deletion of FcγRIIB on B cells 
alone has no effect 
In Experiment 1, a low dose of NTS (1:20) was administered to WT, FcγRIIB-/- and 
FcγRIIBCD19Cre mice on a pure C57BL/6 background to confirm that complete deletion of 
FcγRIIB exacerbates accelerated NTN and to assess whether expression of FcγRIIB on B 
cells alone is important in protection. Mice were sacrificed at day 5 after induction of NTN, 
because the mice with the full deletion of FcγRIIB started to show serious disease symptoms, 
including severe proteinuria.  
To assess kidney function serum urea and albuminuria, expressed as a ratio of urinary 
albumin/creatinine, were measured in all mice. FcγRIIB-/- mice had significantly higher 
serum urea titres (105 (7.7-155) mmol/L) and albuminuria (9.8 (0.010-23) mg/mmol) 
compared to WT mice (serum urea: 7.9 (5.7-25) mmol/L, p<0.01; albuminuria: 0.085 (0.010-
6.8) mg/mmol, p<0.05) and FcγRIIBCD19Cre mice (serum urea: 7.6 (6.3-29) mmol/L, p<0.01; 
albuminuria: 0.14 (0.010-13) mg/mmol, p<0.05) (Figure 5.3 A and Figure 5.3 B).  
Histological damage, in the form of glomerular capillary thrombosis, was assessed on 
PAS-stained sections (Figure 5.4 A). FcγRIIB-/- mice had significantly more thrombotic 
glomeruli (2.2 (0.12-3.1)) compared to WT mice (0.00 (0.00-2.2), p<0.001) and 
FcγRIIBCD19Cre mice (0.040 (0.00-1.4), p<0.01) (Figure 5.4 B). There was no significant 
difference between WT and FcγRIIBCD19Cre mice. 
Kidney sections collected at the termination of Experiment 1 were stained for 
macrophage (CD68) infiltration as a measure of inflammation (Figure 5.5 A). FcγRIIB-/- mice 
had significantly greater glomerular macrophage infiltration (8.3 (5.8-12)/gcs) compared to 
WT mice (2.1 (1.8-5.9)/gcs, p<0.001) and FcγRIIBCD19Cre mice (3.3 (1.7-10)/gcs, p<0.05) 
(Figure 5.5 B).  
These results demonstrate that deletion of FcγRIIB on B cells alone is not sufficient to 
increase susceptibility to NTN compared to WT mice, whereas FcγRIIB-/- mice develop 
severe disease under the same conditions. This suggests the involvement of FcγRIIB on other 
cell types in the protection from NTN.  
 




Figure 5.3 Measurement of serum urea and urinary albumin/creatinine ratio in WT 
and FcγRIIB knockout mice with NTN, Experiment 1. 
(A) Serum urea and (B) urinary albumin/creatinine ratio were measured in WT and FcγRIIB 
knockout mice with NTN from Experiment 1. FcγRIIB-/- (-/-) mice had significantly higher 
serum urea and urinary albumin/creatinine ratio than WT and FcγRIIBCD19Cre (CD19) mice. 
All data represent individual values with the median. The data were analysed using Dunn’s 
Multiple Comparison Test (p*<0.05, p**<0.01). Dashed lines represent values for a group of 






























































Figure 5.4 Quantification of histologically abnormal glomeruli in WT and FcγRIIB 
knockout mice following induction of NTN, Experiment 1. 
(A) Representative PAS staining of glomeruli from WT, FcγRIIBCD19Cre and FcγRIIB-/- mice. 
Arrow highlights area of thrombosis in FcγRIIB-/- glomerulus. (B) Thrombosis score 5 days 
after the administration of NTS in WT mice and mice with a cell-specific deletion of FcγRIIB 
out 5 days after the administration of NTS. FcγRIIB-/- (-/-) mice had significantly more 
thrombotic glomeruli compared to WT and FcγRIIBCD19Cre (CD19) mice. All data represent 
individual values with the median. The data were analysed using Dunn’s Multiple 
Comparison Test (p**<0.01, p***<0.001). Dashed line represents values for a group of 
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Figure 5.5 Glomerular macrophage infiltration in WT and FcγRIIB knockout mice 
following induction of NTN, Experiment 1. 
(A) Immunohistochemistry for macrophages (CD68) on WT, FcγRIIBCD19Cre, and FcγRIIB-/-
kidney sections. Arrows highlight macrophages. (B) Macrophage infiltration per glomerular 
cross section (50 glomeruli scored per section) from Experiment 1. FcγRIIB-/- (-/-) mice had 
significantly more infiltrating glomerular macrophages that WT and FcγRIIBCD19Cre (CD19) 
mice. All data represent individual values with the median. The data were analysed using 
Dunn’s Multiple Comparison Test (p*<0.05, p***<0.001). Dashed line represents values for 
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5.4.3.2 FcγRIIB-/- had exacerbated disease compared to FcγRIIBcEBPαCre mice, 
FcγRIIBCD11cCre mice, and FcγRIIBMcpt5Cre mice, when mild NTN was induced 
Monocytes/macrophages, neutrophils, dendritic cells and mast cells have all been 
shown to play a role in the development of NTN and are known to express FcγRIIB. As the 
deletion of FcγRIIB on B cells alone had no effect on the susceptibility of mice to NTN the 
next step was to investigate the role of FcγRIIB on individual immune effector cells. In 
Experiment 2, a low dose of NTS (1:20) was administered to WT, FcγRIIBCD11cCre, 
FcγRIIBMcpt5Cre, FcγRIIBcEBPαCre and FcγRIIB-/- mice on a pure C57BL/6 background to assess 
whether FcγRIIB expression by immune effector cells is important in protection from renal 
injury. FcγRIIB-/- mice were sacrificed at day 6 due to severe disease; all other mice were left 
till day 8 to allow disease to develop further.  
To assess kidney function serum urea and albuminuria, expressed as a ratio of urinary 
albumin/creatinine, were measured in all mice. FcγRIIB-/- mice had significantly higher 
serum urea titres (131 (12-190) mmol/L) compared to WT mice (8.3 (6.9-12) mmol/L, 
p<0.001), FcγRIIBCD11cCre mice (9.5 (7.4-13) mmol/L, p<0.05) and FcγRIIBcEBPαCre mice (8.9 
(7.8-12) mmol/L, p<0.01) but not FcγRIIBMcpt5Cre mice (11 (8.2-14) mmol/L) (Figure 5.6 A). 
FcγRIIB-/- mice also had significantly higher levels of albuminuria (10 (0.013-28) mg/mmol) 
compared to WT mice (0.078 (0.014-0.85) mg/mmol, p<0.05) and FcγRIIBCD11cCre mice 
(0.019 (0.012-1.4) mg/mmol, p<0.001) but there was no significant difference between the 
other groups of mice (FcγRIIBMcpt5Cre mice (0.15 (0.010-2.9) mg/mmol, FcγRIIBcEBPαCre mice 
(0.43 (0.010-8.5) mg/mmol) (Figure 5.6 B). 
Histological damage, in the form of glomerular capillary thrombosis, was assessed in 
mice on PAS-stained sections (Figure 5.7 A). FcγRIIB-/- mice had significantly more 
thrombotic glomeruli (0.76 (0.020-1.1)) than WT mice (0.010 (0.00-0.22), p<0.001), 
FcγRIIBCD11cCre mice (0.00 (0.00-0.12), p<0.001) and FcγRIIBcEBPαCre mice (0.10 (0.00-0.40), 
p<0.01) but not FcγRIIBMcpt5Cre mice (0.020 (0.00-0.20)) (Figure 5.7 B). 
Kidney sections collected at the termination of Experiment 2 were stained for 
macrophage (CD68) and neutrophil (Gr-1) infiltration as a measure of inflammation (Figure 
5.8 A and Figure 5.9 A, respectively). FcγRIIB-/- mice had a significantly greater glomerular 
macrophage infiltration (3.7 (1.0-4.9)/gcs) compared to WT mice (0.48 (0.080-1.1)/gcs, 
p<0.01), FcγRIIBCD11cCre mice (0.48 (0.18-2.2)/gcs, p<0.05), FcγRIIBMcpt5Cre mice (0.18 
(0.020-1.1)/gcs, p<0.001) and FcγRIIBcEBPαCre mice (0.30 (0.020-1.2)/gcs, p<0.001) (Figure 
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5.8 B). FcγRIIB-/- mice also had significantly more glomerular neutrophils (2.2 (0.94-
2.8)/gcs) than WT mice (0.42 (0.10-0.70)/gcs, p<0.001), FcγRIIBCD11cCre mice (0.44 (0.32-
0.74)/gcs, p<0.01), FcγRIIBMcpt5Cre mice (0.50 (0.14-1.3)/gcs, p<0.05) and FcγRIIBcEBPαCre 
mice (0.45 (0.26-0.74)/gcs, p<0.001) (Figure 5.9 B). 
These results demonstrate that, at a low dose of NTS, deletion of FcγRIIB on immune 
effector cells alone is not sufficient to increase susceptibility to NTN compared to WT mice, 
whereas FcγRIIB-/- mice develop severe disease under the same conditions. This indicates 
that no one cell type is able to reconstitute fully the increased disease susceptibility of the full 
gene deletion.  
  




Figure 5.6 Measurement of serum urea and urinary albumin/creatinine ratio in WT 
and FcγRIIB knockout mice with NTN, Experiment 2. 
(A) Serum urea and (B) urinary albumin/creatinine ratio were measured in WT and FcγRIIB 
knockout mice with NTN from Experiment 2. FcγRIIB-/- (-/-) mice had significantly higher 
serum urea than WT, FcγRIIBCD11cCre (CD11c) and FcγRIIBcEBPαCre (cEBPα) mice and 
significantly higher urinary albumin/creatinine ratio than WT and FcγRIIBCD11cCre mice 
(Mcpt5 = FcγRIIBMcpt5Cre). All data represent individual values with the median. The data 
were analysed using Dunn’s Multiple Comparison Test (p*<0.05, p**<0.01, p***<0.001). 




























































Figure 5.7 Quantification of histologically abnormal glomeruli in WT and FcγRIIB 
knockout mice following induction of NTN, Experiment 2. 
(A) Representative PAS staining of glomeruli from WT, FcγRIIBCD11cCre, FcγRIIBMcpt5Cre, 
FcγRIIBcEBPαCre and FcγRIIB-/- mice. Arrow highlights area of thrombosis in the FcγRIIB-/- 
glomerulus. (B) Thrombosis score 6 to 8 days after the administration of NTS in WT and 
FcγRIIB knockout mice. FcγRIIB-/- (-/-) mice had significantly more thrombotic glomeruli 
than WT, FcγRIIBCD11cCre (CD11c), and FcγRIIBcEBPαCre (cEBPα) mice (Mcpt5 = 
FcγRIIBMcpt5Cre). All data represent individual values with the median. The data were 
analysed using Dunn’s Multiple Comparison Test (p**<0.01, p***<0.001). Dashed line 
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Figure 5.8 Glomerular macrophage infiltration in WT and FcγRIIB knockout mice 
following induction of NTN, Experiment 2. 
(A) Immunohistochemistry for macrophages (CD68) on WT, FcγRIIBCD11cCre, 
FcγRIIBMcpt5Cre, FcγRIIBcEBPαCre and FcγRIIB-/- sections. Arrows highlight macrophages. (B) 
Macrophage infiltration per glomerular cross section (gcs) (50 glomeruli scored per section) 
from Experiment 2. FcγRIIB-/- (-/-) mice had significantly more macrophages compared to all 
other groups of mice in both experiments (CD11c = FcγRIIBCD11cCre, Mcpt5 = 
FcγRIIBMcpt5Cre, cEBPα = FcγRIIBcEBPαCre). All data represent individual values with the 
median. The data were analysed using Dunn’s Multiple Comparison Test (p*<0.05, 

































Figure 5.9 Glomerular neutrophil infiltration in WT and FcγRIIB knockout mice 
following induction of NTN, Experiment 2. 
(A) Immunohistochemistry for neutrophils (Gr-1) on WT, FcγRIIBCD11cCre, FcγRIIBMcpt5Cre, 
FcγRIIBcEBPαCre and FcγRIIB-/- kidney sections. Arrows highlight neutrophils. (B) Neutrophil 
infiltration per glomerular cross section (gcs) (50 glomeruli scored per section) from 
Experiment 2. FcγRIIB-/- (-/-) mice had significantly more glomerular neutrophils than all 
other groups of mice (CD11c = FcγRIIBCD11cCre, Mcpt5 = FcγRIIBMcpt5Cre, cEBPα = 
FcγRIIBcEBPαCre). All data represent individual values with the median. The data were 
analysed using Dunn’s Multiple Comparison Test (p*<0.05, p**<0.01, p***<0.001). Dashed 
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5.4.3.3 Deletion of FcγRIIB on myeloid cells increases susceptibility to renal failure, 
histological damage and glomerular neutrophil infiltration compared to WT mice and 
deletion on B cells alone, following a higher dose of NTS 
As FcγRIIB-/- mice are highly susceptible to developing NTN following a low dose of 
NTS, we decided to repeat the experiment using a higher dose of NTS (1:10) and omitting 
these mice in order to determine if FcγRIIBcEBPαCre and FcγRIIBCD19Cre mice would then 
become more susceptible to disease. In Experiment 3, nephritis was induced in the B cell and 
myeloid cell knockout mice, to dissect fully the role of FcγRIIB on B cells and immune 
effector cells, and compared to WT mice only. Mice were sacrificed at day 7-post induction 
of NTN because the FcγRIIBcEBPαCre mice started to show clinical signs of disease. 
To assess kidney function serum urea and albuminuria, expressed as a ratio of urinary 
albumin/creatinine, were measured in all mice. FcγRIIBcEBPαCre mice had significantly higher 
levels of serum urea (48 (46-124) mmol/L) compared to FcγRIIBCD19Cre mice (8.1 (3.7-81) 
mmol/L, p<0.05) but not WT mice (12 (6.5-51) mmol/L) (Figure 5.10 A). FcγRIIBcEBPαCre 
mice also had significantly more albuminuria compared to FcγRIIBCD19Cre mice 
(FcγRIIBcEBPαCre 6.3 (3.1-16) mg/mmol, FcγRIIBCD19Cre 1.3 (0.010-3.3) mg/mmol, p<0.01) 
and WT mice (1.2 (0.05-4.8) mg/mmol, p<0.05) (Figure 5.10 B). 
Histological damage, in the form of glomerular capillary thrombosis, was assessed in 
mice on PAS-stained sections (Figure 5.11 A). FcγRIIBcEBPαCre mice had significantly more 
thrombotic glomeruli (1.5 (0.78-2.9)) than both WT and FcγRIIBCD19Cre mice (thrombosis 
score: WT 0.20 (0.10-1.2), p<0.05; FcγRIIBCD19Cre mice 0.050 (0.00-1.3), p<0.01) (Figure 
5.11 B).  
Kidney sections collected at the termination of Experiment 3 were stained for 
macrophage (CD68) and neutrophil (Gr-1) infiltration as a measure of inflammation (Figure 
5.12 A and Figure 5.13 A, respectively). There was no significant difference in glomerular 
macrophage numbers between the three groups of mice (macrophages/gcs: WT 1.3 (0.90-
3.3), FcγRIIBCD19Cre 1.9 (0.74-3.3), FcγRIIBcEBPαCre 2.0 (1.4-6.1)) (Figure 5.12 B). However, 
FcγRIIBcEBPαCre mice had a significantly greater infiltration of glomerular neutrophils than 
WT mice (FcγRIIBcEBPαCre 1.5 (0.72-2.2)/gcs, WT 0.62 (0.32-1.1)/gcs, p<0.05) but there was 
no significant difference between the two groups with FcγRIIBCD19Cre mice (0.59 (0.23-
1.7)/gcs) (Figure 5.13 B). 
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These results clearly demonstrate an important role for FcγRIIB on myeloid cells in 
vivo in NTN. However, taken with the results from Section 5.4.3.2, FcγRIIBcEBPαCre mice are 
not as susceptible to NTN as FcγRIIB-/- mice, suggesting other cell types may also play a 
protective role at a lower dose of NTS.  




Figure 5.10 Measurement of serum urea and urinary albumin/creatinine ratio in WT 
and FcγRIIB knockout mice with NTN, Experiment 3. 
(A) Serum urea and (B) urinary albumin/creatinine ratio were measured in WT and FcγRIIB 
knockout mice with NTN from Experiment 3. FcγRIIBcEBPαCre (cEBPα) mice had 
significantly higher serum urea than FcγRIIBCD19Cre (CD19) mice and urinary 
albumin/creatinine ratio than WT and FcγRIIBCD19Cre (CD19) mice and significantly lower 
serum albumin than WT and FcγRIIBCD19Cre mice. All data represent individual values with 
the median. The data were analysed using Dunn’s Multiple Comparison Test (p*<0.05, 

























































Figure 5.11 Quantification of histologically abnormal glomeruli in WT and FcγRIIB 
knockout mice following induction of NTN, Experiment 3. 
(A) Representative PAS-stained of glomeruli from WT, FcγRIIBCD19Cre and FcγRIIBcEBPαCre 
mice. Arrow highlights area of thrombosis in FcγRIIBcEBPαCre glomerulus. (B) Thrombosis 
score in WT mice and mice with FcγRIIB conditionally knocked out 7 days after the 
administration of NTS. FcγRIIBcEBPαCre (cEBPα) mice had significantly more thrombotic 
glomeruli compared to WT and FcγRIIBCD19Cre (CD19) mice. All data represent individual 
values with the median. The data were analysed using Dunn’s Multiple Comparison Test 
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Figure 5.12 Glomerular macrophage infiltration in WT and FcγRIIB knockout mice 
following induction of NTN, Experiment 3. 
(A) Immunohistochemistry for macrophages (CD68) on WT, FcγRIIBCD19Cre, and 
FcγRIIBcEBPαCre kidney sections. Arrows highlight macrophages. (B) Macrophage infiltration 
per glomerular cross section  (gcs) (50 glomeruli scored per section) from Experiment 3. 
There was no significant difference between the three groups (CD19 = FcγRIIBCD19Cre, 
cEBPα = FcγRIIBcEBPαCre). All data represent individual values with the median. The data 
were analysed using Dunn’s Multiple Comparison Test. Dashed line represents values for a 
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Figure 5.13 Glomerular neutrophil infiltration in WT and FcγRIIB knockout mice 
following induction of NTN, Experiment 3. 
(A) Immunohistochemistry for neutrophils (Gr-1) on WT, FcγRIIBCD19Cre and FcγRIIBcEBPαCre 
kidney sections. Arrows highlight neutrophils. (B) Neutrophil infiltration per glomerular 
cross section (gcs) (50 glomeruli scored per section) from Experiment 3. FcγRIIBcEBPαCre 
(cEBPα) mice had significantly more glomerular neutrophils than WT mice (CD19 = 
FcγRIIBCD19Cre). All data represent individual values with the median. The data were 
analysed using Dunn’s Multiple Comparison Test (p*<0.05). Dashed line represents values 
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5.4.4 Systemic immune responses 
The immune responses of the mice from all three experiments were assessed as before 
(Section 3.4.5). Circulating total mouse anti-sheep IgG levels were measured by ELISA. 
Despite having less disease, the FcγRIIBCD19Cre mice had higher circulating anti-sheep 
antibody titres, showing that increased antibody production is not the determining factor for 
heightened susceptibility to NTN. In Experiment 1, FcγRIIBCD19Cre mice had significantly 
higher levels of circulating antibodies compared to FcγRIIB-/- mice (p<0.05). In Experiment 
2, FcγRIIBCD11cCre mice and FcγRIIBMcpt5Cre mice had significantly higher levels of 
circulating antibodies compared to FcγRIIB-/- mice (p<0.01 for both). In Experiment 3, 
FcγRIIBCD19Cre mice had significantly higher circulating antibody titres compared to 
FcγRIIBcEBPαCre mice (p<0.05) (Table 5.1 and Figure 5.14).  
Frozen kidney sections were stained for deposited sheep and mouse IgG by direct 
immunofluorescence on tissue taken at the end of the experiment. Total glomerular sheep and 
mouse IgG were measured by quantitative immunofluorescence with the results expressed as 
arbitrary fluorescence units (AFU) or visual fluorescence units (VFU) (depending upon 
availability of equipment at the time the experiments were run). There was no significant 
difference in glomerular sheep IgG deposition between any of the groups of mice in any of 
the experiments (Table 5.1, Figure 5.15 and Figure 5.16). In Experiment 1, FcγRIIB-/- mice 
had significantly greater deposition of mouse IgG compared to WT mice (p<0.01) and 
FcγRIIBCD19Cre mice (p<0.01). In Experiment 2, FcγRIIB-/- mice had significantly greater 
mouse IgG deposition compared to FcγRIIBcEBPαCre mice (p<0.05). There was no significant 
difference in deposited mouse IgG between any of the groups of mice in Experiment 3 (Table 
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 Mouse Serum 
anti-sheep 







Experiment 1 WT 1.2 (0.12-1.5) 101 (61-159) 1055 (266-1236) 
 FcγRIIBCD19Cre 1.2 (1.0-1.4) 63 (22-109) 1111 (739-1502) 
 FcγRIIB
-/- 0.95 (0.87-1.6) 79 (0-147) 1537 (1195-1840) 
Experiment 2 WT 0.80 (0.12-1.2) 2.5 (1.0-3.0) 1.8 (0.5-2.5) 
 FcγRIIBCD11cCre 0.91 (0.65-1.2) 2.8 (1.0-3.0) 1.8 (1.5-2.5) 
 FcγRIIBMcpt5Cre 0.92 (0.66-1.0) 2.0 (1.5-3.0) 1.0 (0.5-2.5) 
 FcγRIIBcEBPαCre 0.83 (0.059-0.93) 2.0 (1.0-3.0) 1.0 (0.5-1.5) 
 FcγRIIB
-/- 0.65 (0.21-0.76) 2.5 (2.0-3.0) 2.5 (0.5-3.0) 
Experiment 3 WT 1.0 (0.50-1.8) 51 (35-73) 97 (69-125) 
 FcγRIIBCD19Cre 1.6 (0.018-1.8) 59 (38-118) 114 (90-161) 
 FcγRIIBcEBPαCre 0.42 (0.0090-1.2) 36 (24-86) 114 (67-167) 
Table 5.1 Circulating total mouse anti-sheep IgG levels and deposited glomerular 
sheep and mouse IgG in WT and FcγRIIB knockout mice with NTN. 
All results are expressed as median (range). Experiment 1 and Experiment 3, deposited 
glomerular sheep IgG and mouse IgG are represented as AFU. Experiment 2, deposited 
glomerular sheep and mouse IgG are represented as VFU. 
 




Figure 5.14 Total circulating mouse anti-sheep IgG levels in WT and FcγRIIB 
knockout mice following induction of NTN. 
Circulating mouse anti-sheep IgG was measured by ELISA in (A) Experiment 1, (B) 
Experiment 2, and (C) Experiment 3. In Experiment 1 and Experiment 2, FcγRIIB-/- (-/-) mice 
had less circulating mouse anti-sheep IgG compared to FcγRIIBCD19Cre (CD19), 
FcγRIIBMcpt5Cre (Mcpt5) and FcγRIIBCD11cCre (CD11c) mice. In Experiment 3, FcγRIIBcEBPαCre 
(cEBPα) mice had significantly less circulating mouse anti-sheep IgG compared to 
FcγRIIBCD19Cre mice. All data represent individual values with the median. The data were 

































































Figure 5.15 Immunofluorescence for glomerular sheep IgG deposition in WT and 
FcγRIIB knockout mice following induction of NTN. 
The relative mean glomerular immunofluorescence was measured quantitatively, expressed 
as arbitrary fluorescence units (AFU), or semi-quantitatively, expressed as visual 
fluorescence units (VFU). There was no significant difference in deposited sheep IgG 
between any of the groups in (A) Experiment 1, (B) Experiment 2 or (C) Experiment 3 
(CD19 = FcγRIIBCD19Cre, cEBPα = FcγRIIBcEBPαCre). All data represent individual values with 











































































Figure 5.16 Immunofluorescence for glomerular sheep IgG deposition in WT and 
FcγRIIB knockout mice from Experiment 1, Experiment 2, and Experiment 3. 
Representative glomeruli from (A) WT mice, (B) FcγRIIB-/- mice, (C) FcγRIIBCD19Cre mice, 
(D) FcγRIIBcEBPαCre mice, (E) FcγRIIBCD11cCre mice and (F) FcγRIIBMcpt5Cre mice showing 
sheep IgG deposition. All images were taken using the same settings.  
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Figure 5.17 Immunofluorescence for glomerular mouse IgG deposition in WT and 
FcγRIIB knockout mice following induction of NTN. 
The relative mean glomerular immunofluorescence was measured quantitatively, expressed 
as arbitrary fluorescence units (AFU), or semi-quantitatively, expressed as visual 
fluorescence units (VFU). FcγRIIB-/- (-/-) mice had more deposited mouse IgG compared to 
WT and FcγRIIBCD19Cre (CD19) mice in (A) Experiment 1 and FcγRIIBcEBPαCre (cEBPα) mice 
in (B) Experiment 2 (CD11c = FcγRIIBCD11cCre, Mcpt5 = FcγRIIBMctp5Cre). There was no 
difference in deposited mouse IgG in (C) Experiment 3. All data represent individual values 

















































































Figure 5.18 Immunofluorescence for glomerular mouse IgG deposition in WT and 
FcγRIIB knockout mice from Experiment 1, Experiment 2, and Experiment 3. 
Representative glomeruli from (A) WT mice, (B) FcγRIIB-/- mice, (C) FcγRIIBCD19Cre mice, 
(D) FcγRIIBcEBPαCre mice, (E) FcγRIIBCD11cCre mice, and (F) FcγRIIBMcpt5Cre mice showing 
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5.4.5 mRNA expression of cytokines and other mediators 
In Experiment 3, despite FcγRIIBcEBPαCre mice having increased susceptibility to NTN 
compared to WT and FcγRIIBCD19Cre mice, there was no significant difference in macrophage 
infiltration between the three groups. This suggests the differences seen may be due to 
increased macrophage activation in the FcγRIIBcEBPαCre mice. To investigate further the 
mechanism of injury, mRNA was extracted from whole kidney of WT, FcγRIIBCD19Cre and 
FcγRIIBcEBPαCre mice from Experiment 3. mRNA expression levels of cytokines and other 
mediators of macrophage activation were measured by qRT-PCR. Mediators measured were: 
MCP-1, involved in macrophage recruitment; TNF-α, produced by classically and 
alternatively activated macrophages; MR, a marker of alternatively activated macrophages; 
and IFN-γ, involved in the classically activated macrophage pathway. Data represent relative 
expression, calculated using GAPDH as the housekeeping gene and an untreated WT mouse 
as the reference. 
Relative expression of MCP-1 in whole kidney from FcγRIIBCD19Cre mice (3.5 (2.4-
13)) was significantly greater than FcγRIIBcEBPαCre mice (1.4 (0.6-3.7), p<0.05), there was no 
significant difference with WT mice (3.4 (0.54-6.1)). There was no significant difference in 
relative expression of TNF-α or MR between the three groups of mice (TNF-α: WT 1.2 
(0.45-11), FcγRIIBCD19Cre 1.8 (0.48-3.9), FcγRIIBcEBPαCre 1.1 (0.60-2.7); MR: WT 0.86 (0.24-
2.6), FcγRIIBCD19Cre 0.45 (0.35-1.2), FcγRIIBcEBPαCre mice 0.54 (0.38-1.8)). Although MR 
expression appeared to be slightly downregulated compared to control WT mice without 
NTN. IFN-γ expression was significantly greater in both WT mice (3.1 (2.2-13)) and 
FcγRIIBCD19Cre mice (3.3 (2.0-6.4)) compared to FcγRIIBcEBPαCre mice (0.85 (0.20-2.3), 
p<0.01 and p<0.05 respectively) (Figure 5.19). Therefore none of these markers were able to 
differentiate between the groups. It may be that the timepoint of analysis was late in the 
disease process, or that it is necessary to isolate glomeruli to assess the differences more 
specifically.  
 




Figure 5.19 Relative expression of MCP-1, TNF-α, MR and IFN-γ in whole kidney of 
WT, FcγRIIBCD19Cre, and FcγRIIBcEBPαCre mice with NTN, Experiment 3. 
Relative expression of (A) MCP-1, (B) TNF-α, (C) MR and (D) IFN-γ were measured in 
whole kidney mRNA extracts. FcγRIIBCD19Cre (CD19) and WT mice had significantly greater 
expression of IFN-γ than FcγRIIBcEBPαCre (cEBPα) mice and FcγRIIBCD19Cre mice had 
significantly greater expression of MCP-1 than FcγRIIBcEBPαCre mice. There was no 
significant difference in the relative expression of TNF-α and MR. All data represent 
individual values with the median. The data were analysed using Dunn’s Multiple 




























































































These results confirm that complete deletion of FcγRIIB from C57BL/6 mice causes 
exacerbated disease following the induction of accelerated NTN, as shown by increased renal 
dysfunction, histological damage, and cellular infiltration, compared to WT counterparts. 
Deletion of FcγRIIB from B cells, dendritic cells, mast cells or myeloid cells was not found 
to increase the incidence of accelerated NTN at a low dose of NTS, however we have then 
gone on to show at a higher dose of NTS that FcγRIIB expressed by myeloid cells, but not B 
cells, is important in protection from disease, despite an increased systemic antibody 
response in the FcγRIIBCD19Cre mice and similar levels of glomerular macrophage infiltration 
between WT, FcγRIIBCD19Cre and FcγRIIBcEBPαCre mice. There was no difference in deposited 
mouse IgG between the three groups; however FcγRIIBcEBPαCre mice had an increased 
glomerular neutrophil infiltration. These results indicate that FcγRIIB on myeloid cells is 
important in regulating myeloid cell activity in NTN and that expression of FcγRIIB on B 
cells, and raised antibody levels, are not important in the effector phase of GN in this model.  
 
 
FcγRIIB is one of the most widely expressed FcγR, being found on most leukocytes, 
with the exception of T cells and NK cells. It functions as a negative regulator for activating 
receptors, such as the FcγR or BcR, and is also involved in immune complex uptake and 
antigen presentation, meaning it is a key player in regulating innate and adaptive immunity. 
The generation of mice carrying a cell-specific deletion, using cre-loxP recombination, has 
made it possible to decipher the precise roles of diverse molecules in different cell types in 
disease development. Using this technology, FcγRIIB was deleted from B cells, dendritic 
cells, mast cells and myeloid cells. The efficiency of the deletion was measured by flow 
cytometry by staining for FcγRIIB and specific cellular markers. There was good deletion of 
FcγRIIB from B cells, dendritic cells and mast cells. The myeloid cell knockout, using the 
cEBPα promoter, produced a good deletion from granulocytes and monocytes in the blood, 
however there was only partial deletion from macrophages and dendritic cells in the spleen. 
Within the haematopoietic system, cEBPα is exclusively expressed in early myeloid 
progenitors, making it a good target for creating myeloid cell knockouts (Akashi et al., 2000). 
cEBPα-/- mice were found to lack mature granulocytes, but not monocytes and macrophages, 
both circulating and in haematopoietic organs (Zhang et al., 1997). This suggests that cEBPα 
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is not essential for monocyte and macrophage maturation. It would be of interest to compare 
FcγRIIB expression on other tissue resident macrophages, such as resident renal 
macrophages, Kupffer cells in the liver and alveolar macrophages in the lung. The deletion of 
FcγRIIB on circulating monocytes and splenic macrophages in the FcγRIIBLysMCre mice was 
extremely poor (data not shown). Effective deletion of the target gene is dependent upon 
high-level expression of Cre in the cell type of interest, so it is possible that the levels of Cre 
generated by the Lysozyme M promoter were not sufficient. It has also been shown that 
Lysozyme M is not constitutively expressed in resident splenic macrophages (Keshav et al., 
1991). 
The increased severity of NTN in the FcγRIIB-/- mice on a pure C57BL/6 background 
supports previous work that FcγRIIB expression is an important factor in determining disease 
outcome and that the severity seen, following deletion, is not solely an effect of the 129-
derived flanking sequences on Chromosome 1 (Boross et al., 2011; Sharp et al., 2012; Suzuki 
et al., 1998).  
At both the lower and higher doses of NTS, in Experiment 1 and Experiment 3 
respectively, there was no increase in susceptibility to NTN in mice with FcγRIIB deleted 
from their B cells compared to WT mice. FcγRIIB on B cells is involved in the negative 
regulation of the BcR, and therefore plays a key role in antibody production. FcγRIIB-/- mice 
have already been shown to have hyper-reactive B cells that produce increased antibody titres 
in response to both thymus-dependent and thymus-independent antigens both on the 129/B6 
and the pure B6 background (Boross et al., 2011; Takai et al., 1996). Interestingly, FcγRIIB-/- 
mice had lower levels of circulating mouse anti-sheep IgG compared to FcγRIIBCD19Cre mice 
in Experiment 1 and FcγRIIBCD11cCre and FcγRIIBMcpt5Cre mice in Experiment 2. This is likely 
due to the increase in glomerular damage, as these mice had severe levels of proteinuria. In 
Experiment 3, mice lacking FcγRIIB on B cells had increased circulating levels of total 
mouse anti-sheep IgG, that were significantly higher than myeloid cell knockouts but not the 
WT mice, most likely due to the wide range of antibody responses produced by the WT mice. 
There was no significant difference in antibody responses between the WT mice and the 
FcγRIIBcEBPαCre mice, although the WT mice trended towards having higher levels of 
circulating antibody. This can again be attributed to the wide range of antibody responses by 
the WT mice and the increased proteinuria in the myeloid cell knockout mice. Ideally, for a 
more accurate measure of immune response, circulating antibody should be studied before 
the onset of proteinuria. 
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Transgenic overexpression of FcγRIIB on B cells was associated with reduced 
severity of CIA and SLE in mice, and reduced anti-collagen titres (Brownlie et al., 2008). 
However, NTN is not an autoimmune model and it is possible that, in the situation of 
generating antibody to foreign antigen, the antibody response is already sufficient in WT 
mice to produce enough antibody to induce maximal nephritis. In contrast, in the situation of 
autoimmunity, such as SLE or EAG (Sharp et al., 2012) tolerance mechanisms exist to 
prevent excessive production of autoantibodies in WT mice. In this situation, the 
overproduction of antibody induced by the deficiency of FcγRIIB on B cells may be more 
critical in the generation of disease.  
In addition, the levels of antibody themselves may not be a key determinant of NTN 
disease severity, as T cell responses are also important. This was highlighted in a study using 
mice lacking the µ immunoglobulin heavy chain gene. Homozygous µ-chain deficient mice 
fail to develop mature B cells or produce antibody but have intact cell-mediated immunity, 
whereas heterozygous µ-chain deficient mice demonstrate normal antibody responses. 
Following induction of NTN, there was no difference in the severity of renal injury between 
the two groups of mice, despite mouse immunoglobulin being absent from the serum and 
glomeruli of the homozygous mice, suggesting glomerular damage can occur independent of 
the humoral immune response to planted glomerular antigen (Li et al., 1997).  
There was no significant difference in glomerular deposition of sheep IgG between 
any of the mice in the three experiments. However, FcγRIIB-/- had greater deposition of 
mouse IgG in glomeruli than WT and FcγRIIBCD19Cre mice in Experiment 1 and 
FcγRIIBcEBPαCre mice in Experiment 2. There was no significant difference in glomerular 
deposition of mouse IgG between the three groups of mice in Experiment 3. These results are 
difficult to interpret fully, due to the glomerular damage in the mice with more disease. 
However, FcγRIIB has been found to be involved in immune complex clearance by liver 
endothelial cells (Mousavi et al., 2007) and could be playing similar role within the 
glomerulus. This also provides a possible explanation for the lower levels of homologous 
antibody deposition in the FcγRIIBCD19Cre mice in Experiment 3, despite increased circulating 
titres.  
At a higher dose of NTS, there was an increase in renal dysfunction (increased serum 
urea and increased albuminuria), neutrophil infiltration and glomerular injury (thrombosis) in 
the myeloid cell knockouts compared to WT and B cell knockouts, directly linking 
expression of FcγRIIB on myeloid cells to the development of GN. This supports previous 
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work looking at activating FcγR in accelerated NTN. Bergtold et al. generated transgenic 
FcRγ-/- mice expressing FcRγ on myeloid cells alone, under the control of the CD11b 
promoter. Induction of NTN resulted in severe disease in the WT mice whereas FcRγ-/- mice 
were protected. However, mice only expressing FcRγ on their myeloid cell compartment 
developed moderate disease, indicating that the presence of activating Fc receptors on 
CD11b-expressing cells is sufficient for NTN induction (Bergtold et al., 2006). In our recent 
publication, deletion of FcγRIIB on myeloid cells alone did not increase the incidence of 
EAG compared to full knockouts. However, first it must be noted that this publication used 
Cre expressed under the Lysozyme M promoter so there was only a 50% reduction of 
FcγRIIB expression on circulating monocytes and a smaller reduction in expression on 
circulating neutrophils and splenic macrophages (Sharp et al., 2012). Secondly, EAG is an 
autoimmune model of GN and it is necessary to break tolerance to induce disease. Therefore, 
it could be that FcγRIIB needs to be deleted from both the myeloid cells and B cells to 
increase susceptibility in EAG.  
A small influx of neutrophils and macrophages into the glomerulus was seen in all 
three groups of mice. Mice lacking FcγRIIB on myeloid cells had a significantly greater 
neutrophil infiltration compared to WT and B cell knockouts; however, interestingly, there 
was no significant difference in macrophage infiltration. Neutrophils are one of the first 
inflammatory cells recruited to sites following the initiation of an immune reaction. FcγR are 
thought to play a role in neutrophil recruitment; FcRγ-/- and FcγRIII-/- mice both display 
strongly diminished recruitment of neutrophil effector cells during anti-GBM disease (Coxon 
et al., 2001). Therefore, FcγRIIB expression on neutrophils could be playing a role in the 
negative regulation of neutrophil recruitment.  
Macrophages are known to be important effector cells in GN. Reduced surface 
expression of FcγRIIB on macrophages was associated with heightened responses following 
activatory FcγR cross-linking; including increased intracellular calcium flux, superoxide 
production, and pro-inflammatory cytokine release (Clatworthy and Smith, 2004; Pritchard et 
al., 2000). In a study looking at the role of FcγRIV in accelerated NTN, treatment with 
intravenous Ig (IVIG) was found to protect mice from developing renal pathology. Closer 
examination revealed IVIG induced on macrophages, but not neutrophils, upregulation of 
FcγRIIB and downregulation of FcγRIV. Additionally, the protective properties of IVIG were 
ablated in FcγRIIB-/- mice (Kaneko et al., 2006). The mechanism for IVIG protection has 
recently been determined. Th2 cytokines, such as IL-4, are known to upregulate myeloid 
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expression of FcγRIIB (Pricop et al., 2001). The sialylated IgG component of human IVIG 
binds to a lectin receptor on dendritic cells, leading to secretion of IL-33. IL-33 in turn 
upregulates IL-4 secretion by basophils, leading to increased expression of FcγRIIB on 
myeloid cells (Anthony et al., 2011). These results support the importance of FcγRIIB on 
myeloid cells in the protection from GN. Therefore, a mechanism of action of IVIG may be 
the modulation of expression of FcγRIIB on myeloid cells.  
Reduced expression of FcγRIIB on macrophages, leading to uncontrolled activation, 
could be involved in exacerbating GN in the myeloid cell knockouts. To determine if there 
was overactivation of macrophages in FcγRIIBcEBPαCre mice we analysed whole kidney 
mRNA levels for MCP-1, TNF-α, MR and IFN-γ. However, we did not find any significant 
increase in cytokines associated with the activation of macrophages in the myeloid cell 
knockout mice. As mentioned in Section 3.5, the use of whole kidney mRNA is not ideal to 
study cytokine expression levels because it is not possible to determine which cells are 
producing which cytokines. An alternative would be to isolate the glomeruli by sieving 
before mRNA analysis, or culture the glomeruli and measure cytokine secretion into the 
supernatant. Again though, from using whole glomeruli it would not be clear whether 
resident renal cells, such as mesangial cells, or infiltrating macrophages, are producing the 
cytokines or chemokines. To decipher fully the role of FcγRIIB on macrophages and 
neutrophils in GN, Cre would need to be downstream of more specific promoter.  
At a low dose of NTS, there was no significant increase in susceptibility to renal 
dysfunction or inflammation in the mice with FcγRIIB deleted from dendritic cells, mast cells 
or myeloid cells compared to WT mice, whereas FcγRIIB-/- mice showed severe signs of 
disease. The presence of disease in the FcγRIIB-/- mice, as well as circulating anti-sheep IgG 
and deposited glomerular sheep and mouse IgG, suggests that expression of FcγRIIB by other 
circulating cells, and possibly intrinsic renal cells such as mesangial cells (Ichii et al., 2008; 
Radeke et al., 2002), can protect from NTN during mild disease.  
As already mentioned, cEBPα is expressed in early myeloid cell progenitors. In the 
myeloid cell knockout mice this has lead to the deletion of FcγRIIB on a subset of splenic 
dendritic cells. Blockade of FcγRIIB on dendritic cells was found to result in their 
spontaneous maturation (Boruchov et al., 2005; Dhodapkar et al., 2005). Mature tissue-
resident dendritic cells are potent APC and activators of T cells. Dendritic cells from 
FcγRIIB-/- mice were found to generate a stronger and longer lasting immune response 
(Kalergis and Ravetch, 2002). Therefore, the deletion of FcγRIIB on dendritic cells could be 
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contributing to the exacerbation of disease seen in these mice. To answer this question, it 
would be necessary to repeat the higher dose experiment in the mice with FcγRIIB 
expression under the control of the CD11c promoter. It would also be of interest to compare 
dendritic cell and T cell infiltration in the mice and to look more specifically at T cell 
responses by measuring both proliferation and cytokine production in vitro. This could help 
determine whether antigen presentation is enhanced by deletion of FcγRIIB on dendritic cells 
and whether this is contributing to the increased susceptibility to disease seen in FcγRIIB-/- 
mice. 
Recently, mast cells have been implicated in GN, where they can exert either 
beneficial or detrimental effects, dependent on whether disease is acute or chronic, 
respectively. Mast cell-deficient mice were found to be protected from disease in non-
accelerated NTN (Timoshanko et al., 2006); however, following induction of accelerated 
NTN or vasculitic GN, renal injury was exacerbated (Eller et al., 2011; Gan et al., 2012; 
Hochegger et al., 2005; Kanamaru et al., 2006). Both Eller et al. and Gan et al. have gone on 
to show that during acute disease mast cells migrate to the draining lymph nodes where they 
enhance immunosuppression by Treg (Eller et al., 2011; Gan et al., 2012), likely through the 
production of IL-10 (Gan et al., 2012). However, they disagree on which cells recruit which; 
Eller et al. claim IL-9 production by Treg recruits mast cells whereas Gan et al. believe IL-10 
production by mast cells recruits Treg (Eller et al., 2011; Gan et al., 2012). It would be 
interesting to locate mast cells in our disease model and determine whether FcγRIIB-/- mast 
cells secrete IL-10 in GN to the same extent as WT mast cells. It is difficult to predict the 
outcome of FcγRIIB deletion on mast cells, as we cannot compare directly complete cell 
deletion with single receptor deletion. Mast cell degranulation is enhanced in FcγRIIB-/- mice, 
suggesting that accelerated NTN could be exacerbated in FcγRIIBMcpt5Cre mice. We did not 
see an effect in the FcγRIIBMcpt5Cre mice when a mild form of disease was induced in 
Experiment 2, but this experiment was performed only once and further work is required to 
optimise the disease induction.  
As already shown, FcγRIIB-/- mice show enhanced macrophage recruitment compared 
to WT mice, whereas glomerular macrophage infiltration is similar between WT and 
FcγRIIBcEBPαCre mice. This suggests that FcγRIIB expression on macrophages is not involved 
in the recruitment of the cells to sites of inflammation. One of the key cytokines involved in 
the recruitment of macrophages is MCP-1, which can be produced by intrinsic renal cells 
(Zoja et al., 1991). Therefore, it could be that FcγRIIB on intrinsic renal cells is involved in 
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the negative regulation of cytokine production, and therefore macrophage recruitment, to the 
glomerulus during injury. It would be of interest to compare directly the macrophage 
recruitment properties of WT and FcγRIIB-/- mesangial cells using a cell migration assay. 
A limitation of these experiments was that it was necessary to terminate some of the 
experiments at an earlier time point than planned after the induction of NTN due to the fact 
that the FcγRIIB-/- mice were highly susceptible to disease. Generally it is preferable to 
maintain mice for at least 7 days to allow the development of glomerular crescents. In all 
experiments mice were monitored closely and sacrificed if they were showing signs of ill 
health. The degree of proteinuria and GN generated is determined to an extent on operator 
dependent differences in the generation of the immunogen for preimmunisation and can be 
difficult to predict. In addition, prevalent immunogens in the environment of different animal 
facilities, which may differ at different times, can also influence the course of GN, and these 
experiments were performed at LUMC, whereas the rest of the experiments discussed in this 
thesis were performed at Imperial College London.  
 
5.6 Conclusion 
In conclusion, FcγRIIB-/- mice on a pure C57BL/6 background have exacerbated 
disease following induction of accelerated NTN compared to WT mice. Deletion of FcγRIIB 
on B cells alone was insufficient to demonstrate the phenotype at either a low or high dose of 
NTS. However, at a high dose of NTS, mice lacking FcγRIIB on myeloid cells had increased 
susceptibility to NTN compared with WT mice. This highlights the importance of FcγRIIB 
on myeloid cells in NTN. However, mice with myeloid cell deletion of FcγRIIB were not as 
susceptible to NTN as mice with full deletion of FcγRIIB. It is unclear whether this is 
because the Cre-mediated deletion on myeloid cells was not fully complete, or whether 
FcγRIIB on intrinsic renal cells is playing a role. This possibility is investigated in the next 
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FcγRIIB is widely expressed, being found on most cells of the lymphatic system, 
where it negatively regulates the activating FcγR and BcR. However, expression of FcγRIIB 
is not limited to these cells, as it has also been found to be expressed on non-lymphoid tissue, 
such as mesangial cells in the kidney (Radeke et al., 2002). Results presented in Chapter 5 
showed that FcγRIIB-/- mice were highly susceptible to renal injury following a low dose of 
NTS. However, mice lacking FcγRIIB only on myeloid cells were less susceptible to disease 
than mice with the full deletion. This suggests expression of FcγRIIB by other cells could 
play a role in protecting the mice from accelerated NTN. We have ruled out a role for 
FcγRIIB on B cells in disease. Therefore, it was essential to investigate the importance of 
FcγRIIB expressed by intrinsic renal cells in the development of GN. To do this we created 
bone marrow chimeric mice because a cell-specific promoter for mesangial cells is not 
available. To confirm the role of FcγRIIB on myeloid cells, FcγRIIB-/- mice transplanted with 
WT bone marrow were compared to control FcγRIIB-/- mice transplanted with FcγRIIB-/- 
bone marrow. To assess whether FcγRIIB expressed on intrinsic renal cells was important in 
protection from NTN, WT mice were transplanted with FcγRIIB-/- bone marrow and 
compared to WT mice transplanted with WT bone marrow. We also confirmed that 








The final chapter of this thesis was focused on assessing whether expression of 
FcγRIIB on intrinsic renal cells plays a role in protection from accelerated NTN or whether it 
is down to myeloid cell FcγRIIB expression alone. I also confirmed mesangial cell 
expression of FcγRIIB. 
 
 
6.3 Experimental design 
In order to investigate if FcγRIIB expression on intrinsic renal cells, as well as 
myeloid cells, plays a role in protection from accelerated NTN, bone marrow transplantation 
experiments were performed. A single dose of whole body gamma irradiation was used to 
ablate the bone marrow of WT and FcγRIIB-/- mice. Immediately following irradiation, the 
mice received an intravenous injection of whole bone marrow. WT mice received bone 
marrow cells from FcγRIIB-/- mice (FcγRIIB-/-→WT) and vice versa (WT→FcγRIIB-/-). This 
resulted in WT mice expressing FcγRIIB on their intrinsic renal cells but not on their 
circulating leukocytes and FcγRIIB-/- expressing FcγRIIB on their circulating leukocytes but 
not on their intrinsic renal cells. As controls, WT mice were transplanted with WT bone 
marrow (WT→WT) and FcγRIIB-/- mice were transplanted with FcγRIIB-/- bone marrow 
(FcγRIIB-/-→FcγRIIB-/-). NTN was induced and disease was assessed in WT and FcγRIIB-/-
bone marrow chimeric mice as previously described (see Section 3.3). 
To confirm expression of FcγRIIB on mesangial cells, mesangial cells were isolated 
from WT and FcγRIIB-/- mice and cultured in vitro. mRNA was extracted from unstimulated 
and stimulated WT and FcγRIIB-/- mesangial cells and FcγRIIB expression assessed by qRT-
PCR. Mesangial cells were also stained with a FITC-labelled monoclonal antibody specific 








6.4.1 Bone marrow reconstitution 
8Gy of irradiation was used, as previously optimised by Dr. Ruth Tarzi. The 
irradiated mice were intravenously injected with 1x107 bone marrow cells harvested from the 
femur, tibia and humerus of donor sex-matched mice.  
Bone marrow reconstitution was assessed by semi-quantitative PCR of DNA purified 
from blood taken at the end of the experiment. By mixing different concentrations of WT and 
FcγRIIB-/- DNA, I determined that the WT band could be determined if it constituted 5% or 
more of the total DNA, whereas the FcγRIIB-/- band could be detected if it constituted 25% or 
more of the total DNA (Figure 6.1). The greater sensitivity of the PCR for the WT band is 
likely to be because this band is shorter (359bp) in comparison to the FcγRIIB-/- band 




















Figure 6.1 Assessment of bone marrow reconstitution in chimeric mice by PCR. 
Different proportions of WT and FcγRIIB-/- DNA were mixed and subjected to PCR as 
described in Section 2.2.1.2. The WT band is 359bp and the FcγRIIB-/- band is 600bp. Note 
that the limit of detection of the WT band was 5% whereas the limit of detection of the 
FcγRIIB-/- band was 25%. In the same PCR reaction DNA from the two chimeric groups of 
mice were also run to examine the relative percentage of bone marrow reconstitution. In the 
WT to FcγRIIB-/- transplanted mice there was only the WT band indicating that the 
reconstitution was >75% (lane labelled +/+ to -/-). In the FcγRIIB-/- to WT transplanted mice 
both bands were detected, however the signal from the FcγRIIB-/- band was stronger, 
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6.4.2 Nephrotoxic nephritis in WT and FcγRIIB-/- bone marrow chimeric mice 
The experiments performed are detailed in Table 6.1.  In Experiments 1 and 2 male 
mice were used, and identical experiments were repeated in female mice in Experiments 3 
and 4. Mice of both sexes were used due to the availability of mice and the requirements of 
the UK Home Office. After irradiation, bone marrow reconstitution was allowed to occur for 
9 weeks before the induction of NTN. The female mice developed more disease than the 
male mice and needed to be sacrificed at an earlier time point after the injection of NTS 
(Table 6.1).  
In Experiments 1 and 3, we determined whether the presence of FcγRIIB on intrinsic 
renal cells would protect from NTN by comparing WT mice transplanted with FcγRIIB-/- 
bone marrow with FcγRIIB-/- mice transplanted with FcγRIIB-/- bone marrow. In Experiments 
2 and 4, we determined whether the absence of FcγRIIB on intrinsic renal cells would 
exacerbate disease in WT mice. 
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Experiment 1 Male FcγRIIB-/- WT 11 14   
  FcγRIIB-/- FcγRIIB-/- 10    
Experiment 2 Male WT FcγRIIB-/- 12 12   
  WT WT 10    
Experiment 3 Female FcγRIIB-/- WT 9 7*   
  FcγRIIB-/- FcγRIIB-/- 8    
Experiment 4 Female WT FcγRIIB-/- 6 7   
  WT WT 10    
Table 6.1 Summary of bone marrow transplant experiments in WT and FcγRIIB-/- 
mice. 
* One mouse in the FcγRIIB-/- group of mice transplanted with FcγRIIB-/- bone marrow was 
found dead at day 4, and another four in the same group sacrificed at day 5 due to renal 
disease. One mouse in the WT group transplanted with FcγRIIB-/- bone marrow was 
sacrificed at day 5. The remaining mice were sacrificed at day 7.   
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6.4.3 Mice with full deletion of FcγRIIB are more susceptible to NTN than WT mice 
transplanted with FcγRIIB-/- bone marrow, suggesting a role for FcγRIIB on intrinsic 
renal cells in protecting from disease 
In Experiment 1, a low dose of NTS (1:20) was administered to WT and FcγRIIB-/- 
male mice transplanted with FcγRIIB-/- bone marrow. Whilst it is not always possible to 
control the severity of disease in this model, owing to the variations in the disease induced, a 
low dose was chosen so that only mild disease was induced, as otherwise the effect of the 
deletion of FcγRIIB on myeloid cells may have masked any protection from FcγRIIB on 
intrinsic renal cells. 
PAS-stained kidney sections (Figure 6.2) were assessed for histological damage 
measured by glomerular capillary thrombosis and crescents. Transplantation of FcγRIIB-/- 
bone marrow into WT mice led to less susceptibility to thrombosis and crescents compared to 
FcγRIIB-/- mice transplanted with FcγRIIB-/- bone marrow (thrombosis: FcγRIIB-/-→ 
FcγRIIB-/- 0.47 (0.16-1.3), FcγRIIB-/-→WT 0.00 (0.00-0.12), p<0.0001; crescents: FcγRIIB-/-
→FcγRIIB-/- 4.0 (0.00-18) %, FcγRIIB-/-→WT 0.00 (0.00-0.00) %, p=0.0041) (Figure 6.3 A 
and Figure 6.3 B). 
Twenty-four hour urine collections were obtained prior to sacrificing the animals and 
albuminuria was measured, expressed as a urinary albumin/creatinine ratio. Transplantation 
of FcγRIIB-/- bone marrow into WT mice led to less susceptibility to albuminuria when 
compared to FcγRIIB-/- mice transplanted with FcγRIIB-/- bone marrow (FcγRIIB-/-
→FcγRIIB-/- 10 (0.36-18) mg/mmol, FcγRIIB-/-→WT 0.026 (0.010-1.3) mg/mmol, p=0.0004) 
(Figure 6.4 A). Mouse sera collected at the end of the experiment were assessed for levels of 
serum urea. FcγRIIB-/- mice transplanted with FcγRIIB-/- bone marrow had significantly 
higher levels of serum urea compared to WT mice transplanted with FcγRIIB-/- bone marrow 
(FcγRIIB-/-→FcγRIIB-/- 23 (12-40) mmol/L, FcγRIIB-/-→WT 15 (12-23) mmol/L, p=0.045) 
(Figure 6.4 B).  
Frozen kidney sections were stained for macrophage and neutrophil infiltration as a 
measure of inflammation at day 14 post NTS administration with anti-CD68 (macrophage) 
antibody (Figure 6.5 A) and anti-Gr-1 (neutrophil) antibody (Figure 6.6 A). FcγRIIB-/- mice 
transplanted with FcγRIIB-/- bone marrow had significantly more glomerular macrophages 
compared to WT mice transplanted with FcγRIIB-/- bone marrow (macrophages/gcs: 
FcγRIIB-/-→FcγRIIB-/- 1.6 (0.64-3.1), FcγRIIB-/-→WT 0.60 (0.12-1.7), p=0.0083) (Figure 
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6.5 B). There was no significant difference in glomerular neutrophil infiltration between 
either group of bone marrow transplanted mice (neutrophils/gcs: FcγRIIB-/-→FcγRIIB-/- 0.71 
(0.40-1.1), FcγRIIB-/-→WT 0.78 (0.32-1.2, p=0.92) (Figure 6.6 B). 
In Experiment 3, using female mice, a low dose of NTS (1:20) was again 
administered. On this occasion, the disease was more severe and unfortunately one of the 
nine FcγRIIB-/- mice transplanted with FcγRIIB-/- bone marrow was found dead at day 4 and 
4/9 had to be killed at day 5, whereas only 1/8 WT mouse transplanted with FcγRIIB-/- bone 
marrow had to be killed at day 5. The rest of the mice were killed on day 7. Consistent with 
the results in Experiment 1, and allowing for the fact that there was no histology on one 
mouse that died early, there was a trend to more glomerular thrombosis in the FcγRIIB-/- mice 
transplanted with FcγRIIB-/- bone marrow compared to the WT mice transplanted with 
FcγRIIB-/- bone marrow (thrombosis score: FcγRIIB-/-→FcγRIIB-/- 1.6 (0.28-3.0), FcγRIIB-/-
→WT 0.34 (0.004-3.2), p=0.07) and there was a tendency to increased serum urea in the 
FcγRIIB-/- mice transplanted with FcγRIIB-/- bone marrow where serum was available 
(FcγRIIB-/-→FcγRIIB-/- 49 (40-50) mmol/l, FcγRIIB-/-→WT 20 (7.9-50) mmol/l, p=0.13). 
These results from both Experiment 1 and Experiment 3 suggest that, in addition to 
expression of FcγRIIB on myeloid cells, FcγRIIB on intrinsic renal cells may also play a role 
in protection from NTN as the disease was worse in FcγRIIB-/- mice transplanted with 
FcγRIIB-/- bone marrow. Whilst these experiments were not performed concurrently, these 
results also highlight that female mice are much more susceptible to disease compared to 
their male counterparts.  
 
  







Figure 6.2 PAS staining of kidneys from bone marrow transplanted mice with NTN, 
Experiment 1. 
Representative PAS staining: FcγRIIB-/-→FcγRIIB-/-mouse showing a thrombosed, crescentic 
glomerulus (arrow highlights area of thrombosis) and a FcγRIIB-/-→WT mouse showing a 
healthy glomerulus.  
FcγRIIB-/-→FcγRIIB-/- FcγRIIB-/-→WT 
20µm 




Figure 6.3 Quantification of histologically abnormal glomeruli in bone marrow 
transplanted mice with NTN, Experiment 1. 
(A) Thrombosis and (B) crescents in bone marrow transplanted mice after NTN induction 
scored on PAS-stained kidney sections. FcγRIIB-/- mice that received FcγRIIB-/- bone marrow 
had more severely damaged glomeruli than WT mice receiving FcγRIIB-/- bone marrow (+/+ 
= WT, -/- = FcγRIIB-/-). All data represent individual values with the median. The data were 
analysed using Mann-Whitney U-test (p**<0.01, p****<0.0001). Dashed line represents 










































































































Figure 6.4 Measurement of urinary albumin/creatinine ratio and serum urea in bone 
marrow transplanted mice with NTN, Experiment 1. 
(A) Urinary albumin/creatinine ratio and (B) serum urea titres following administration of 
NTS to bone marrow transplanted mice. FcγRIIB-/- mice transplanted with FcγRIIB-/- bone 
marrow had a wider range of values for both urinary albumin/creatinine ratio and serum urea, 
with exacerbated disease compared to WT mice transplanted with FcγRIIB-/- bone marrow 
(+/+ = WT, -/- = FcγRIIB-/-). All data represent individual values with the median. The data 
were analysed using Mann-Whitney U-test (p*<0.05, p***<0.001). Dashed line represents 
values for a group of normal WT mice.  
A) 
B) 



























Figure 6.5 Glomerular macrophage infiltration in bone marrow transplanted mice 
with NTN, Experiment 1. 
(A) Immunohistochemistry for macrophages (CD68) on FcγRIIB-/-→ FcγRIIB-/- and 
FcγRIIB-/-→WT kidney sections. Arrows highlight macrophages. (B) Macrophage infiltration 
per glomerular cross section (gcs) (50 glomeruli scored per cross section). FcγRIIB-/- mice 
transplanted with FcγRIIB-/- bone marrow had significantly more glomerular macrophages 
than WT mice transplanted with FcγRIIB-/- bone marrow (+/+ = WT, -/- = FcγRIIB-/-). All 
data represent individual values with the median. The data were analysed using Mann-































Figure 6.6 Glomerular neutrophil infiltration in bone marrow transplanted mice 
with NTN, Experiment 1. 
(A) Immunohistochemistry for neutrophils (Gr-1) on FcγRIIB-/-→FcγRIIB-/- and FcγRIIB-/-
→WT kidney sections. Arrows highlight neutrophils. (B) Neutrophil infiltration per 
glomerular cross section (gcs) (50 glomeruli scored per cross section). There was no 
significant difference in neutrophil infiltration between the groups of mice (+/+ = WT, -/- = 
FcγRIIB-/-). All data represent individual values with the median. The data were analysed 
using Mann-Whitney U-test (ns= non-significant). Dashed line represents values for a group 
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6.4.4 There is not enough evidence to show that deletion of FcγRIIB on intrinsic renal 
cells alone can exacerbate disease 
In Experiment 2, the same dose of NTS (1:20) was administered to WT and FcγRIIB-
/- male mice transplanted with WT bone marrow as in Experiment 1, to induce mild disease 
and to further assess the role of FcγRIIB on intrinsic renal cells or circulating leukocytes. 
PAS-stained kidney sections were assessed for histological damage measured by 
glomerular capillary thrombosis and crescents (Figure 6.7). FcγRIIB-/- mice transplanted with 
WT bone marrow did not have exacerbated disease compared to WT mice transplanted with 
WT bone marrow (thrombosis: WT→FcγRIIB-/- 0.00 (0.00-0.30), WT→WT 0.00 (0.00-0.00), 
p=0.086; crescents: WT→FcγRIIB-/- 0.00 (0.00-2.0) %, WT→WT 0.00 (0.00-4.00) %, 
p=0.66) (Figure 6.8 A and Figure 6.8 B), despite the deletion of FcγRIIB on intrinsic renal 
cells.  
Twenty-four hour urine collections were obtained prior to sacrificing the animals and 
albuminuria was measured, expressed as a urinary albumin/creatinine ratio. FcγRIIB-/- mice 
transplanted with WT bone marrow had significantly higher levels of albuminuria compared 
to WT mice transplanted with WT bone marrow (WT→FcγRIIB-/- 0.003 (0.0044-1.5) 
mg/mmol, WT→WT 0.0043 (0.0030-0.0098) mg/mmol, p=0.0072) (Figure 6.9 A), although 
most of the mice did not show significant albuminuria. Mouse sera samples collected at the 
end of the experiment were assessed for levels of serum urea. Surprisingly, in view of the 
lack of histological injury or albuminuria, WT mice transplanted with WT bone marrow had 
significantly higher serum urea compared to FcγRIIB-/- mice transplanted with WT bone 
marrow (WT→FcγRIIB-/- 6.4 (5.2-11) mmol/L, WT→WT 10 (7.3-12) mmol/L, p=0.005) 
(Figure 6.9 B). This anomalous result is unexplained, although the samples were not 
measured in our laboratory but in the clinical biochemistry department. 
Frozen kidney sections were stained for macrophage and neutrophil infiltration at day 
12 post NTS administration with anti-CD68 (macrophage antibody) (Figure 6.10 A) and anti-
Gr-1 (neutrophil) antibody (Figure 6.11 A). FcγRIIB-/- mice transplanted with WT bone 
marrow had significantly more glomerular macrophages than WT mice transplanted with WT 
bone marrow (macrophages/gcs: WT→FcγRIIB-/- 0.30 (0.040-2.1), WT→WT 0.060 (0.00-
0.72), p=0.0050) (Figure 6.10 B). There was no significant difference in glomerular 
neutrophil infiltration between either groups of bone marrow transplanted mice at this point, 
but neutrophil infiltration would be expected to be greater earlier in the course of disease 
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(neutrophils/gcs: WT→FcγRIIB-/- 0.76 (0.34-2.2), WT→WT 0.060 0.88 (0.16-1.7), p=0.64) 
(Figure 6.11 B). 
In Experiment 4, using female mice, all mice were sacrificed on day 7 as the disease 
was more severe than in Experiment 2. As was found in Experiment 2, FcγRIIB-/- mice 
transplanted with WT bone marrow had significantly increased albuminuria (2.6 (0.0072-13) 
mg/mmol) compared with WT mice transplanted with WT bone marrow (0.032 (0.0029-1.5) 
mg/mmol, p=0.036) and there was a non-significant tendency towards increased glomerular 
capillary thrombosis (FcγRIIB-/- →WT 0.2 (0.0-1.0), WT→WT 0.060 (0.0-0.20), p=0.06). 
There was no significant difference in the macrophage infiltration between the groups and, 
unfortunately, we did not obtain enough serum from 2/6 FcγRIIB-/- mice transplanted with 
WT bone marrow to measure serum urea, so there were not enough samples for statistical 
analysis. 
Therefore, whilst Experiment 1 and 3 showed evidence of a protective effect of 
FcγRIIB-/- on intrinsic renal cells, we were unable to demonstrate a clear exacerbation of 
disease in FcγRIIB-/- mice transplanted with WT bone marrow, other than a mild increase in 
albuminuria which was found in both Experiment 2 and Experiment 4, but no other 
statistically significant effects were consistently demonstrated. 
  





Figure 6.7 PAS staining of kidneys from bone marrow transplanted mice with NTN, 
Experiment 2. 


















































Figure 6.8 Quantification of histologically abnormal glomeruli in bone marrow 
transplanted mice with NTN, Experiment 2. 
(A) Thrombosis and (B) crescents in bone marrow transplanted mice after NTN induction 
scored on PAS-stained kidney sections. There was no significant difference between the 
groups of mice (+/+ = WT, -/- = FcγRIIB-/-). All data represent individual values with the 
median. The data were analysed using Mann-Whitney U-test (ns= non-significant). Dashed 
line represents values for a group of normal WT mice.  
A) 
B) 




























































Figure 6.9 Measurement of urinary albumin/creatinine ratio and serum urea in bone 
marrow transplanted mice with NTN, Experiment 2. 
(A) Urinary albumin/creatinine ratio and (B) serum urea levels following administration of 
NTS to bone marrow transplanted mice. FcγRIIB-/- mice transplanted with WT bone marrow 
had a significantly higher urinary albumin/creatinine ratio and significantly lower serum urea 
than WT mice transplanted with WT bone marrow (+/+ = WT, -/- = FcγRIIB-/-). All data 
represent individual values with the median. The data were analysed using Mann-Whitney U-
test (p**<0.01). Dashed line represents values for a group of normal WT mice.   
A) 
B) 



























Figure 6.10 Glomerular macrophage infiltration in bone marrow transplanted mice 
with NTN, Experiment 2. 
(A) Immunohistochemistry for macrophages (CD68) on WT→FcγRIIB-/- and WT→WT 
kidney sections. Arrow highlights macrophage. (B) Macrophage infiltration per glomerular 
cross section (gcs) (50 glomeruli scored per cross section). FcγRIIB-/- mice transplanted with 
WT bone marrow had significantly more glomerular macrophages than WT mice 
transplanted with WT bone marrow (+/+ = WT, -/- = FcγRIIB-/-). All data represent 
individual values with the median. The data were analysed using Mann-Whitney U-test 
(p**<0.01). Dashed line represents values for a group of normal WT mice.  
 
A) WT→FcγRIIB-/- WT→WT 
B) 
25µm 




























Figure 6.11 Glomerular neutrophil infiltration in bone marrow transplanted mice 
with NTN, Experiment 2. 
(A) Immunohistochemistry for neutrophils (Gr-1) on WT→FcγRIIB-/- and WT→WT kidney 
sections. Arrows highlight neutrophils. (B) Neutrophil infiltration per glomerular cross 
section (gcs) (50 glomeruli scored per cross section). There was no significant difference in 
neutrophil infiltration between the groups of mice in each experiment (+/+ = WT, -/- = 
FcγRIIB-/-). All data represent individual values with the median. The data were analysed 
using Mann-Whitney U-test (ns= non-significant). Dashed line represents values for a group 
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6.4.5 Systemic immune responses of bone marrow transplanted mice 
Mouse serum, collected at the end of the experiments, was tested for the antigen-
specific immune response against sheep IgG. The circulating mouse anti-sheep IgG levels 
were measured by ELISA (results expressed as median optical density at 405nm (OD 
405nm)). In Experiment 1, FcγRIIB-/- mice receiving FcγRIIB-/- bone marrow had 
significantly less circulating mouse anti-sheep IgG than FcγRIIB-/- mice receiving WT bone 
marrow (FcγRIIB-/-→FcγRIIB-/- vs. FcγRIIB-/-→WT p=0.043) despite the fact that they had 
more renal disease. This is possibly explained by prolonged proteinuria with leakage of 
immunoglobulin into the urine. In Experiment 2, WT mice receiving WT bone marrow had 
significantly less circulating mouse anti-sheep IgG than WT mice receiving FcγRIIB-/- bone 
marrow (WT→FcγRIIB-/- vs. WT→WT p=0.048). However, this is of uncertain significance 
as there was no difference in deposited glomerular IgG between the two groups (Table 6.2 
and Figure 6.12). 
Frozen kidney sections were stained for deposited sheep and mouse IgG by direct 
immunofluorescence on tissue taken at the end of the experiment (Figure 6.13 A, Figure 6.14. 
A, Figure 6.15A, and Figure 6.16 A). Total glomerular sheep and mouse IgG were measured 
by quantitative immunofluorescence with the results expressed as arbitrary fluorescence units 
(AFU) or visual fluorescence units (VFU) (depending upon availability of equipment at the 
time the experiments were run). In Experiment 1, there was no significant difference between 
deposited sheep IgG (FcγRIIB-/-→FcγRIIB-/- vs. FcγRIIB-/-→WT p=0.28) (Figure 6.13 B) but 
there was significantly less deposited mouse IgG in FcγRIIB-/- mice transplanted with 
FcγRIIB-/- bone marrow (FcγRIIB-/-→FcγRIIB-/- vs. FcγRIIB-/-→WT p=0.032). This could be 
due to increased glomerular damage in these mice (Figure 6.15 B). In Experiment 2, there 
was no significant difference between the two groups for deposited sheep IgG 
(WT→FcγRIIB-/- vs. WT→WT p=0.54) (Figure 6.14 B) or mouse IgG (WT→FcγRIIB-/- vs. 
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Experiment 1 FcγRIIB-/- FcγRIIB-/- 2.1 (1.2-2.5) 27 (16-75) 24 (17-32) 
 FcγRIIB-/- WT 2.4 (1.9-2.6) 30 (18-90) 30 (11-40) 
Experiment 2 WT FcγRIIB-/- 2.1 (1.8-2.7) 3.0 (1.0-3.0) 115 (62-170) 
 WT WT 1.9 (1.5-2.3) 3.0 (2.0-3.0) 97 (66-212) 
Table 6.2 Deposited glomerular sheep and mouse IgG and circulating anti-sheep 
IgG levels in bone marrow transplanted mice with NTN. 
All results are expressed as median (range). 




Figure 6.12 Circulating mouse anti-sheep IgG levels in bone marrow transplanted 
mice with NTN, Experiment 1 and Experiment 2. 
Circulating mouse anti-sheep IgG was measured in (A) Experiment 1 and (B) Experiment 2 
by ELISA. In Experiment 1, WT mice transplanted with FcγRIIB-/- bone marrow had slightly 
elevated levels of circulating mouse anti-sheep IgG compared to FcγRIIB-/- mice transplanted 
with FcγRIIB-/- bone marrow. In Experiment 2, FcγRIIB-/- mice transplanted with WT bone 
marrow, had slightly elevated levels of circulating mouse anti-sheep IgG compared to WT 
mice transplanted with WT bone marrow (+/+ = WT, -/- = FcγRIIB-/-). All data represent 
























































Figure 6.13 Immunofluorescence for glomerular sheep IgG deposition in bone 
marrow transplanted mice with NTN, Experiment 1. 
(A) Representative glomeruli from FcγRIIB-/-→FcγRIIB-/- mice and FcγRIIB-/-→WT mice 
showing sheep IgG deposition. All images were taken using the same settings. (B) Relative 
mean glomerular immunofluorescence was measured quantitatively and expressed as 
arbitrary fluorescence units (AFU). There was no significant difference in deposited sheep 
IgG between the mice (+/+ = WT, -/- = FcγRIIB-/-). All data represent individual values with 








































































Figure 6.14 Immunofluorescence for glomerular sheep IgG deposition in bone 
marrow transplanted mice with NTN, Experiment 2. 
(A) Representative glomeruli from WT→FcγRIIB-/- mice and WT→WT mice showing sheep 
IgG deposition. All images were taken using the same settings. (B) Relative mean glomerular 
immunofluorescence was measured quantitatively and expressed as visual fluorescence units 
(VFU). FcγRIIB-/- mice transplanted with WT bone marrow had significantly less deposited 
sheep IgG compared to WT mice transplanted with WT bone marrow (+/+ = WT,   -/- = 
FcγRIIB-/-). All data represent individual values with the median. The data were analysed 













Figure 6.15 Immunofluorescence for glomerular mouse IgG deposition in bone 
marrow transplanted mice with NTN, Experiment 1. 
(A) Representative glomeruli from FcγRIIB-/-→FcγRIIB-/- mice and FcγRIIB-/-→WT mice 
showing mouse IgG deposition. All images were taken using the same settings. (B) Relative 
mean glomerular immunofluorescence was measured quantitatively and expressed as 
arbitrary fluorescence units (AFU). FcγRIIB-/- mice transplanted with FcγRIIB-/- bone 
marrow had significantly less deposited mouse IgG than WT mice transplanted with  
FcγRIIB-/- bone marrow (+/+ = WT, -/- = FcγRIIB-/-). All data represent individual values 











































Figure 6.16 Immunofluorescence for glomerular mouse IgG deposition in bone 
marrow transplanted mice with NTN, Experiment 2. 
(A) Representative glomeruli from WT→FcγRIIB-/- mice and WT→WT mice showing 
mouse IgG deposition. All images were taken using the same settings. (B) Relative mean 
glomerular immunofluorescence was measured quantitatively and expressed as arbitrary 
fluorescence units (AFU). There was no significant difference in deposited mouse IgG 
between the two groups (+/+ = WT, -/- = FcγRIIB-/-). All data represent individual values 
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6.4.6 Characterisation of mesangial cells and expression of FcγRIIB 
Expression of FcγRIIB on intrinsic renal cells, specifically mesangial cells, has been 
previously reported (Radeke et al., 2002). Next we set out to confirm this by culturing both 
WT and FcγRIIB-/- mesangial cells.  
WT and FcγRIIB-/-mesangial cells were characterised by immunofluorescence studies 
and their characteristic stellate morphology. Mesangial cells were stained for myosin and 
pancytokeratin. As expected, WT and FcγRIIB-/- mesangial cells were positive for myosin 
and negative for pancytokeratin (Figure 6.17). 
To confirm expression of FcγRIIB by cultured mesangial cells we used qRT-PCR and 
direct immunofluorescence. A FITC-labelled anti-FcγRIIB (clone Ly17.2) antibody was used 
on cytospins. WT mesangial cells were positive for FcγRIIB whereas FcγRIIB-/- mesangial 
cells were negative (Figure 6.18). For the qRT-PCR, mRNA was extracted from unstimulated 
and LPS stimulated WT mesangial cells (LPS has been shown to alter FcγRIIB expression 
(Radeke et al., 2002)) and unstimulated FcγRIIB-/- mesangial cells using the TRIzol method. 
mRNA was amplified with FcγRIIB specific primers. FcγRIIB was detected from both the 
unstimulated and stimulated mesangial cells, with no significant difference in expression 
following stimulation (unstimulated WT mesangial cells 2.2 (1.0-2.5), stimulated WT 
mesangial cells 3.7 (3.5-5.7), p=0.10) (Figure 6.19). FcγRIIB was not detected in the 
FcγRIIB-/- mesangial cells. 
  





Figure 6.17 Characterisation of WT and FcγRIIB-/- mesangial cells. 
WT and FcγRIIB-/- mesangial cells were stained for myosin and pancytokeratin; both were 









Figure 6.18 Direct immunofluorescence for FcγRIIB on mesangial cells. 
WT and FcγRIIB-/- mesangial cells were stained for FcγRIIB. WT mesangial cells were 













Figure 6.19 Mesangial cell mRNA expression of FcγRIIB following stimulation with 
LPS. 
Levels of mRNA expression of FcγRIIB were measured in mesangial cell mRNA extracts. 
There was no significant difference in FcγRIIB mRNA expression between unstimulated and 
LPS stimulated WT mesangial cells. All data represent individual values with the median. 




























The results here show that FcγRIIB expressed on radioresistant renal cells plays a role 
in protection from NTN, as measured by reduced serum urea, reduced albuminuria and 
reduced glomerular thrombosis and crescent formation in the WT mice transplanted with 
FcγRIIB-/- bone marrow compared to the FcγRIIB-/- mice transplanted with FcγRIIB-/- bone 
marrow in Experiment 1 and this is supported by the need to sacrifice more of the FcγRIIB-/- 
mice transplanted with FcγRIIB-/- bone marrow early in Experiment 3. A possible candidate 
for renal cell expression of FcγRIIB is the mesangial cell (Radeke et al., 2002). However, 
deletion of FcγRIIB from intrinsic renal cells alone does not appear to play a major role in 
exacerbating injury; following induction of mild disease we did not see a large difference 
between FcγRIIB-/- mice transplanted with WT bone marrow compared to WT mice 
transplanted with WT bone marrow, within the limitations of the experimental model. 
There was a greater infiltration of macrophages into the glomerulus in the mice 
lacking FcγRIIB on their intrinsic renal cells in both Experiment 1 and Experiment 2; 
however, glomerular neutrophil infiltration was similar between the groups of mice. At the 
day 12-14 timepoints neutrophil infiltration is not as prominent as it might be earlier in the 
course of the disease. To examine neutrophil infiltration fully we would need to look at an 
earlier timepoint, for example 2-24 hours after injection of NTS. There was slightly less 
circulating mouse anti-sheep IgG and deposited mouse IgG in the FcγRIIB-/- mice 
transplanted with FcγRIIB-/- bone marrow than the WT mice transplanted with FcγRIIB-/- 
bone marrow in Experiment 1, possibly due to the increased proteinuria and glomerular 
damage. Ideally we should have looked for the presence of immunoglobulin in the urine by 
ELISA. In Experiment 2, despite an increase in circulating antibody in FcγRIIB-/- mice 
transplanted with WT bone marrow there was no difference in deposited mouse IgG and no 
major increase in disease compared to WT mice transplanted with WT bone marrow. 
 
Intrinsic renal cells, such as mesangial cells, have been shown to express both the 
activating and inhibitory FcγR (Radeke et al., 2002; Uciechowski et al., 1998). Activation of 
cultured mesangial cells, via their FcγR has been shown to induce the secretion of pro-
inflammatory cytokines such as MCP-1 (Uciechowski et al., 1998) and TNF-α (Gomez-
Guerrero et al., 1994) which led to the hypothesis that FcγR on intrinsic renal cells play a role 
in glomerular inflammation. However, by using bone marrow chimeras, a role for activating 
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FcγR in both accelerated NTN and lupus nephritis (using NZB x NZW mice) has been 
excluded (Bergtold et al., 2006; Tarzi et al., 2002). To determine whether intrinsic renal cell 
expression of FcγRIIB plays a role in protecting mice from NTN, we created bone marrow 
chimeras by transplanting FcγRIIB-/- bone marrow into WT mice and comparing them to 
FcγRIIB-/- mice transplanted with FcγRIIB-/- bone marrow. We also performed the reciprocal 
experiment by transplanting WT bone marrow into WT mice and FcγRIIB-/- mice. 
In contrast to the results obtained above looking at activating FcγR on intrinsic renal 
cells, WT mice transplanted with FcγRIIB-/- bone marrow were protected from developing 
renal disease compared to FcγRIIB-/- mice transplanted with FcγRIIB-/- bone marrow, 
highlighting a role for intrinsic renal cell FcγRIIB expression in the protection from NTN. On 
the reverse, whilst there was no significant increase in renal histology, FcγRIIB-/- mice 
transplanted with WT bone marrow had a mild increase in glomerular macrophage 
infiltration and albuminuria compared to WT mice transplanted with WT bone marrow. In 
both experiments there was a good deletion (~75-95%) of recipient circulating cells; 
however, the PCR method used to measure reconstitution is biased towards shorter products, 
and therefore not sensitive enough to detect FcγRIIB-/- DNA when it constitutes less than 
25% of the total DNA. Ideally we should have confirmed chimerism using FACS (see 
Chapter 4), but as we followed the same protocol as before we can be confident chimerism is 
likely to be high. It could be argued that radioresistant resident renal macrophages and 
dendritic cells could be remaining within the kidney and contributing to the protective effects 
seen in the WT mice transplanted with FcγRIIB-/- bone marrow. However, by creating bone 
marrow chimeras expressing different copies of the CD45 allotype (CD45.1 and CD45.2), we 
have previously shown that resident tissue cells within the kidney are mostly replaced 
following bone marrow transplantation to the same degree as the circulating cells (Tarzi et 
al., 2011). There was a small population of recipient macrophages and dendritic cells left in 
the kidney and we cannot exclude that these have a role; however, these results suggest a role 
for intrinsic renal cell expression of FcγRIIB in protection from GN. Whilst it may be that 
FcγRIIB expressed on intrinsic renal cells is sufficient to protect from disease, its absence 
alone is not sufficient to exacerbate disease. 
As already mentioned, despite intrinsic renal cells expressing activating FcγRs, they 
do not play a role in the development of accelerated NTN (Tarzi et al., 2002). This further 
supports our observation that deletion of FcγRIIB from intrinsic renal cells alone is not 
enough to exacerbate disease. However, if FcγRIIB expression on intrinsic renal cells plays a 
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role in protecting from renal injury, this suggests a possibility for cross-talk between FcγRIIB 
and other receptors. Recently, a negative regulatory interaction has been suggested between 
FcγRIIB and the C5a receptor via dectin-1 (Karsten et al., 2012). Highly galactosylated IgG1 
immune complexes promote the association of FcγRIIB with dectin-1, resulting in 
phosphorylation of SHIP and spleen tyrosine kinase, respectively. This then inhibits the 
phosphorylation of ERK1/2 downstream of the C5a receptor, blocking C5a effector functions 
in vitro and inflammatory responses in vivo (Karsten et al., 2012). IgG1 is a significant 
component of the murine immune response (data not shown). In order to determine whether 
this pathway could be important in NTN we would need to determine whether dectin-1 is 
expressed on mesangial cells, the galactosylation status of the NTS, as well as the 
galactosylation status of the murine IgG. 
Also, in accelerated NTN, MR-deficient mice were protected from developing renal 
injury (Chavele et al., 2010). MR is a prototypic marker of alternatively activated 
macrophages; however, it is also known to be expressed by mesangial cells (Linehan et al., 
1999) and has been found to interact with FcγR by binding the mannose residues found on 
immunoglobulins (Chavele et al., 2010). MR on mesangial cells was found to enhance FcγR 
responses, with increased production of pro-inflammatory cytokines, such as IFN-γ, IL-1 and 
TNF-α, as well as chemokines, for example MCP-1. MR-/- mice were also found to have 
fewer infiltrating glomerular macrophages (Chavele et al., 2010). Therefore it is a possibility 
that if MR can enhance the effects of immunoglobulin binding to FcγR, interaction with 
FcγRIIB may well dampen the effects. 
We, and others (Radeke et al., 2002), have shown expression of FcγRIIB by 
mesangial cells suggesting a possible role for mesangial cell FcγRIIB in NTN. Although 
there was no significant difference, we found FcγRIIB expression to increase slightly in 
growth arrested mesangial cells following stimulation with LPS. This is similar to the result 
seen by Radeke et al., who found minimal change in FcγRIIB expression following LPS 
stimulation alone (Radeke et al., 2002). Unfortunately, due to the difficulties in culturing 
mesangial cells, we were not able to study directly the effects of FcγRIIB-deficiency on the 
cells in culture. However, it would be of interest to compare cytokine and chemokine 
production in WT and FcγRIIB-/- cells following stimulation with IgG. 
Although mesangial cells have been shown to express FcγRIIB, this does not mean 
mesangial cells are the only site of FcγRIIB expression within the glomerulus. Recently, 
podocytes have been found to play a role in GN (Cook et al., 2011). Therefore, it is of 
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importance, to further investigate sites of FcγRIIB expression within both healthy and 
diseased kidney. If other cells are found to express FcγRIIB it would be of interest to culture 
these cells and compare them with WT cells to see if FcγRIIB deficiency is found to have an 
effect. 
A small influx of macrophages and neutrophils was measured in the glomeruli of all 
mice from both experiments.  Interestingly, there was no significant difference in glomerular 
neutrophil accumulation between the two groups of mice in each experiment. In Experiment 
1, all circulating cells were FcγRIIB-deficient, whereas in Experiment 2, all circulating cells 
expressed FcγRIIB. This further supports the hypothesis in Chapter 5 that expression of 
FcγRIIB on neutrophils is involved in their recruitment to the glomerulus and subsequent 
activation. On the contrary, in both Experiment 1 and Experiment 2, mice deficient in 
FcγRIIB on their intrinsic renal cells had a greater influx of glomerular macrophages 
compared to mice expressing FcγRIIB on intrinsic renal cells. Taken with the observations in 
Chapter 5, that FcγRIIB-/- mice have an increase in glomerular macrophage accumulation 
compared to WT mice and FcγRIIBcEBPαCre mice, this suggests that expression of FcγRIIB on 
intrinsic renal cells, rather than the macrophages themselves, is important in macrophage 
recruitment to the glomerulus. To further support this it would be useful to repeat the bone 
marrow transplant experiments comparing WT mice transplanted with FcγRIIB-/- bone 
marrow and WT mice transplanted with WT bone marrow. Again, it would also be 
interesting to compare directly MCP-1 production by WT and FcγRIIB-/- mesangial cells 
following stimulation to see if there is a significant decrease in expression in the FcγRIIB-
deficient cells. 
In Experiment 2, the WT mice transplanted with WT bone marrow had slightly 
elevated levels of serum urea than the FcγRIIB-/- mice transplanted with WT bone marrow. 
This is despite the mice having no signs of thrombosis. Nevertheless, the urea readings of 
both groups were within the normal limits when compared to a group of WT mice, which 
suggests that this finding is not indicative of renal disease in the WT mice transplanted with 
WT bone marrow. A possible explanation could be that the WT mice transplanted with WT 
bone marrow were slightly larger than the FcγRIIB-/- mice transplanted with WT bone 
marrow. Usually the mice are weighed at the start of the experiment, but this was an omission 
on this occasion. However, no size difference was noted during the experiments and their 
dates of birth were almost identical.  
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Due to availability of mice and the regulations of the UK Home Office, Experiments 
1 and 2 were performed on male mice, whereas Experiments 3 and 4 were performed on 
female mice. Female mice are much more susceptible to NTN than male mice, and therefore 
it was necessary to terminate the experiments in female mice earlier on. In humans, there is a 
higher incidence of autoimmune disease in females compared to males (roughly 3:1). As well 
as genetic polymorphisms and environmental factors being involved, sex hormones also play 
a role in susceptibility. Castration of autoimmune prone NZB/NZW male mice was found to 
accelerate the onset of lupus-like disease, whereas ovariectomised female NZB/NZW mice 
given androgens had reduced lupus-like disease (Roubinian et al., 1977). Although using 
different sexes in the experiments makes it difficult to compare directly the results seen, the 
results follow the same trend. Ideally, if time had allowed, both sets of experiments would be 
repeated in both sexes. 
To try and understand fully the role of FcγRIIB in NTN, both on circulating 
leukocytes and intrinsic renal cells, it would be of interest to transplant bone marrow from 
FcγRIIBcEBPαCre mice into FcγRIIB-/- mice. This will create mice lacking FcγRIIB on intrinsic 
renal cells and myeloid cells which can then be compared to WT mice and complete FcγRIIB 





In conclusion, expression of FcγRIIB by either circulating leukocytes or intrinsic 
renal cells is sufficient to protect mice from the onset of accelerated NTN at a low dose of 
NTS. This is likely due to the role of FcγRIIB in negatively regulating cell activation of 
myeloid cells and possibly negatively regulating cytokine and chemokine production by 
mesangial cells, as we and others have shown mesangial cells to express FcγRIIB in culture. 
However, based on the results presented in Chapter 5, when a higher dose of NTS is 
administered, effector cell activation can override the protective properties of FcγRIIB on 
intrinsic renal cells. This is the first study to show a role for intrinsic renal cell FcγRIIB 
expression in GN. Given the similarities between human and murine FcγR and that FcγR 
have been implicated in human GN, it is likely that these results have relevance for human 
disease. 








7.1 Summary of results 
In Chapter 3, I showed that gld mice were strongly protected from accelerated NTN 
compared to WT mice, which could possibly be due to the reduction in T cell meditated 
immunity, reduction in apoptosis or reduction in pro-inflammatory cytokine production. This 
represents a novel role for FasL in the promotion of GN. 
 
In Chapter 4, I performed bone marrow transplants from WT mice to gld mice and 
vice versa in order to investigate the relative contribution of FasL expressed on circulating 
leukocytes and intrinsic renal cells in the development of disease. With this experiment I was 
able to show that in the model of accelerated NTN, disease is dependent on FasL expression 
by either subset of cells. I also went on to confirm expression of FasL by WT mesangial cells 
and showed that signalling through the IL-1R is defective in the absence of FasL.  
 
In Chapter 5, I investigated the role of FcγRIIB expression on different subsets of 
circulating leukocytes in accelerated NTN. I confirmed that complete deletion of FcγRIIB 
renders mice highly susceptible to renal injury and found expression of FcγRIIB on myeloid 
cells, but not B cells, plays an important role in protecting the mice from disease.  
 
In Chapter 6, I used bone marrow transplants to investigate the role of FcγRIIB on 
circulating leukocytes and intrinsic renal cells in accelerated NTN. Interestingly, I found that 
expression of FcγRIIB on intrinsic renal cells does play a role in conferring protection from 
disease.  
P.E.H.Sharp  2013 
 
 299 
7.2 Thesis limitations 
7.2.1 Limitations of using knockout mice 
Through advances in genetic engineering it is now possible to generate mice with 
either an overexpression or deletion of an individual gene of interest from the entire organism 
or within individual cell subsets and tissues. This has provided us with a tool with which to 
study individual molecules in disease models in vivo, whilst avoiding the disadvantages of 
using pharmacological compounds, such as non-specific effects or a limited ability to reach 
target tissues. However, this does not mean genetic engineering is without limitations. For 
example, following loss of gene function it is possible that previously redundant pathways 
may be activated to compensate, therefore altering the results. Also, about 15% of gene 
knockouts are developmentally lethal and cannot grow into adult mice. There are also issues 
with incomplete deletion of the gene of interest in cell-specific knockouts, as seen in the 
FcγRIIBLysMCre mice. Technically the gld mouse is not a real knockout mouse. The gld 
mutation does not affect expression of FasL, but instead the ability of FasL to bind Fas 
(Takahashi et al., 1994). FasL-knockout mice, generated on a C57BL/6 background, were 
found to have a severe phenotype, with histological signs of GN, compared to gld mice on 
the same background. This accelerated phenotype led to the premature death of more than 
50% of the homozygous mice at 4 months (Karray et al., 2004), highlighting that there is 
some residual activity of FasL in the gld mice.  
Genetic background also needs to be considered when using genetically-engineered 
mice. In NTN, genetic background has been found to play an important role in regulating the 
development of disease (Huang et al., 1997c). Most knockout mice, including the original 
FcγRIIB-/- mice, are created from 129/Sv ES cells. Following genetic modification the ES 
cells are implanted into a C57BL/6 blastocyst to generate chimeric 129/Sv/C57BL/6 mice. 
Backcrossing these mice onto pure C57BL/6 mice produces mice in which both copies of the 
gene (one on each chromosome) are deleted in all tissues. Further backcrossing onto the 
C57BL/6 background for 8-10 generations produces mice with >99% C57BL/6 genotype; 
however there is always a variable region immediately surrounding the deleted gene that is 
129/Sv. Bygrave et al., have shown that epistatic interactions between genes from 129 and 
C57BL/6 genomes can promote an autoimmune phenotype (Bygrave et al., 2004). This is 
seen in FcγRIIB-/- mice. FcγRIIB-/- mice created using 129/Sv ES cells were found to develop 
spontaneous lupus, whereas FcγRIIB-/- mice made by gene-targeting in B6-derived ES cells 
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exhibited a hyperactive phenotype but failed to develop autoimmunity (Boross et al., 2011). 
Genetic background also affects the gld mutation. The gld mutation arose spontaneously in 
the inbred mouse strain C3H/HeJ, which has no predisposition to autoimmunity (Roths et al., 
1984). When crossed to a C57BL/6 background, gld mice develop autoantibodies but GN is 
not seen until 13-16 months and is minimal (Kelley and Roths, 1985). However, intercrossing 
gld mice onto the MRL background results in accelerated onset of GN (Kimura et al., 1992). 
 
7.2.2 Limitations of the accelerated nephrotoxic nephritis model 
The murine model of accelerated NTN is well established and has been used 
extensively to define the roles of macrophages, T cells and other immune pathways in GN 
and to test novel therapeutic strategies. Although NTN is not an autoimmune model, it is 
suitable for looking at effector responses, which would be similar in an immune complex 
disease, such as lupus nephritis. One drawback is the variability in disease induction. The 
degree of proteinuria and GN generated is determined to an extent by operator dependent 
differences. When inducing NTN problems can arise with the pre-immunisation, such as the 
preparation of the immunogen, and the NTS injection, which is difficult to administer. Also, 
different batches of NTS can vary widely, due to differing concentrations of sheep IgG, and, 
in addition, prevalent immunogens in the environment of different animal facilities, which 
may differ at different times, can also influence the course of GN. Therefore, mice with 
similar genetic backgrounds can present with widely differing disease phenotypes. To avoid 
any possible differences, all mice in any one experiment were immunised at the same time 
with the same preparation of sheep IgG in CFA and the same preparation of NTS was used in 
all experiments in each of the projects. With the exception of the experiments in Chapter 5 
that were performed at LUMC, all experiments were performed at Imperial College London. 
Therefore, in order to analyse data, I have compared results from individual experiments. 
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7.3 Hypothesis of the involvement of Fas ligand and Fc gamma receptor 
IIB in nephrotoxic nephritis 
7.3.1 The role of Fas ligand in nephrotoxic nephritis 
The in vivo data presented in this thesis suggest that FasL expression is critical for GN 
development in the model of accelerated NTN. More specifically, expression of FasL on 
either intrinsic renal cells or circulating leukocytes is sufficient to convey protection. The in 
vitro data on mesangial cells demonstrate a possible mechanism by which FasL-deficiency 
protects from disease development. In both WT and gld mice, immunisation with sheep IgG 
in CFA causes the production of an immune response. Administration of NTS localises 
deposition of sheep IgG, and subsequently mouse IgG, to the glomerulus. This leads to the 
activation of FcγR, recruitment of leukocytes, and the production of pro-inflammatory 
cytokines, such as IFN-γ, IL-1β and TNF-α, as well as chemokines, such as MCP-1. Within 
the WT kidney FasL binding to Fas, either on intrinsic renal cells or infiltrating leukocytes, 
induces inflammation by activating NF-κB and caspases, which leads to the secretion of IL-
1β. IL-1β can then activate IL-1R, in either a paracrine or autocrine fashion, leading to the 
production of MCP-1 that works to recruit macrophages to the glomerulus and activate them. 
In gld mice, in the absence of FasL signalling, there is a possible reduction in NF-κB and 
caspase activation causing a reduction in IL-1β secretion and IL-1R activation. MyD88 and 
FADD are both adaptor proteins downstream of the IL-1R and Fas signalling pathways, 
respectively. In the absence of signalling through Fas, FADD associates with MyD88 through 
their death domains, retaining MyD88 in the cytoplasm away from the IL-1R pathway. This, 
taken together with the reduction in IL-1R activation, causes an overall reduction in MCP-1 
production and possibly the activation of macrophages recruited to the glomerulus.  
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7.3.2 The role of FcγRIIB in nephrotoxic nephritis 
The in vivo data presented in this thesis suggest that FcγRIIB expression is critical for 
protection from GN in the model of accelerated NTN. More specifically, FcγRIIB expressed 
on myeloid cells, with a contribution from intrinsic renal cell FcγRIIB, was important for 
protection. In WT and FcγRIIB-/- mice, immunisation with sheep IgG in CFA causes the 
production of an immune response. Administration of NTS localises deposition of sheep IgG, 
and subsequently mouse IgG, to the glomerulus. This leads to the activation of FcγR, 
recruitment of leukocytes, and the production of pro-inflammatory cytokines, such as IFN-γ, 
IL-1β and TNF-α, as well as chemokines, such as MCP-1. A proposed mechanism is 
expression of FcγRIIB on myeloid cells, such as macrophages, monocytes, neutrophils and 
possibly dendritic cells and mast cells, works to regulate their cellular activation and control 
their inflammatory response. In addition, FcγRIIB on neutrophils is involved in their 
recruitment to the site of inflammation. Within the kidney, FcγRIIB expressed on intrinsic 
renal cells is also involved in protection from NTN by possibly regulating the activation of 
mesangial cells and being involved in the recruitment of macrophages to the glomerulus.  
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7.4 Further questions arising from this Thesis 
The results presented in this thesis raise further questions about the roles of FasL and 
FcγRIIB in accelerated NTN and in order to answer them further experiments need to be 
performed.  
 
7.4.1 Is macrophage activation affected by Fas ligand deficiency? 
Macrophage accumulation within the glomerulus is closely related to renal injury 
(Nikolic-Paterson and Atkins, 2001); however, glomerular macrophage infiltration still 
occurred in gld mice and gld mice transplanted with gld bone marrow, despite these mice 
being protected from NTN. This suggests that macrophage activation and phenotype, rather 
than numbers, determine disease outcome. Two studies, in rats, support this (Cook et al., 
1999; Lai et al., 2001). Further to this, FasL has been implicated as playing a role in 
macrophage activation (Chakour et al., 2009). Therefore, it is important to study the 
activation status of gld macrophages compared to WT macrophages. This can be done in 
vitro and in vivo. Firstly, WT and gld BMDM can be cultured and stimulated with IFN-γ or 
IL-4, to induce pro- and anti-inflammatory phenotypes, respectively. ELISA can then be used 
to measure the secretion of cytokines and other mediators of inflammation, such as iNOS, IL-
6, MR, and TNF-α. However, this would only tell us about the behaviour of macrophages in 
vitro and would not necessarily be representative of macrophages in vivo. Alternatively, to 
study macrophage phenotype in vivo, NTN would need to be induced in WT and gld mice, 
the macrophages isolated from the kidney by cell sorting, RNA extracted and markers for 
pro- or anti-inflammatory phenotypes measured by qRT-PCR.  
 
7.4.2 Does downregulating Fas ligand with siRNA in mesangial cells replicate the 
knockout phenotype? 
In culture, gld mesangial cells had an attenuated response to IL-1β compared to WT 
mesangial cells, producing significantly less MCP-1. A different way of proving that this is 
due to FasL-deficiency would be to use WT mesangial cells and to knockdown FasL 
expression with siRNA specific for the FasL gene. The success of the knock down can be 
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measured at the RNA and protein level, as well as functionally by stimulating with TNF-α or 
IL-1β and assessing MCP-1 production. 
 
7.4.3 What are the differences in downstream signalling pathways in gld mesangial 
cells compared to WT mesangial cells? 
The gld mutation has been suggested to disrupt the activation of NF-κB and caspases 
downstream of IL-1β by FADD sequestering MyD88 away from the signalling pathway 
(Bannerman et al., 2002). This can be confirmed in vitro by measuring NF-κB and caspase 1 
activation of IL-1β-stimulated mesangial cells by western blotting. It would also be of 
interest to stimulate the gld mesangial cells with both IL-1β and FasL to see if this restores 
NF-κB and caspase 1 activation back to WT levels. Staining kidney sections from WT and 
gld mice with NTN for the activated molecules can support these results in vivo. To further 
explore the role of FADD and MyD88 in this process, immunoprecipitation of FADD from 
WT and gld mesangial cells stimulated with IL-1β can be carried out and MyD88 association 
measured by western blot.  
 
7.4.4 Do other intrinsic renal cells express Fas ligand? Does Fas ligand on these cells 
play a role in NTN?  
In vitro we have concentrated on the effects of FasL deficiency on mesangial cells. 
However, glomerular endothelial cells, podocytes and tubular epithelial cells have also been 
shown to express FasL within the kidney (Linkermann et al., 2011; Lorz et al., 2000; Ortiz et 
al., 1999; Ross et al., 2005) as well as be potential sources of MCP-1 (Natori et al., 1997; 
Tesch et al., 1999). It would be of interest to investigate the effect of gld mutation on these 
different renal cells, to compare MCP-1 production with WT cells following IL-1β and TNF-
α stimulation, as well as NF-κB and caspase activation. It would also be interesting to further 
investigate the role of FasL on the individual cells within NTN. If possible, it would be 
interesting to knockout FasL in either glomerular endothelial cells, podocytes or tubular 
epithelial cells and, following induction of NTN, see if there is a reduction in either 
thrombosis, proteinuria, or interstitial macrophage infiltration, respectively.  
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7.4.5 What role does Fas ligand induced apoptosis play in NTN? 
Overall, our data suggest that, following the induction of NTN, a reduction in the pro-
inflammatory effect of FasL is responsible for protection in gld mice. However, this does not 
address whether the reduction in apoptosis is also contributing to protection. To answer this 
we would need to look at a model of nephritis that requires apoptosis for repair, such as anti-
Thy-1 nephritis in the rats (Shimizu et al., 1995). To do this, one would need to induce anti-
Thy-1 nephritis and block the effects of FasL with a blocking antibody. It could be 
hypothesised that blocking FasL would render the rats more susceptible to renal injury 
compared to untreated rats, as apoptosis plays an important part in kidney remodelling in this 
disease model. 
 
7.4.6 Does soluble Fas ligand play a role in NTN? Is it responsible for the pro-
inflammatory effects seen? 
Cleavage of FasL into its soluble form is thought to act to downregulate its apoptotic 
activity (Dupont and Warrens, 2007; O' Reilly et al., 2009; Schneider et al., 1998) and sFasL 
has been shown to play a role in the production of pro-inflammatory cytokines (Ahn et al., 
2001; O' Reilly et al., 2009). To date, little work has been done looking at the role of sFasL in 
GN. Unfortunately, we were unable to detect sFasL in the serum of WT mice, as it would 
have been interesting to see if the levels of circulating sFasL increase during disease. It 
would also have been of interest to measure levels of sFasL in the urine of healthy and 
diseased mice. An alternative method of studying the role of sFasL in NTN would be to 
induce NTN in mice expressing either the membrane-bound form of FasL or the soluble form 
only (O' Reilly et al., 2009). This would also give us further insight into whether the 
reduction in apoptosis or the pro-inflammatory effects of FasL play a greater role in 
protection from NTN, as mice expressing sFasL only developed a severe SLE-like 
autoimmune kidney disease whereas the mice expressing membrane-bound FasL only 
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7.4.7 Does FcγRIIB deficiency result in macrophage overactivation during NTN? 
FcγRIIBcEBPαCre mice show increased renal dysfunction despite similar numbers of 
glomerular infiltrating macrophages compared to WT mice. Reduced surface expression of 
FcγRIIB on macrophages has been associated with their overactivation following cross-
linking of activating FcγR (Clatworthy and Smith, 2004; Jiang et al., 2000; Pritchard et al., 
2000). To determine whether infiltrating macrophages are overactivated in FcγRIIBcEBPαCre 
mice, a similar technique could be employed as mentioned in Section 7.4.1. One would need 
to induce NTN in WT, FcγRIIBcEBPαCre, and FcγRIIB-/- mice, isolate the macrophages from 
the kidney by cell sorting, extract RNA, and measure the production of pro-inflammatory 
cytokines, such as IL-1β, IFN-γ, MCP-1 and TNF-α, by qRT-PCR. 
 
7.4.8 What is the role of FcγRIIB on dendritic cells, mast cells, macrophages, and 
neutrophils in NTN? 
At a low dose of NTS, deletion of FcγRIIB on dendritic cells, mast cells or myeloid 
cells alone did not exacerbate disease. However, following a higher dose of NTS, mice 
carrying the deletion of FcγRIIB on myeloid cells showed signs of severe renal dysfunction, 
due to the increased dose of heterologous antibody to glomerular antigens inducing a greater 
immune response, which could overcome the protective effects of FcγRIIB expressed on 
other cell types. As well as deleting FcγRIIB on macrophages and neutrophils, the myeloid 
cell knockout mice are also deficient in FcγRIIB on dendritic cells, and possibly mast cells, 
although we did not stain for this. Therefore, it is possible that FcγRIIB expressed on 
dendritic cells and mast cells is contributing to protection from NTN. FcγRIIB on dendritic 
cells is thought to play a role in dendritic cell maturation and antigen presentation (Boruchov 
et al., 2005; Dhodapkar et al., 2005). Therefore, it would also be important to investigate 
whether T cell responses are modified by loss of FcγRIIB on dendritic cells. To answer these 
questions it would be necessary to repeat the experiment with the FcγRIIBCD11cCre and 
FcγRIIBMcpt5Cre mice using the higher dose of NTS. To understand fully the role of FcγRIIB 
on macrophages and neutrophils in NTN an alternative promoter would need to be used with 
complete deletion of FcγRIIB from all subsets of cells.  
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7.4.9 Does FcγRIIB deficiency affect the production of cytokines by mesangial cells? 
Does FcγRIIB on mesangial cells interact with other receptors? 
Our data suggest a role for intrinsic renal cell expression of FcγRIIB in the protection 
from NTN. We, and others, have shown that mesangial cells, in culture, express FcγRIIB 
(Radeke et al., 2002). To further understand the role of FcγRIIB on mesangial cells in NTN it 
would be of interest to culture WT and FcγRIIB-/-mesangial cells, stimulate them with IgG 
immune complexes, and measure cytokine secretion into the supernatant by ELISA. 
Activating FcγR expressed on intrinsic renal cells do not contribute to the development of 
NTN (Tarzi et al., 2002), therefore it is possible FcγRIIB may be negatively regulating other 
receptors expressed on the surface of mesangial cells. To test this, WT mesangial cells could 
be incubated with IgG immune complexes and the cell lysates immunoprecipitated with anti-
FcγRIIB and analysed for possible protein interactions, such as MR, by Western blot.  
 
7.4.10 What role does FcγRIIB play in cellular recruitment? 
Our data suggest FcγRIIB may be involved in the recruitment of leukocytes to the 
glomerulus. FcγRIIB expressed on intrinsic renal cells appears to play a role in the 
recruitment of macrophages, whereas neutrophil recruitment appears to be dependent on 
FcγRIIB expressed on the neutrophils themselves. To support this hypothesis, in vitro cell 
migration assays could be employed. WT and FcγRIIB-/- mesangial cells could be cultured 
with WT and FcγRIIB-/- BMDM or PMN. Alternatively; it would be of interest to repeat the 
four groups in the bone marrow transplant experiments at the same time to compare directly 
cellular infiltration into the glomerulus.  
 
7.4.11 Is FcγRIIB expressed by other cells in the kidney and does it contribute to 
protection from NTN? 
Although we have concentrated on mesangial cell expression of FcγRIIB, this does 
not mean mesangial cells are the only intrinsic renal cells expressing the receptor. It would be 
interesting to culture other WT intrinsic renal cells, such as tubular epithelial cells or 
podocytes, and look at FcγRIIB expression by qRT-PCR (gene expression level), Western 
blot or direct immunofluorescence on cytospins (protein expression level). WT cells found to 
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express FcγRIIB could then be compared to FcγRIIB-deficient cells by stimulating with IgG 
and measuring cytokine secretion into the supernatant by ELISA. 
 
7.4.12 Can the phenotype of FcγRIIB-/- mice be restored by the deletion of FcγRIIB on 
intrinsic renal cells and myeloid cells? 
Deletion of FcγRIIB on intrinsic renal cells or myeloid cells alone does not restore the 
extreme phenotype seen in FcγRIIB-/- mice, following induction of accelerated NTN. It 
would be interesting to transplant bone marrow from FcγRIIBcEBPαCre mice into FcγRIIB-/- 
mice, to delete FcγRIIB in both cellular compartments, and compare the severity of disease to 
FcγRIIB-/- mice. This would give us further insight into the mechanism of protection offered 
by FcγRIIB expression.  
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7.5 The role of Fas ligand and Fc gamma receptor IIB in other nephritis 
models 
The NTN model has been widely employed to study the pathogenesis of autoimmune 
GN. However, there are drawbacks to using NTN. Firstly, NTN has a characteristic 
thrombotic phenotype that is not representative of human pathology. Secondly, NTN is not a 
real autoimmune model of GN as it does not require tolerance to be broken. For these 
reasons, and in order to understand fully the roles of FasL and FcγRIIB in autoimmune renal 
diseases, it would be useful to study other nephritis models such as EAG and EAV.  
 
7.5.1 The role of Fas ligand and FcγRIIB in a murine model of experimental 
autoimmune glomerulonephritis 
EAG is the murine model of human anti-GBM disease and is induced by 
immunisation with purified non-collagenous domain of α3 chain type IV collagen in CFA 
(Dean et al., 2005), the target antigen in human disease. We have already looked at the role of 
FcγRIIB in EAG and found mice carrying the full deletion of FcγRIIB were highly 
susceptible to developing disease. However, deletion of FcγRIIB on B cells or myeloid cells 
alone did not increase susceptibility of the mice to developing nephritis (Sharp et al., 2012). 
The role of FasL in EAG has not currently been investigated. From my observations that gld 
mice are protected from NTN one hypothesis is that gld mice would be protected from EAG. 
However, EAG is an autoimmune model and gld mice develop autoimmune renal disease 
later on in life, so the FasL defect could be found to enhance disease. To test this gld and WT 
mice could be immunised with purified α3 chain of type IV collagen and the disease assessed.   
 
7.5.2 The role of Fas ligand and FcγRIIB in a murine model of ANCA-associated 
vasculitis 
EAV is an experimental model of human AAV. MPO and PR3 are thought to be the 
two main target antigens for the disease and various models have been developed against 
these. The findings that FasL deficiency protects mice from NTN but FcγRIIB deficiency 
increases susceptibility to NTN and EAG imply that both FasL and FcγRIIB may play a role 
in induction of AAV. It can be hypothesised that EAV would be aggravated in FcγRIIB-/- 
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mice. However, the effects of the gld mutation on the development of EAV are unclear. 
Judging by the results seen with the model of EAE, the effects may be complicated. The 
model of MPO vasculitis is passive, suggesting the mice may be protected. To test both these 
hypotheses, a model of EAV could be induced in gld or FcγRIIB-/- mice, either by transfer of 
anti-MPO antibodies (Xiao et al., 2002a) or injection of purified MPO in CFA (Little et al., 
2005; Little et al., 2009), and the resulting vasculitis compared to WT mice. 
 
 
7.6 The role of Fas ligand and Fc gamma receptor IIB in other 
inflammatory diseases 
The role of FasL in models of inflammatory diseases is well established. Through the 
use of gld and lpr mice, FasL has been shown to play a role in acute lung inflammation (Neff 
et al., 2005), autoimmune diabetes (Chervonsky et al., 1997; Itoh et al., 1997; Mohamood et 
al., 2007), CIA (Ma et al., 2004; Tu-Rapp et al., 2004), EAE (Sabelko et al., 1997; Sabelko-
Downes et al., 1999; Waldner et al., 1997), EAU (Wahlsten et al., 2000), experimental stroke 
(Niu et al., 2011), and spinal cord injury (Letellier et al., 2010).  
The role of FcγRIIB in other inflammatory diseases has also been investigated. 
FcγRIIB-/- mice show exacerbated disease when induced with CIA (Boross et al., 2011; 
Yuasa et al., 1999), allergic airway inflammation (Dharajiya et al., 2010), and patients with 
chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune disease similar 
to MS, were found to have consistently lower levels of FcγRIIB expression on naïve B cells 
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7.7 Therapeutic approach to glomerulonephritis using Fas ligand and Fc 
gamma receptor IIB 
7.7.1 Current therapeutic approach for glomerulonephritis 
Current treatment of GN is through the use of steroids and immunosuppressive drugs. 
Although effective, they also have non-specific side effects and their continued use has 
detrimental effects on the patient’s health, resulting in the patients suffering from infections 
and malignancies. Ideally, rather than targeting the entire immune system, therapeutic drugs 
would target specific pathways or components of pathways. The most effective way to target 
molecules and control them is the application of antibodies. Two currently available 
treatments for autoimmune diseases are infliximab, an anti-TNF-α antibody, and rituximab, 
an anti-CD20 antibody. However, even these drugs are not without their problems; the use of 
infliximab and rituximab comes with risks (Hadjinicolaou et al., 2012; Rosenblum and 
Amital, 2011). 
 
7.7.2 Fas ligand and FcγRIIB as new therapeutic targets 
Unfortunately, due to the autoimmunity-enhancing effects of FasL deficiency, the use 
of anti-FasL blocking antibodies may be more detrimental than beneficial as a treatment for 
GN in humans, unless it is possible to determine the exact pathway by which FasL deficiency 
offers protection. However, the in vivo data represented in this thesis suggest that FcγRIIB 
may be a novel therapeutic target for treatment of GN. Since FcγRIIB deficiency on myeloid 
cells is associated with exacerbated disease and treatment of macrophages with IVIG 
upregulates FcγRIIB expression (Kaneko et al., 2006; Tackenberg et al., 2009), this study 
offers further insight into the anti-inflammatory properties of IVIG for the treatment of 
autoimmune diseases (Anthony et al., 2008). 
 
This project is all an original work. My study is the first report linking FasL 
expression on intrinsic renal cells and FcγRIIB expression on intrinsic renal cells and 
myeloid cells to the development of GN. I have shown that gld mice are completely protected 
from accelerated NTN, but expression of FasL on either circulating leukocytes or intrinsic 
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renal cells is enough to result in disease. I have also shown that FasL deficiency on mesangial 
cells results in impaired signalling through the IL-1R, resulting in reduced expression of 
MCP-1. Conversely, I have shown FcγRIIB expression on myeloid cells and intrinsic renal 
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Appendix 2 Published Papers 
Appendix 2a Mice with defective Fas ligand are protected from crescentic 
glomerulonephritis. 
Appendix 2b Increased incidence of anti-GBM disease in Fcgamma receptor 2b 
deficient mice, but not mice with conditional deletion of Fcgr2b on either B cells or 
myeloid cells alone. 
Appendix 2c FcγRIIB on myeloid cells and intrinsic renal cells rather than B cells 
protects from nephrotoxic nephritis. 
Mice with defective Fas ligand are protected from
crescentic glomerulonephritis
Ruth M. Tarzi1, Phoebe E.H. Sharp1, John P. McDaid1, Liliane Fossati-Jimack1, Paul E. Herbert1,
Charles D. Pusey1, H. Terence Cook1 and Anthony N. Warrens1
1Renal Section, Department of Medicine, Hammersmith Campus, Imperial College London, London, UK
Fas ligand is a well-known inducer of apoptosis in cells
expressing its receptor Fas; it also prevents autoimmunity
by inducing apoptosis of activated T cells. However,
Fas ligand also mediates non-apoptotic functions involving
inflammatory cell migration and cytokine responses. We
sought here to study the role of Fas ligand in nephrotoxic
nephritis, a model of crescentic glomerulonephritis, using
generalized lymphoproliferative disorder (GLD) mice on a
C57BL/6 background, which have defective Fas ligand and
display only mild autoimmunity. These mice were
significantly protected from glomerular crescent formation,
glomerular thrombosis, renal impairment, and albuminuria
15 days after the induction of glomerulonephritis in
comparison with wild-type mice. There were a reduced
number of apoptotic cells in the glomeruli of nephritic GLD
mice but no defect in their antibody responses or splenocyte
proliferation at 15 days following the induction of
glomerulonephritis. Bone marrow transplantation from wild-
type mice restored disease susceptibility to GLD mice;
however, wild-type mice were not protected when
transplanted with bone marrow from GLD mice. Mesangial
cells express Fas ligand in vitro, and these cells isolated from
GLD mice produced lower amounts of monocyte
chemoattractive protein-1 following interleukin-1 stimulation
compared with cells from wild-type mice. Thus, Fas ligand-
defective mice are protected from nephrotoxic nephritis, a
disease in which both circulating and intrinsic renal cells
appear to have a role.
Kidney International (2012) 81, 170–178; doi:10.1038/ki.2011.319;
published online 14 September 2011
KEYWORDS: apoptosis; cytokines; glomerulonephritis; mesangial cells
Fas ligand (FasL, CD95L) belongs to the tumor necrosis
factor (TNF) family, and has a well-characterized role in
inducing apoptosis in target cells by crosslinking the receptor,
Fas (CD95), on the cell surface.1 Deficiency of FasL can lead
to autoimmunity in humans and mice on certain genetic
backgrounds, due to the lack of activation-induced cell death
of T lymphocytes.2 However, paradoxically, deficiency of FasL
has also been associated with protection from inflammation.
FasL is involved in apoptosis of mesangial cells by macro-
phages.3 Non-apoptotic functions of FasL including cell
survival and migration, nuclear factor kappa B activation,
and cytokine release are increasingly recognized.4,5 Soluble
FasL has been implicated in chemotaxis of neutrophils and
monocytes.6–8 FasL also has been implicated in facilitating the
release of cytokines such as monocyte chemoattractive
protein (MCP)-1, interleukin (IL)-6, and IL-12 in response
to IL-1 and Toll-like receptor 4 stimulation.9–11
FasL is expressed in the kidney in human glomerulone-
phritis and animal models of glomerulonephritis,12,13 but its
functional effects are not known. We therefore set out to
determine the role of FasL in nephrotoxic nephritis and to
determine the relative roles of FasL expression on circulating
and intrinsic renal cells.
Generalized lymphoproliferative disorder (GLD) mice
have a defective form of FasL with a point mutation in the
extracellular region of FasL,2,14 affecting the binding of
the protein to Fas. On permissive genetic backgrounds (for
example, MRL), GLD mice developed lymphadenopathy,
splenomegaly, and autoimmunity. However, in other strains
(for example, C57BL/6), a defective Fas/FasL system induced
autoantibodies, but only mild glomerulonephritis.15 We have
used mice on a C57BL/6 background for these studies.
RESULTS
GLD mice on a C57BL/6 background developed glomerular
immune complex deposition, but no significant renal
damage during the time course of the NTN experiments
Mice used in the nephrotoxic nephritis (NTN) experiments
were between 2 and 4 months of age. We therefore
investigated GLD mice of these ages for evidence of
spontaneous renal disease. At 2 months, histology and
immunofluorescence of the GLD mice were normal. At
4 months, there was some granular immunoglobulin (Ig)G
or ig ina l a r t i c l e http://www.kidney-international.org
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deposited in the glomeruli, but the kidneys were histologi-
cally normal (Supplementary Figure S1 online). There was no
albuminuria or renal dysfunction in any of the groups and no
significant difference in glomerular macrophage numbers
between GLD and WT at 2 and 4 months (Table 1). There
were no crescents or glomerular thrombosis in unmanipu-
lated wild-type (WT) and GLD mice at 2 and 4 months.
GLD mice were protected from renal injury in NTN
Nephrotoxic nephritis was induced in GLD mice and WT
C57BL/6 controls. Mice were killed at Day 8 and Day 15 after
the induction of disease (Figures 1 and 2 (Day 15) and
Supplementary Figure S2 online (Day 8)). FasL-defective GLD
mice were strongly protected from renal injury compared
with WT mice, in terms of glomerular thrombosis (Po0.01),
glomerular crescents (Po0.001), albuminuria (Po0.001),
serum albumin (Po0.001), and serum urea (Po0.01). TUNEL
staining revealed lower numbers of glomerular apoptotic cells
in the GLD than in the WTmice (Po0.001; Figure 1f).
There was no reduction in glomerular neutrophil or
macrophage infiltration, but interstitial inflammation was
reduced in GLD mice
Despite protection from injury, the GLD mice had a
macrophage infiltrate in the glomeruli that was not
significantly different from WT nephritic mice (median
1.86 versus 1.24 CD68-positive cells/glomerular cross-section
in WT versus GLD, not significant; Figures 2 and 3a). In
contrast, in the interstitial regions, there was a reduction in
the macrophage infiltration in the GLD mice compared with
WT (Po0.01, Figures 2 and 3b). This was mirrored by
reduced MCP-1 mRNA in whole-kidney mRNA extracts at
Day 15 (Figure 3c, Po0.001). At 24 h after injection of
nephrotoxic serum, there was no significant difference in the
glomerular neutrophil infiltrate between WT and GLD mice
(Figure 3d), although there was a wide range, possibly
because of the transient nature of the neutrophil population.
Antibody and T-cell responses to the nephritogenic antigen
To determine the mechanism for the protection of disease,
the systemic and local immune responses were analyzed.
Murine IgG deposited in glomeruli was quantified at Day 1,
Day 8, and Day 15 after the induction of disease. Compared
with WT, there was a delay in the glomerular antibody
deposition in GLD mice, as there was significantly less in
GLD glomeruli at Day 1 (Po0.01), no difference at Day 8
and more mouse IgG (Po0.01) deposited at Day 15 after
induction of disease (Figure 4a). Similarly, in terms of
circulating mouse anti-sheep IgG, there was no significant
difference between WTand GLD at Day 1, but relative to WT,
there was significantly more circulating anti-sheep IgG at Day
8 and Day 15 in the GLD mice (Po0.05 and Po0.01,
respectively; Figure 4b).
Splenocyte proliferation to sheep IgG was determined
after preimmunization only (primary immune response) and
in a separate experiment at the termination (Day 10). There
was reduced splenocyte proliferation to antigen in the GLD
mice after preimmunization alone (Figure 5a); however, by
Table 1 | Control data: unmanipulated mice
WT (n=8) GLD (n=8) WT (n=8) GLD (n=8)
Age (in months) 2 2 4 4
Glomerular mouse IgG Negative Negative Negative Granular
Serum urea (mmol/l) 9.4 (7.7–11.6) 7.5 (5.8–8.4) 7.2 (6.8–8.9) 11.3 (11.1–12.9)
Serum creatinine (mmol/l) 49.0 (45.5–50.0) 39.5 (37.0–42.5) 42.5 (38.0–49.0) 37.0 (35.0–41.0)
Macrophages/gcs 0.1 (0.02–0.19) 0.12 (0–0.56) 0.33 (0.24–0.044) 0.49 (0.34–0.54)
Urinary albumin/creatinine ratio (mg/mmol) 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.01 (0.01–0.01)









































































































Figure 1 | Functional and histological parameters at Day 15
after induction of nephrotoxic nephritis (NTN) in wild-type
(WT) and generalized lymphoproliferative disorder (GLD)
mice. (a) Glomerular thrombosis score, (b) percentage glomerular
crescents, (c) urinary albumin/creatinine ratio (mg/mmol),
(d) serum albumin (g/l), (e) serum urea (mmol/l), (f) apoptotic
bodies/gcs. Dashed lines represent values for a group of normal
WT mice. gcs, glomerular cross-section.
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the end of the experiment, the proliferation was equal
between WT and GLD (Figure 5b). Analysis of cytokines
produced by splenocytes after preimmunization and re-
challenge with sheep IgG in vitro showed reduced interferon
gamma (IFN-g) production by GLD splenocytes (Po0.05)
and a tendency to a reduced IL-17A production (P¼ 0.09;
Figure 5a). In the Day-10 experiment, the supernatant IFN-g
production was below the limit for detection by the enzyme-
linked immunosorbent assay (ELISA). The IL-4 production
by splenocytes in response to sheep IgG was barely above the
detection limit of the assay, and not significantly different
between the two groups. Therefore, there was a defect in
T-cell responses early in the phase of the disease, although
this was not evident at Day 10 post NTN.
To investigate this further, intrarenal T cells and cytokines
were analyzed. There was a reduction in CD4-positive T-cell
infiltration in the GLD mice at Day 15 after induction of
NTN (median 0.38 (interquartile range 0.19–0.57) CD4-
positive T cells/glomerular cross-section in the WT mice
versus 0.19 (0.1–0.23) CD4þ cells/glomerular cross-section
in the GLD mice; Figure 6a). In parallel with this observation,
we saw reduced mRNA for IFN-g in the kidneys of the
nephritic GLD mice (Po0.05, Figure 6b). IL-4 mRNA was
downregulated in nephritic kidneys compared with non-
diseased kidneys, and there was no significant difference
between WT and GLD nephritic mice (Figure 6c). mRNA for
IL-12p40, a component of IL-12 and IL-23, was significantly
reduced in the GLD kidneys compared with WT nephritic
kidneys (Po0.001, Figure 6d). Taken together, there was a
moderate reduction in the systemic T-cell response at an early
stage of NTN, but not at later.
Fas ligand derived from either bone marrow-derived or
radioresistant intrinsic renal cells was sufficient to restore
susceptibility to NTN
Bone marrow transplant experiments were conducted to
compare the role of bone marrow-derived and radioresistant
cell expression of FasL. GLD mice were transplanted with WT
bone marrow and WT mice were transplanted with GLD
bone marrow, as well as isografts performed as controls. To
assess reconstitution of circulating leukocytes, mice were
transplanted with bone marrow marked with the allotype
marker CD45.1 rather than CD45.2, the C57BL/6 allotype.
A median of 92.2% (range 90.9–93.4%) of CD45-positive
circulating leukocytes were of CD45.1 donor origin, as
opposed to the recipient CD45.2 cells in peripheral blood at
8 weeks after bone marrow transplantation (Supplementary
Figure 2 |Histology at Day 15 after induction of nephrotoxic
nephritis (NTN). (a) Periodic acid-Schiff-stained wild-type (WT)
kidney section showing glomerular hypercellularity, and a
glomerular crescent; (b) generalized lymphoproliferative disorder
(GLD) kidney at Day 15 after induction of NTN showing mild
glomerular hypercellularity only. (c, e) Immunoperoxidase staining
for CD68 in WT kidney showing interstitial and glomerular
macrophage infiltration. (d, f) Immunoperoxidase staining for
CD68 in GLD kidney showing glomerular, but little interstitial,
macrophage infiltration. Apoptotic bodies were present in WT






































































Figure 3 |Day 15 after induction of NTN. (a) CD68-positive
macrophages/glomerular cross-section (gcs); (b) CD68-positive
macrophage interstitial infiltration assessed by image analysis;
(c) relative expression of MCP-1 mRNA in GLD and WT mice post
nephrotoxic nephritis (NTN) compared with control wild-type
(WT) and generalized lymphoproliferative disorder (GLD) mice;
(d) neutrophils/gcs 24 h after induction of NTN. Dashed lines
represent values for a group of normal WT mice. MCP, monocyte
chemoattractive protein; ns, not significant.
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Figure S3 online). Semiquantitative PCR of DNA extracted
from whole blood at the termination of the experiments was
compared with a standard curve of known mixtures of WT
and GLD DNA. More than 95% of DNA extracted from
circulating blood was of donor origin in both the WT to GLD
and the GLD to WT transplants (not shown).
Ten weeks post bone marrow transplantation, mice were
induced with NTN, and were killed at Day 8 after the
injection of nephrotoxic serum. WT bone marrow restored
disease susceptibility, as GLD mice transplanted with WT
bone marrow had more renal damage than GLD mice
transplanted with GLD bone marrow (Po0.05 for glomer-
ular thrombosis, crescents, serum urea, and urinary albumin/
creatinine ratios; Figure 7a–d). As noted in previous
experiments, there was no significant difference in the
glomerular macrophage infiltrate between any of the groups,
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Figure 4 | Deposited and circulating immunoglobulin (Ig)G responses in WT and GLD mice after the induction of nephrotoxic nephritis
(NTN). (a) Quantification of deposited glomerular mouse IgG at Day 1, Day 8, and Day 15 after induction of NTN (minimum n¼ 7/group).
(b) Enzyme-linked immunosorbent assay (ELISA) for serum total sheep IgG (1:1000 dilution) at Day 1, Day 8, and Day 15 after induction








































Figure 5 | Splenocyte 3H thymidine incorporation at 72 h after exposure to 100mcg/ml sheep IgG (left panels), and cytokine
release into supernatant (right hand panel) after exposure to sheep IgG in vitro. (a) Splenocytes collected 7 days after immunization
alone, without injection of nephrotoxic serum; (b) splenocytes collected at 10 days after induction of nephrotoxic nephritis with
preimmunization and nephrotoxic serum. c.p.m., counts per minute; GLD, generalized lymphoproliferative disorder; IgG, immunoglobulin G;
IFN, interferon; IL, interleukin; NS, not significant; NTN, nephrotoxic nephritis; WT, wild type.
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but there were reduced interstitial macrophages, only in the
GLD to GLD transplants (not shown). Only the GLD to
GLD transplants had reduced levels of glomerular apoptosis
(Figure 7f).
However, our results suggest that FasL expression by
radioresistant cells in the kidney is also sufficient to induce
renal injury in NTN, as WT mice transplanted with GLD
bone marrow were not protected from NTN as compared
with WTmice transplanted with WT bone marrow (Figure 7).
To determine whether there was chimerism of resident
kidney leukocytes post bone marrow transplantation,
C57BL/6 (CD45.2) mice were transplanted with CD45.1
bone marrow using the same protocol. Ten weeks later,
kidney cells were dissociated, stained for CD45.1, CD45.2,
F4/80, and CD11c, and analyzed by flow cytometry (n¼ 7).
The chimerism of resident kidney cells was broadly similar to
blood with total leukocytes median 88% (range 87.3–91.8%),
CD11cþ F4/80þ 95.4 (92.3–95.6), and CD11cþ F4/80#
93.4% (90.7–96.3%), Supplementary Figure S3 online. These
results suggest a role for intrinsic renal cell FasL in NTN
pathogenesis.
FasL mRNA increases in the kidney during NTN, and is
expressed by cultured mesangial cells
mRNA for FasL was increased in whole-kidney lysates after
the development of NTN, indicating that FasL in the kidney
itself could have a local effect (Figure 8a); however, the
mRNA results cannot distinguish whether this is originating
from circulating or intrinsic renal cells. We therefore assessed
the expression of FasL on mesangial cells, cultured overnight
in the presence of a metalloproteinase inhibitor to inhibit
cleavage to soluble FasL. By flow cytometry, we could detect
FasL on 18.4% of the cultured mesangial cells using a FasFc
conjugate, compared with 1.96% positive cells with the
secondary antibody alone (Figure 8b). As defective FasL
signaling has been associated with reduced responses to IL-1,
we then examined MCP-1 secretion by WT and GLD
mesangial cells after stimulation with IL-1 or TNF-a. There
was significantly reduced MCP-1 secretion by GLD mesangial
cells after stimulation with IL-1 but not TNF-a (representa-
tive results from one of five experiments for IL-1 and three
experiments for TNF-a are shown in Figure 8c and d).
DISCUSSION
Our results show that FasL mutant (GLD) mice on a C56BL/
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Figure 6 | Intrarenal T-cell infiltration and intrarenal cytokine
mRNA at Day 15 after induction of nephrotoxic nephritis.
(a) CD4-positive T cells/gcs; (b) relative expression of IFN-g mRNA
between wild-type (WT) and, generalized lymphoproliferative
disorder (GLD) mice at Day 15 post nephrotoxic nephritis (NTN);
(c) relative expression of interleukin (IL)-4 mRNA; (d) relative
expression of IL-12p40 mRNA. WT and GLD controls refer to
unmanipulated age-matched control mice. gcs, glomerular


















































































































































































































Figure 7 |Nephrotoxic nephritis in bone marrow-transplanted
mice at Day 8 after induction of NTN. (a) Glomerular thrombosis
score; (b) percentage glomerular crescents; (c) serum urea
(mmol/l); (d) urinary albumin/creatinine ratio (mg/mmol);
(e) Enzyme-linked immunosorbent assay (ELISA) for serum
anti-sheep immunoglobulin (Ig)G; (f) apoptotic bodies/glomerular
cross-section. Dashed lines refer to normal values for a group
of control wild-type (WT) mice. gcs, glomerular cross-section;
NTN, nephrotoxic nephritis; OD, optical density.
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functional renal injury, using the nephrotoxic nephritis
model of glomerulonephritis. T-cell-mediated systemic im-
munity was reduced in the early phase of the disease, which
may have contributed to protection from injury. However,
the bone marrow transplant results did not support an
exclusive role for FasL expressed by circulating cells in
mediating injury, making it less likely that differences in the
immune response are completely responsible for the protec-
tion of GLD mice from glomerulonephritis. We showed
expression of FasL in the kidney in NTN, and our results
would suggest that local expression of FasL in the kidney by
circulating or intrinsic renal cells can facilitate injury in this
model.
GLD mice have been found to be protected from a
number of models of injury.10,16–19 Similar to our findings,
T-cell proliferation to antigen was not reduced at the end
of the experiments in either collagen-induced arthritis10 or
experimental allergic encephalomyelitis.18 In these models,
the immune response at earlier stages of disease was not
examined.
A Th2-deviated immune response protects from murine
nephrotoxic nephritis.20 Th2-deviated immune responses have
been found in human patients with Fas and FasL muta-
tions causing autoimmune lymphoproliferative syndrome.11
We noted significantly increased IL-4 production by GLD
splenocytes after polyclonal stimulation (data not shown).
However, we could not demonstrate enhanced antigen-
specific Th2 responses systemically or in the kidney, and
thus this mechanism is unlikely to explain protection from
disease in our model.
Interestingly, there was no reduction in glomerular
macrophage or neutrophil infiltration into glomeruli in
GLD mice with NTN. Although FasL is involved in migration
of neutrophils6,7 and macrophages8 to inflammatory sites,
FasL does not have a major role in the entry of inflammatory
cells to glomeruli in this model. It is likely that other
mechanisms such as Fc receptor- or complement-mediated
events have a larger role in models in which immune
complexes are deposited.
It is striking that the glomerular injury and subsequent
interstitial injury and inflammation was markedly reduced,
despite the lack of reduction in glomerular macrophage
infiltration. This suggests that in the absence of functional
FasL, the ability of the cells to induce glomerular damage was
reduced. We saw reduced apoptotic bodies in the kidneys of
the GLD mice induced with NTN. FasL induces apoptosis of
cells, including mesangial cells.3 The reduction in apoptosis
may be responsible for protection from injury. An alternative
possibility is that the presence of FasL in the glomerulus is
involved in cell activation. Indeed, FasL has been reported to
function synergistically with IFN-g to enhance macrophage
activation.21 In addition, FasL can activate the intracellular
a b
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Figure 8 | Expression of Fas ligand (FasL) in the kidney and analysis of functional effects of generalized lymphoproliferative
disorder (GLD) mutation in mesangial cells. (a) Relative expression of FasL mRNA in whole kidney in unmanipulated wild-type (WT) mice
(WT control) and WT mice at Day 15 after the induction of nephrotoxic nephritis (NTN) (WT NTN). (b) Flow cytometry for FasL on cultured
mesangial cells. Dotted line: fluorescein isothiocyanate (FITC)-conjugated antihuman immunoglobulin (Ig)G secondary antibody only; black
line, recombinant FasFc protein ((Fas conjugated to human Fc) plus secondary antibody). (c) Monocyte chemoattractive protein (MCP)-1
measured in supernatant of serum-starved mesangial cells unstimulated, or stimulated with 10 ng/ml interleukin (IL)-1 (representative
results from five separate experiments). (d) MCP-1 levels measured in supernatants of serum-starved mesangial cells unstimulated,
or stimulated with 10 ng/ml tumor necrosis factor (TNF)-a (representative of three separate experiments). ns, not significant.
Kidney International (2012) 81, 170–178 175
RM Tarzi et al.: Fas ligand in glomerulonephritis o r ig ina l a r t i c l e
mediator nuclear factor kappa B, a key transcription factor
for inflammatory responses,22 and facilitates signaling
through the IL-1 receptor.10 Binding of FasL to Fas activates
caspases, which process IL-1b for secretion.
Transplantation of WT bone marrow to GLD mice was
sufficient to restore susceptibility to NTN, indicating that
expression of FasL by circulating cells was sufficient to induce
NTN. However, transplantation of GLD bone marrow to WT
mice did not protect from disease, despite good deletion of
circulating WT bone marrow-derived cells. There were some
(B10%) WT circulating and intrinsic renal cells present in
these bone marrow transplants, and we cannot exclude the
possibility that these are sufficient to induce disease.
However, a lack of reduction of disease does suggest that
there is a source of FasL from radioresistant cells in the
kidney that is permissive for the development of NTN. This is
in contrast to results from similar experiments conducted in
experimental allergic encephalomyelitis and uveitis, where
FasL expressed on circulating cells was responsible for
protection from disease.19,23 We confirm that mesangial cells
in vitro express FasL. FasL on intrinsic renal cells is
functional, as there is a previous report of a functional role
for FasL expression by tubular cells in inducing apoptosis of
surrounding tubular cells in a model of cisplatin-induced
acute tubular necrosis.24 A role for FasL on intrinsic renal
cells in glomerulonephritis has not been previously shown.
GLD mesangial cells had attenuated responses to IL-1-b in
terms of the production of MCP-1 in vitro, consistent with
previous reports in other cell types expressing FasL.10,25
There was a large reduction in mRNA for MCP-1 in the GLD
kidneys, consistent with this finding, and a large reduction in
macrophages in the interstitium, which may indicate that
similar mechanisms operate to regulate MCP-1 production in
the interstitial compartment. MCP-1 is involved in cell
activation and chemotaxis.26
The autoimmunity-enhancing effects of FasL blockade
may preclude its use as a therapeutic agent. However, this
study highlights the importance of FasL in renal injury and
highlights a possible role for intrinsic renal cell FasL
expression in the pathogenesis of glomerulonephritis.
MATERIALS AND METHODS
Mice
GLD mice on a C57BL/6 background were purchased from Jackson
Laboratory (Maine, ME) and bred in-house, and C57BL/6 WTmice
were purchased from Harlan (Blackthorn, UK). Animal experiments
were conducted according to the institutional and the UK Home
Office guidelines. Mice were genotyped using a protocol available on
the Jackson Laboratory website. Experimental groups were matched
for sex and age.
Induction of nephrotoxic nephritis
Sheep anti-mouse nephrotoxic globulin was prepared as described
previously.27 The endotoxin content of the nephrotoxic globulin was
undetectable, measured using a Biowhittaker 1000-QCL LPS assay
kit (Biowhittaker, Walkersville, MD). Mice were immunized
intraperitoneally with 0.2mg of sheep IgG in a 50:50 mix of saline
and complete Freund’s adjuvant (Sigma Chemical, St Louis, MO).
Five days later, 0.2ml of nephrotoxic globulin was injected
intravenously. Mice were monitored clinically and the experiments
were terminated if the mice were showing signs of the disease.
Histological studies and quantitative immunofluorescence
Glomerular crescents and thrombosis were scored on samples fixed
in Bouin’s solution and stained with periodic acid-Schiff, by an
observer blinded to the experimental group. Glomerular thrombosis
was assessed by scoring individual glomeruli for periodic acid-
Schiff-positive material as follows: grade 0: no periodic acid-Schiff-
positive material; grade 1: 0–25% of glomerular cross-section
periodic acid-Schiff positive; grade 2: 25–50%; grade 3: 50–75%;
grade 4: 75–100%. Fifty glomeruli were scored per kidney.
Glomerular crescents were defined as glomeruli containing two or
more layers of cells in Bowman’s space.
Glomerular mouse and sheep IgG were visualized by direct
immunofluorescence on frozen kidney sections using fluorescein
isothiocyanate-conjugated goat anti-mouse IgG (Fc-specific) and
fluorescein isothiocyanate-conjugated monoclonal mouse anti-sheep
IgG clone GT34 (Sigma, Dorset, UK). To quantify immunofluores-
cence, sections were examined at ! 40 magnification using an
Olympus BX4 fluorescence microscope (Olympus Optical, London,
UK) and a Photonic Science Colour Coolview camera (Photonic
Science, Robertsbridge, UK). Samples from each experiment were
stained on the same occasion and measured together. Images of the
sections were captured using Image Pro (MediaCybernetics,
Bethesda, MD) and the total pixel intensity for each glomerulus
was measured and averaged for 20 glomeruli per section.
For cell markers, kidneys were fixed in periodate-lysine-
paraformaldehyde. Sections of 5 mm were stained for macrophages
with FA11 (monoclonal rat anti-mouse CD68, Serotec, Oxford, UK)
or CD4 cells (GK1.5, BDPharmingen, Oxford, UK), and developed
using the Polink-2 plus HRP rat detection kit (Newmarket Scientific,
Newmarket, UK). Macrophages and T cells in 50 glomeruli/sample
were counted and averaged to obtain cells/glomerular per cross-
section. For interstitial macrophage infiltration, five high-power
fields per kidney were photographed. The proportion of the pictures
with brown peroxidise pigmentation was calculated using the
ImagePro software (MediaCybernetics) and averaged for the five
high-power fields. All slides from a single experiment were analyzed
simultaneously TUNEL staining was used to detect apoptotic cells
on formalin-fixed sections of mouse kidney using the ApopTag
Fluorescein Kit (Qbiogene, Carlsbad, CA).
Quantitative RT-PCR
Total RNA was extracted from whole kidneys using the TRIzol
method. Real-time qRT-PCR was performed on an ABI 7500
Sequence Detection System (Applied Biosystems, Warrington, UK)
using Brilliant II SYBR Green qRT-PCR Master Mix, 1 Step
(Stratagene, Cambridge, UK). RNAwas used at a final concentration
of 5–10 ng/ml and all samples were run in duplicates. Results were
exported to the 7500 Fast System SDS software (Applied Biosystems),
and Ct values were determined for all the genes analyzed. The
relative expression levels, normalized to GAPDH gene expression,
were determined by using the 2"DDCt method. The following
primers were used: MCP-1 forward: 50-ATGCAGTTAATGCCC
CACTC-30; MCP-1 reverse: 50-AGCTGGAAGCCACTGACACT-30;
GAPDH forward: 50-GGGTGTGAACCACGAGAAAT-30; GAPDH
reverse: 50-GTCTTCTGGGTGGCAGTGAT-30; IFN-g forward: 50-GCA
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TCTTGGCTTTGCAGCTC-30; IFN-g reverse: 50-CGACTCC
TTTTCCGCTTCCT-30; IL-4 forward: 50-ACAGGAGAAGGGACGC
CAT-30; IL-4 reverse: 50-GAAGCCCTACAGACGAGCTCA; IL-12-
p40 forward: 50-GGAAGCACGGCAGCAGAATA-30; IL-12-p40
reverse: 50-AACTTGAGGGAGAAGTAGGAAT-30; FasL forward:
50-ACCCCCACTCAAGGTCCAT-30; FasL reverse: 50-CGAAGTAC
AACCCAGTTTCGT-30.
Serum urea, albumin, and urinary albumin/creatinine ratio
Serum urea and urinary creatinine were measured in the Depart-
ment of Clinical Chemistry, Imperial College Healthcare NHS Trust.
Serum albumin was measured using the AssayMax mouse albumin
ELISA kit (AsssayPro, St Charles, MO). Albuminuria was assessed by
radial immunodiffusion against a rabbit anti-mouse albumin
(Biogenesis, Poole, UK), as previously described.27
Circulating antibody and T-cell immune responses
Serum mouse anti-sheep IgG levels were measured by sandwich
ELISA as previously described.27 Detecting antibody for IgG
(g-chain specific) was obtained from Sigma. Samples were tested
in duplicate at 1:500 and 1:1000 dilutions. Background fluorescence
in uncoated wells was subtracted, and normal serum from
unimmunized mice served as a control.
For splenocyte proliferation assays, single-cell suspensions were
created and red cells were lysed. Cells were cultured at 1! 106 cells/ml
for 72 h in HL1 serum-free medium (Lonza, Basel, Switzerland), in
the presence or absence of 100 ng/ml heat-aggregated sheep IgG, or
100 ng/ml phorbol myristate acetate plus ionomycin (500 ng/ml) as
a positive control. At 72 h, 1 mCi/well 3H thymidine was added for
24 h before assessing splenocyte proliferation using standard
procedures and a Wallac 1450 microbeta counter (Perkin Elmer,
Waltham, MA). Supernatants collected at 72 h were assayed for IL-4
and IFN-g using ELISA kits, according to the manufacturer’s
instructions (eBioscience, Hatfield, UK), and IL-17alpha (R&D
Systems, Minneapolis, MN). Lower limits for detection were 1, 15,
and 15 pg/ml.
Bone marrow chimeras
Chimeric mice were made by irradiation with a dose of 8Gy and
reconstituted with 10! 106 donor bone marrow cells. Nephritis
experiments were conducted at 10 weeks after this. Confirmation of
chimerism was obtained using PCR on DNA extracted from 0.1ml
blood obtained at the terminal bleed. PCR was performed as
recommended on the Jackson laboratory website, except that the
reverse primer was labeled with the fluorescent marker 6-carboxy-
fluoroscein. The products were run on Genescan (Applied
Biosystems) and the ratio of the mutant (108 bp) versus WT
(88 bp) product was calculated and compared with known mixtures
of WT and GLD DNA (0, 5, 50, 90, 95, and 100% mutant DNA). In
addition, to confirm chimerism, blood was taken from mice
transplanted with CD45.1 allotype bone marrow and the mice were
bled at 10 weeks post transplantation. Red cells were lysed, and Fc
receptors were blocked with 2.4G2 and stained with CD45.1 APC
and CD45.2 APC. Kidney single-cell suspensions were prepared as
previously described.28 Briefly, kidneys were removed and sliced into
six pieces using a scalpel, followed by digestion with DNase I 100
and 0.5 mg/ml Collagenase D (Roche Diagnostics, Burgess Hill, UK).
Kidneys were mashed and filtered through a 100-mm nylon mesh.
Kidney suspensions were incubated with 2.4G2 (eBiosciences) to
block Fc receptors, and then stained with the following antibodies
obtained from eBiosciences: APC-CD45.1, PE-CD45.2, fluorescein
isothiocyanate F4/80, and PerCP Cy5.5 CD11c. Flow cytometry was
performed using a FACScalibur flow cytometer and analyzed using
the FlowJo (TreeStar, Ashland, OR) software.
Mesangial cell cultures
Glomeruli were collected from WT and GLD kidneys and digested
with collagenase as previously described.29 Mesangial cells were
cultured in RPMI containing 20% fetal calf serum, and passaged
8–12 times before use. Mesangial cells were characterized as anti-
myosin positive, CD11b, and pancytokeratin negative, with
characteristic stellate morphology. Briefly, 106 cells/well were
cultured in a six-well plate (Nunc, Rochester, NY) for 24 h, after
which the cells were serum-starved overnight. Cells were stimulated
with 10 ng/ml IL-1b, TNF-a, or left unstimulated in serum-free
mesangial media for 24 h. Supernatant MCP-1 levels were
analyzed by ELISA according to the manufacturer’s instructions
(eBioscience). Cytokine levels were corrected for cell numbers and
were compared with the end of the experiment using the MTT assay
according to the manufacturer’s instructions (Sigma). There tended
to be more cells in the GLD wells at the termination of the
experiments, possibly because of reduced apoptosis in these cells.
Mesangial cell FasL expression
Mesangial cells were cultured in the presence of 10mmol/l GM6001
(Sigma) for 24h before collecting (protease inhibitor to prevent
cleavage of membrane-bound FasL). Cells were collected using
Cell Dissociation Solution (Sigma), and nonspecific binding
was blocked using 10% normal mouse serum. A measure of 1mg
FasFc conjugate (Sigma) was added to 0.5! 106 cells, followed by
washing in phosphate-buffered saline/1% fetal calf serum. Bound FasFc
was detected using fluorescein isothiocyanate-conjugated antihuman
IgG (Sigma). Flow cytometry was performed using a FACSCalibur flow
cytometer and analyzed using the FlowJo (TreeStar) software.
Statistics
Results are quoted as median (interquartile range), unless otherwise
stated. Lines on graphs represent median value. For comparing two
groups, the Mann–Whitney U-test was used, and for three or more
groups a one-way analysis of variance with Bonferroni’s post test
was used. GraphPad Prism (GraphPad Software, San Diego, CA) was
used to analyze the data. Differences were considered significant
when Po0.05.
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SUPPLEMENTARY MATERIAL
Figure S1. Histology from unmanipulated WT and GLD mice at
2 months and 4 months of age.
Figure S2. Functional and histological parameters at Day 8 after
induction of NTN in wild-type (WT) and GLD mice.
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Figure S3. A-B: Flow cytometry of blood and kidney leukocytes
10 weeks post bone marrow transplantation, to demonstrate the
degree of chimerism.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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a  b  s  t  r  a  c  t
Fcgamma  receptor  2b  (Fcgr2b)  is the  only  inhibitory  Fcgamma  receptor  in  both  humans  and  mice,  and  is
implicated  in  both  antibody  production  and  effector  responses  to antibody  complexes.  Reduced  function
of Fcgr2b  has previously  been  associated  with  anti-glomerular  basement  membrane  antibody  (anti-GBM)
disease  in  mice.  However,  the  mice  used  had  129  genetic  elements  flanking  the  deleted  Fcgr2b  gene,  which
are known  to increase  susceptibility  to autoimmunity.  In order  to confirm  a role  for  Fcgr2b  in protection
from  anti-GBM  disease,  wild  type  (WT)  mice,  mice  lacking  Fcgr2b  on  a pure  C57BL/6  background,  or
mice  lacking  Fcgr2b  on a C57BL/6  background  with  129  flanking  sequences,  were  immunized  with  the
recombinant  NC1  domain  of alpha  3 Type  IV  collagen.  Twenty  two  weeks  after  immunization,  there  was
a higher  incidence  of  crescentic  glomerulonephritis,  macrophage  infiltration  and  renal  dysfunction  in
both groups  of  Fcgr2b−/−  mice,  indicating  an  important  role  of  Fcgr2b  in  regulating  the  development  of
anti-GBM  disease,  on  both  genetic  backgrounds.  In  order  to  determine  the  cellular  origin  of  the Fcgr2b-
associated  effect,  disease  was  induced  in  mice  with  deficiency  of  Fcgr2b  on either  B cells  alone  (CD19Cre),
or  a subset  of  myeloid  cells  (LysozymeMCre).  Neither  B cell  nor  myeloid  specific  knockout  mice  developed
crescentic  glomeruonephritis  with  higher  incidence  than  WT  mice  indicating  that  Fcgr2b  deficiency  on
either B cells  or a subset  of  myeloid  cells  alone  is  not  sufficient  to increase  susceptibility  to  anti-GBM
disease,  but  that  a combination  of  cell  types,  or deficiency  of  Fcgr2b  in  a  different  cell  type, is also  required.
© 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Fcgamma receptor 2b (Fcgr2b) is the only inhibitory Fc recep-
tor for IgG found in humans and mice. It has a role in regulating
Abbreviations: Fcgr2b−/−, Fcgamma receptor 2b deficient mice;
Fcgr2b−/−(129), Fcgamma receptor 2b deficient mice created using 129
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Fcgamma receptor 2b deficient mice created on a pure C57BL/6 background;
Fcgr2b−/−/CD19cre, Fcgr2b−/− mice expressing CD19 Cre-recombinase;
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WT,  wild type.
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antibody production (Takai et al., 1996) via its expression on B
cells, and in effector responses via its expression on cells such
as neutrophils, monocytes and macrophages. We have recently
shown that in mice Fcgr2b acts as a modifier of autoimmune dis-
eases such as lupus (Boross et al., 2011). Loss of Fcgr2b on a pure
C57BL/6 background is not sufficient to induce the development of
lupus. However, in a previously studied Fcgr2b knockout mouse
model, generated by gene targeting in 129 derived embryonic
stem cells and backcrossed into C57BL/6 background, (Bolland and
Ravetch, 2000) epistatic interactions between the FcgRIIb allele and
autoimmune susceptibility loci present in the 129 derived genomic
flanking region result in high incidence of lupus (Boross et al., 2011).
Wandstrat et al. (2004) have identified the highly polymorphic
SLAM/CD2 cluster within the 129 genome Fcgr2b flanking region
which has a regulatory function in both innate and adaptive immu-
nity and is associated with B and T cell tolerance.
Goodpasture’s syndrome or anti-glomerular basement mem-
brane antibody disease (anti-GBM disease) is caused by loss of
tolerance to the NC1 domain of the alpha 3 chain of Type IV col-
lagen (!3(IV)NC1) leading to the deposition of antibodies in a
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linear fashion on the glomerular basement membrane and cres-
centic glomerulonephritis (Salama and Pusey, 2002; Wieslander
et al., 1987). Models of anti-GBM disease have been established
in the Wistar Kyoto rat by a single immunization with bovine or rat
glomerular basement membrane extract (Naito and Sado, 1989;
Reynolds et al., 2003) or the recombinant protein of rat !3(IV)NC
(Ryan et al., 2001). Mouse models have been developed with immu-
nization of recombinant human !3(IV)NC1 (Hopfer et al., 2003). In
addition, Fcgr2b−/− mice created on a 129 background and back-
crossed to C57BL/6 developed anti-GBM disease when immunized
with bovine Type IV collagen whilst WT  C57BL/6 mice did not
(Nakamura et al., 2000). As an explanation for this, there was loss
of tolerance to murine Type IV collagen in the Fcgr2b−/− mice to a
greater degree than WT  mice.
In order to definitively determine whether loss of Fcgr2b rather
than flanking 129 elements was responsible for the increased inci-
dence of anti-GBM disease, we have used mice lacking Fcgr2b
created on a pure C57BL/6 background. The relative contribution of
Fcgr2b on B cells compared with myeloid effector cells to protec-
tion from anti-GBM disease is not known. We  have used mice with
conditional deletion of Fcgr2b on B cells and a subset of myeloid
cells to investigate this question.
2. Materials and methods
2.1. Mice
The Fcgr2b−/−(129) mice were a gift of Dr. Toshi Takai (Depart-
ment of Experimental Immunology, Institute of Development,
Ageing and Cancer, Tohoku University, Sendai, Japan) (Takai et al.,
1996), and were backcrossed in Leiden University Medical Cen-
ter onto C57BL/6J for eight generations. The Fcgr2b−/−(B6) mice
were generated in Leiden University Medical Center as previously
described (Boross et al., 2011). CD19Cre mice were kindly provided
by Dr. Ari Waisman (Cologne) (Rickert et al., 1997) and were on a
C57BL/6 background. The Lysozyme MCre mice were kindly pro-
vide by Dr. Bjorn Clausen (Amsterdam) (Clausen et al., 1999) and
were on a C57BL6 background. Littermate WT  controls were used.
Mice were bred and housed in the animal facility, Leiden Univer-
sity Medical Center, Leiden, The Netherlands. Experiments were
performed in accordance with the regulations of the ethics com-
mittee at Leiden University Medical Center. Production of antigen,
and analysis of serology and histology was performed at Imperial
College London, UK.
2.2. Cloning, expression and purification of recombinant
˛3(IV)NC1
The recombinant NC1 domain of alpha3 Type IV collagen
(!3(IV)NC1) conjugated to a Flag tag, was expressed in human
embryonic kidney cells, as previously described (Reynolds et al.,
2005). The amino acid sequence was of rat !3(IV)NC1, which has
a high homology to mouse !3(IV)NC1 (Ryan et al., 1998). The
recombinant !3(IV)NC1 was purified from the supernatant by
affinity chromatography using an anti-FLAG-M2 affinity column
(Sigma–Aldrich). The protein was quantitated by spectrophotom-
etry and was characterized by Western blotting as previously
described (Reynolds et al., 2005).
2.3. Immunization protocol and induction of disease
Age-matched male mice were used for the experiments. The
mice were housed in a pathogen free environment, with free access
to food and water. The immunization protocol was modified from
that of Hopfer et al. (2003).  On Day 0, mice were immunized with
25 "g recombindant !3(IV)NC1 emulsified in complete Freund’s
adjuvant, subcutaneously. At Weeks 1–3, mice were immunized
subcutaneously with 25 "g r-!3(IV)NC1 emulsified in incomplete
Freund’s adjuvant. Mice were bled at Day 28 and at the termination
of the experiment for assessment of the immune response. One
mouse in the Fcgr2b−/−(B6) group died at Week 17 and tissues
were not obtained.
2.4. Histology and immunohistochemistry
Glomerular crescents were scored on samples fixed in Bouin’s
fixative and stained with PAS. Histological samples were assessed
by an observer blinded to the experimental group. Crescents were
defined as having two or more layers of cells in Bowman’s space,
and fifty glomeruli were scored per kidney and the percentage of
crescents was  calculated for each mouse.
For immunofluorescence, frozen kidney sections of 5 "m were
fixed in acetone. Glomerular mouse and sheep IgG were visualized
using FITC-conjugated goat anti-mouse IgG (Fc-specific) (Sigma)
and FITC-conjugated monoclonal mouse anti-sheep IgG clone GT34
(Sigma). To quantitate immunofluorescence, sections were exam-
ined at ×40 magnification using an Olympus BX4 fluorescence
microscope (Olympus Optical, London, UK) and a Photonic Science
Colour Coolview camera (Photonic Science, Robertsbridge, UK).
Samples from each experiment were stained on the same occasion
and measured together. The total pixel intensity for each glomeru-
lus was  measured and averaged for 20 glomeruli per section.
For cell markers, kidneys were fixed in periodate lysine
paraformaldehyde as previously described (Tarzi et al., 2002).
Sections were stained for macrophages with FA11 (monoclonal
rat anti-mouse CD68, Serotec, Oxford, UK) or CD4 cells (GK1.5,
BDPharmingen), and developed using the Polink-2 plus HRP rat
detection kit (Newmarket Scientific, UK).
2.5. Renal function and proteinuria
Serum urea and urinary creatinine were measured in the
Department of Clinical Chemistry, Imperial College Healthcare NHS
Trust. Serum albumin was measured using the AssayMax mouse
albumin ELISA kit (AssayPro, UK). Albuminuria was  assessed by
radial immunodiffusion against a rabbit anti-mouse albumin (Bio-
genesis, Poole, UK), as previously described (Tarzi et al., 2002), and
proteinuria was  semi-quantitatively measured using Siemens Mul-
tistix SG.
2.6. Assessment of immune response to ˛3(IV)NC1 and murine
Type IV collagen
In order to determine the immune response to !3(IV)NC1, 96
well plates were coated with 5 mcg/ml !3(IV)NC1 in carbonate
buffer. Plates were blocked with 3% BSA for 1 h at 37 ◦C, washed
and incubated with diluted serum. Secondary antibody used was
goat anti-mouse IgG conjugated to alkaline phosphatase (1:1000),
and samples were developed using p-nitrophenyl phosphate buffer
and read on an ELISA plate reader at 405 nm.
Antibodies to mouse Type IV collagen were detected by the
use of the BIOCOAT® cellware mouse C-IV 96-well plate assay,
as previously described (Nakamura et al., 2000) (Becton Dick-
inson Labware). The diluted serum (1:200–1:400) was added at
50 "l/well and allowed to react overnight at 4 ◦C. The wells were
washed three times with PBS containing 0.05% Tween 20, incubated
with 50 "l of a 1:200 dilution of goat anti–mouse IgG conjugated to
alkaline phosphatase (Sigma Chemical Co.) at 4 ◦C for 2 h, washed
three times with PBS containing 0.05% Tween 20, developed at
room temperature for 30 min  with p-nitrophenyl phosphate buffer,
and read on an ELISA plate reader at 405 nm.
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Fig. 1. Histological and renal parameters 22 weeks after first immunization with recombinant !3(IV)NC1. WT  = wild type C57BL/6, 2B−/−(129) = Fcgr2b−/− mice generated
using  129 embryonic stem cells and backcrossed to C57BL/6 for eight generations; 2B−/−(B6) = Fcgr2b−/− mice generated on a pure C57BL/6 background. (A) Percentage
glomerular crescents, (B) serum urea mmol/l, (C) glomerular macrophages/glomerular cross section and (D) urinary albumin/creatinine ratio (mg/mmol). (A) Chi-squared
test  used to compared incidence of crescentic GN and (B–D) one way ANOVA.
For electron microscopy, pieces of kidney were cut into 1 mm3
cubes, and fixed for 4 h in 3% glutaradehyde in 0.1 M cacodylate
buffer. The fixed kidney pieces were washed in cacodylate buffer,
dehydrated through graded alcohols and embedded in Spurr’s
resin. Ultra-thin sections were stained with uranyl acetate and
Reynold’s lead citrate. Sections were imaged using a Hitachi H-7650
transmission electron microscope.
2.7. Flow cytometry
Heparinised whole blood was obtained and stained for CD11b,
CD19, Gr-1 (BD Pharmingen) and Fcgr2b (clone Ly17.2) expres-
sion. Spleen was digested with Liberase TL (Roche) in order to
release resident macrophages and dendritic cells from connective
tissue. Single cell suspensions were prepared and cells were stained
for CD11b, F4/80, CD11c, CD19 and Fcgr2b expression. Blood and
spleen were obtained from Fcgr2b−/− mice, Fcgr2b−/−(CD19Cre),
Fcgr2b−/−(LysMCre) and WT  mice. In blood, B cells were gated
as lymphocytes in FSC/SSC and further as CD19+ CD11b− cells.
Blood monocytes were gated as SSClow, CD11b+ and granulocytes
as SSChigh Gr1+ cells. Resident macrophages were gated as CD11b+
F4/80+ CD11c− cells. Samples were acquired using a FACSCalibur
(BD Biosciences) and data analysis was performed with FlowJo soft-
ware (Tree Star).
2.8. Statistical analysis
Non-parametric statistics were employed, except the flow
cytometry analysis, where unpaired t-tests were performed.
Groups of two  were compared by Mann–Whitney U test, and groups
of three or more were compared by one-way ANOVA. In comparing
the incidence of crescentic glomerulonephritis, a chi-squared test
was used. Results were significant if p < 0.05.
3. Results
3.1. Fcgr2b−/− mice had a higher incidence of crescentic
glomerulonephritis after immunization with ˛3(IV)NC1 than WT
mice
Mice were immunized on four occasions at weekly intervals
with recombinant !3(IV)NC1. The disease patterns in Fcgr2b−/−
mice on a full C57BL/6 background (FcgRIIb−/− (B6) were com-
pared with Fcgr2b−/− mice generated with 129 embryonic stem
cells and extensively backcrossed to C57BL/6 (Fcgr2b−/−(129)),
and WT  C57BL/6 mice. Mice were sacrificed 22 weeks after ini-
tial immunization (Figs. 1 and 2). At the termination of the
experiment, 1/9 (11%) WT  mice developed glomerular crescents,
compared to 7/12 (58%) Fcgr2b−/−(129) mice and 4/11 (36%)
Fcgr2b−/−(B6) mice (chi-squared test p < 0.001 for Fcgr2b−/−(129)
vs WT  and p < 0.01 for Fcgr2b−/−(B6) vs WT (Fig. 1a). One addi-
tional Fcgr2b−/−(B6) mouse died at Week 17, and no tissues
were obtained. This mouse was excluded from the analysis. The
serum urea was  significantly higher in both Fcgr2b−/− groups
than WT  mice at the termination of the experiment (p < 0.05, one
way ANOVA) (Fig. 1B). There were significantly more glomerular
macrophages in the Fcgr2b−/− mice than WT (Fig. 1C). How-
ever, proteinuria was  not a significant feature of the disease and
there was  no overall difference in urinary albumin:creatinine ratio
between the groups (Fig. 1D). The experiment shown is represen-
tative of two  experiments performed, demonstrating an increased
incidence of glomerulonephritis in both groups of Fcgr2b−/− mice
compared with WT  mice.
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Fig. 2. (A–C) PAS-stained kidney sections, 22 weeks after first immunization with !3(IV)NC1. (A) WT C57BL/6 kidney showing preserved glomerular architecture; (B)
Fcgr2b−/−(129)  kidney showing glomerular crescent; (C) Fcgr2b−/−(B6) kidney showing glomerular crescent. (D) immunofluorescence of glomerulus for IgG showing
granular  immune complex deposition, (E) immunofluorescence for glomerular IgG showing predominantly linear IgG deposition, (F) electron micrograph of WT kidney; (G)
electron  micrograph of Fcgr2b−/−(B6) kidney. There was  increased mesangial matrix, more marked in Fcgr2b−/− (white stars). (F) WT shows scanty subepithelial deposits
(inset  arrow). (G) Fcgr2b−/−(B6) shows mesangial deposits (star) as well as extensive subendothelial deposits (arrow head) and subepithelial deposits (long arrow).
3.2. Analysis of immune response
ELISA for circulating IgG against the !3(IV)NC1 protein
immunogen, showed a tendency to higher levels of antigen specific
IgG in both groups of Fcgr2b−/− mice compared to WT,  although
the range was large, and this did not reach statistical significance
(Fig. 3A). Circulating IgG against mouse Type IV collagen (whole
molecule) was also assessed (Fig. 3B). This showed a similar ten-
dency to higher antibody titres in the Fcgr2b−/− mice as was seen
to the recombinant antigen, with significantly higher levels in the
Fcgr2b−/−(129) mice than WT  mice. These results are not unex-
pected, as B cell Fcgr2b is involved in the regulation of antibody
production.
The fluorescence patterns for deposited glomerular IgG ranged
from linear to mixed linear/granular and granular (Fig. 2D and
E). There was no overall difference in the fluorescence intensity
between WT,  Fcgr2b−/−(129) and Fcgr2b−/−(B6) (not shown),
although there was  a greater tendency for linear rather than mesan-
gial staining patterns in the Fcgr2b−/− mice. Electron microscopy
was performed on 3 WT mice and 2 Fcgr2b−/−(B6) mice. In the WT
mice, deposits were more scanty and predominantly localized to
the mesangium, whereas in the Fcgr2b−/−(B6) mice, there were
deposits in subendothelial, subepithelial and mesangial areas, and
increased mesangial matrix (Fig. 2F and G).
3.3. Unlike Fcgr2b−/− mice, conditional deletion of Fcgr2b on a
subset of myeloid cells (Lysozyme MCre) or B cells (CD19Cre)
alone did not significantly increase susceptibility to crescentic
glomerulonephritis
Mice with conditional deletion of Fcgr2b on mono-
cytes/macrophages and B cells were created by crossing
floxed Fcgr2b−/−(B6) mice with heterozygous expression of
Cre recombinase under the control of the LysozymeM promoter
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Fig. 3. (A) serum IgG against !3(IV)NC1, determined on serum taken at Day 28 after immunization. (B) Serum IgG against mouse Type IV collagen whole molecule taken at
Day  28 after immunization (dilution 1:400). (C) Quantitative immunofluorescence for deposited glomerular IgG, 22 weeks after first immunization with !3(IV)NC1.
(monocyte/macrophages) or the CD19 promoter (B cells). The
resultant mice were compared with littermate floxed controls, not
expressing Cre, and Fcgr2b−/−(B6) mice. Expression of Fcgr2b on
various cell types in the conditional knockout mice was  assessed
by flow cytometry (Fig. 4). There was excellent deletion of Fcgr2b
from B cells in the Fcgr2b−/−/CD19Cre mice (Fig. 4A), with no off-
target effects (Fig. 4B–D). In Fcgr2b−/−/LysMCre mice there was
a 50% reduction in expression of Fcgr2b on circulating monocytes
(Fig. 4B), and there was a small reduction of expression on splenic
macrophages (p < 0.05, Fig. 4D). The expression levels of Fcgr2b
on neutrophils were low (Fig. 4C) and not significantly different
between WT  and Fcgr2b−/−/LysMCre mice. Of note, there was no
reduction in Fcgr2b expression on CD11chigh, CD11b+/− splenic
dendritic cells in the Fcgr2b−/−(LysMCre) mice (not shown). The
analyses shown in Fig. 4 were taken on healthy mice. As disease-
induced mice may  display a different phenotype to healthy mice,
we also characterized expression of Fcgr2b on granulocytes and
monocytes in Fcgr2b−/−/LysMCre mice at 22 weeks after immu-
nization with !3(IV)NC1. The expression levels were similar to
untreated Fcgr2b−/−/LysMCre mice (Supplementary Fig. 1).
Mice were sacrificed 22 weeks after induction of disease.
1/12 (8%) Fcgr2b−/−LysMCre mice developed crescentic glomeru-
lonephritis, compared with 1/9 (11%) WT  mice, p = NS, chi-squared
test. For the CD19-Cre mice, the incidence of crescentic glomeru-
lonephritis was 2/9 (22%) mice (p = NS compared to WT,  chi-squared
test), Fig. 5A. One Fcgr2b−/−(B6) mouse died at 17 weeks and
was excluded from the analysis. Of the remainder, 4/11 (36%)
developed crescentic glomerulonephritis (p < 0.01 when com-
pared with WT,  chi-squared test) (Fig. 5A). In addition to the
glomerular crescents, there were significantly more glomerular
macrophages in the Fcgr2b−/−(B6) mice than the WT  litter-
mate controls or the Fcgr2b−/−CD19Cre mice (Fig. 5B), p < 0.05).
The serum urea was higher in the Fcgr2b−/−(B6) mice than
the WT  mice, but there was no significant difference in renal
function between WT  mice and either of the conditional knock-
out groups (Fig. 5C). Proteinuria was not a prominent feature
in this model, and there was no overall difference between the
groups.
Fig. 4. Flow cytometry of blood and spleen cells for Fcg2b expression in the
conditional knockout mice. (A) Fcgr2b expression on B cells in blood show-
ing good deletion in Fcgr2b−/−/CD19Cre mice (p < 0.001 compared to WT),
(B) % circulating monocytes (CD11b+, Gr1+) expressing Fcgr2b, (C) Fcgr2b
expression on neutrophils in blood (CD11b−, Gr1+), and (D) Fcgr2b expression
on  splenic macrophages (CD11b+/CD11c−). LysMCre = Fcgr2b−/−/LysozymeMCre
mice; CD19Cre = Fcgr2b−/−/CD19Cre mice. Bars represent standard deviation,
n  = 3–4/group, representative of 3 replicates.
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Fig. 5. Histological and functional parameters 22 weeks after immunization with !3(IV)NC1. (A) Percentage glomerular crescents; (B) macrophages/glomerular cross section;
(C)  serum urea (mmol/l); (D) urinary albumin/creatinine ratio (mg/mmol). One of the Fcgr2b null mice died before the end of the experiment and was excluded from the
analysis. WT = wild type littermate control mouse (C57BL/6), LysMCre = Fcgr2b−/−/LysMCre mouse, CD19Cre = Fcgr2b−/−/CD19Cre mouse, and Fcgr2b−/− = Fcgr2b−/− (B6).
The mouse anti-!3(IV)NC1 (Fig. 6A) and mouse anti-mouse Type
IV collagen IgG responses (Fig. 6B) were determined. As expected,
a proportion of the Fcgr2b−/− mice and the Fcgr2b−/−(CD19Cre)
mice had higher titres of specific IgG than WT  mice, but the overall
differences were not statistically significant, due to large differ-
ences between individual mice.
4. Discussion
These results demonstrate that after immunization with recom-
binant !3(IV)NC1 protein there is a significantly higher incidence of
glomerulonephritis in Fcgr2b−/− mice than WT  mice, both in terms
of glomerular crescents, macrophage infiltration and renal dysfunc-
tion highlighting the importance of Fcgr2b in the pathogenesis of
this disease. Previous work has demonstrated that Fcgr2b−/− mice
with 129 Chromosome 1 flanking segments have increased suscep-
tibility to anti-GBM disease after immunization with bovine Type IV
collagen (Nakamura et al., 2000). We have confirmed these findings,
using a different immunogen, and also in mice on a pure C57BL/6
background, demonstrating that it is not solely an effect of the 129
genes on Chromosome 1 related to the creation of the knockout
mouse strain using 129 embryonic stem cells. In humans, a poly-
morphism of Fcgr2b (I232T), associated with low function of the
receptor, was  demonstrated to be a risk factor for the development
of anti-GBM disease in a Chinese population (Zhou et al., 2010b)
and increased copy number of the activatory Fcgamma receptor
3A was also associated with anti-GBM disease. Taken together,
Fcgr2b is strongly implicated in protection from anti-GBM disease.
Fig. 6. Serum IgG levels in mice, 28 days after immunization with !3(IV)NC1 protein (A) serum IgG mouse anti-!3(IV)NC1 protein (1:400 dilution) and (B) serum IgG
anti-collagen Type IV IgG (1:400 dilution).
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Secondly, we have used mice with conditional deletion of Fcgr2b on
B cells or a subset of myeloid cells to investigate the cellular basis
for these effects. Despite a very effective deletion of Fcgr2b from B
cells, the Fcgr2b−/−/CD19Cre mice did not have an increased inci-
dence of anti-GBM disease over WT  mice, indicating that deficiency
on other cell types, or more than one cell type is required.
We  have used a new model of anti-GBM disease in mice, by
immunizing with recombinant !3(IV)NC1. This model was  modi-
fied from that of Hopfer et al. (2003),  where recombinant human
!3(IV)NC1 was used. The use of a recombinant protein antigen as an
immunogen has the advantage of reproducibility when compared
to bovine collagen Type IV, or other crude extracts. As the recom-
binant protein used is almost identical to mouse !3(IV)NC1, it also
has the advantage that it is a true auto-immune model, rather than
being induced using a foreign antigen. However, in contrast to the
model used by Nakamura et al. (2000),  we did not see pulmonary
haemorrhage. This may  relate to the differences in the immunogen
or the health status of the mice.
Both Fcgrb−/− mice with 129 genetic elements flanking Fcgr2b
and Fcgr2b−/− mice on a pure C57BL/6 background had an
increased incidence of glomerulonephritis after immunization with
!3(IV)NC1. There was no significant difference in the incidence
of disease between the groups, suggesting that the deficiency of
Fcgr2b itself is the major factor. However, there was a trend to an
increase in the incidence of disease in the Fcgr2b−/−(129) mice.
We also saw higher antibody titres to collagen Type IV in these
mice, although not to the !3(IV)NC1 peptide. Genes of 129 origin
in that location are known to be autoimmune susceptibility factors
associated with B and T cell tolerance, which may explain this trend
(Wandstrat et al., 2004).
Previous work in Dr. Verbeek’s laboratory has shown that female
Fcgr2b−/− mice with 129 elements flanking the Fcgr2b deleted
gene did develop autoantibodies and a degree of spontaneous SLE
at one year of age, however this was not see in Fcgr2b−/−(B6) mice
(Bolland and Ravetch, 2000; Boross et al., 2011). We  used male
mice in these experiments, which are less susceptible to SLE-like
syndromes. In addition, we saw macrophage influx, glomeru-
lonephritis and renal impairment in both Fcgr2b−/−(129) and
Fcgr2b−/−(B6) mice, whilst our previous work has shown a higher
incidence of SLE only in Fcgr2b−/−(129) mice (Boross et al., 2011).
In addition, we did not see splenomegaly in the Fcgr2b−/− mice
(data not shown), and therefore we do not believe that sponta-
neous SLE is a major contributor to the glomerulonephritis seen in
this model.
Loss of Fcgr2b on B cells alone or on a subset of mono-
cytes/macrophages was not sufficient to increase the incidence of
crescentic glomerulonephritis over WT  littermate controls. This
was despite very effective deletion of Fcgr2b from B cells in the
Fcgr2b−/−/CD19cre mice. Fcgr2b is involved in regulating the pro-
duction of antibody by cells of the B cell lineage, and may  have
a role in B cell tolerance (Boross et al., 2011). We  did see a ten-
dency to increased antibody titres in these mice and mice with full
deletion of Fcgr2b. However, we only saw increased incidence of
glomerulonephritis in mice with a full deletion of Fcgr2b on all cell
types. This result implies that loss of Fcgr2b on B cells alone is not
sufficient to increase susceptibility to anti-GBM disease but that
dysfunction of Fcgr2b on other cell types is also required.
Mice with conditional deletion of Fcgr2b on mono-
cytes/macrophages were induced by using Cre under control
of the LysozymeM promoter. The deletion was not complete, espe-
cially on resident macrophages. However, there was a significant
reduction in the expression of Fcgr2b on circulating monocytes
and a smaller reduction on splenic macrophages but no visible
reduction on splenic dendritic cells. Nevertheless, modest effects
on the levels of expression of Fcgr2b on myeloid cells have previ-
ously been shown to have clinical effects in models of infection,
and therefore these reductions are likely to be clinically relevant
(Brownlie et al., 2008). We  did not see an increased incidence
of glomerulonephritis amongst the Fcgr2b−/−/LysMcre mice
compared to WT  mice. This may  be either because the deletion
was not effective enough, or a combination of defects is required,
in multiple cell types, leading for example to enhanced loss of
tolerance and increased effector responses. Another factor to
consider is that Fcgr2b expression has been demonstrated on
cultured mesangial cells (Radeke et al., 2002), and expression of
Fcgr2b on intrinsic renal cells may  also play a role in anti-GBM
disease.
5. Conclusions
In conclusion, Fcgr2b−/− mice were more susceptible to cres-
centic glomerulonephritis induced by !3(IV)NC1 than WT mice.
Deletion of Fcgr2b on B cells was insufficient to demonstrate the
phenotype, indicating that enhanced antibody production alone is
not sufficient to induce disease, but that reduced function of Fcgr2b
on effector cells is also required, either from myeloid cells, or intrin-
sic renal cells. Given that Fc receptors have also been shown to
be important in human anti-GBM disease (Zhou et al., 2010a,b),
it is likely that these results also have relevance for the human
condition.
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FcgRIIb on Myeloid Cells and Intrinsic Renal Cells Rather
than B Cells Protects from Nephrotoxic Nephritis
Phoebe E. H. Sharp,*,1 Javier Martin-Ramirez,†,2 Sara M. Mangsbo,†,3 Peter Boross,†,4
Charles D. Pusey,* Ivo P. Touw,‡ H. Terence Cook,* J. Sjef Verbeek,†,5 and Ruth M. Tarzi*,5
FcgRIIb is the sole inhibitory FcR for IgG in humans and mice, where it is involved in the negative regulation of Ab production
and cellular activation. FcgRIIb-deficient mice show exacerbated disease following the induction of nephrotoxic nephritis (NTN).
In this study, we determined the cellular origin of the FcgRIIb-knockout phenotype by inducing NTN in mice with a deficiency of
FcgRIIb on either B cells alone (FcgRIIBfl/fl/CD19Cre+) or myeloid cells (FcgRIIBfl/fl/CEBPaCre+). Deletion of FcgRIIb from
B cells did not increase susceptibility to NTN, compared with wild-type (WT) mice, despite higher Ab titers in the FcgRIIBfl/fl/
CD19Cre+ mice compared with the WT littermate controls. In contrast, mice lacking FcgRIIb on myeloid cells had exacerbated
disease as measured by increased glomerular thrombosis, glomerular crescents, albuminuria, serum urea, and glomerular neu-
trophil infiltration when compared with WT littermate controls. The role for FcgRIIb expression on radioresistant intrinsic renal
cells in the protection from NTN was then investigated using bone marrow chimeric mice. FcgRIIb2/2 mice transplanted with
FcgRIIb2/2 bone marrow were more susceptible to NTN than WT mice transplanted with FcgRIIb2/2 bone marrow, indicating
that the presence of WT intrinsic renal cells protects from NTN. These results demonstrate that FcgRIIb on myeloid cells plays
a major role in protection from NTN, and therefore, augmentation of FcgRIIb on these cells could be a therapeutic target in
human Ab-mediated glomerulonephritis. Where there was a lack of FcgRIIb on circulating myeloid cells, expression of FcgRIIb
on intrinsic renal cells provided an additional level of protection from Ab-mediated glomerulonephritis. The Journal of Immu-
nology, 2013, 190: 340–348.
F cgRIIb is a low-affinity FcR for the constant part of IgGand the sole inhibitory FcgR in both humans and mice. Itis the most broadly expressed, being found on most cells
of myeloid lineage, and it is the only FcgR found on B cells. On
B cells, cross-linking of FcgRIIb and the BCR activates a distinct
pathway that inhibits cell proliferation, maturation, and the pro-
duction of cytokines (1); however, cross-linking of FcgRIIb in the
absence of the BCR initiates a bim-dependent apoptosis pathway
(2). Reduced expression of FcgRIIb is associated with enhanced
activation and proliferation of B cells and plasma cells (3), as well
as increased Ab production to T-dependent Ags (3, 4) and in-
creased macrophage activation by immune complexes (4–6).
Reduced functionality of FcgRIIb has been associated with
systemic lupus erythematosus in humans (7), and several auto-
immune strains of mice have a polymorphism in the promoter
region of the FcgRIIb gene that is associated with reduced cell-
surface expression on macrophages and activated B cells (5).
When combined with other autoimmune susceptibility genes,
mice deficient in FcgRIIb develop systemic lupus erythematosus,
whereas on a pure C57BL/6 background, they do not develop
severe autoimmunity, indicating that FcgRIIb is a modifier of au-
toimmune susceptibility determined by other genetic loci. How-
ever, C57BL/6 FcgRIIb2/2 mice do show enhanced Ab responses
and are highly susceptible to anti–glomerular basement membrane
Ab disease and nephrotoxic nephritis (NTN) (8–10). This could be
due to increased Ab production by FcgRIIb-deficient B cell line-
ages or, alternatively, due to increased myeloid cell activation.
Mesangial cells have also been shown to express FcgRIIb (11, 12),
adding another possible checkpoint in the prevention of severe Ab-
mediated glomerulonephritis.
The model of NTN (accelerated NTN) used in this study is
a well-characterized disease model that closely resembles human
Ab-mediated glomerulonephritis. The animals are preimmunized
against sheep IgG. Five days later, the mice are injected i.v. with
polyclonal sheep anti-mouse glomerular basement membrane Ab,
which is then planted on the mouse glomerular basement mem-
brane. As the mice are presensitized to sheep IgG, this results in
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immediate generation and deposition of mouse anti-sheep Ig in the
glomerulus, which progresses over several days and leads to cel-
lular infiltration of neutrophils, followed by macrophages, pro-
teinuria, glomerular injury, glomerular crescents, and, in severe
cases, progressive uremia. Previous studies of murine NTN have
highlighted roles for the involvement of many immune effectors in
glomerulonephritis, including macrophages, FcgR, Th1 and Th17
cells, complement, and intrinsic renal cells.
In order to determine the role of FcgRIIb on specific cell types
in NTN, we have crossed floxed FcgRIIb mice on a C57BL/6
background with mice expressing Cre recombinase either under
control of the human CD19 promoter to delete FcgRIIb in only
B cell lineages or under control of the CEBPa promoter to delete
FcgRIIb in myeloid lineages. The cell-type–specific FcgRIIb-
knockout offspring have been compared with littermate controls.
Because a Cre-transgenic strain that expresses Cre under control
of a mesangial cell–specific promoter was not available, we have
created bone marrow chimeras to determine the role of FcgRIIb
on radioresistant cells in the kidney.
Materials and Methods
Mice
The FcgRIIb2/2 (C57BL/6) mice were generated in Leiden University
Medical Center as previously described (4). CD19Cre mice were kindly
provided by Ari Waisman (Cologne, Germany) (13). CEBPaCre mice
were kindly provided by Dr. Ivo Touw (Rotterdam, The Netherlands) (14).
All mice were on a C57BL/6 background. Littermate wild-type (WT)
controls were used. Mice were bred and housed in the animal facility at
Leiden University Medical Centre (Leiden, The Netherlands). Experiments
were performed in accordance with the regulations of the ethics committee
at Leiden University Medical Center. Analysis of serology and histology
was performed at Imperial College London. For experiments involving
bone marrow–transplanted mice, FcgRIIb2/2 (C57BL/6) mice were bred
at the Biological Services Unit, Hammersmith Hospital (London, U.K.).
Control age- and sex-matched C57BL/6 WT mice were purchased from
Charles River Laboratories. All mice were housed with free access to food
and water and kept in a specific pathogen-free environment, according to
institutional guidelines. Experiments were performed under the terms of
a license issued by the UK Home Office. All mice used in this study were
between 6 and 15 wk of age.
Phenotyping expression of FcgRIIb by flow cytometry
Heparinized whole blood was obtained and stained for CD11b, CD19, Gr-1
(BD Pharmingen), and FcgRIIb (clone Ly17.2). Spleen was digested with
liberase TL to release resident macrophages from connective tissue.
Single-cell suspensions were prepared, and cells were stained for CD11b,
F4/80, CD11c, CD19, and FcgRIIb. Blood and spleen were obtained from
FcgRIIb2/2 mice, FcgRIIbfl/fl/CD19Cre+, FcgRIIbfl/fl/CEBPaCre+, and
WT C57BL/6 mice.
Induction of accelerated nephrotoxic nephritis
Sheep anti-mouse nephrotoxic globulin was prepared as described previ-
ously (15). Mice were preimmunized i.p. with 0.2 mg sheep IgG in a 50:50
mix of saline and CFA (Sigma-Aldrich, Dorset, U.K.). Five days later,
mice were injected i.v. with 0.2 ml nephrotoxic globulin via the tail vein.
Mice were monitored clinically by using dipstick for detection of pro-
teinuria and hematuria, and the experiments were terminated if the mice
showed signs of ill health.
Histology and immunohistochemistry
Glomerular crescents and thrombosis were scored on samples fixed in
Bouin’s solution and stained with periodic acid-Schiff (PAS) reagent.
Histological samples were assessed by an observer blinded to the experi-
mental group. Crescents were defined as two or more layers of cells in the
Bowman’s space. Glomerular thrombosis was assessed by scoring individ-
ual glomeruli for PAS-positive material: grade 0, no PAS-positive material;
grade 1, 0–25% of the glomerular section PAS positive; grade 2, 25–50%;
grade 3, 50–75%; and grade 4, 75–100%. Fifty glomeruli were scored for
crescents and thrombosis for each kidney, and a mean was calculated.
Glomerular mouse and sheep IgG were visualized by direct immuno-
fluorescence staining on 5-mm frozen kidney sections fixed in acetone
for 10 min using FITC-conjugated goat anti-mouse IgG (Fc-specific)
(Sigma-Aldrich) and FITC-conjugated monoclonal mouse anti-sheep
IgG clone GT34 (Sigma-Aldrich). To quantitate immunofluorescence,
sections were examined at 340 original magnification using an Olympus
BX4 fluorescence microscope (Olympus Optical, London, U.K.) and a
Photonic Science Color Coolview camera (Photonic Science, Roberts-
bridge, U.K.). Samples from each experiment were stained on the same
occasion and measured together. Images of the sections were captured
using Image Pro (MediaCybernetics, Bethesda, MD), and the total pixel
intensity for each glomerulus was measured and averaged for 20 glomeruli
per section.
For cell markers, kidneyswere fixed in periodate-lysine-paraformaldehyde.
Sections of 5 mm were stained for macrophages with FA11 (monoclonal
rat anti-mouse CD68; Serotec, Oxford, U.K.) and neutrophils with Gr-1
(monoclonal rat anti-mouse; Serotec) and developed using the Polink-2
plus HRP rat detection kit (Newmarket Scientific, Newmarket, U.K.). Mac-
rophages and neutrophils in 50 glomeruli/sample were counted and averaged
to obtain cells/glomerular cross-section (gcs).
Renal function and proteinuria
Urinary creatinine was measured in the Department of Clinical Chemistry,
Imperial College Healthcare NHS Trust. Serum albumin was measured
using the AssayMax mouse albumin ELISA kit (AssayPro, St. Charles,
MO). Serum urea was measured using the Urea/Ammonia ultraviolet-method
kit (R-Biopharm, Darmstadt, Germany). Albuminuria was assessed by
radial immunodiffusion against a rabbit anti-mouse albumin (Biogenesis,
Poole, U.K.), as previously described (15).
Bone marrow chimeras
Chimeric mice were made by irradiation with a dose of 8 Gy and recon-
stituted with 10 3 106 donor bone marrow cells. Nephritis experiments
were conducted at 10 wk posttransplant. Confirmation of chimerism was
obtained using PCR on DNA extracted from 0.1 ml blood obtained at the
terminal bleed, as previously described (4).
Mesangial cell cultures
Kidneys from WT and FcgRIIb2/2 mice were homogenized with a sy-
ringe plunger and forced through a series of sterile sieves with succes-
sively smaller pore sizes of 150, 106, and 45 mm. Glomeruli retained on
the 45-mm sieve were retrieved, washed in ice-cold PBS, and spun down
at 1000 rpm for 5 min. Glomeruli were digested with 380 U/ml collage-
nase (Sigma-Aldrich) for 30 min at 37˚C, spun down 1200 rpm for 5 min,
and resuspended in RPMI 1640 (Invitrogen) supplemented with 20% FCS
(Biosera), 100 U/ml penicillin, 100 g/ml streptomycin (Invitrogen), and
1% insulin/selenium/transferrin growth supplement (Sigma-Aldrich). Mesan-
gial cells were characterized as anti-myosin positive and pancytokeratin
negative, with characteristic stellate morphology.
Mesangial cell FcgRIIb expression
Expression of FcgRIIb on mesangial cells was confirmed by direct im-
munofluorescence on cytospin preparations. Briefly, cytospin slides were
prepared, air-dried, and cells fixed in acetone for 10 min and stained with
FITC-conjugated anti-FcgRIIb Ab (clone Ly17.2). Immunofluorescence
was visualized at 340 original magnification using an Olympus BX4
fluorescence microscope (Olympus Optical) and a Photonic Science Color
Coolview camera (Photonic Science, Robertsbridge, U.K.). Images of the
sections were captured using Image Pro (MediaCybernetics, Bethesda, MD).
Quantitative real-time PCR was performed as previously described (16)
using FcgRIIb-specific primers (12) and normalizing to GAPDH.
Statistics
Results are quoted as median (interquartile range), unless otherwise stated.
Lines on graphs represent median values. For comparing two groups, the
Mann–Whitney U test was used, and for three or more groups, the Kruskal-
Wallis test was used, with Dunn’s multiple comparisons test (p values
given are from Dunn’s test). GraphPad Prism (GraphPad Software, San
Diego, CA) was used to analyze the data. Differences were considered
significant when p , 0.05.
Results
Phenotype of FcgRIIb conditional knockouts
Mice with deletion of FcgRIIb on either myeloid cells or B cells
were created by crossing FcgRIIbfl/fl (pure C57BL/6 background)
mice with transgenic mice expressing Cre recombinase under the
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control of the CEBPa promoter or the CD19 promoter. The re-
sultant mice were compared with littermate FcgRIIbfl/fl controls
and FcgRIIb2/2 (C57BL/6) mice. Expression of FcgRIIb on vari-
ous cell types was assessed by flow cytometry (Fig. 1). There was
excellent deletion of FcgRIIb from B cells in the FcgRIIbfl/fl/
CD19Cre+ mice with no reduction of expression of FcgRIIb on
monocytes or granulocytes in blood or macrophages in the spleen
(Fig. 1A). In FcgRIIbfl/fl/CEBPaCre+ mice, there was excellent
deletion from circulating monocytes and granulocytes and partial
deletion from splenic macrophages and dendritic cells, with no
effect on B cell expression of FcgRIIb (Fig. 1B).
Mice lacking FcgRIIb on B cells did not have enhanced
susceptibility to NTN compared with WT mice
NTN was induced in preimmunized FcgRIIb2/2mice, FcgRIIbfl/fl/
CD19Cre+ mice, and WT littermate controls. Nephrotoxic serum
(NTS) was administered at a 1:20 dilution. Mice were monitored
clinically and killed at day 5 after induction of NTN, because the
mice with the full deletion of FcgRIIb started to show serious
disease symptoms including severe proteinuria and hematuria. At
this time point, there was no increase in injury in the FcgRIIbfl/fl/
CD19Cre+ mice compared with the WT mice (Fig. 2A–D). The
FcgRIIbfl/fl/CD19Cre+ mice had more deposited glomerular mouse
IgG than the WT mice (Fig. 2F), whereas there was a large range
in the circulating anti-sheep IgG titers and no overall difference
between WT and FcgRIIbfl/fl/CD19Cre+ mice.
This was in marked contrast with the FcgRIIb2/2 mice that
showed a strongly increased susceptibility to disease compared
with WT littermate controls (Fig. 2). The FcgRIIb2/2 mice had
significantly more glomerular thrombosis (p , 0.001 compared
with WT mice and p, 0.01 compared with FcgRIIbfl/fl/CD19Cre+
mice), increased glomerular macrophage infiltration (median:
FcgRIIb2/2 8.3 CD68-positive cells/gcs [interquartile range 7.3–
11]; WT: 2.1 [1.8–4.2] [p , 0.001]; and FcgRIIbfl/fl/CD19Cre+ 3.3
[2.4–5.6] [p , 0.05]), increased serum urea (p , 0.01), and in-
creased albuminuria (p , 0.05) than WT or FcgRIIbfl/fl/CD19Cre+
mice (Fig. 2A–D).
These results demonstrate that lack of FcgRIIb on B cells alone
was not sufficient to worsen NTN compared with WT mice,
whereas mice with the full deletion of FcgRIIb under the same
conditions (5 d after the induction of NTN) had markedly increased
disease. This suggests the involvement of FcgRIIb on cell types
other than B cells in the protection from NTN.
Mice lacking FcgRIIb on myeloid cells were more susceptible
to NTN than WT
As myeloid cells such as monocytes, neutrophils, and macro-
phages infiltrate the kidney abundantly in glomerulonephritis and
are known to express FcgRIIb, we then investigated the role of
FcgRIIb on these cell types in NTN. For this purpose, FcgRIIbfl/fl/
CEBPaCre+ mice were used and compared with FcgRIIbfl/fl/
CD19Cre+ mice and WT littermate controls. On this occasion,
full FcgRIIb2/2 mice were not used, which allowed us to use a
higher dose of NTS (1:10 dilution) and maintain the mice for a
longer period after injection of NTS. One FcgRIIbfl/fl/CEBPaCre+
mouse was sacrificed at day 5 due to clinical signs of disease, and
all other mice were sacrificed day 7 post–NTS injection. Although
the FcgRIIbfl/fl/CEBPaCre+ mice showed clinical signs of disease,
FIGURE 1. Flow cytometry to demonstrate specificity of conditional Cre deletion. (A) FcgRIIbfl/fl/CD19Cre+ showing deletion on circulating and splenic
B cells but not granulocytes, monocytes, or macrophages. (B) FcgRIIbfl/fl/CEBPaCre+ showing full deletion in circulating monocytes and granulocytes and
partial deletion in splenic macrophages and dendritic cells. SSC, Side scatter.
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the WT and FcgRIIbfl/fl/CD19Cre+ mice remained well. Analysis
of the histology showed that FcgRIIbfl/fl/CEBPaCre+ mice had
increased incidence of glomerular thrombosis compared with WT
mice (p , 0.05) and FcgRIIbfl/fl/CD19Cre+ mice (p , 0.01)
(Figs. 3A, 4A–C), increased levels of albuminuria (p , 0.05
when compared with WT mice and p , 0.01 when compared
with FcgRIIbfl/fl/CD19Cre+ mice), and increased serum urea
(p , 0.05 when compared with FcgRIIbfl/fl/CD19Cre+ mice)
(Fig. 3B, 3C). Surprisingly, there was no significant difference
in glomerular macrophage infiltration among WT, FcgRIIbfl/fl/
CD19Cre+, and FcgRIIbfl/fl/CEBPaCre+ mice (medians 1.3, 1.9,
and 2.0 CD68-positive cells/gcs, respectively), although this
may have been masked by increased glomerular thrombosis in
the FcgRIIbfl/fl/CEBPaCre+ mice (Figs. 3D, 4D–F). However,
FcgRIIbfl/fl/CEBPaCre+ mice did have increased glomerular
neutrophil infiltration compared with WT mice (median WT: 0.62
[interquartile range 0.36–0.88], FcgRIIbfl/fl/CD19Cre+: 0.59
[0.37–1.1], FcgRIIbfl/fl/CEBPaCre+: 1.5 [1.2–1.6], p , 0.05)
(Figs. 3E, 4G–I).
Circulating mouse anti-sheep total IgG titers were measured
in all mice. Despite the fact that FcgRIIbfl/fl/CD19Cre+ mice had
less disease than FcgRIIbfl/fl/CEBPaCre+ mice, they had higher
circulating anti-sheep Ab titers (p , 0.05, 2-way ANOVA).
These results clearly demonstrate the importance of FcgRIIb on
myeloid cells in vivo in immune complex glomerulonephritis and
show that increased mouse anti-sheep IgG titers are not the main
determining factor of the heightened susceptibility of FcgRIIb2/2
mice to NTN.
Role of FcgRIIb in intrinsic renal cells
Although FcgRIIbfl/fl/CEBPaCre+ mice had increased NTN com-
pared with WT mice, their disease susceptibility was not as
marked as mice with a full deletion of FcgRIIb, as they were able
to tolerate a higher dose of NTS and be maintained longer than
mice with the full deletion of FcgRIIb. In addition, it was possible
to titrate the dose of NTS down such that FcgRIIbfl/fl/CEBPaCre+
mice developed little disease, whereas mice with a full deletion of
FcgRIIb continued to have increased susceptibility to disease
compared with WT controls (data not shown). This may be due
to the fact that the deletion of FcgRIIb from myeloid cells in the
conditional knockout was not absolutely complete (Fig. 1B).
However, expression of FcgRIIb on intrinsic renal cells has pre-
viously been reported (11), and an FcgRIIb on intrinsic renal cells
was suggested by experiments in which a blocking anti-FcgRIIb
Ab was injected under the kidney capsule (17). We therefore sought
to determine whether there was a contribution of disease sus-
ceptibility from intrinsic renal cells to explain the slightly in-
creased susceptibility to disease in the full FcgRIIb2/2 mice
compared with FcgRIIbfl/fl/CEBPaCre+ mice.
Expression of FcgRIIb by mesangial cells
Expression of FcgRIIb by cultured mesangial cells was assessed
by real-time quantitative PCR. Transcripts were detected in WT
mesangial cells, and stimulation with LPS increased the expression,
although not significantly. No transcripts were detected in FcgRIIb-
deficient mesangial cells (data not shown). We also assessed
FIGURE 2. Functional and histological parameters at
day 5 after induction of NTN. (A) Glomerular thrombosis
score. (B) CD68-positive macrophages/gcs. (C) Serum urea
(mmol/L). (D) Urinary albumin/creatinine ratio (mg/mmol).
(E) ELISA for serum anti-sheep IgG. (F) Quantitative im-
munofluorescence for deposited glomerular mouse IgG.
CD19Cre, FcgRIIbfl/fl/CD19Cre+ mouse (n = 9); FcgRIIb2/2,
FcgRIIb2/2 mice generated on a pure C57BL/6 background
(n = 10); WT, WT littermate control mouse (C57BL/6)
(n = 9). If not marked, differences were not statistically
significant. *p , 0.05, **p , 0.01, ***p , 0.001.
The Journal of Immunology 343
expression of FcgRIIb on cultured mesangial cells by immuno-
fluorescence staining using an mAb. Cytospins of WT and
FcgRIIb2/2 mesangial cells were incubated with an FITC-labeled
anti-FcgRIIb Ab (Ly 17.2 clone). WT mesangial cells were found
to express FcgRIIb, whereas FcgRIIb2/2 mesangial cells were
negative (Fig. 5).
Expression of FcgRIIb on radioresistant cells in the kidney
induced relative protection from NTN compared with mice with
a full deletion of FcgRIIb
Unfortunately, a mouse with mesangial cell–specific Cre-recombinase
expression is not available. We therefore used bone marrow chi-
meric mice to investigate the role of FcgRIIb on radioresistant
intrinsic renal cells. By transplanting CD45.1 allogeneic bone
marrow into CD45.2 mice and using flow cytometry of blood and
dissociated kidney cells, our previous studies have shown that
our method of bone marrow transplantation results in 95% re-
placement of resident renal CD68-positive macrophages and
CD11c-positive dendritic cells, as well as excellent chimerism of
circulating neutrophils, monocytes, and B cells (16).
First, WT mice transplanted with FcgRIIb2/2 bone marrow were
compared with FcgRIIb2/2 mice transplanted with FcgRIIb2/2
bone marrow using male mice. Mild disease was induced with a
low dose of NTS (1:20 dilution), as otherwise the effect of the
lack of myeloid FcgRIIb may have masked any protection from
FcgRIIb on intrinsic renal cells. The mice were maintained to day
14 after induction of nephritis. FcgRIIb2/2 mice transplanted with
FcgRIIb2/2 bone marrow developed more disease than WT mice
transplanted with FcgRIIb2/2 bone marrow. FcgRIIb2/2 male
mice with FcgRIIb2/2 bone marrow had significantly more glo-
merular thrombosis (p , 0.0001), glomerular crescents (p , 0.01),
albuminuria (p , 0.001), and glomerular macrophage infiltration
(p , 0.01) than WT mice transplanted with FcgRIIb2/2 bone
marrow (Fig. 6A–D).
These results cannot be explained by differences in Ab titer
between the groups, as the FcgRIIb2/2 mice transplanted with
FcgRIIb2/2 bone marrow had lower circulating and deposited Ab
titers compared with WT mice transplanted with FcyRIIb2/2 bone
marrow (deposited mouse IgG; p , 0.05) (Fig. 6E, 6F). These
results suggest that, in addition to the role of myeloid FcgRIIb in
protection from immune complex glomerulonephritis, FcgRIIb on
intrinsic renal cells may also play a role in protection from disease.
Subsequently, the reciprocal experiment was performed to
determine whether the lack of FcgRIIb on intrinsic renal cells
alone was sufficient to increase susceptibility to NTN. Mild
disease was again induced with a low dose of NTS, and the mice
were maintained to day 14 after injection of NTS. The disease
induced in both groups was mild, and there was no overall dif-
ference in glomerular crescents and thrombosis. The degree of
albuminuria in both groups was minimal in most animals, but
there was a statistically significant increase in the FcgRIIb2/2
mice transplanted with WT bone marrow compared with WT
mice transplanted with WT bone marrow (p , 0.01) (Fig 7C).
There were also more glomerular infiltrating macrophages in
the FcgRIIb2/2 mice transplanted with WT bone marrow than
the WT mice transplanted with WT bone marrow (Fig. 7D, p ,
FIGURE 3. Functional and histological parameters at
day 7 after induction of NTN. (A) Glomerular thrombosis
score. (B) Urinary albumin/creatinine ratio (mg/mmol). (C)
Serum urea (mmol/L). (D) CD68-positive macrophages/
gcs. (E) Gr-1–positive neutrophils/gcs. (F) ELISA for serum
anti-sheep IgG. *p, 0.05 for CD19Cre versus CEBPaCre.
CD19Cre, FcgRIIbfl/fl/CD19Cre+ mouse (n = 8); CEBPa-
Cre, FcgRIIbfl/fl/CEBPaCre+ mouse (n = 7); WT, WT
littermate control mouse (C57BL/6) (n = 7). *p , 0.05,
**p , 0.01.
344 CELL-TYPE–SPECIFIC DELETION OF FcgRIIb IN GLOMERULONEPHRITIS
0.01). There was no significant difference in deposited glomer-
ular mouse IgG or circulating anti-sheep IgG between the two
groups (Fig. 7E, 7F).
Discussion
Despite a good deletion of FcgRIIb from B cells, the FcgRIIbfl/fl/
CD19Cre+ mice did not show increased susceptibility to NTN
compared with WT mice. However, mice with FcgRIIb deleted
from their myeloid cells had increased susceptibility to NTN
compared with WT littermate controls. This is important direct
evidence of a role of myeloid rather than B cell FcgRIIb in pro-
tection from glomerulonephritis. Additionally, we have confirmed
expression of FcgRIIb on cultured mesangial cells, and our results
would suggest that in addition to myeloid cell expression, local
expression of FcgRIIb on intrinsic renal cells contributes to pro-
tection from injury in NTN.
These results support our previous work looking at a model of
experimental autoimmune glomerulonephritis in FcgRIIb-deficient
mice on a pure C57BL/6 background, where we also found that
loss of FcgRIIb on B cells alone was not sufficient to exacerbate
experimental autoimmune glomerulonephritis (10). In contrast,
transgenic overexpression of FcgRIIb on B cells was found to
reduce the severity of collagen-induced arthritis in mice as well as
lower the level of anti-collagen Abs (18). Our results suggest that
in glomerulonephritis, B cell expression of FcgRIIb is not the sole
determinant of protection from injury.
Deletion of FcgRIIb on B cells results in hyperreactive B cells
that produce increased Ab titers in response to both thymus-
dependent and -independent Ags (3). We did see a wide range
of anti-sheep Ab titers in our experiments, and the results were
also complicated by the presence of renal disease and proteinuria.
Nevertheless, we did see increased levels of deposited murine
IgG in mice lacking FcgRIIb on B cells, supporting the presence
of increased levels of Ab throughout the disease course. Full
FcgRIIb2/2 mice had slightly lower levels of circulating anti-
sheep total IgG than WT mice, for unknown reasons, possibly
due to heavy proteinuria (Fig. 2E).
FcgRIIbfl/fl/CEBPaCre+ mice showed good deletion of FcgRIIb
on myeloid cells, with complete deletion from circulating monocytes
and neutrophils and partial deletion on tissue-resident macro-
phages and dendritic cells. FcgRIIbfl/fl/CEBPaCre+ mice had
significantly more renal injury in terms of albuminuria, glomerular
thrombosis, crescent formation, and serum urea than WT mice,
highlighting the importance of myeloid FcgRIIb in protection
from severe injury in glomerulonephritis. FcgRIIbfl/fl/CEBPaCre+
FIGURE 4. Histology at day 7 after the in-
duction of NTN. (A–C) PAS-stained kidney
sections. (A) WT littermate control C57BL/6
kidney showing mild thrombosis. (B) FcgRIIbfl/fl/
CD19Cre+ mice showing mild thrombosis. (C)
FcgRIIbfl/fl/CEBPaCre+ mice showing severe
thrombosis. Immunoperoxidase staining for CD68
showing similar glomerular macrophage infil-
tration among WT kidney (D), FcgRIIbfl/fl/
CD19Cre+ kidney (E), and FcgRIIbfl/fl/CEBPa-
Cre+ kidney (F). Immunoperoxidase staining for
Gr-1 showing similar glomerular neutrophil infil-
tration between WT kidney (G) and FcgRIIbfl/fl/
CD19Cre+ kidney (H) and increased glomerular
neutrophil infiltration in FcgRIIbfl/fl/CEBPaCre+
kidney (I). Original magnification320.
FIGURE 5. FcgRIIB expression on mesangial cells. Immunofluores-
cence staining showing expression of FcgRIIb on mesangial cells: WT
mesangial cells (a) and FcgRIIb2/2 mesangial cells (b). Original magni-
fication 310.
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mice had more infiltrating glomerular neutrophils than WT and
FcgRIIbfl/fl/CD19Cre+ mice. FcgR are known to play a role in
neutrophil recruitment. FcRg2/2 and FcgRIII2/2 mice both dis-
play strongly abrogated recruitment of neutrophil effector cells
during heterologous anti-glomerular basement membrane disease
(17), suggesting FcgRIIb may play a role in the negative regula-
tion of neutrophil recruitment.
Surprisingly, there was no significant difference in glomerular
macrophage infiltration between the WT mice and myeloid cell
knockouts. FcgRIIb clearly plays a role in the recruitment of
macrophages to the glomerulus, as the FcgRIIb-deficient mice had
significantly greater macrophage infiltration than WT mice. This
suggests that expression of FcgRIIb on macrophages is not critical
for their recruitment. This is supported by previous work looking
at the role of activating FcgR in NTN. There was no significant
difference in glomerular macrophage infiltration among WT mice,
WT mice transplanted with FcRg2/2 bone marrow, and FcRg2/2
mice transplanted with FcRg2/2 bone marrow (15). Despite
similar numbers of infiltrating macrophages among the three
groups of mice, FcgRIIbfl/fl/CEBPaCre+ mice had increased dis-
ease. This could be explained by the fact that the macrophages are
likely to show enhanced activation. Reduced surface expression of
FcgRIIb on macrophages was associated with heightened re-
sponses following activatory FcgR cross-linking, including in-
creased intracellular calcium flux, superoxide production, and
proinflammatory cytokine release (5, 6, 19). On the contrary, ad-
ministration of i.v. Ig (IVIG) in accelerated NTN was found to
upregulate FcgRIIb on effector macrophages in the kidney and
protected mice from fatal disease (20). Indeed, IVIG was not ef-
fective in protecting FcgRIIb2/2 mice from NTN, indicating that
this is an important mechanism of action for IVIG (20). Th2
cytokines, such as IL-4, are known to increase myeloid expression
of FcgRIIb (21). Recently, it has been determined that the sialy-
lated IgG component of human IVIG binds to a lectin receptor
dendritic cell–specific intracellular adhesion molecule 3–grabbing
nonintegrin on dendritic cells, leading to the secretion of IL-33,
which upregulates IL-4 secretion by basophils and leads to the
increased expression of FcgRIIb on myeloid cells (22). Taken
together with our results, these findings offer insights into the
mechanism of action of IVIG for the treatment of human auto-
immune disease, specifically the critical importance of FcgRIIb
expression on myeloid cells in the protection from Ab-mediated
injury (23).
We have confirmed expression of FcgRIIb on mesangial cells
in culture. However, due to the absence of a mesangial cell–
specific Cre, bone marrow chimeras were used to investigate the
role of FcgRIIb on radioresistant cells, and therefore, we are not able
categorically to determine the radioresistant cell type involved.
WT mice transplanted with FcgRIIb2/2 bone marrow were not as
susceptible to NTN as FcgRIIb2/2 mice transplanted with
FcgRIIb2/2 bone marrow. PCR of blood-derived DNA demon-
strated that at least 95% of circulating DNA was of donor origin,
in addition to our previous work showing that there is a similar
high degree of chimerism of resident macrophages and dendritic
cells in the kidney (16). Bone marrow–derived cells of recipient
origin are therefore unlikely to explain the significant differences
FIGURE 6. Functional and histological parameters in
male bone marrow–transplanted mice at day 12 post-
induction of nephrotoxic nephritis. (A) Glomerular throm-
bosis score. (B) Percentage of glomerular crescents. (C)
Urinary albumin/creatinine ratio (mg/mmol). (D) Macro-
phages/gcs. (E) ELISA for serum anti-sheep IgG. (F) Quan-
titative immunofluorescence for deposited glomerular
mouse IgG. +/+, WT littermate control mice; 2/2, FcgRIIb2/2
mice. 2/2 transplanted into 2/2 (n = 10), 2/2 transplanted
into +/+ (n = 11). *p , 0.05, **p , 0.01, ***p , 0.001,
****p , 0.0001.
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between these two groups, and it is likely that FcgRIIb on radio-
resistant intrinsic renal cells plays a part in protecting from immune
complex glomerulonephritis. In the converse experiment, in which
WT bone marrow was transplanted to FcgRIIb mice and compared
with WT mice transplanted with WT marrow, the evidence for lack
of FcgRIIb on intrinsic renal cells alone to exacerbate NTN sig-
nificantly was weaker. We did see an increase in the glomerular
macrophage infiltration in the FcgRIIb2/2 mice transplanted with
WT bone marrow compared with WT controls, but other renal
parameters were not significantly different. Therefore, the presence
of FcgRIIb on intrinsic renal cells was sufficient to afford some
protection from NTN, but the lack of FcgRIIb on radioresistant
cells alone was not sufficient to exacerbate disease significantly.
Although expression of FcgRIIb on radioresistant cells, possibly
mesangial cells, did appear to afford some protection from NTN,
we did not see protection from disease in mice lacking activatory
FcgR from intrinsic renal cells in our previous work (15). These
data suggest FcgRIIb may be interacting with an alternative receptor
on mesangial cells. For instance, a negative regulatory interaction
between FcgRIIb and the C5a receptor has been implicated in a
recently published study (24).
Interestingly, in both of the transplant experiments, mice lacking
FcgRIIb on their intrinsic renal cells had more glomerular mac-
rophage influx than mice with WT intrinsic renal cells. Taken with
the observations that mice completely lacking FcgRIIb also had
increased glomerular macrophage infiltration compared with WT
mice, but mice with FcgRIIb only deleted from myeloid cells did
not, this suggests that FcgRIIb expression by intrinsic renal cells,
such as mesangial cells, acts to downregulate recruitment of
macrophages to the glomerulus. It also appears that macrophage
recruitment can be uncoupled from macrophage activation, as
there was only an increase in disease when FcgRIIb was not
expressed on the macrophages themselves rather than the in-
trinsic renal cells.
In summary, deletion of FcgRIIb on B cells alone was not
sufficient to exacerbate NTN, indicating that enhanced Ab pro-
duction does not contribute to disease in this model. However,
deletion of FcgRIIb on myeloid cells did increase susceptibility to
renal injury in the mice, confirming the important regulatory
function of this inhibiting FcgR on myeloid cells in Ab-mediated
inflammatory diseases. Therapeutic means to enhance the ex-
pression of FcgRIIb on myeloid cells have the potential to be of
importance in the treatment of human glomerulonephritis.
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FIGURE 7. Functional and histological parameters in
male bone marrow–transplanted mice at day 14 post-
induction of NTN. (A) Glomerular thrombosis score. (B)
Percentage glomerular crescents. (C) Urinary albumin/
creatinine ratio (mg/mmol). (D) Macrophages/gcs. (E)
ELISA for serum anti-sheep IgG. (F) Quantitative immu-
nofluorescence for deposited glomerular mouse IgG. +/+,
WT littermate control mice; 2/2, FcgRIIb2/2 mice. +/+
transplanted into 2/2 (n = 16); +/+ transplanted into +/+
(n = 11). **p , 0.01.
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